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Abstract 
Photodynamic therapy (PDT) requires a photosensitiser, light and oxygen to generate 
reactive oxygen species and cell death. The hydrophobicity of photosensitisers can be 
overcome using nanoparticles. Furthermore, nanoparticles can be functionalised with 
cancer-specific ligands to increase selectivity towards tumours. The aim of this thesis 
was to investigate the use of nanoparticles for PDT of breast cancer. 
Gold nanoparticles (AuNPs) were functionalised with polyethylene glycol (PEG) and a 
zinc phthalocyanine photosensitiser (Pc). Two Pcs differing in the length of the carbon 
chain that connects the Pc to the gold, three (C3Pc) or eleven (C11Pc) carbon atoms, 
were explored. Fluorescence emission intensity was higher for free C11Pc. Conversely, 
on the surface of the AuNPs, it was higher for C3Pc. The higher fluorescence emission 
intensity of C3Pc-PEG-AuNPs correlated with an increased production of singlet oxygen 
(1O2). SK-BR-3 cells internalised both nanosystems but cell death was enhanced with 
C3Pc-PEG-AuNPs (80 %), due to metal-enhanced fluorescence, as compared to C11Pc-
PEG-AuNPs (10 %). The conjugation of the AuNPs with a breast cancer-specific antibody 
improved the internalisation and PDT efficacy of both nanosystems. 
The potential use of a carbohydrate, lactose, to target the galectin-1 receptor on breast 
cancer cells was studied. Lactose and either C3Pc or C11Pc were conjugated to AuNPs. 
Two breast cancer cell lines, SK-BR-3 and MDA-MB-231, were used. While lactose-
C11Pc-AuNPs only induced phototoxicity to SK-BR-3 cells, lactose-C3Pc-AuNPs induced 
effective PDT for both cell lines. Evidence of targeting galectin-1 was only observed for 
MDA-MB-231 cells.  
The use of upconverting nanoparticles (UCNPs) functionalised with the photosensitiser 
Rose Bengal (RB) for near-infrared PDT was investigated. Energy transfer between the 
UCNPs and RB upon excitation at 980 nm allowed the generation of 1O2. SK-BR-3 cells 
successfully internalised the UCNPs and induced effective PDT at 15 μg/mL, leading to 
minimal dark toxicity and effective cell death following irradiation. 
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Chapter 1 
Introduction 
Cancer is a serious health problem. It has a high incidence rate; cancer will be diagnosed 
to 1 in 2 people in the UK, with cancer cases becoming increasingly common due to the 
an ageing population, and it is one of the principal causes of death in the world for both 
men and women.1,2 Specifically, lung, stomach, liver, colon and breast cancer lead the 
number of cancer-related deaths yearly.3 Therefore, it is vital to find treatments for the 
prevention and therapy of tumours.  
Photodynamic action has been known for over 100 years, when it was inadvertently 
discovered by Raab and von Tappeiner, as described by Anand et al.4 and Ackroyd et 
al..5 These authors realised that photodynamic action is a two-step process that 
requires a photosensitising molecule and light, together with a suitable amount of 
molecular oxygen in the environment, in order to induce tissue damage. The 
investigation of photodynamic therapy has since then attracted great interest, 
especially for the treatment of malignant tumours.4 More recently, the combination of 
nanotechnology and cancer-specific targeting molecules with photodynamic therapy 
has gained remarkable attention for an enhanced photodynamic effect. 
In this chapter, a review of photodynamic therapy will be explored. Additionally, the 
choice of photosensitising molecules available for photodynamic therapy as well as the 
photosensitisation mechanisms that they undergo will be discussed. Targeted 
photodynamic therapy via the introduction of cancer-specific targeting agents will also 
be covered. Finally, a review on the use of different types of nanoparticles for 
photodynamic therapy will be studied.  
 
1.1.  Photodynamic therapy and its mechanism of action 
Photodynamic therapy (PDT) of cancer, sometimes referred to as photochemotherapy 
of cancer, is a minimally invasive treatment that involves the use of two components, 
a photosensitiser (PS) and visible light.4-22 Additionally, the presence of molecular 
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oxygen is essential for effective PDT. These three elements by themselves, PS, light and 
oxygen, are non-toxic. During the treatment, the PS is activated with visible light. 
Reaction of the excited PS with molecular oxygen leads to the production of reactive 
oxygen species (ROS), capable of inducing toxicity to cells and tissues.4-22 Advantages 
of PDT over conventional cancer treatments include cost-effectiveness, low systemic 
toxicity, the prevention of toxic side effects such as the ones seen after chemotherapy 
or radiotherapy (i.e., tiredness, weakness, nausea and vomiting, hair loss, dry skin, 
peripheral neuropathy, infertility and problems in the heart, lungs and bladder) as well 
as higher cure rates, and excellent cosmetic results following treatment, which is 
especially important for skin cancer lesions.6-9,23 PDT is particularly useful for the 
treatment of early and localised tumours, due to the selective delivery of the PS 
towards cancerous tissue.6,8 Furthermore, PDT can be easily combined with other 
therapies, such as conventional chemotherapy, for an improved destruction of 
tumours.6 However, PDT also has its limitations. The main problem related to PDT is 
the presence of skin photosensitivity, i.e., skin remains sensitive to light, for some time 
following treatment.6 Additionally, complete cure of metastatic tumours is more 
challenging since irradiation of the whole body is not possible.7,8 
During photosensitisation (Figure 1.1), the PS is irradiated with light of a specific 
wavelength, usually between 400-800 nm.10 The PS in the ground state (S0) absorbs 
light, which provides energy for the PS to reach an electronically excited singlet state 
(S1). The S1 state has a short half-life (10-9-10-6 s)11, which is unstable and thus prone to 
quickly undergo deactivation. Deactivation can occur via different pathways, either 
radiative, such as fluorescence, or non-radiative, such as intersystem crossing (ISC). 
Both fluorescence and ISC occur from the lowest energy level within the S1 state, which 
the PS reaches via non-radiative vibrational relaxation (VR). Effective PS follow ISC, 
which induces a change in spin multiplicity leading to a triplet excited state (T1). The T1 
state has a longer half-life (10-3-1 s)11 than S1, which allows the PS to go through the 
next steps of photosensitisation. Two mechanisms of photosensitisation can be 
followed, type I or type II. Type I involves direct reaction between a PS in the T1 state 
and a substrate, which concludes with the formation of free radicals via electron or 
hydrogen transfer. Upon reaction with molecular oxygen (3O2), ROS are formed, 
including the superoxide anion, hydrogen peroxide, and the highly reactive hydroxyl 
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radical. Type II involves the transfer of energy from the PS in the T1 state to molecular 
oxygen, producing a highly reactive ROS, singlet oxygen (1O2). All of these ROS induce 
oxidative stress in the cells and tissues, which lead to cell death and tumour 
destruction.6,7,9-16   
 
It is generally accepted that the most common type of photosensitisation that leads to 
PDT photodamage is Type II.6,7,9,13,14,17 However, the ratio by which type I and type II 
photosensitisation occur during PDT depends on several factors, including the choice 
of PS, the subcellular localisation of the PS, the binding affinity between the PS and the 
substrate and the presence of 3O2.6,9,12,17 As a result, in situations where molecular 
oxygen is not readily available, known as hypoxia and anoxia, type I is the pathway 
followed for effective PDT.6,7,13 Following production of the ROS, the PS decays back to 
the ground state and thus multiple cycles of photosensitisation can take place during 
PDT until the concentration of oxygen in the tissue is depleted.8  
Given that type II is the most common mechanism followed in PDT, 1O2 is the most 
important cytotoxic species that leads to cell death. In the ground state, molecular 
oxygen presents two unpaired electrons (same spin) in the 2p antibonding orbitals.9 
S0
S1
T1
ISC
Fluor.
Phosphor.
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Figure 1.1. Simplified Jablonski diagram including a schematic representation of the PDT 
photosensitisation mechanisms leading to the production of ROS. The arrows represent 
excitation (red), fluorescence and phosphorescence (green), intersystem crossing (blue), 
non-radiative vibrational relaxation (black) and energy transfer (purple). 
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However, upon excitation, singlet oxygen presents two paired electrons (different spin) 
in the 2p antibonding outer orbital. Effective excitation of 3O2 to produce 1O2 requires 
at least 94.5 kJ/mol of energy (Figure 1.2).9,16 The half-life of 1O2 in water is ca. 3 μs, 
but it is diminished in the cytoplasm to ca. 10-320 ns.9,14,15,24 As a result, the maximum 
radius of action for 1O2 within the cellular environment is ca. 10-55 nm.14,24 Considering 
the diameter of a typical cell ranges between 10-100 μm, it is easily seen that the 
localisation of the PS inside the cells is vital for an effective photodynamic cell kill.9,13,15 
 
Following the production of ROS, there are three main mechanisms that can lead to 
malignant cell death; direct photodamage, vascular shutdown and the activation of an 
immune response.6,7,12,17,18 The ratio in which each of these mechanisms contribute to 
tumour destruction is dependent on the localisation of the PS, the light dose and the 
type of tumour being treated.6  
Photodamage refers to the direct killing of the tumour cells as a result of the cellular 
damage caused by the ROS.12 There are three main cell death pathways that can be 
followed in PDT, apoptosis, necrosis and autophagy.14,24 The pathway followed 
depends not only on the cell type but also on the localisation of the PS within the cells, 
the light dose and the oxygen concentration available for the treatment.6,13,17 
Additionally, the localisation of the PS within the cells will depend on the type of PS, its 
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Figure 1.2. Energy level diagrams of molecular oxygen (3O2) and the long-lived 1Δg excited 
state of singlet oxygen (1O2). Energy of at least 94.5 kJ/mol is required for the transition 
from 3O2 to 1O2. 
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chemical properties and the concentration at which it is administered.6 It has been 
reported that PS that locate in the mitochondria lead to apoptosis, whereas those PS 
located in the lysosomes and the plasma membrane are most likely to induce necrosis 
or autophagy.23,25 Direct photodamage has its limitations because the distribution of 
the PS within the tumour is not always homogeneous. It is further limited by the 
amount of oxygen in the malignant tissue, most of which is consumed during the PDT 
treatment itself, which can reduce the direct damage to the cells.12  
Vascular shutdown refers to damage not to the cancer cells themselves, but to the 
blood vessels that surround them. These blood vessels are essential for tumour growth, 
since they provide all the nutrients and oxygen the cells need. Therefore, damage to 
the blood vessels can lead to cell death. PDT has been shown to induce microvascular 
collapse, which in turn constraints the oxygen supply to the malignant tissue. As a 
result, microvascular collapse can lead to vascular constriction, thrombus formation 
and inhibition of tumour growth.12 Vascular constriction is easily identified because it 
leads to haemorrhage and erythema.17  
Finally, some studies have reported that leukocytes, lymphocytes and macrophages 
have been found in PDT-treated cells and tissue. This implies that PDT could lead to the 
activation of an immune response against tumour cells, which is characteristic for the 
stimulation of an inflammatory reaction.12,14 Inflammation is manifested via a localised 
gross oedema and it appears as a consequence of damage to the vasculature.14 It has 
been suggested that the mechanism followed by the PDT treatment depends on the 
dose and the incubation time within the tissue.12 
The efficacy of PDT relies on several parameters, such as the selectivity of the PS 
towards tumour tissue, the interval between administration of the PS and light 
irradiation and the wavelength of light and light dose used for the treatment.12 The 
accumulation of the PS is partially selective towards tumour cells. The reasoning behind 
this selectivity is not completely understood but it is most likely related to the special 
characteristics of the tumour such as the presence of leaky vasculature and the lack of 
lymphatic drainage. The selectivity of PS towards tumour tissue will be further 
reviewed in section 1.2.1.6 Additionally, the use of hydrophobic PS yields more 
selective accumulation than hydrophilic PS, due to their rapid diffusion into tumour 
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cells.6,24 Further information on the types of PS and their selectivity towards cancer 
cells will be reviewed in section 1.1.1. Light dosimetry is an important concept in PDT 
as it will determine the uniform distribution of light over the tumour, as well as the 
potential irradiation of healthy tissue.4,26 An ideal dose should minimise irradiation of 
the healthy cells surrounding the tumour.26 Dosimetry is an important parameter in 
deciding not only the light dose but also the fluence rate and the time of 
photoexposure.4 Additionally, the selection of the irradiation wavelength plays an 
important role in PDT.14 Blue light is the least efficient choice since it penetrates 
biological tissue only slightly. The most efficient wavelength range is between 600-
1,200 nm and the longer the wavelength used, the deeper the penetration into the 
tissue and thus the ability to reach deeper-lying tumours. However, the production of 
1O2 requires relatively high energy (94.5 kJ/mol) and only the range 600-800 nm is 
energetic enough to induce its generation. As a result, the most efficient light is red 
light.14  
 
1.1.1.  Photosensitisers 
An ideal PS should have a series of properties in order to enhance its efficacy for PDT 
while minimising side effects. In order to produce ROS in sufficient concentrations, 
efficient PS should have a high quantum yield for the triplet state together with a 
relatively long half-life.6,9,13,19,24 Furthermore, the PS’s absorption maximum should be 
between 680-850 nm.6,9,13,14,19,26 This wavelength region ensures a deeper penetration 
into the target tissue, ca. 8 mm but reaching up to 2-3 cm under favourable conditions, 
while providing enough energy for the effective excitation of molecular oxygen in order 
to generate ROS.6,14,19 
One of the most important properties for an effective PS is the selectivity towards the 
tumour.6,9,13,19,26 As reported in section 1.1, the mechanism by which some PS are more 
selectively accumulated in the tumour is poorly understood. However, it has been 
described to be due to specificities in the tumour’s structure. The main factors are the 
presence of leaky vasculature created around the tumour, a reduction in the lymphatic 
drainage, a lower pH in the tumour’s extracellular compartment and a high affinity of 
hydrophobic PS for endothelial/cancer cells via low-density lipoprotein receptor-
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mediated endocytosis.9 These factors and the selective accumulation of PS in tumours 
will be reviewed in section 1.2.1. Selectivity towards the target tissue would avoid 
undesirable toxicity to the healthy tissue surrounding the tumour.13  
Another important property is low dark toxicity.6,9,13,14,19,26 Photosensitisers should not 
be toxic, the toxicity of the treatment should only occur after light irradiation, with the 
production of ROS. Having minimal side effects is also beneficial.9,14,26 This includes 
limited in vivo stability for a fast biological clearance from the human body so the 
patient does not need to avoid bright light during the months following PDT (skin 
photosensitivity).19,24,26 Furthermore, the PS should not cause mutagenic effects, which 
are usually related to the intracellular localisation.9,26 Therefore, to avoid this effect, 
efficient PS will not be located inside the nucleus of the cells.9 
The chemical properties of the PS are also key for their efficiency. PS should be a stable, 
chemically pure compound with a constant composition that will induce a reliable PDT 
treatment.6,9,13,24,26 Additionally, the solubility of the PS is another factor to consider.9,26 
Hydrophobic photosensitisers are efficient for the reaction with the lipid bilayers of the 
cell membrane, as well as the selective delivery towards tumour tissue. However, 
hydrophilicity is required for an effective delivery and transport of the PS through the 
body. As a result, amphiphilicity is an important property for PS.9 
The administration of the PS is also important as it should not lead to toxic effects such 
as allergic reactions.9 Furthermore, the administration of the PS should be fairly easy 
and pain-free. The pain-free property should be extended throughout the irradiation 
period.9,26 Other important considerations are the cost26 and availability19, as well as 
the potential to use PDT with other therapies. Consequently, ideal PS should not 
prevent combination therapy. For example, in order to use PDT in combination with 
fluorescence diagnosis, the PS should have at least some fluorescence emission.9 
According to the time when they were developed and their characteristics, 
photosensitisers can be divided in two main groups; first generation photosensitisers 
and second generation photosensitisers.  
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First generation photosensitisers 
First generation photosensitisers refer to haematoporphyrin derivatives (HpD) mainly. 
The structure of haematoporphyrin and its parent compound the porphyrin, based on 
a tetrapyrrole backbone, are shown in Figure 1.3.24  
 
 
 
 
 
 
 
The modern period of PDT started with Schwartz and Lipson in 1960 at the Mayo Clinic 
(USA).4-6,10,12,18 The treatment of haematoporphyrin with acetic acid and sulfuric acid 
produced a water-soluble mixture of porphyrins known as haematoporphyrin 
derivative (HpD), which was found to have tumour localising properties. The discovery 
of the activation of HpD using red light led to the development of HpD for PDT in a 
variety of clinical trials.10,12 HpD was the first approved photosensitiser for PDT and it 
was later purified, to remove the least active porphyrins, to porfimer sodium, 
commonly known as Photofrin®.4,18 Photofrin was initially approved in Canada for the 
prophylactic treatment of bladder cancer in 1994.6,11 Since then, it has been approved 
in more than 125 countries6 for a variety of lesions including non-small cell lung cancer, 
oesophageal cancer, early-stage gastric cancer and early-stage cervical cancer.11,13 Even 
though Photofrin is non-toxic, reliable, pain-free and still successfully used in the clinics, 
it suffers from a series of disadvantages.6,11,13,14,19,20,26 Photofrin is a complex mixture of 
more than 60 compounds, making its reproducibility quite challenging.6,13 Photofrin 
absorbs light at 630 nm with a low extinction coefficient, which means the penetration 
Figure 1.3. Chemical structure of (A) porphyrin and (B) haematoporphyrin, from which 
haematoporphyrin derivative (HpD) and Photofrin® are derived. 
(A) (B) 
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into the tissue is limited to ca. 5 mm.11,13,19 Additionally, the tumour selectivity is 
limited and the PS is slowly cleared from the body, leading to skin photosensitivity for 
ca. 2-3 months.6,11,13,14,19,20 As a result of these drawbacks, improved PS were 
developed, which are known as second generation photosensitisers.11 
Second generation photosensitisers 
The second generation of photosensitisers offers certain advantages over the first 
generation, such as a shorter period of skin photosensitivity, a longer irradiation 
wavelength (675-800 nm) that allows for a deeper penetration into the tissue, an 
improved tumour selectivity and higher quantum yields of the triplet excited state and 
thus of 1O2 production.11,20 Within the porphyrins, a special type of second generation 
photosensitiser is 5-aminolevulinic acid (5-ALA), Figure 1.4. 5-ALA is a naturally 
occurring prodrug, involved in the biosynthesis of haem.5,6,13,20 During the biosynthesis 
of haem, 5-ALA is a precursor of the photosensitiser protoporphyrin IX (PpIX), Figure 
1.4.5,6 This is an example of endogenous photosensitisation.5,6,14 The administration of 
5-ALA leads to a porphyria-like phenomenon by which an excess of PpIX is secreted and 
accumulated within cancerous tissue.5,6,11 5-ALA offers several advantages over HpD, 
including a shorter photosensitivity period of only 24 h, fast biological clearance and 
the possibility of oral and topical administration.5,6 On the other hand, 5-ALA also 
presents some drawbacks, the main one being its hydrophilic character, which prevents 
efficient internalisation and limits its action to superficial tumours.6 However, the 
synthesis of novel 5-ALA-esters is becoming increasingly popular as a way to increase 
the hydrophobicity of the compound and avoid this problem, including the 5-ALA hexyl 
ester Hetvix® and the methyl ester-aminolevulinate Metvix®.6 Additionally, 5-ALA PDT 
can be painful.26 Nevertheless, 5-ALA is clinically approved for actinic keratoses of the 
face and scalp, basal-cell carcinoma, brain, bladder, head and neck and gynaecological 
tumours.12-14 
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Second generation photosensitisers include several families within the tetrapyrrole 
backbone, such as phthalocyanines, naphthalocyanines, chlorins, bacteriochlorins, 
texaphyrins, and purpurins.11,20 Figure 1.5 shows the parent compound of the most 
commonly employed families. These parent compounds give rise to many derivatives 
that are used as photosensitisers in PDT. 
 
 
 
 
 
 
 
 
 
Figure 1.5. Chemical structure of (A) phthalocyanine, (B) naphthalocyanine, (C) chlorin and 
(D) bacteriochlorin. 
Figure 1.4. Chemical structure of (A) 5-aminolevulinic acid (5-ALA) and (B) the active 
photosensitiser protoporphyrin IX (PpIX). 
(A) (B) 
(A) (B) 
(C) (D) 
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Phthalocyanines are the most promising second generation photosensitisers.13 Their 
monomeric form has a strong absorption band at ca. 680 nm with a high extinction 
coefficient. Furthermore, phthalocyanines can be modified by addition of a central 
metal ion, such as Zn2+ or Al3+, which can further increase the triplet quantum yield 
leading to an increased production of 1O2.13 The silicon phthalocyanine Pc4 is being 
used for clinical trials in the United States for the treatment of cutaneous T-cell 
lymphoma.14 Zinc phthalocyanines are gaining interest for in vitro investigations and 
they are being tested in clinical trials in combination with liposomal formulations.24 
There are a couple of clinically approved PS belonging to the chlorin family. The best 
known chlorin approved for treatment is tetra(m-hydroxyphenyl)chlorin (mTHPC), also 
known as Foscan®. The chlorin mTHPC is 100 times more potent than the first 
generation PS Photofrin and it leads to effective PDT using low concentration and light 
dose.11 In Europe, mTHPC is clinically approved for the treatment of neck and head 
cancers.14 Other examples include the benzoporphyrin derivative known as 
verteporfin, and chlorin e6, a naturally occurring chlorophyll derivative.24 The use of 
verteporfin, commercialised as Visudyne®, has been clinically approved for the 
treatment of age-related macular degeneration in ophthalmology since 2001 in more 
than 60 countries.6,27 Another photosensitiser that belongs to the chlorins is tin 
etiopurpurin (Purlytin®). Tin etiopurpurin is clinically approved in the USA for PDT of 
cutaneous metastatic breast cancer and Kaposi’s sarcoma, as well as other non-
cancerous diseases.11 Purlytin is derived from the porphyrins but its structure, 
especially the addition of tin metal, allows for a longer absorption wavelength (650-
680 nm), thus making it a more efficient PS. 
Other second generation PS not derived from the tetrapyrrole backbone have been 
investigated.24 Molecules that act as PS and can be classified as synthetic dyes include 
phenothiazinium salts, Rose Bengal, squaraines, boron-dipyrromethene (BODIPY) dyes, 
phenalenones and transition metal compounds. Within the phenothiazinium salts, the 
most commonly used PS is methylene blue (Figure 1.6), which is especially used for 
antimicrobial PDT rather than anticancer PDT. The PS Rose Bengal (Figure 1.6), 
belonging to the xanthenes, is widely used as a photoactive dye with interest in 
antimicrobial PDT, anticancer PDT and tissue bonding applications.24 
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Natural products can also be used as PS for PDT. The most widely studied ones are 
hypericin, hypocrellin, riboflavin and curcumin.24 Even though the selectivity towards 
tumour tissue is improved in the second generation of photosensitisers, it is still 
limited. In an attempt to increase the PS selectivity to the tumour, third generation 
photosensitisers are being developed.11,14,19 Third generation PS are based on the 
conjugation of the PS to biological ligands for targeted PDT, which will be reviewed in 
section 1.2.1. 
 
1.2.  Nanoparticles for photodynamic therapy 
Effective PS are usually hydrophobic in nature, as mentioned in section 1.1.1, in order 
to interact with the lipid bilayers of the cell membrane and be efficiently internalised 
by the cells.9 As a result, the PS delivery and intravenous administration into the body 
becomes challenging as the PS can easily aggregate in aqueous solutions, leading to a 
decrease in quantum yield and thus reduced 1O2 production.28,29 Additionally, the PS 
selectivity towards tumour tissue in vivo is limited, even for the most recently 
developed third generation PS, which incorporate a targeting ligand on their 
surface.21,29 Therefore, there is a need to develop PS delivery systems that allow the 
solubilisation of the hydrophobic PS in aqueous media while increasing the selectivity 
towards cancerous tissue.23 The use of nanoparticles as vehicles for the selective 
delivery of PS in PDT has received significant attention over the past 10-15 years.30 
Nanoparticles are ideal candidates for PDT due to their small size (1-100 nm), their high 
surface area-to-volume ratio, their photophysical and photochemical properties as well 
(A) (B) 
Figure 1.6. Chemical structure of (A) methylene blue and (B) Rose Bengal. Ref. 24. 
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as the extensive possibilities for size and shape control.23,28,31,32 Nanoparticles can be 
made water soluble while the PS they carry retain its hydrophobic properties.28 This 
provides the amphiphilicity the PS needs in order to circulate through the blood and 
maintain its monomeric active form without aggregation.23,24,29,31,32 Furthermore, 
nanoparticles enhance the selectivity towards cancerous tissue via the enhanced 
permeability and retention effect (EPR)23,25,28-32, which will be discussed in section 
1.2.1. The selectivity towards cancer cells can be further improved by the addition of 
chemical and/or biological ligands with strong binding affinities towards certain cell 
receptors overexpressed on the surface of tumours.23,28-34 This is known as targeted 
PDT and will be further discussed in section 1.2.1. 
The high surface area-to-volume ratio of nanoparticles allows for their 
functionalisation with many different ligands. The nanoparticles can thus 
accommodate a high number of PS molecules, which increases the amount of PS 
delivered to the cancer cells and results in an enhanced production of 1O2 and other 
ROS.28,32 Other advantages of the use of nanoparticles for PDT include the possibility of 
specifically controlling the release of the PS into the target tissue and the possibility to 
obtain multifunctional nanoplatforms.23,25,32 Multifunctional nanoplatforms are those 
nanoparticles functionalised with different ligands to allow for theranostic 
applications, i.e., perform diagnosis and therapy at the same time. Theranostics can 
refer to the use of the nanoparticle system for both imaging and PDT. Additionally, PDT 
can be combined with other therapeutic modalities such as photothermal therapy 
(PTT), chemotherapy and magnetically-guided therapies.25,32 
The nanoparticles used for PDT can be divided into two categories, passive and active 
nanoparticles, based on their participation in the photosensitisation process.23,32,35 As 
defined by their name, passive nanoparticles are only carriers of the PS.32,35 Passive 
nanoparticles can be either biodegradable or non-biodegradable, the main difference 
between them being that biodegradable nanoparticles effectively release the PS into 
the cytoplasm whereas non-biodegradable nanoparticles induce the generation of ROS 
without releasing the PS.21,23,29,32,35,36 Biodegradable nanoparticles include liposomes, 
dendrimers, synthetic polymer-based micelles and natural macromolecules.32,36 Non-
biodegradable nanoparticles offer some advantages over the biodegradable type, 
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mainly their resistance to changes in pH and temperature, the tunability in size, shape 
and porosity during synthesis and the resistance towards microbial attack.21,32,36 Non-
biodegradable nanoparticles include metallic nanoparticles, silica nanoparticles, 
magnetic nanoparticles, ceramic-based nanoparticles and polyacrylamide-based 
nanoparticles.23,32 On the contrary, active nanoparticles are involved in the production 
of ROS and can be further classified into nanoparticles that act as PS by themselves and 
nanoparticles that generate an energy transfer to the PS.32 Active nanoparticles that 
act as PS include titanium dioxide (TiO2) nanoparticles, zinc oxide (ZnO) nanoparticles 
and fullerenes.29,32,35 These nanoparticles have unique absorption properties that allow 
them to induce the generation of ROS.32 The second class of active nanoparticles are 
those nanoparticles that not only carry the PS but are also involved in energy transfer 
processes. These include upconverting nanoparticles, X-ray activatable nanoparticles, 
quantum dots and two-photon absorbing nanoparticles.32 
This section will focus on a review on the use of gold nanoparticles and upconverting 
nanoparticles for PDT of cancer, which are the two types of nanoparticles explored 
during the investigations reported in this thesis. 
 
1.2.1.  Targeted photodynamic therapy 
As it has been mentioned throughout Chapter 1, the selectivity of PS towards 
cancerous tissue is limited. Such selectivity can be increased by the conjugation of the 
PS to nanomaterials. The increase in selectivity with the use of nanoparticles is called 
passive targeting. Passive targeting refers to the preferential internalisation of 
nanoparticles by cancer cells due to the specific properties of tumours in contrast to 
healthy tissue, the enhanced permeability and retention effect (EPR). The EPR effect is 
related to the appearance of fenestrations in the tumour vasculature as well as the lack 
of lymphatic drainage.37 The uncontrolled growth of cancer cells requires increasing 
amounts of oxygen and nutrients in order for the cells to survive. As a result, new blood 
vessels need to be rapidly created, a process known as angiogenesis. Angiogenesis 
leads to the formation of abnormal, leaky, disorganised and loosely-connected blood 
vessels with an increased vessel permeability.25,36,37 The increased permeability 
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appears as fenestrations with sizes of 100-600 nm.25 Conversely, fenestrations in the 
vasculature of healthy tissue are less than 10 nm in size. Therefore, nanoparticles 
permeate through tumour vasculature more easily than healthy tissue.37 Healthy tissue 
is continuously drained via the lymphatic vessels, allowing for the regeneration of the 
interstitial fluid. However, tumours present a reduced, minimal lymphatic drainage. 
Therefore, once nanoparticles have been internalised, they will be retained due to the 
inability of tumours to renew and clean the interstitial fluid.25,36,37 The EPR effect plays 
an important role in tumour selectivity. Even though the tumour biology is essential for 
the development of the EPR effect, the physicochemical properties of the PS also 
influence the effectiveness of selective uptake via EPR.37 One of the limitations of the 
EPR effect is the high variability in vascular permeation in different human tumours. 
Gastric, pancreatic and highly metastatic cancers typically show low vascularisation, 
which restricts the nanoparticle accumulation via EPR.38 
As it was mentioned in section 1.2, the use of nanoparticles further provides the 
opportunity to use biological ligands in order to increase the potential selectivity that 
occurs through the EPR effect in a complementary manner.37 The use of biomolecules 
for the selective targeting of cancer cells is known as active targeting.25,33,36,37 In 
contrast to third generation PS, nanoparticles can be functionalised with multiple 
targeting ligands on their surface, which increases the selectivity.33 The idea for active 
targeting is the use of ligands that specifically recognise certain receptors 
overexpressed on the surface of cancer cells but not on healthy cells.33,36 The most 
typically used receptors for active targeting are, as shown in Figure 1.7,  the human 
epidermal growth factor receptor 2 (HER2), the folate receptor, the transferrin 
receptor, nucleolin, the αvβ integrins, the cluster determinants 44 (CD44), 
carbohydrates and endogenous lectins.25,33,37 One of the carbohydrates is the 
Thomsen-Friedenreich carbohydrate antigen (T antigen), overexpressed in more than 
90 % of primary tumours.33 The lectin Jacalin, specific towards the T antigen, has been 
used as the targeting ligand in previous studies.33,39 
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The HER2 receptor is overexpressed in ca. 10-34 % of aggressive breast cancers. It is 
usually targeted by using a monoclonal antibody, since it has binding affinities in the 
nanomolar range.33 The HER2 receptor and its role in cancer will be discussed in 
Chapter 3. The folate receptor, found overexpressed in more than 90 % of ovarian 
cancers, has been widely chosen for active targeting via folic acid due to their selective 
interaction.25,33 The transferrin receptor, upregulated in several malignancies, has 
become an important target due to its specificity to the glycoprotein transferrin, which 
is typically used as the targeting ligand.37,40,41 Nucleolin has been targeted in previous 
studies using the vascular targeting F3 peptide as well as nucleolin-specific aptamers, 
single-stranded oligonucleotides with high specificity.25,37,42-44 The αvβ integrins are 
transmembrane proteins used as angiogenic biomarkers that are overexpressed in 
tumours.45 The peptide arginine-glycine-aspartic acid (RGD), in its cyclic form, is 
recognised by most integrins and thus, the peptide used as the targeting ligand in 
cancer research.45,46 The expression of CD44 glycoproteins in tumours leads to 
increased metastatic potential.47 As such, these receptors can be used for targeted PDT 
since they selectively bind hyaluronic acid.47 Finally, endogenous lectins have also been 
targeted on cancer cell surfaces. The overexpression of lectins and carbohydrates and 
their use for targeted PDT will be reviewed in Chapter 4. 
Figure 1.7. Schematic representation of a cell membrane, showing some of the cancer cell 
receptors that can be used for selective targeting. It should be noted that these receptors 
are not all present in all cancer cell types. The figure was adapted and modified from Ref. 
28.  
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1.2.2.  Gold nanoparticles  
The following review on gold nanoparticles (AuNPs) for PDT is an up to date version of 
a contribution to a textbook on pre-clinical and clinical PDT, published earlier this 
year.28 The use of gold nanoparticles (AuNPs) in biomedicine, especially PDT, is 
advantageous because of their excellent biocompatibility and the non-toxic nature of 
the gold core.48 Additionally, AuNPs are highly stable and readily synthesised with good 
control over the nanoparticle size. The ease by which the surface can be modified with 
chemical and biological ligands is a further advantage.48-50 The strong interaction 
between gold and sulfur allows for the self-assembly of thiolated species on the gold 
core. As a result, surface modification of AuNPs is typically performed in this manner.51 
The functionalisation of AuNPs with PS induces an enhancement in the production of 
1O2, due to the interactions between the PS and the metal nanoparticle. Therefore, 
AuNPs enable the administration of low doses of the drugs, which in turn leads to a 
reduction in the possible side effects of the therapy.48 
The first time that AuNPs were functionalised with a PS for PDT was reported by Russell 
and co-workers.52-54 The authors synthesised 2-4 nm AuNPs functionalised with a 
thiolated zinc phthalocyanine containing a C11 mercaptoalkyl tether (C11Pc). The phase 
transfer reagent tetraoctylammonium bromide (TOAB) was used to assemble the 
C11Pc on the surface of the AuNPs. Additionally, TOAB enabled the solubilisation of the 
AuNPs in polar solvents to facilitate drug administration.53 The authors reported that 
the C11Pc-AuNPs produced 1O2 with a 50 % increase as compared to the free C11Pc. 
This was confirmed by the significantly higher 1O2 quantum yield of C11Pc-AuNPs 
(φΔ=0.65) than that of the free C11Pc (φΔ=0.45). The increase in 1O2 quantum yield in 
the presence of the AuNPs was assumed to be due to interactions between C11Pc and 
TOAB.53 In vitro studies using HeLa cervical adenocarcinoma cells proved that the 
C11Pc-AuNPs were effectively internalised by the cells after a 4 h incubation.54 The 
internalised C11Pc-AuNPs were irradiated for 20 min with a 690 nm diode laser, to 
induce the generation of 1O2 for PDT. Following PDT treatment, the cells incubated with 
the C11Pc-AuNPs exhibited a considerable decrease in cell viability (43 %), improving 
that of the free C11Pc (74 %). Additionally, the PDT efficacy was further confirmed 
visually by the drastic change in cell morphology due to cell death via apoptosis.54 The 
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promising in vitro results led to in vivo studies for the treatment of a sub-cutaneously 
implanted amelanotic melanoma, a common type of skin cancer, in mice.52 Camerin et 
al. successfully showed inhibition of the tumour growth following application of the 
PDT treatment, just 3 h after nanoparticle administration. Even though the C11Pc-
AuNPs inhibited tumour growth, it was apparent that opsonisation of the C11Pc-AuNPs 
by the reticuloendothelial system (RES), i.e., removal by the phagocytes, to the liver 
and spleen occurred. Such opsonisation reduces the average lifetime of C11Pc in the 
serum, which is key for the success of the PDT treatment. Moreover, the accumulation 
of AuNPs in both the liver and spleen could lead to undesired toxicity and other side 
effects.52  
In a similar approach, Nombona et al. prepared ca. 5 nm AuNPs functionalised with 1,6-
hexanedithiol tetra substituted zinc phthalocyanine (ZnPc), stabilised via the phase 
transfer reagent TOAB.55 The ZnPc-AuNPs were tested in vitro in MCF-7 human 
malignant breast cancer cells, where they were shown to induce good phototoxicity 
and an increased cell death as compared to studies with healthy fibroblast cells. The 
major drawback of this system was that the use of AuNPs only induced a moderate 
increase in PDT efficacy as compared to the free ZnPc. The authors attributed this 
observation to the limited 1O2 production in PBS containing 2 % v/v DMSO, likely to be 
due to the quenching effects of aqueous environments. It was suggested that the 
synthesis of hydrophilic AuNPs would solve this problem and thus improve the PDT 
efficacy.55 
Not only phthalocyanines have been conjugated to AuNPs for PDT; porphyrins have 
also been studied. The first time a porphyrin was conjugated to gold nanoparticles was 
reported by Ohyama et al..56 The authors successfully synthesised gold nanoparticles 
coated with a porphyrin monolayer via a porphyrin tetradentate passivant.56 Following 
that, the first studies using porphyrin coated gold nanoparticles for PDT were 
performed by Gamaleia et al..57 This group synthesised 14.5 and 45 nm AuNPs 
functionalised with haematoporphyrin (Hp) and stabilised with polyvinylpyrrolidone. 
The Hp-AuNPs were more effective at producing ROS than the free Hp in solution, 
which was correlated with a higher PDT efficacy in vitro in MT4 T-cells and Jurkat human 
T-cell leukemia, especially using the 45 nm sized particles.57 The functionalisation of 
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the 14.5 nm AuNPs with the photosensitiser 5,10,15,20-tetrakis(3-
hydroxyphenyl)porphyrin (mTHPP) in a multilayer system was performed by Reum et 
al. via a layer-by-layer technique.58 This technique allows for an effective control of the 
PS concentration, not only by the number of AuNPs, but also by altering the number of 
mTHPP monolayers around the AuNPs.58   
Zaruba et al. conjugated two porphyrin-brucine quaternary ammonium salts to 3-
mercaptopropanoic acid modified AuNPs as potential agents for PDT.59 In vitro and in 
vivo studies in PE/CA-PJ34 basaloid squamous cell carcinoma cells showed 
inconsistencies. In vitro studies showed a lower PDT efficacy for the AuNP conjugates 
than for the free porphyrin-brucine PS, possibly due to the aggregation of the AuNPs in 
cell culture media. However, in vivo studies induced reduction and complete regression 
of the tumours when the AuNPs were used. The authors speculated that the interaction 
between AuNPs and plasma proteins, mainly human serum albumin, in vivo enhanced 
the accumulation of the AuNPs in the cancer cells via an improved EPR effect.59  
The prodrug 5-ALA, which leads to the generation of the photosensitiser PpIX, has 
achieved particular success in PDT. The hydrophilic character of 5-ALA makes 
penetration through lipophilic biological barriers, such as cell membranes, difficult. The 
diagnostic success of 5-ALA is thus related to the disruption of epithelial barriers 
observed in neoplastic diseases, which facilitates 5-ALA penetration through the skin.60 
The conjugation of 5-ALA with AuNPs for an improved delivery and cytotoxic effect in 
PDT has been the subject of several studies.61-64 Xu et al. synthesised 24 nm cationic 
gold nanoparticles electrostatically functionalised with 5-ALA.61 The use of these 5-ALA-
AuNPs had several advantages over free 5-ALA related to selectivity and 1O2 
production. In vitro studies in K562 chronic myelogenous cells showed an increased 
delivery of 5-ALA with a high selectivity for tumour tissue for the 5-ALA-AuNPs. The 
authors attributed the increase in selectivity to the higher negative-zeta potential of 
tumour cells over healthy cells, which enables their binding to the cationic AuNPs. 
Additionally, the production of 1O2 by PpIX was reported to be higher when 5-ALA was 
combined with AuNPs, as compared to free PpIX. The surface plasmon absorption band 
of the AuNPs might contribute to an increased absorption of light by the system, which 
thus results in a higher generation of 1O2. The ability to produce more 1O2 by the 5-ALA-
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AuNPs also significantly improved the PDT efficacy.61 The use of 5-ALA functionalised 
AuNPs for the treatment of skin cancer, Mel-Rm metastatic melanoma cells, was 
reported by Mohammadi et al..62 The results of this study were similar to those 
obtained by Xu et al. since the ideal incubation time was found to be 4 h and the 
phototoxic damage following PDT was twice as high for the AuNPs as compared to free 
5-ALA.62 Other research groups63,64 have studied the cooperative effect when AuNPs 
and 5-ALA are used in combination but without actual conjugation between the two. It 
was reported that the combination of AuNPs with 5-ALA for PDT is beneficial since it 
requires a smaller amount of 5-ALA to induce good phototoxicity. As a result, the PS 
can be used in reduced quantities, which can avoid the potential harmful effects of high 
concentrations on healthy cells.64  
PpIX has also been directly combined with AuNPs for PDT.65-67 Khaing Oo et al. studied 
the effect of the AuNPs size on the enhancement of ROS production using 19, 66 and 
106 nm AuNPs electrostatically functionalised with PpIX.65 In solution, the 
enhancement of the generation of ROS was found to correlate with the increase in 
AuNP size, with the 106 nm producing the highest levels of ROS. The size-dependence 
of ROS generation was speculated to be relative to the localised plasmonic field of 
AuNPs, which is larger in AuNPs of bigger sizes. However, in vitro studies with MDA-
MB-231 human breast adenocarcinoma cells showed that the 66 nm AuNPs performed 
the best, producing both the highest ROS and the highest toxicity. This effect was 
attributed to the low uptake of the large (106 nm) AuNPs by the cells. Nevertheless, 
the use of AuNPs of any size induced a higher degree of cytotoxicity (> 50 % cell death) 
compared to free PpIX (22.6 % cell death).65 In another study, PpIX was used to 
functionalise smaller AuNPs (7 nm diameter) via 6-mercapto-1-hexanol ligands 
attached to the surface of the AuNPs. The conjugates were tested in vitro with HeLa 
cervical cancer cells and were found to be good delivery vehicles to produce a high 
photodynamic cytotoxicity. The major drawback of this method was the limited 
selectivity towards the tumour site, which the authors suggested could be improved by 
the use of active targeting.66 Ashjari et al. further evaluated the combination of PpIX 
conjugated to AuNPs via cysteine.67 The increase in ROS production as well as in vitro 
cytotoxicity, 24 % cell death for free PpIX versus 59 % cell death for the PpIX-cysteine-
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AuNPs, was found to be a result of the energy transfer from the surface plasmon of the 
AuNPs to PpIX on their surface.67 
Studies with other photosenstisers such as bacteriochlorins are less widespread but 
have also been reported.68 As an example, Pantiushenko et al. reported the synthesis 
of a thiolated bacteriochlorophyll a. The combination of this PS with AuNPs increased 
the circulation time in the blood of rats bearing sarcoma M-1 and increased the 
specifity towards the tumour tissue due to the EPR effect.68 
Use of polyethylene glycol for steric stabilisation 
From the above studies, it is apparent that using AuNPs as drug carriers has a positive 
effect in PDT of cancer. However, one of the biggest limitations is the opsonisation of 
the nanoparticles by the reticuloendothelial system (RES), which leads to a short half-
life in the serum and thus rapid clearance from the body. A solution to this problem is 
the modification of the AuNPs with water soluble polyethylene glycol (PEG), which is 
approved for human intravenous application.69-71 PEG provides stealth-like properties 
to the AuNPs and it has a high resistance to protein adsorption.25,32,70 As a result, the 
conjugates are not easily taken up by the RES, which leads to an increased circulation 
time in the blood. This is a clear advantage since rapid clearance by the RES limits the 
potential of the functionalised AuNPs for selective accumulation within the tumour 
tissue through the EPR effect, which in turn leads to the accumulation of the AuNPs in 
the liver, kidney and spleen.25,31  
The Burda group70,72-74 focused on the use of 5 nm PEGylated gold nanoparticles 
functionalised with a silicon phthalocyanine (Pc4). Pc4 was non-covalently bound to 
the AuNPs via a N-Au bond to the terminal amine group on the Pc4 axial ligand. This 
bond is relatively weak and the production of stable Pc4-AuNP conjugates is possible 
due to the stabilisation provided by the PEG ligands.70 PEG stabilises the AuNPs by steric 
repulsion to avoid aggregation. Furthermore, PEG provides stabilisation to the Pc4 
ligand through van der Waals interactions taking place at the PEG end closest to the 
surface of the AuNPs.72 The result is a cage-type structure which can deliver the 
hydrophobic Pc4 within cells. The nanoparticles enter the tumour tissue via the EPR 
effect and then Pc4 is released into lipid membranes of the cells.70,74 Initial in vitro 
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studies using HeLa cancer cells were promising, showing a negligible dark toxicity of the 
particles but with a phototoxicity of 90 %. The biggest improvement as compared to 
the use of Pc4 alone was that the incubation time required for accumulation within the 
target tissue was only 2 h for the nanoparticles, rather than 2 days when non-
conjugated Pc4 was administered.70 This research group extended their work by 
studying the excretion pathways of the nanoparticles over a 7-day period. The 
conjugates were injected in mice, where they were shown to produce no adverse 
effects, and their pathway was followed using fluorescence. It was suggested that even 
though some of the AuNPs were retained in the spleen and liver, the most likely 
excretion route was through the renal and hepatobiliary systems.74  
Localisation of phthalocyanine-gold nanoparticle conjugates has also been studied in 
vivo by Camerin et al. over an 8-week period.75 PEGylated AuNPs functionalised with a 
self-assembled C11Pc photosensitiser (C11Pc-PEG-AuNPs) were intravenously 
administered to C57/BL6 mice bearing a subcutaneous B78H1 amelanotic melanoma. 
The C11Pc-PEG-AuNPs were initially found in the serum in high quantities, which is 
advantageous for a good cytotoxic effect. The mice were treated with light either 3 h 
or 24 h following injection of the AuNPs. The optimum results were obtained with light 
irradiation after 3 h, which induced vascular damage to the tumour leading to the mice 
staying tumour-free for 18 days. Most importantly, 40 % of the mice showed no tumour 
regrowth and complete survival, up to 45 days after the treatment.75 The fate and 
excretion of the AuNPs was also investigated. The C11Pc-PEG-AuNPs, initially located 
in the serum in high concentrations, started to move towards the liver and the spleen 
1 week after administration. At this time period, there was a maximum accumulation 
in these organs, which was later decreased by 70 % in the liver and 30 % in the spleen 
8 weeks after administration. These results suggest that AuNPs are internalised 
selectively within the melanoma and subsequently eliminated via the bile-gut 
pathway.75  
Active targeting for PDT 
Another significant advantage of using PEGylated AuNPs is that the terminal carboxylic 
acid moiety of the PEG can be functionalised with chemical and/or biological ligands 
for active targeted PDT. Stuchinskaya et al. used anti-HER2 antibodies conjugated to 
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C11Pc-PEG-AuNPs in order to target human epidermal growth factor receptor 2 (HER2) 
positive breast cancers.69 The antibody was attached to the PEG on the surface of the 
AuNPs via an amide linkage between the amine groups of the antibody and the 
terminal carboxyl group of the PEG ligand. These AuNP conjugates were used in vitro 
in HER2 positive SK-BR-3 human breast adenocarcinoma cells, HER2 negative MDA-MB-
231 human breast cancer cells and healthy mammary epithelial MCF-10A cells. Cell 
cytotoxicity was significantly higher for the HER2 positive SK-BR-3 cells (60 % cell death) 
as compared to either HER2 negative MDA-MB-231 breast cancer cells (25 % cell death) 
or the healthy MCF-10A cells (7 % cell death). Therefore, it was concluded that the 
internalisation of the AuNPs is enhanced by the selective binding of the anti-HER2 
antibodies to the HER2 receptors.69 Obaid et al. used the same C11Pc-PEG-AuNPs 
conjugates to prove the targeting ability of the lectin Jacalin towards the T antigen 
overexpressed in HT-29 human colorectal adenocarcinoma cells.33,39 Nanoparticle 
uptake by the colon cancer cells was effectively enhanced with the Jacalin targeting 
agent. Moreover, the higher selectivity to tumorigenic cells induced a significant 
increase in PDT efficacy (95-98 % cell death).39 Both the anti-HER2 antibody and the 
Jacalin conjugated C11Pc-PEG-AuNPs were found to locate in the acidic organelles, i.e., 
the lysosomes, inside the cells following receptor-mediated endocytosis.33 A 
comparative study between the two targeting agents, anti-HER2 antibody and Jacalin, 
was performed in both SK-BR-3 and HT-29 cells.33 The levels of cytotoxicity induced by 
both biomolecules were comparable. However, the main difference was seen in dark 
toxicity, since the anti-HER2 antibody AuNP conjugates were less toxic than the Jacalin 
AuNP conjugates in the absence of light.33  
The use of peptides as targeting agents has been studied particularly for brain tumours. 
Glioma cancer cells overexpress the epidermal growth factor receptor (EGFR) on their 
surface, which can be specifically targeted using EGF peptides. The Burda group 
conjugated EGF peptides to their previously developed Pc4-PEG-AuNPs via the PEG 
ligand.72,76 In vitro studies showed that the drug was taken up by the cells through 
receptor-mediated endocytosis, with the particles just acting as delivery vehicles and 
not being internalised by the cells. More importantly, in vivo experiments in mice 
showed that the conjugates successfully go through the blood-brain barrier (BBB). The 
accumulation and selectivity towards the tumour was reported to be 10 times higher 
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when the EGFR targeting agents were present. Moreover, only 4 h incubation with the 
conjugates after drug administration was required for successful PDT.72 The EGFR 
conjugated AuNPs stayed longer in circulation than the untargeted AuNPs and were 
specifically delivered into the tumour tissue as well as the liver.76 Even though the EGF 
targeted AuNPs circulated longer in the serum, the conjugates were efficiently excreted 
from the body 7 days after administration via the spleen and urinary tracts.76 Brain 
tumours were further targeted by the Broome group using transferrin as the targeting 
ligand.50 The authors used 5 nm AuNPs loaded with Pc4 and a seven amino acid 
transferrin peptide (Tfpep) to target the overexpressed transferrin receptor in glioma 
cells. The targeted AuNPs were internalised by the cells only 1 h after incubation, a 2-3 
fold improvement compared to the untargeted AuNPs. The enhanced internalisation 
correlated with an improved phototoxic effect following PDT, both in vitro and in vivo, 
with the targeted AuNPs being able to induce effective cell death at concentrations 10 
times lower than the untargeted AuNPs.50 In an attempt to increase selectivity even 
further, the Broome group attempted the use of dual targeted AuNPs. The authors 
functionalised Pc4-AuNPs with both EGF peptides and Tfpep.77 Even though the dual 
targeted AuNPs showed a considerable improvement over untargeted AuNPs in PDT 
efficacy and in vivo delivery crossing the BBB, there was only a slight enhancement over 
the single targeted AuNPs using either Tfpep or EGF peptides alone.77 The use of 
transferrin as a targeting agent was also explored by Yu et al..78 These authors 
synthesised AuNPs functionalised with a polymer layer to which the PS methylene blue 
and transferrin were attached. HeLa cells overexpressing the transferrin receptor 
effectively internalised these targeted conjugates via receptor-mediated endocytosis 
three times as much as the non-conjugated AuNPs, which in turn improved the 
photodynamic efficiency.78 
The protein nucleolin, found overexpressed in the cytoplasm and plasma membrane of 
some cancer cells, was targeted using the aptamer AS1411, a guanine-rich 
nucleotide.42,79 In order to bind to the nucleolin receptors on the cells, AS1411 adopts 
the stable G-quadruplex structure. G-quadruplex structures have been shown to bind 
intercalatively to cationic porphyrins. Ai et al. synthesised 13 nm AuNPs and 
functionalised these particles with a thiolated AS1411 aptamer conjugated to the PS N-
methylmesoporphyrin IX (NMM).42 In vitro studies with HeLa human cervical cancer 
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cells, that overexpress nucleolin, showed a high amount of the particles being taken 
up. The incubation of those same cells with non-conjugated AuNPs showed significantly 
less uptake, highlighting that the selectivity towards the tumour was increased by the 
AS1411 aptamer.42  
A special type of active targeting was reported by Li et al..80 The authors took advantage 
of the glutathione (GSH)-response within cells, which consists of the cleavage of 
disulfide bonds and it has been reported to be overexpressed in tumour cells as 
compared to healthy cells. Therefore, the activation of the GSH-response is a potential 
platform to deliver drugs more selectively to cancer cells. In this study, Li et al. 
developed a GSH-responsive nanoplatform for the selective delivery of the PS 
pheophorbide A (PheoA).80 PheoA was conjugated to a thiolated heparin (H), selected 
for its good water solubility and biocompatibility as well as its anti-inflammation, anti-
angiogenesis and anti-tumour cell proliferation properties. The PheoA-H was attached 
to the surface of 30 nm AuNPs. The conjugation of PheoA with the AuNPs inhibited the 
fluorescence and the photo-activity of the PS due to fluorescence resonance energy 
transfer (FRET) between the light-excited PheoA and the AuNPs, which act as FRET 
acceptors. In vitro studies were performed using A549 adenocarcinomic human 
alveolar basal epithelial cells, which have a higher level of GSH activity as compared to 
healthy lung cells. The in vitro studies revealed that internalisation of PheoA was 
enhanced by the conjugation to the AuNPs. Following internalisation, GSH induces the 
release of H-PheoA by breaking the thiol bond between the PheoA-H and the AuNPs. 
Consequently, PheoA regains its photoactivity and, upon irradiation with light, can 
induce phototoxic effects to the cells. These results were further confirmed in vivo in 
A549 tumour-bearing SKH1 mice.80  
Other gold nanostructures 
Other gold nanostructures, including gold nanorods, gold nanoclusters and gold 
nanostars have also been considered as drug carriers for PDT. Huang et al. have used 
silica coated fluorescent gold nanoclusters (SiO2-AuNCs) functionalised with the 
photosensitiser chlorin e6 (Ce6).81 The silica coating was used to enhance the 
photostability and chemical stability of the fluorescent AuNCs. In vivo experiments in 
mice showed that the PDT efficacy and thus the tumour regression was improved using 
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the Ce6-SiO2-AuNC conjugates as compared to Ce6 alone. Furthermore, the use of NIR 
fluorescence enabled the location of the AuNCs to be monitored during PDT.81 Li et al.82 
functionalised gold nanorods (AuNRs) with a sulfonated aluminium phthalocyanine 
(AlPcS) via electrostatic interactions. The conjugation of AlPcS to the AuNRs resulted in 
a 5-fold increase of its fluorescence due to metal-enhanced fluorescence. The AlPcS-
AuNRs were effectively taken up by QGY liver cancer cells and were shown to provide 
improved PDT efficiency as compared to the free AlPcS.82 An aluminium phthalocyanine 
was also used by Hu et al. and attached to gold nanorings in a layer-by-layer approach 
for effective PDT.83 The use of endoperoxides as a chemical source of 1O2 for PDT was 
explored in combination with AuNRs.84 Chemical generation of 1O2 by these 
endoperoxides has the potential to avoid the problems related to the tumour inherent 
hypoxia and tissue penetration in order to enhance the effects of PDT.84  
The use of targeted PDT with gold nanostructures other than spheres has also been 
reported. The use of folic acid in combination with either PpIX-AuNRs85 or Chlorin e6-
gold nanoclusters86 has led to an enhanced and selective internalisation by cancer cells 
and thus improved PDT efficiency. Additionally, Kuo et al. used AuNRs to target A549 
human lung carcinoma malignant cells, which overexpress the epidermal growth factor 
receptor (EGFR) on their surface.87 The AuNRs were functionalised with the PS 
indocyanine green and anti-EGFR antibodies. These conjugates were shown to be 
efficient PDT agents as well as probes for bioimaging in the NIR region.87  
Combination therapies 
The combination of PDT with other therapies for the treatment of cancer is gaining 
particular interest. The combination of PDT with immune system activation has been 
described as promising for the treatment of metastatic breast cancer. Marrache et al. 
synthesised a hybrid nanoparticle platform composed of polymeric nanoparticles 
conjugated to a ZnPc photosensitiser, which were then coated with AuNPs.88 The 
AuNPs were functionalised with 5’-purine-purine/T-CpG-pyrimidine-pyrimidine-3’-
oligodeoxynucleotides (CpG-ODN). The CpG-ODN is a single-stranded DNA 
immunostimulant capable of activating dendritic cells and thus initiating an immune 
response. In vitro studies using 4T1 metastatic mouse breast carcinoma cells showed 
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not only a high photodynamic effect following PDT (IC50=2.8 nM), but also substantial 
immune activation.88  
The combination of AuNPs-PDT with chemotherapy is also being increasingly studied. 
Li et al. loaded the PS chlorin e6 and the chemotherapeutic agent doxorubicin (DOX) in 
mesoporous silica coated AuNPs.89 HeLa cells effectively internalised the conjugates 
into the cytoplasm, allowing for the delivery of DOX into the nucleus for effective 
chemotherapy. Following laser irradiation at 660 nm, the combination of 
chemotherapy and PDT induced an IC50 of 1.152 μg/mL, a considerable improvement 
from either chemotherapy (IC50=3.215 μg/mL) or PDT (IC50=7.232 μg/mL) performed 
individually.89 
The largest interest in combination therapies in conjunction with AuNPs lies with the 
simultaneous use of photothermal therapy (PTT) and PDT. PTT involves the use of light-
absorbing molecules or nanoparticles, the photothermal agents, that lead to the 
heating of the local tumour environment.90,91 Following light absorption, the excited 
photothermal agent releases energy non-radiatively through vibrational modes, which 
induces an increase in the kinetic energy of the matrix species around the 
photothermal agent and thus an increase in temperature.90 The combination of 
PDT/PTT with AuNPs has been investigated in a variety of studies.92-94 Kang et al. 
synthesised a hybrid nanomaterial composed of 5-7 nm AuNPs encapsulated with the 
PS PheoA, which was conjugated to hyaluronic acid.92 The AuNPs act as the PTT agent, 
the PheoA is responsible for the generation of ROS for PDT, and hyaluronic acid is the 
targeting agent towards the overexpressed CD44 receptor on lung cancer cells. The 
hybrid nanomaterial was selectively internalised by the tumour via receptor-mediated 
endocytosis only 3 h after administration and it induced cell death levels of 78.6 % 
following combined PDT/PTT in vitro.92 Hari et al.93 used the PS acridine orange (AO), 
which mainly accumulates in lysosomes. In vitro studies with MCF-7 breast cancer cells 
showed that AO-AuNPs were internalised twice as much as free AO. As a result, the 
efficacy of the PDT/PTT cancer therapy was improved, inducing 78.6 % of cell death.93 
Chen et al. created core-shell micelles formed by the combination of polymers with the 
dye 5,10,15,20-tetrakis(pentafluorophenyl)-21H,23H-porphine (PF6), which acts as the 
PS.94 Furthermore, the micelles were decorated with AuNPs as effective PTT agents. 
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The cells were readily internalised by A549 lung cancer cells and induced 80 % cell 
death following combined PDT/PTT.94 
The combination of PTT/PDT with other gold nanostructures has also been extensively 
studied.95-104 Kuo et al. used indocyanine green functionalised AuNRs for combined 
PTT/PDT. The integration of the two therapies was found to effectively enhance the 
cell killing as compared to the use of PDT on its own.104 Jang et al.95 effectively 
combined near infrared (NIR) fluorescence imaging with PTT/PDT of cancer. The 
authors used AuNRs with PEG conjugated to the PS aluminium (III) phthalocyanine 
tetrasulfonate (AlPcS4). In vitro studies in squamous cell carcinoma (SCC7) cells showed 
that the use of AuNRs improves by 4-fold the internalisation as well as the selectivity 
towards cancerous cells as compared to free AlPcS4, which results in an improved 
photodynamic activity. These in vitro results were further confirmed in vivo through 
the treatment of female athymic nude mice with implanted SCC7 squamous cell 
carcinoma cells. Acute apoptosis and tissue loss was observed for mice treated with 
the AlPcS4-AuNR followed by PDT, reducing tumour growth by 79 %. The effect was 
intensified with dual PTT/PDT therapies, reducing tumour growth by up to 95 %.95 The 
main drawback in this study was the need of two different laser sources for PDT 
(670 nm) and PTT (810 nm).95 NIR combined PTT/PDT was also demonstrated for 
AuNRs conjugated to a silicon naphthalocyanine with similar positive results.96 
Additionally, Tham et al. further improved the effective use of AuNRs for PTT/PDT by 
using an external targeting agent, hyaluronic acid, which targets the CD44 receptors 
overexpressed on cancer cells.97 Other studies with gold nanoshells98, gold nanorings99, 
gold nanostars100 and gold nanocages101 have also shown the improved destruction of 
cancer cells when PDT and PTT are used in combination. Within these studies, it is 
important to note the advantage of the gold nanocages functionalised with the natural 
PS hypocrellin.101 In this study, the authors were able to perform PDT and PTT 
simultaneously using a single laser source at 790 nm, which could induce the 
generation of 1O2 and the production of heat at the same time.101 More importantly, 
the ability to magnetically guide the drugs to the tumour cells is an additional 
improvement for combined PTT/PDT. Bhana et al. developed gold nanopopcorns with 
an iron oxide core, which were functionalised with a silicon naphthalocyanine.102 The 
iron oxide core provides the paramagnetism that allows the nanopopcorns to be 
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selectively guided towards the tumours via an external magnet for effective PTT/PDT. 
Indeed, the use of the external magnet induced a 92.9 % cell death compared to only 
73.7 % when PTT/PDT were performed without the external guiding.102 The 
combination of PDT with other techniques such as surface-enhanced Raman scattering 
(SERS) imaging103,105-107 for theranostics, or gene delivery108 is also being studied. 
Use of AuNPs as photosensitisers 
A particularly exciting development is the possibility of AuNPs and other gold 
nanostructures to act as 1O2 generators by themselves without the presence of any PS 
when exposed to light irradiation. The first observation of this effect was reported by 
Vankayala et al. in 2011.109 These authors reported that the irradiation of metallic 
nanoparticles, including AuNPs, at their surface plasmon absorption band induced the 
generation of 1O2.109 Since then, other groups have reported similar observations. 
Misawa et al. showed how AuNPs contribute to the production of ROS, including 1O2, 
following UV and X-ray irradiation.110 The authors highlighted the possibility of using 
AuNPs in combination with X-ray radiological and PDT destruction of tumours.110 Jiang 
et al. showed how AuNPs (40 nm) and AuNRs could act as PS and induce the production 
of 1O2 when exposed to one- and two-photon excitation.111 El-Hussein et al. compared 
the ability to produce 1O2 by AuNPs and silver nanoparticles (AgNPs).112 Even though 
both AuNPs and AgNPs were able to induce the generation of 1O2, AgNPs were found 
to have a more powerful effect. The better action of AgNPs was thought to be due to 
the higher absorption efficiency of AgNPs in the therapeutic window as compared to 
AuNPs.112 Recently, Chadwick et al. investigated the reasons why metallic nanoparticles 
are able to act as PS.113 These authors found that the behaviour of metallic 
nanoparticles as PS was due to the presence of ‘hot electrons’. The term ‘hot electrons’ 
refers to the electrons found in the conduction band, which can reach very high 
temperatures when they absorb light from a short laser pulse.113 The use of AuNPs as 
PS has several potential advantages over conventionally used PS. The most important 
one is the high extinction coefficients of AuNPs, between 3-5 times higher than that of 
conventional PS, which could lead to an increased production of 1O2.109 
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1.2.3.  Upconverting nanoparticles  
Upconverting nanoparticles (UCNPs) have been classified as active nanoparticles for 
PDT because they actively participate in the generation of 1O2.32 Even though the 
UCNPs are unable to produce 1O2 by themselves, UCNPs are active in the energy 
transfer to the PS, which then allows the production of 1O2 and other ROS.23 UCNPs are 
excited with near-infrared (NIR) light, which is followed by their emission of higher 
energy visible light.30,31 This property is achieved by the use of rare-earth metals, mainly 
lanthanides, doped into a solid state host lattice.23,31 A description on the synthesis of 
UCNPs, the choice of host lattice and dopants, as well as the mechanisms of 
upconversion will be discussed in Chapter 5. 
The visible light emission of UCNPs following excitation with NIR radiation can be used 
to excite a PS located near the surface of the UCNPs, which thus leads to the generation 
of 1O2 (Figure 1.8).30-32 As a result, the use of NIR light for the excitation of the UCNPs 
allows for a deeper penetration into the tissue, reaching tumours that are situated 
further from the skin surface.27,30,31 The functionalisation of UCNPs with a PS can be 
achieved by different techniques, including the encapsulation of the PS in a silica layer 
that surrounds the core of the UCNPs, the covalent linkage of the PS to the UCNPs, the 
physical adsorption of the PS to the surface of the UCNPs via hydrophobic interactions, 
the direct coating of the UCNPs with a layer of PS, and the use of electrostatic 
interactions,30,32 as shown in Figure 1.8. The use of UCNPs for PDT requires that these 
nanoparticles are biocompatible and selective towards the cancer tissue.30 The 
biocompatibility and water dispersibility of the UCNPs can be achieved via several 
methods of surface modification, including the use of a silica layer and the 
functionalisation of the UCNPs with water-soluble polymers such as PEG. Additionally, 
the energy transfer between the UCNPs and the PS should be high enough to allow for 
an efficient photosensitisation and the PS itself should not leak from the nanoparticle.30 
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The use of UCNPs for PDT with or without active targeting 
A. Silica layer 
In 2007, Zhang and co-workers reported the use of silica-coated UCNPs for PDT for the 
first time.114 These authors synthesised sodium yttrium fluoride (NaYF4) UCNPs 
codoped with ytterbium (Yb3+) and erbium (Er3+) with a size ranging between 60-
120 nm due to batch-to-batch variations. The UCNPs were coated with a silica layer, in 
which the photosensitiser merocyanine 540 (M-540) was embedded. Additionally, the 
UCNPs were conjugated with anti-MUC1/episialin antibody, selective towards the 
MUC1/episialin receptor overexpressed on the surface of MCF-7/AZ breast cancer cells. 
Irradiation of these UCNPs with a 974 nm laser induced the emission of light at ca. 
537 nm and ca. 635 nm, which was used to excite M-540 to stimulate the production 
of 1O2. In vitro studies in MCF-7/AZ cells showed the selective targeting of the UCNPs 
followed by effective PDT after 36 min NIR irradiation, which induced cell death for the 
samples treated with the functionalised UCNPs.114 This group also explored the use of 
other photosensitisers embedded in the silica layer for efficient 1O2 production. The 
use of tris(bipyridine)ruthenium(II) (Ru(bpy)32+) was found to be efficient for the 
generation of 1O2 and thus a potential candidate for use in PDT.115 
Figure 1.8. (A) Schematic representation of the production of 1O2 due to the energy 
transfer taking place between the UCNPs and the PS. Following irradiation with NIR light, 
the UCNPs emit visible light, which can be used for both excitation of the PS that leads to 
the generation of 1O2 and for bioimaging. (B) Schematic representation of the different PS 
loading mechanisms on the surface of the UCNPs. (A-B) The photosensitiser is shown in 
red. Figure adapted from Refs. 30-32.  
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Even though the use of a silica layer for the encapsulation of the PS in the UCNPs has 
shown great potential in PDT, it is limited by a series of problems.32,116,117 The 
incorporation of PS within the silica shell is variable and difficult to control because of 
the weak interaction between the PS and silica, mainly consisting of hydrogen bonds 
and van der Waals forces.32,116,117 The site of action of 1O2 is also limited since the silica 
layer blocks the exit of the 1O2 from the cells.117 Additionally, the possibility of UCNPs 
aggregation is high due to the low stability of amorphous silica in physiological 
conditions.32 As a result, the PDT efficiency for silica-coated UCNPs is low.116,117 A 
possibility to enhance the PDT efficacy of silica-coated UCNPs is to modify the 
interaction between the PS and the silica layer to lead to stronger covalent bonds, so 
the incorporation of the PS on the silica layer will be improved and more easily 
controlled.116 Yang et al. combined a naturally occurring PS, hypericin, to ca. 20 nm 
silica-coated NaYF4 (Yb3+, Er3+) UCNPs via a strong covalent interaction.116 The covalent 
interaction was possible due to the conjugation of hypericin with (3-
isocyanatopropyl)triethoxysilane (TESPIC). Hypericin-TESPIC was then co-hydrolised 
and co-condensed with tetraethoxysilane (TEOS) and (3-aminopropyl)triethoxysilane 
(APTES) to allow the covalent conjugation between hypericin and the silica layer on the 
surface of the UCNPs. The authors found that the 1O2 production for this system was 
significantly higher than for the UCNPs where hypericin was directly encapsulated 
within the silica layer, primarily due to the higher loading ability of hypericin via 
covalent conjugation. For selective tumour uptake, the UCNPs were further 
functionalised with folic acid to selectively target the overexpressed folate receptors 
on cancer cells. Indeed, in vitro studies showed a higher uptake in HeLa cervical cancer 
cells as compared to healthy human embryonic kidney 293T cells. Furthermore, 
following NIR irradiation (980 nm) for 10 min, the folic acid-hypericin functionalised 
UCNPs were effective at inducing cell death via apoptosis for the HeLa cell line.116 
Another method to enhance the PDT efficacy of silica-coated UCNPs is the use of 
mesoporous silica materials.32,117 Mesoporous silica (mSiO2) provides improved water 
solubility than amorphous silica since it allows for a greater efficiency of energy transfer 
and it has a large surface area and porous structure.32,117,118 Guo et al. developed 90 nm 
NaYF4 (Yb3+, Er3+) UCNPs coated with a mesoporous silica shell and attached a ZnPc into 
the pores of the mSiO2.117 In vitro studies in MB49-PSA bladder cancer cells showed 
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efficient intracellular 1O2 production, which led to 1O2-induced apoptosis following 
irradiation at 980 nm, as confirmed by changes in the morphology of the cell nucleus, 
DNA fragmentation, and cytochrome c release from the mitochondria. The main 
drawback with this system was the increase in dark toxicity concomitant with an 
increase in the concentration of UCNPs.117 In another study, Xu et al. used vitamin B12 
(VB12) as a PS, given its porphyrin-like structure.119 VB12 was conjugated to the 20 nm 
thick mSiO2 shell on ca. 20 nm NaYF4 (Yb3+, Er3+) UCNPs. The PDT effect was evaluated 
in MDA-MB-231 human breast adenocarcinoma cells. The authors reported that the 
980 nm PDT-induced cell death was dependent on the concentration of VB12 within the 
UCNPs, as well as the irradiation time to which the cells were exposed.119  
A problem associated with the use of a mSiO2 layer to load the PS is the high chance of 
PS release when the surface of the mesoporous silica layer is unmodified.118 In order to 
avoid the leaking of the PS from the UCNPs, Hou et al. added a cross-linked lipid as the 
outer layer in the mSiO2-coated UCNPs.118 The lipid layer was made of an amphiphilic 
polymer, PEG linked to octadecyl-quaternised polyglutamic acid (OQPGA), to which the 
peptide arginine-glycine-aspartic acid (RGD) was attached (RGD-PEG-OQPGA). The use 
of RGD-PEG-OQPGA not only avoided the release of the PS from the UCNPs thanks to 
the presence of OQPGA, it also increased the circulation time of the UCNPs within the 
serum with the presence of PEG. Additionally, the RGD-PEG-OQPGA also enhanced the 
selective uptake of the UCNPs by cancer cells due to the presence of the targeting 
ligand RGD. The RGD peptide is selective towards the αvβ integrin, overexpressed in 
HeLa cervical cancer cells.118 The result was a triple-layered system made of a 25 nm 
NaYF4 (Yb3+, Er3+) core, a 25 nm mSiO2 shell in which the PS ZnPc was encapsulated, and 
a cross-linked lipid outer layer with great potential for PDT treatment.118 
One of the first investigations of in vivo PDT with UCNPs was performed with mSiO2-
coated UCNPs, as reported by Idris et al..120 The authors synthesised NaYF4 (Yb3+, Er3+) 
UCNPs covered by a mSiO2 shell, in which two PS, M-540 and ZnPc, were embedded for 
a dual-PS approach. The combination of two PS within the same nanoparticle system 
enhanced the production of 1O2, which was higher than for UCNPs functionalised only 
with either M-540 or ZnPc alone. The higher production of 1O2 correlated in vitro with 
a higher PDT efficacy in B16-F0 melanoma cells. Additionally, the authors injected 
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C57BL/6 mice bearing melanoma tumours with the dual-functionalised UCNPs for in 
vivo therapy. Following NIR-PDT at 980 nm, the tumour growth rate was shown to be 
slower than for the control groups not treated with the UCNPs. In order to improve the 
in vivo efficacy, the UCNPs were further functionalised with PEG and folic acid. The 
addition of PEG increases the circulation in the blood, as previously mentioned, while 
the presence of folic acid selectively targets the overexpressed folate receptors on the 
surface of melanoma cells. The authors found that the active targeting was important 
to strengthen the therapeutic efficacy and significantly reduce tumour growth in the 
treated mice. Unfortunately, complete tumour regression was not possible under these 
conditions.120 
B. Polyethylene glycol 
The use of PEG for the water-solubility of UCNPs has also been reported.121-125  PEG 
does not only provide aqueous solubility, it also induces biocompatibility and increases 
the circulation time of the UCNPs in the serum, as previously mentioned. The first 
report on the use of PEG for UCNPs was published in 2009 by Ungun et al..121 These 
authors synthesised 160 nm NaYF4 (Er) UCNPs loaded with tetraphenylporphyrin (TPP) 
and an outer layer of PEG-block-poly(caprolactone) (PEG-b-PCL), as potential 
candidates for NIR-PDT.121 In vitro studies were first performed by Shan et al..122 Their 
UCNPs were similar to those reported by Ungun et al. but using a slightly different PEG 
copolymer. PEG-b-PCL was substituted by PEG-block-poly(DL)lactic acid (PEG-b-PLA) 
due to its higher stability in physiological conditions.122 The 100 nm NaYF4 (Yb3+, Er3+) 
UCNPs loaded with TPP and PEG-b-PLA were tested in HeLa cervical cancer cells. The 
UCNPs were shown to induce no dark toxicity. However, following 978 nm NIR-PDT 
(45 min irradiation at 134 W/cm2) those cells treated with the functionalised UCNPs 
presented 75 % cell death.122 The use of PEG without conjugation to other copolymers 
was reported by González-Béjar et al..123 These authors described the synthesis of ca. 
30 nm oleate-capped NaYF4 (Yb3+, Er3+), which they coated with PEG for water-
solubility. Additionally, a diiodo substituted BODIPY PS was embedded in the PEG coat. 
These BODIPY-PEG functionalised UCNPs were shown to generate 1O2 following 
irradiation at 975 nm. In vitro studies in human neuroblastoma SH-SY5Y cells confirmed 
ca. 50 % of the treated cells died following PDT (45 min irradiation at 239 mW) via 
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apoptosis. Furthermore, the BODIPY-PEG functionalised UCNPs showed only limited 
dark toxicity with 10 % death in the absence of NIR irradiation.123 
The investigation on the use of PEGylated UCNPs for in vivo PDT was first reported by 
Wang et al..124 Oleate-capped NaYF4 (Y3+, Yb3+, Er3+) UCNPs of 30 nm in diameter were 
functionalised with the amphiphilic polymer PEG-grafted poly (maleic anhydride-alt-1-
octadecene), to which the PS chlorin e6 was attached via hydrophobic interactions. The 
synthesised UCNPs were shown to induce good phototoxicity in vitro following 980 nm 
NIR-PDT (10 min irradiation at 0.5 W/cm2). The promising results in vitro were further 
tested in vivo using Balc/c mice bearing 4T1 murine breast tumour. Intratumoural 
injection of the functionalised UCNPs was followed by 980 nm NIR-PDT (30 min 
irradiation at 0.5 W/cm2). Out of the 10 treated mice, the tumours of 7 were completely 
eliminated over a 2-week period, reaching survival periods of more than 60 days. The 
fate of the functionalised UCNPs was also studied, reaching the conclusion that the 
UCNPs are initially located around the injection site but move towards the liver and 
spleen two weeks later due to opsonisation by the RES system. Complete clearance 
from these organs was seen 60 days after injection. The advantages of using NIR-PDT 
was further investigated by blocking the tumours on the mice using 8 mm thick pork 
tissue. While PDT using a 660 nm laser induced no reduction in tumour growth, 
980 nm-PDT led to a slower tumour progression.124 
The use of an inorganic photosensitiser, titanium dioxide (TiO2), was reported by Zhang 
and co-workers.125,126 Core-shell 25 nm NaYF4 (Yb3+, thulium (Tm3+)) UCNPs were 
synthesised and functionalised with a thin layer of TiO2. Excitation at 980 nm confirmed 
the production of hydroxyl radicals, superoxide anions and hydrogen peroxide, but not 
1O2, showing that TiO2 follows Type I photosensitisation.126 However, in vitro studies of 
this nanosystem only induced 53-58 % cell death. As a result, the authors conjugated 
the UCNPs with maleimide-PEG-silane for further stability and PDT efficacy.125 In vitro 
studies with oral squamous carcinoma cells showed significantly enhanced cell death 
when the PEG was present, reaching values of up to 78 % cell death. Additionally, the 
authors performed in vivo studies by intratumourally injecting female balb/c mice with 
the UCNPs. There was significant decrease in tumour growth following PDT, especially 
with the PEG-UCNPs.125 
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C. Other functionalisation methods 
The Gu group investigated the use of the polysaccharide chitosan as a potential ligand 
to induce hydrophilicity to UCNPs, due to its low toxicity and high 
biocompatibility.127,128 The authors synthesised oleate-capped NaYF4 (Yb3+, Er3+) UCNPs 
and functionalised them with amphiphilic N-succinyl-N’-octyl chitosan (SOC) and ZnPc 
via hydrophobic interactions.127 Following excitation at 980 nm, efficient production of 
1O2 by energy transfer from the UCNPs to the ZnPc correlated with a good phototoxic 
effect in vitro in MCF-7 human breast adenocarcinoma cells with no dark toxicity. In 
vivo studies were performed on female Kunming mice bearing a S180 tumour model. 
PDT treatment at 980 nm for 15 min (0.4 W/cm2) in mice treated with the UCNPs 
reduced the tumour progression rate by 76 % as compared to the saline-treated mice. 
During the 14-day period, over which the mice were monitored, there was not one 
death for the ZnPc-SOC-UCNPs treated mice, whereas the control groups showed 14-
day survival rates of 50-67 %.127 To further enhance the selectivity towards tumour 
tissue, the Gu group conjugated their ZnPc-SOC-UCNPs with folic acid.128 The presence 
of folic acid was proven to be essential for an enhanced internalisation via receptor-
mediated endocytosis, both in vitro and in vivo.128 In another study, Zhou et al. used O-
carboxymethylated chitosan (OCMC) to coat NaYF4 (Yb3+, Er3+) UCNPs.129 The PS 
pyropheophorbide a (Ppa) was then loaded with the targeting peptide cyclic RGD. Two 
cell lines with either high expression of αvβ integrin, U87-MG human glioblastoma 
cancer cells, or low expression of αvβ integrin, MCF-7 human breast cancer cells, were 
tested for in vitro PDT efficacy. The presence of cyclic RGD on the UCNPs, which 
selectively targets the αvβ integrin on the surface of the cells, led to the Ppa-OCMC 
UCNPs being internalised by the U87-MG cells much better than MCF-7 cells. This 
translated into an improved PDT efficacy for the U87-MG cells, reaching cell death 
values of up to 50 % following 980 nm NIR-PDT (5 min irradiation at 0.5 W/cm2).129 
The use of the prodrug 5-ALA conjugated to UCNPs for PDT was evaluated by Punjabi 
et al..130 The authors used a shell of calcium fluoride (CaF2) to coat cubic NaYF4 (Yb3+, 
Er3+) UCNPs (ca. 26 nm), to which 5-ALA was attached using a covalent hydrazone 
linkage. The use of CaF2 increases the stability and biocompatibility of the system and 
prevents the leakage of the PS. The hydrazone linkage between 5-ALA and the UCNPs 
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is pH sensitive, which allows for the release of 5-ALA inside the cells due to the low pH 
in cancer. In this study, the red emission of the UCNPs was maximised by modulating 
the amount of Yb3+ in the system, finding that 80 % is the ideal concentration. The 
optimal functionalised UCNPs were studied in vitro and in vivo. In both cases, the 
functionalised UCNPs following 980 nm NIR-PDT (0.5 W/cm2) were found to induce 
good phototoxicity. Additionally, the use of NIR-PDT was advantageous over direct 
excitation of 5-ALA given that NIR light can penetrate pork tissue placed between the 
laser and the tumour up to 1.2 cm thick.130 
Other studies on UCNPs for PDT have explored the use of nucleotides as templates for 
their synthesis131 and the use of electrospun fibres to encapsulate UCNPs,132 which 
would stabilise the emission of the UCNPs. Even though the most common types of 
UCNPs synthesised and reported for PDT involve the host lattice NaYF4, investigations 
on other structures such as LiFY4 have also been reported.133,134  
The use of UCNPs for PDT and bioimaging 
As it can be seen in Figure 1.8, the visible light emitted from the UCNPs can not only be 
used to excite a PS for PDT, but also for tumour imaging. Therefore, numerous studies 
have become interested in the investigation of the simultaneous use of imaging and 
PDT.135-147 Silica-coated UCNPs have been reported to be potential candidates for 
multimodal imaging and PDT.135-137 However, as specified earlier, the use of silica 
results in a low loading of the PS within the system and thus low PDT efficacy. As a 
result, the use of other water-solubility methods, such as PEG, are encouraged. 
The Zhang group developed 20 nm NaYF4 (Yb3+, Er3+) UCNPs, made hydrophilic by 
addition of 2-aminoethyl dihydrogen phosphate (AEP), and covalently conjugated to 
the PS Rose Bengal.138 Additionally, a PEG ligand was attached in order to include the 
targeting molecule folic acid for the selective detection of cancer cells. This nanosystem 
was found to be internalised by JAR choriocarcinoma cells, which overexpress the 
folate receptor, and cell viability was decreased only after 980 nm NIR-PDT 
(1.5 W/cm2). As a result, the synthesised UCNPs hold great potential for theranostics 
acting as dual agents for cancer cell imaging and therapy.138 In a similar study, the Zhang 
group used NaYF4 (Yb3+, Er3+) UCNPs functionalised with poly(allylamine) (PAAm) for 
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water-solubility and covalently conjugated to a monomalonic fullerene acting as PS.139 
A PEG ligand and folic acid targeting ligand were also included in the system. Similar 
results were obtained as the functionalised UCNPs were only internalised by folate 
receptor overexpressing HeLa cells, leading to efficient cell death following 980 nm 
NIR-PDT (1.37 W/cm2).139 The use of ca. 31 nm PEGylated core-shell NaYF4 (Yb3+, 
Er3+)@NaYF4 (Yb3+, Er3+) UCNPs conjugated with chlorin e6 by physical adsorption was 
reported by Chen et al..140 These UCNPS were easily internalised and effective at 
inducing cell death following 980 nm NIR-PDT (1.5 W/cm2) in vitro without the need of 
a targeting agent.141 The main problem with these studies was the high radiation doses 
needed for effective PDT, much higher than the 980 nm continuous-wave laser 
maximum permissible skin exposure of 0.73 W/cm2 permitted by the American 
National Standard for Safe Use of Lasers.30,130  In order to reduce the high radiation 
doses needed, the Zhang group synthesised a similar system to those previously 
reported; ca. 30 nm NaYF4 (Yb3+, Er3+) UCNPs made hydrophilic by addition of PAAm 
and covalently conjugated to the PS ZnPc.141 As previously, PEG was attached in order 
to include folic acid for targeted PDT. This system could be simultaneously used for cell 
imaging, due to their emission at 540 nm, and PDT, due to their emission at 660 nm, 
used to excite ZnPc. Promising results both in vitro and in vivo were obtained via folate 
targeting by using a much lower laser dose of 0.39 W/cm2. The ability to kill cells at 
such low doses was possible due to the addition of the doping ion Yb3+ at high 
concentrations (25 %), which led to enhanced red luminescence emission.141  
Other groups have also reported the use of polymer-coated UCNPs for in vitro 
theranostics.142-147 Dou et al. developed NaYF4 (Yb3+, Tm3+) UCNPs made hydrophilic by 
the addition of (3-aminopropyl) triethoxysilane (APTES) and covalently conjugated to 
chlorin e6.142 Even though the UCNPs were efficiently internalised by MCF-7 human 
breast cancer cells, good PDT efficacy (ca. 50 % cell death) was only achieved with 
higher radiation doses of 2.43 W/cm2.142 Improved results were obtained by Yuan et al. 
using a G4-aptamer for targeted imaging and PDT.143 The G4-aptamer was created by 
linking a guanine-rich DNA fraction with the sgc8 aptamer that selectively binds the 
protein tyrosine kinase 7 (PTK7) overexpressed on the surface of CCRF-CEM 
lymphoblastic leukaemia cells. The conjugation of the G4-aptamer to 15 nm sodium 
lutetium fluoride (NaLuF4) (Gd3+, Yb3+, Er3+) UCNPs allowed for the attachment of the 
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PS TMPyP4, a porphyrin derivative. The G4-aptamer has a high affinity for PTK7, 
(kd=0.8 nM), which induced effective targeted bioimaging as well as effective targeted 
PDT. Indeed, CEM cells reached up to 89.6 % cell death following 980 nm NIR-PDT 
(0.5 W/cm2). The use of the targeting G4-aptamer was proven to be essential since cells 
without PTK7 overexpression only reached 15 % cell death at the same 
concentration.143 Dual-targeting bioimaging and PDT was reported by Wang et al. with 
the use of 3-aminophenylboronic acid (APBA), specific towards polysialic acid, and 
hyaluronic acid, specific towards CD44 receptors.144 These authors synthesised NaYF4 
(Yb3+, Gd3+, Tm3+) functionalised with APBA and a hyaluronated fullerene, where 
fullerene acts as the PS. The authors concluded that the use of a dual-targeting 
nanosystem was beneficial for the increased selectivity towards cancer cells over 
single-targeting nanosystems.144 The use of amphiphilic polymers for the stabilisation 
of UCNPs, with or without targeting ligands, have also been shown to be good 
candidates for combined bioimaging and PDT.145-147 
The use of multi-imaging modalities has become an important area of research. In 
particular, the combination of imaging from the emitted luminescence of UCNPs (UCL) 
with magnetic resonance imaging (MRI) has been explored. Imaging via the non-
invasive MRI requires the presence of contrast agents.148 The lanthanide gadolinium 
(Gd) has magnetic properties due to the seven inner 4f unpaired electrons shielded by 
outer electrons, which enhances the electronic relaxation time and magnetic moment 
of Gd.148 Therefore, the use of UCNPs doped with Gd3+ opens the possibility for 
multimodal imaging including MRI.148-152 Qiao et al. developed NaGdF4 (Yb3+, Er3+) 
UCNPs coated with CaF2 and a shell of mSiO2.148 The PS, either haematoporphyrin or 
silicon phthalocyanine dihydroxide (SPCD), was covalently attached to the pores of the 
mSiO2 shell. The PDT treatment and UCL imaging were both found to be efficient in 
HeLa cells. Additionally, the magnetic relaxivity (r1) and relaxation time (t1) were 
comparable to those of commercially available contrast agents based on Gd. The T1-
weighted MR images were of good quality and slightly better for the UCNPs 
functionalised with SPCD.148 In another study, the Gd was present in the shell rather 
than the core of the UCNPs.149 Park et al. synthesised rod-shaped NaYF4 (Yb3+, 
Er3+)@NaGdF4 UCNPs conjugated to PEG for water-solubility and the PS chlorin e6 via 
physical adsorption. This nanosystem was tested in vivo in balb/c mice injected with a 
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U87-MG glioblastoma tumour and was proven to be efficient for PDT, T1-weighted MRI 
and UCL.149 The combination of active targeting with PDT/MRI/UCL was reported by 
Zhang et al..150 The authors prepared NaGdF4 (Yb3+, Tm3+) UCNPS covered with a silica 
shell and a shell of the PS TiO2. Furthermore, the UCNPs were modified with APTES, to 
which the targeting ligand folic acid was conjugated. This nanosystem was 
biocompatible and efficient for the treatment of MCF-7 tumours via 980 nm NIR-PDT 
(0.6 W/cm2 during 20 min), reaching cell death values of up to 69 % in vitro and 88.6 % 
tumour reduction in vivo as compared to control samples. Additionally, Gd efficiently 
acted as a good T1-weighted MRI agent.150 
The use of Gd as a MRI contrast agent in combination with UCNPs has been reported 
in different structural systems.151,152 Wei et al. used UCNPs based on a ZnO host lattice 
doped with Gd3+, Er3+ and Yb3+.151 The r1 of this nanosystem was found to be larger than 
that of commercially available Gd-based contrast agents. As a result, the ZnO-UCNPs 
(Gd3+, Er3+, Yb3+) have been shown to have great potential for T1-weighted MRI. 
Additionally, in combination with methylene blue, the nanosystem can also be used for 
PDT due to its low cytotoxicity in the absence of 980 nm light.151 In another study by Li 
et al., the UCNPs were based on a Gd2O3 host lattice doped with Yb3+ and Er3+.152 
Similarly, in combination with either methylene blue or 5-ALA, the nanosystem was 
found to be a useful agent for combined PDT/MRI.152 
Other possibilities for the synthesis of MRI-active UCNPs include the use of an iron 
oxide (Fe3O4) core.153 Zeng et al. synthesised NaYF4 (Yb3+, Er3+) UCNPs containing a 
Fe3O4 core to which the PS AlPcS4 was electrostatically attached. The functionalised 
UCNPs were effective for T2-weighted MRI, due to the presence of Fe3O4, UCL imaging 
and PDT, reaching values of up to 70 % cell death in vitro following 980 nm NIR-PDT 
(20 mW/cm2 for 3 min).153 Huang et al. studied the use of NaxYbF3+x UCNPs loaded with 
a shell of strontium fluoride (SrF2) for combined MRI and computed tomography (CT) 
due to the high transverse relaxivity of the Yb3+ ions.154 In combination with ZnPc, the 
nanosystem could also be used for 915 nm NIR-PDT.154 Finally, the use of UCNPs doped 
with manganese (Mn2+) has also been studied as a potential contrast agent for MRI.155 
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The use of combination therapies with UCNPs 
The synthesis and application of multifunctional UCNPs to perform various cancer 
therapies simultaneously is an important advance. PDT has been combined with gene 
therapy by Wang et al..156 These authors synthesised ca. 30 nm oleate-capped NaGdF4 
(Gd3+, Yb3+, Er3+) UCNPs functionalised with a multilayer of various polymers. For PDT, 
the PS chlorin e6 was attached via hydrophobic interactions. For the gene therapy, a 
small interfering RNA (siRNA) was bound to the functionalised UCNPs. The siRNA is 
selective towards the oncogene polo-like kinase 1 (Plk1), overexpressed in numerous 
types of cancer. The downregulation of Plk1 with siRNA leads to the activation of cell 
apoptosis. In vitro studies in HeLa cancer cells showed that the combination of 980 nm 
NIR-PDT (0.8 W/cm2 for 20 min) with gene therapy induced higher levels of cell death 
than either of the therapies on their own.156 
As discussed with the AuNPs explained in section 1.2.2, the combination of PDT with 
PTT has received increasing interest for UCNPs.157-159 Chen et al. synthesised NaGdF4 
(Yb3+, Er3+) UCNPs modified with bovine serum albumin for biocompatibility.157 The 
addition of the PDT agent Rose Bengal and the PTT agent IR825, a NIR-absorbing dye 
was performed via hydrophobic interactions. Two lasers were required to induce PDT 
(980 nm at 0.4 W/cm2) and PTT (808 nm at 0.5 W/cm2). While either therapy alone only 
induced partial tumour destruction in vivo, combination of the two therapies induced 
severe tumour damage.157 The combination of PTT and PDT using the same laser 
irradiation would be beneficial. Therefore, He et al. prepared 25 nm PEGylated silica-
coated NaYF4 (Yb3+, Er3+) with a ZnPc embedded in the silica layer and modified with 
gold clusters that would act as the PTT agents.158 The combination of PDT/PTT with a 
single laser light (980 nm at 15.9 W/cm2) was possible for enhanced cell killing, leading 
to 20 % more cell death than PTT alone. However, the main drawback of this method 
was the high laser power required for effective therapy.158 Additionally, Lv et al. also 
performed PDT/PTT with a single 980 nm laser using a TiO2-based compound.159 
The combination of PDT and chemotherapy is an effective method to induce enhanced 
cancer cell death. Chemotherapy drug release can be achieved by different methods, 
including pH-sensitive UCNPs,160 polymer degradation due to the NIR light activation of 
UCNPs161-164 or the combination of the two.165,166 Tian et al. synthesised ca. 20-30 nm 
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NaYF4 (Yb3+, Er3+) UCNPs modified with α-cyclodextrin and conjugated to the PS chlorin 
e6 and the chemotherapeutic drug doxorubicin (DOX) via hydrophobic interactions.160 
At acidic conditions, DOX becomes more hydrophilic and it is easily released from the 
UCNPs. This pH-sensitive release mechanism is advantageous for tumours since tumour 
tissue presents low pH in its surroundings. The authors confirmed that the combination 
of PDT and pH-chemotherapy induces more cell death following NIR irradiation than 
either of the therapies alone.160 The use of biodegradable polymers for the release of 
DOX has also been investigated. The Chang group developed silica-coated NaYF4 (Yb3+, 
Er3+) UCNPs to which the PS Rose Bengal and the polymer poly-(1,4-phenyleneacetone 
dimethylenethioketal) (PPADT) conjugated to DOX were covalently attached.161 Yang 
et al. chose to covalently conjugate silica-coated NaY(Mn)F4 (Yb3+, Er3+) UCNPs with a 
PEGylated polymer, the PS chlorin e6 and DOX.162 Zhang et al. selected the polymer 4-
(2-carboxy-ethylsulfanylmethyl)-3-nitro-benzoic acid (CNBA), which was attached to 
the PS hypocrellin A doped silica-coated NaYF4 (Yb3+, Tm3+) UCNPs.163 In these three 
cases, 980 nm irradiation induces the biodegradation of the polymers, which in turn 
enables the release of DOX into the cells. Release of DOX, together with the generation 
of 1O2 by the respective PS, induces more cell death than either chemotherapy or PDT 
alone in all three studies.161-163 A novel type of polymer degradation was reported by 
Zhang et al..164 These authors used chlorin e6 covalently conjugated to silica-coated 
NaYF4 (Yb3+, Er3+) UCNPs, to which a thioketal linker and DOX were attached. In this 
case, the degradation of thioketal is not directly related to the NIR excitation, rather it 
depends on the generation of ROS by the PS, which induces the breakage of the 
thioketal linker and allows the release of DOX into the environment.164 The 
combination of pH- and NIR-sensitive release mechanisms for DOX and targeted cell 
delivery have been investigated. Yuan et al. used DOX covalently linked to a PEGylated 
conjugated polyelectrolyte (CPE) to hydrophobically encapsulate NaYF4 (Yb3+, Tm3+) 
UCNPs, which were further functionalised with the targeting ligand cyclic RGD.165 
Additionally, Zeng et al. conjugated a PEGylated APTES polymer to TiO2-coated NaYF4 
(Yb3+, Tm3+) UCNPs further functionalised with folic acid.166 In these two examples, the 
release of DOX was triggered by both the excitation with NIR-light and the presence of 
an acidic environment. Furthermore, the cancer cell uptake was enhanced by the 
inclusion of targeting agents in both systems.165,166 In another study, Yin et al. reported 
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a similar release mechanism.167 In this case, silica-coated NaGdF4 (Yb3+, Tm3+) UCNPs 
were functionalised with a TiO2 layer, hyaluronic acid and DOX. Hyaluronic acid acted 
not only as the targeting ligand but also induced the release of DOX due to its 
degradation when conjugated to the hyaluronidase (Hyal) enzyme. The presence of 
Hyal, together with an acidic environment, induces the degradation of hyaluronic acid 
and thus DOX release.167 
To end this section, it is important to mention that the combination of more than two 
therapies is also being investigated. The combination of PDT, chemotherapy and 
radiotherapy was reported by Fan et al. for an enhanced therapeutic effect as 
compared to mono- or dual-therapeutic approaches.168 Additionally, the combination 
of PDT/PTT with chemotherapy has also been reported by the Lin group.169,170 These 
authors not only combined these three therapies together, they also opened the 
possibility for multimodal imaging (UCL, CT and MRI) within the same system.169,170 
The use of 808 nm NIR-PDT 
The majority of UCNPs used for biomedical applications, including PDT, use Yb3+ ion as 
the energy donor.171 As a result, the excitation wavelength is usually ca. 980 nm, as 
seen throughout this section. The main problem associated with this wavelength is the 
notable absorption of water, which leads to an overheating effect and limits the 
penetration depth.171 The absorption of water is minimised at ca. 800 nm and the 
development of UCNPs with excitation within this region is being studied. The use of 
neodymium ion (Nd3+) as the energy donor facilitates excitation at 808 nm and thus a 
minimal overheating effect and increased penetration depth.171 Several investigations 
on the development of UCNPs for PDT at 808 nm have been reported.171 
Ai et al. synthesised chlorin e6 functionalised core-shell-shell UCNPs based on NaYbF4 
(Nd3+)@NaGdF4 (Yb3+, Er3+)@NaGdF4 and compared their excitation at conventional 
976 nm with excitation at 808 nm.171 The use of 808 nm as the excitation source not 
only reduced the laser toxicity at longer irradiation periods, it also allowed for a deeper 
penetration. Studies for the production of 1O2 using a 15 mm thick pork muscle tissue 
located between the UCNPs and the laser showed that only excitation at 808 nm was 
able to generate 1O2 under such conditions, suggesting that deeper penetration is only  
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possible with the shorter wavelength.171 A similar approach was reported by Wang et 
al..172 These authors synthesised Rose Bengal functionalised core-shell-shell UCNPs 
based on NaYF4 (Yb3+, holmium (Ho3+))@NaYF4 (Nd3+)@NaYF4. Comparison between 
excitation at 808 nm and 980 nm yielded better results and lower overheating effect 
for the shorter excitation wavelength.172 The Lin group also showed the superiority of 
808 nm excitation using a core NaYF4 (Yb3+, Tm3+) covered by four shells NaGdF4 (Yb3+), 
NaNdF4 (Yb3+), NaGdF4 and a final mSiO2 shell functionalised with the PS TiO2.173 The 
nature of this nanosystem allowed for enhanced PDT at 808 nm and also for 
multimodal imaging, UCL, MRI and CT.173 Their work was further improved by the 
functionalisation of UCNPs with two PS, TiO2 and hypocrellin A, which was able to 
inhibit tumour growth in vivo more effectively than UCNPs with one single PS.174 
 
1.2.4. Conclusions 
Numerous studies highlight the advantages of using nanoparticles for PDT. Gold 
nanoparticles are easily synthesised with great potential for surface functionalisation. 
Upconverting nanoparticles offer further advantages due to their ability to convert NIR 
light into visible light, which offers an increased penetration depth to reach deeper-
lying tumours. The functionalisation of both AuNPs and UCNPs with water soluble 
moieties such as PEG enables the delivery of hydrophobic photosensitisers in aqueous 
media. Additionally, the use of PEG increases the circulation time in the serum while 
preventing opsonisation by the RES. As a result, the PS is selectively delivered into the 
tumour via the EPR effect. Tumour selectivity can be further enhanced by conjugation 
of the nanoparticles with active targeting ligands. Both AuNPs and UCNPs hold great 
potential for combination therapies. For AuNPs, the combination of PDT with PTT has 
been particularly studied for improved tumour destruction. For UCNPs, the use of PDT 
in combination with PTT and chemotherapy has been shown to induce effective tumour 
death. Additionally, UCNPs can be doped with ions with magnetic properties and thus 
be used as contrast agents for MRI. The use of UCNPs for theranostics is not only limited 
to MRI because UCNPs can also be used for UCL and CT imaging. It is clear that 
nanoparticles, especially AuNPs and UCNPs, will play an important role in the future of 
photodynamic therapy. 
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1.3.  Thesis outline 
The research presented in this thesis focuses on the use of gold nanoparticles 
functionalised with two different zinc phthalocyanine derivatives for photodynamic 
therapy. Additionally, the use of upconverting nanoparticles for photodynamic therapy 
was investigated. 
A detailed description of the materials, instruments and experimental procedures 
performed throughout this research is given in Chapter 2. The comparison of two zinc 
phthalocyanines conjugated to gold nanoparticles for PDT is reported in Chapter 3. The 
comparison of the two photosensitisers leads to the investigation of metal-enhanced 
fluorescence as a potential approach to improve PDT efficacy. Additionally, the 
targeting of breast cancer with anti-HER2 antibody is explored. Cell viability assays and 
confocal laser scanning microscopy are used to study the internalisation and PDT 
efficacy of the synthesised functionalised gold nanoparticles for PDT. 
Chapter 4 describes the use of lactose as a potential targeting ligand for the galectin-1 
receptor in breast cancer cells. The expression of galectin-1 in two breast cancer cell 
lines, SK-BR-3 and MDA-MB-231 cells, is quantified with an InCell enzyme-linked 
immunosorbent assay (ELISA). Gold nanoparticles functionalised with lactose are 
synthesised and their PDT efficacy assessed via cell viability assays. Additionally, the 
potential selective targeting between lactose and galectin-1 on the surface of the 
breast cancer cells is investigated. 
The use of upconverting nanoparticles for PDT is explored in Chapter 5. Upconverting 
nanoparticles functionalised with Rose Bengal, kindly provided by Markus Buchner 
from Dr Thomas Hirsch’s group at the University of Regensburg (Germany), are used 
for PDT in breast cancer cells. Multi-photon microscopy is required for the visualisation 
of the UCNPs internalisation by the cells. Additionally, the PDT efficacy of the 
functionalised UCNPs is investigated in vitro using cell viability assays and confocal laser 
scanning microscopy. 
Finally, Chapter 6 provides a summary of the results and final conclusions for the 
research reported throughout this thesis. Suggestions for future experiments to 
continue research in this area are described.  
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Chapter 2 
Experimental 
This chapter details the materials and experimental procedures used for the 
experiments described throughout this thesis. 
 
2.1. Materials and instruments 
2.1.1. Starting materials and solvents 
All reagents were of analytical grade, used as received and purchased from Sigma-
Aldrich (UK) unless otherwise stated. Tetrahydrofuran (THF), toluene, sterile deionised 
water (dH2O) and sodium hydrogen orthophosphate dehydrate (Na2HPO4∙2H2O) were 
purchased from Fisher Scientific (UK). Sodium dihydrogen orthophosphate dihydrate 
(NaH2PO4∙2H2O), sodium chloride (NaCl), phosphate buffered saline (PBS) tablets, 
foetal bovine serum (FBS), 75 cm2 Nunc Easy tissue culture flasks with porous caps, 
Nunc 6-well multidishes, Nunc Nunclon™ Δ Surface 96-well white-bottom and clear-
bottom microplates, 18 mm diameter glass coverslips, Nunc cryo tubes (1.8 mL), a 
cryogenic freezing container and InCell ELISA colorimetric detection kit were purchased 
from Thermo Fisher Scientific (UK). Costar™ sterile disposable reagent reservoirs, 
sterile centrifuge tubes and sterile disposable serological pipettes were purchased 
from Corning B.V. Life Sciences (The Netherlands). Trypsin 0.25 % with 
ethylenediaminetetraacetic acid (EDTA), trypsin 0.05 % with EDTA, Gibco™ Molecular 
Probes™ soybean trypsin inhibitor, McCOY’s 5A phenol red-free medium containing L-
glutamine, McCOY’s 5A medium containing phenol red, high glucose phenol red-free 
Dulbecco’s Modified Eagle Medium (DMEM), L-glutamine (200 mM), sodium pyruvate 
and LysoSensor™ green DND-189 (1 mM in DMSO) were all purchased from Invitrogen 
(UK). Mammary epithelial basal medium (MEBM) and its supplements bovine pituitary 
extract (BPE), hydrocortisone, human epidermal growth factor (hEGF) and insulin were 
purchased from Lonza (UK). CellTiter-Blue® cell viability assay and ApoTox-Glo™ Triplex 
assay were purchased from Promega (UK). Millex GP syringe driven filter units 
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(0.22 μm) were purchased from Millipore Corporation (USA). Sodium hydrogen 
carbonate (NaHCO3) was purchased from BDH Laboratory Supplied Poole (UK). 
Vivaspin™ 500 (100 kDa MWCO; PES membrane) centrifuge columns were purchased 
from Sartorius Stedim Biotech (UK). The α-thio-ω-carboxy polyethylene glycol 
(3,000 Da; PEG) was purchased from Iris Biotech GmbH (Germany). Thiol-dPEG®4-acid 
(sPEG) was purchased from Stratech (UK). Staurosporine free base (> 99 %) was 
purchased from LC Laboratories (USA). Rat monoclonal anti-ErbB2 antibody, rabbit 
monoclonal anti-galectin-1 antibody and recombinant human galectin-1 protein were 
purchased from Abcam (UK). Holey carbon film 300 mesh copper grids were obtained 
from Agar Scientific (UK). A JDS Uniphase 633 nm Helium-Neon (HeNe) laser (10 mW) 
was purchased from Edmund Optics (USA). A 980 nm near-infrared (NIR) laser 
(200 mW) was purchased from Picotronic (Germany). 
SK-BR-3 human breast adenocarcinoma cells were purchased from LGC Standards and 
kindly provided by Prof Dylan R. Edwards (Norwich Medical School, University of East 
Anglia, UK). MDA-MB-231 human breast adenocarcinoma cells and MCF-10A human 
mammary epithelial cells were purchased from ATCC in partnership with LGC 
Standards. 
 
2.1.2. Instrumental techniques 
The instrumental techniques used were ultraviolet-visible (UV-vis) spectroscopy, 
fluorescence spectroscopy, transmission electron microscopy (TEM), confocal laser 
scanning microscopy, multi-photon microscopy and time-resolved luminescence 
spectroscopy. 
UV-vis spectra of the samples were recorded using a Hitachi U-300 spectrophotometer 
at room temperature. Quartz cuvettes with a 1 cm path length were used. Fluorescence 
excitation and emission spectra of the samples were obtained using a Hitachi F-4500 
fluorescence spectrometer in quartz cuvettes with a 1 cm path length. For the plate 
assays, absorbance, fluorescence and luminescence measurements were performed 
using a CLARIOstar® (BMG Labtech) microplate reader at room temperature.  
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TEM images were obtained using a JEOL JEM-2010 Electron Microscope operating at 
200 kV. The samples were deposited on holey carbon film 300 mesh copper grids. 
Assistance of Dr Colin McDonald (School of Chemistry, University of East Anglia, 
Norwich, UK) to obtain the TEM images is gratefully acknowledged. 
Centrifugation of Eppendorf tubes (1.5 mL) and vivaspin™ 500 columns was performed 
using a Beckman Coulter Allegra™ X-22R centrifuge. Centrifugation of biological 
samples in 15-50 mL centrifuge tubes was performed using an Eppendorf 5810R 
centrifuge.  
Confocal microscopy was performed using a Carl Zeiss LSM 510 META confocal laser 
scanning microscope. The images were acquired with a plan-apochromat 63x/1.4 Oil 
DIC objective and processed using ImageJ/Fiji software.  
Multi-photon microscopy was performed using a TriM Scope II multi-photon 
microscope (LaVision BioTec, Bielefeld, Germany). The images were acquired with a 
63x/1.4 NA PlanApochromat objective lens (Carl Zeiss Ltd., Cambridge, UK). The images 
were processed using InspectorPro and ImageJ/Fiji software. Assistance of Dr Paul 
Thomas (School of Biological Sciences, University of East Anglia, Norwich, UK) to obtain 
the multi-photon microscopy images is gratefully acknowledged. 
Time-resolved luminescence spectroscopic measurements were performed to obtain 
information regarding the singlet oxygen quantum yields of the phthalocyanine 
nanoparticle conjugates, with the kind assistance of Prof Andrew Beeby (Department 
of Chemistry, University of Durham, Durham, UK). The samples were irradiated at 
355 nm using the third harmonic of a Q-switched Nd:YAG laser (Spectra Physics GCR 
150-10) with pulse energies between 0.05-1.00 mJ/pulse. The luminescence was 
collected at 90 ° and passed through a narrow band-pass interference filter at 
1,270 nm. The luminescent signal was detected by a germanium photodiode (North 
Coast EO-817P) previously cooled with liquid nitrogen. The signal was recorded and 
averaged over 2-32 shots with a digital oscilloscope (Tektronix TDS320).  
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2.1.3. Buffer solutions and imaging medium 
Phosphate buffered saline (PBS) was prepared in 10 mM phosphate buffer (PB) 
containing NaCl (150 mM) and calcium chloride dihydrate (CaCl2∙2H2O; 100 μM). The 
10 mM PB was prepared using NaH2PO4·2H2O and Na2HPO4∙2H2O stock solutions 
(200 mM). The pH of the PBS was adjusted to 7.4 using aqueous solutions of sodium 
hydroxide (NaOH; 5 M) and hydrochloric acid (HCl; 0.6 M). 
Phosphate buffered saline for the biological experiments (PBS-B) was prepared by 
dissolving 10 PBS tablets in dH2O (1 L). The solution was sterilised by autoclaving at 
110 °C for 10 min. The final PBS solution contained Na2HPO4 (8 mM), potassium 
phosphate monobasic (KH2PO4; 1 mM), NaCl (160 mM), potassium chloride (KCl; 3 mM) 
and a pH of 7.3. 
MES buffer was prepared in dH2O containing 2-(N-morpholino)ethanesulfonic acid 
(MES; 50 mM) and Tween-20 (0.05 %). The pH of the MES buffer was adjusted to 5.5 
using aqueous solutions of NaOH (5 M) and HCl (0.6 M). 
Imaging medium based on Hank’s balanced salt solution (HBSS) for the biological 
experiments was prepared in dH2O containing NaCl (120 mM), KCl (5 mM), CaCl2∙2H2O 
(2 mM), magnesium chloride hexahydrate (MgCl2∙6H2O; 1 mM), NaH2PO4 (1 mM), 
NaHCO3 (1 mM), 4-(2-hydroxyethyl)piperazine-4-ethanesulfonic acid (HEPES; 25 mM), 
D-glucose (11 mM) and bovine serum albumin (BSA; 1 mg/mL). The pH of the imaging 
medium was adjusted to 7.4 using an aqueous solution of NaOH (1 M).  
Prior to use, all buffer solutions and imaging media were sterilised by filtration through 
Millex GP syringe driven filter units (0.22 μm). 
 
2.1.4. Cell culture  
SK-BR-3 human breast adenocarcinoma cells were routinely cultured in McCOY’s 5A 
phenol red-free medium containing L-glutamine and supplemented with FBS (10 %). 
MDA-MB-231 human breast adenocarcinoma cells were routinely cultured in high 
glucose DMEM phenol red-free medium supplemented with L-glutamine (1 %), FBS 
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(10 %) and sodium pyruvate (1 mM). MCF-10A human mammary epithelial cells were 
routinely cultured in MEBM medium supplemented with BPE (2 mL), hydrocortisone 
(0.5 mL), hEGF (0.5 mL), insulin (0.5 mL) and cholera toxin (100 ng/mL). All cells were 
grown in an incubator at 37 °C under a 5 % CO2 atmosphere. 
2.1.4.1. Cell passage and cell count 
SK-BR-3 cells, MDA-MB-231 cells and MCF-10A cells were defrosted by rapidly warming 
a cryo tube containing 1 mL of the cells in freezing medium (90 % complete cell culture 
medium and 10 % culture grade DMSO) in a water bath at 37 °C. The cells were 
transferred to a centrifuge tube containing complete cell culture medium (9 mL). The 
cells were centrifuged at 21 °C at either 1,000 relative centrifugal force (rcf) for 5 min 
for the human breast adenocarcinoma cell lines, or at 130 rcf for 7 min for the MCF-
10A cells. Following centrifugation, the supernatant was discarded and the pellet 
containing the cells was resuspended in the appropriate complete cell culture medium 
(12 mL) and transferred to a 75 cm2 Nunc Easy flask. Subcultures were made by 
dislodging the cells from the flask surface by trypsination, as explained below. 
SK-BR-3 and MDA-MB-231 cells were subcultured (1:4) every 5 days, when they 
reached near confluence in the 75 cm2 flasks. The culture medium was discarded and 
the cells were washed with PBS-B (5 mL). The cells were dislodged from the flasks by 
addition of trypsin 0.25 % (1x) EDTA (5 mL) and incubation for 5 min at 37 °C under a 
5 % CO2 atmosphere. Trypsin was deactivated by addition of the respective culture 
medium (5 mL) and removed by centrifugation at 800 rcf for 5 min at 21 °C. The pellets 
containing the cells were then resuspended in their respective complete cell culture 
medium and transferred to two 75 cm2 Nunc Easy flasks. 
MCF-10A cells were subcultured (1:3) every 5 days, when they reached near confluence 
in the 75 cm2 flasks. The culture medium was discarded and the cells were washed with 
PBS-B (5 mL). The cells were dislodged from the flasks by addition of trypsin 0.05 % (1x) 
EDTA (5 mL) and incubation for 15 min at 37 °C under a 5 % CO2 atmosphere. Trypsin 
was deactivated by addition of soybean trypsin inhibitor (5 mL; 1 mg/mL in PBS) and 
removed by centrifugation at 130 rcf for 7 min at 21 °C. The pellet containing the cells 
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was then resuspended in complete MEBM medium and transferred to two 75 cm2 Nunc 
Easy flasks. 
Following trypsination, cells resuspended in complete culture medium were counted 
with a Neubauer haemocytometer. The haemocytometer was cleaned with 70 % 
ethanol and the coverslip assembled. The sample (20 μL) was then pipetted inside the 
chamber. Under the microscope, the haemocytometer gridlines are seen. Cells in the 
four sets of sixteen corner squares are counted with a hand tally counter. The average 
of the four sets was then multiplied by 104 to give the final result in cells per mL. 
2.1.4.2. Freezing cells for long-term storage 
SK-BR-3, MDA-MB-231 and MCF-10A cells were trypsinised as explained above in 
section 2.1.4.1. Following trypsin removal, the cells were resuspended in freezing 
medium (10.5 mL). Freezing medium consists of 90 % complete cell culture medium 
and 10 % culture grade DMSO. Each cell line was placed in 1.8 mL Nunc cryo tubes (1 mL 
per tube). The cryo tubes were placed in a cryogenic freezing container previously filled 
with isopropanol and stored at -80 °C overnight. The following day, the cryo tubes were 
removed from the cryogenic container and stored in a sample box either at -80 °C or in 
liquid nitrogen.  
 
2.2. Gold nanoparticle enhanced and selective targeting photodynamic 
therapy of breast cancer cells  
2.2.1. Synthesis of C11Pc/C3Pc-PEG-AuNPs 
Two  zinc phthalocyanines (Pc) composed of either a three carbon-atom chain (C3Pc) 
or an eleven carbon-atom chain (C11Pc) connecting the macrocycle to the sulfur, see 
Figure 3.5, were kindly provided by Dr Isabelle Chambrier (School of Chemistry, 
University of East Anglia, Norwich, UK).1,2 Gold nanoparticles (ca. 3-5 nm; AuNPs) were 
synthesised by sodium borohydride (NaBH4) reduction and functionalised with a mixed 
monolayer of PEG (3,073 Da) together with either C11Pc or C3Pc; using a previously 
described method3 but with modifications. 
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C11Pc (2.43 mg; 0.95 μmol) or C3Pc (2.22 mg; 0.95 μmol) were dissolved in dry THF 
(1 mL) and left to stir for 5 min at room temperature. Then, PEG (7.5 mg; 2.5 μmol) was 
dissolved in dry THF (2 mL), added to the phthalocyanine solution and stirred at room 
temperature for 5 min. Gold (III) chloride trihydrate (HAuCl4∙3H2O; 1.2 mg; 3.0 μmol) 
was dissolved in dry THF (1.2 mL), added to the Pc-PEG mixtures and stirred at room 
temperature for a further 5 min. Finally, a solution of NaBH4 (1.5 mg; 39.65 μmol) was 
prepared in dH2O (1.2 mL) and added to the Pc-PEG-HAuCl4 mixture rapidly and under 
vigorous stirring. The reaction was stirred overnight (ca. 17 h) at room temperature in 
the dark at moderate speed.  
The resulting solution was a mixture of free Pc, AuNPs functionalised with Pc only, 
AuNPs functionalised with PEG only and AuNPs functionalised with both Pc and PEG. 
To purify the mixture, excess dry THF (5.4 mL) was added rapidly and under vigorous 
stirring, followed by centrifugation in Eppendorf tubes (1.5 mL) at 1,300 rpm for 2 min 
at 4 °C. The supernatant was collected and the brown pellet containing AuNPs 
functionalised only with PEG was discarded. The solvent mixture in the supernatant 
was evaporated by rotary evaporation under reduced pressure at 70 °C. At this point, 
MES buffer (5 mL) was added and the mixture was solubilised using an ultrasonic bath. 
The solution was centrifuged in Eppendorf tubes (1.5 mL) at 14,000 rpm for 30 min at 
4 °C. The pellet containing free Pc and AuNPs functionalised only with Pc, and thus not 
soluble in an aqueous solution, was discarded. The supernatant containing the Pc-PEG-
AuNPs was collected, filtered through a Millex GP syringe driven filter unit (0.22 μm) 
and stored at 4 °C.  
The synthesised Pc-PEG-AuNPs were characterised using UV-vis and fluorescence 
spectroscopies and TEM. The UV-vis extinction spectrum was recorded between 300-
800 nm. The fluorescence emission spectrum was recorded using an excitation 
wavelength of 633 nm between 653-850 nm. The fluorescence excitation spectrum was 
recorded, using an emission wavelength of 780 nm, between 500-750 nm. 
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2.2.2. Functionalisation of Pc-PEG-AuNPs with anti-HER2 antibody 
C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs were further functionalised with anti-HER2 
antibody. The antibody was conjugated to the PEG on the surface of the AuNPs via the 
terminal carboxyl groups in the PEG ligand using a previously reported method but with 
modifications.3,4 The conjugation was performed via an amide linkage through N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHS) coupling.5 EDC (0.8 μL) and NHS (1.2 mg) were added to the 
Pc-PEG-AuNPs in MES buffer (1 mL; ca. 2 μM Pc) and stirred for 30 min at room 
temperature in the dark. Excess EDC/NHS was removed by ultrafiltration in vivaspin™ 
500 columns at 14,000 rpm for 30 min at 4 °C.  The NHS-ester functionalised Pc-PEG-
AuNPs were redispersed in PBS (1 mL) and anti-HER2 antibody (5 μL; 1 mg/mL) was 
added to give a final antibody concentration of 65 nM. The solutions were stirred 
overnight (ca. 17 h) at room temperature in the dark.  
Following overnight incubation, unbound anti-HER2 antibody was removed by 
ultrafiltration in vivaspin™ 500 columns by centrifuging at 14,000 rpm for 30 min at 
4 °C. The washes at the bottom of the vivaspin™ 500 columns were removed and the 
AuNPs pellets retained in the vivaspin™ 500 columns were resuspended in PBS 
(500 μL). This purification step was repeated until no more unbound antibody was left. 
The end point was measured using the UV-vis absorbance of the washes between 200-
500 nm to monitor the decrease in antibody absorption band at ca. 250 nm. The final 
AuNPs pellets were redispersed in FBS-free McCOY’s 5A medium containing L-
glutamine and the samples were stored at 4 °C. 
 
2.2.3. Nanoparticle characterisation by TEM 
The size and morphology of the AuNPs was characterised using TEM. A droplet of the 
AuNPs (20 μL) in MES buffer was placed onto a holey carbon film 300 mesh copper grid 
and left for 2 min to allow the AuNPs to sediment onto the grid. Excess MES buffer was 
then removed by gently poking the side of the grid with filter paper. The grid was left 
to completely dry before imaging. 
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2.2.4. Determination of extinction coefficients of C11Pc and C3Pc 
C11Pc (2.27 mg) was dissolved in THF (2 mL) giving an initial concentration of 443 μM. 
C3Pc (24.5 mg) was dissolved in THF (5 mL) giving an initial concentration of 2,094 μM. 
This initial C11Pc and C3Pc solutions were then further diluted with THF to obtain 
concentrations ranging from 0-5 μM. These dilutions were prepared in volumetric 
flasks (2 mL). The dilutions were analysed by UV-vis spectroscopy between 300-800 nm 
starting with the lowest concentration. A calibration curve at 698 nm was created and 
a value for the extinction coefficient for each phthalocyanine was obtained. 
 
2.2.5. Fluorescence quantum yields of free Pc and Pc-PEG-AuNPs 
The fluorescence quantum yield for both the free Pc and the Pc-PEG-AuNPs were 
obtained using UV-vis and fluorescence spectroscopies. Zinc 2,9,16,23-tetra-tert-butyl-
29H,31H-phthalocyanine (ZnPc) was used as a reference, as it is known to have a 
fluorescence quantum yield of 0.33 in toluene.6 
Free C3Pc (0.52 mg) was dissolved in THF (2 mL) to give an initial concentration of 
111 μM. C3Pc-PEG-AuNPs dissolved in MES buffer at an initial concentration of 3.6 μM 
were used. Free C11Pc (2.27 mg) was dissolved in THF (2 mL) to give an initial 
concentration of 443 μM. C11Pc-PEG-AuNPs dissolved in MES buffer at an initial 
concentration of 1.3 μM were used. The reference standard ZnPc (0.66 mg) was 
dissolved in toluene (2 mL) to give an initial concentration of 411 μM. All samples were 
further diluted to give concentrations ranging from 0-1.2 μM. Five dilutions were 
analysed for each sample. The UV-vis absorption spectra of all samples were recorded 
and the absorbance intensity at 640 nm was noted. Then, the fluorescence emission 
spectra of the samples, using an excitation wavelength of 640 nm, were recorded 
between 660-850 nm.  
The fluorescence quantum yields were obtained by the creation of a calibration curve 
of integrated fluorescence intensity (i.e., area under the curve) vs absorbance at the 
excitation wavelength, 640 nm. The calibration curve produces a straight line with 
gradient m and intercept 0. The gradient is proportional to the fluorescence quantum 
yield of the sample. By comparing the gradient of the unknown samples to the gradient 
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of the reference standard, the fluorescence quantum yields can be estimated. The 
equation used to calculate the fluorescence quantum yields is shown in section 3.2.3.  
 
2.2.6. Synthesis of control PEG-AuNPs 
The synthesis of AuNPs (ca. 2-4 nm) functionalised with PEG (PEG-AuNPs) of a similar 
size to the Pc-PEG-AuNPs was performed. PEG (15.2 mg; 4.95 μmol) was dissolved in 
dH2O (15 mL) and left to stir at room temperature. Then, HAuCl4∙3H2O (1.2 mg; 
3.0 μmol) was dissolved in THF (1.2 mL), added to the PEG solution and stirred at room 
temperature for 5 min. A fresh solution of NaBH4 (1.5 mg; 39.65 μmol) in dH2O (0.5 mL) 
was prepared and added to the PEG-HAuCl4 mixture. The reaction was stirred for a 
further 4 h at room temperature. Purification of the AuNPs was then performed. Firstly, 
the THF was evaporated by rotary evaporation under reduced pressure at 60 °C. The 
final solution in dH2O was transferred to vivaspin™ 500 columns and centrifuged at 
14,000 rpm for 10 min at 4 °C. The PEG-AuNPs were resuspended in MES buffer 
(16.7 mL) and filtered through a Millex GP syringe driven filter unit (0.22 μm). The UV-
vis extinction spectrum was recorded between 250-800 nm. The PEG-AuNPs were 
stored at room temperature. 
 
2.2.7. Measurement of singlet oxygen production 
Production of singlet oxygen (1O2) was measured using the singlet oxygen probe 9,10-
anthracenediyl-bis (methylene) dimalonic acid (ABMA). ABMA (0.63 mg) was dissolved 
in methanol (MeOH; 3 mL) to give an initial concentration of 0.512 mM.  
The Pc-PEG-AuNPs (511 μL) in MES buffer were placed in a 1.5 mL quartz cuvette 
together with ABMA (1 μL; 1 μM) and a magnetic stirrer bar. Oxygen was bubbled 
through the solution and the quartz cuvette was stoppered. The fluorescence emission 
spectrum of the initial solution was recorded using an excitation wavelength of 380 nm 
between 390-600 nm. The sample was then irradiated at 633 nm using a 10 mW HeNe 
laser for 40 min with continuous stirring. The laser was placed 50 cm away from the 
cuvette. The fluorescence emission spectrum of the sample was recorded every 5 min.  
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2.2.8. Singlet oxygen quantum yields 
The singlet oxygen quantum yields of the free Pcs as well as the Pc-PEG-AuNPs were 
measured. The assistance of Prof Andrew Beeby (Department of Chemistry, University 
of Durham, Durham, UK) is gratefully acknowledged. Perinaphthenone was used as the 
reference sample as it is known to have a singlet oxygen quantum yield of 1.0 in 
toluene.7  
The free C3Pc and C11Pc, as well as perinaphthenone were dissolved in toluene. Three 
dilutions of each sample with absorbance values of ≈0.16, ≈0.21 and ≈0.32 at 355 nm 
were prepared. For each set of dilutions, the samples were placed in a 1.5 cm stoppered 
quartz cuvette and irradiated at 355 nm using the third harmonic of a Q-switched 
Nd:YAG laser with pulse energies in the range 0.05-1.00 mJ per pulse. The 
luminescence was collected at 90 ° and passed through a narrow band-pass 
interference filter at 1,270 nm. Only light with a wavelength of 1,270 nm, i.e. the 
luminescence signal from 1O2, will be collected. Detection was performed with a 
germanium photodiode, which had been previously cooled with liquid nitrogen for 
1.5 h. The luminescence signal from 1O2 was recorded and averaged over 2-32 shots 
using a digital oscilloscope. The intensity of 1O2 (I1O2) emission was recorded at different 
laser power intensities, ranging from 1.24-28.1 mV. 
The 1O2 quantum yields were obtained by the creation of a calibration curve of I1O2 vs 
intensity of light absorbed by the sample (Ia). The calibration curve produces a straight 
line with gradient m, which is proportional to the 1O2 quantum yield. By comparing the 
gradient of the unknown samples to the gradient of the reference standard, the 1O2 
quantum yields can be estimated. The equation used for the comparison is shown in 
section 3.2.5. 
The measurement of 1O2 quantum yield for the Pc-PEG-AuNPs was more challenging. 
The AuNPs were dissolved in an aqueous solution, MES buffer. Aqueous solutions lead 
to the quenching of the I1O2 signal. As a result, the signal was too low to be able to 
estimate a value for the 1O2 quantum yield. In an attempt to minimise the quenching 
effect and increase the intensity of the I1O2 signal, C11Pc-PEG-AuNPs and C3Pc-PEG-
AuNPs were dissolved in D2O. However, the signal in D2O was also too low to estimate 
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a value for the 1O2 quantum yields. C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs, dissolved 
in D2O, were diluted to an absorbance value of ≈0.28 at 355 nm. The decay of 1O2 
production was recorded with pulse energies of 4.0 mJ and 4.5 mJ. To confirm that the 
low signals seen were due to the production of 1O2 by the samples, both AuNPs samples 
were deoxygenated by bubbling He through them for 5 min. The signal was again 
recorded after the removal of the majority of the oxygen in the solutions had taken 
place. 
 
2.2.9. MTT cell viability assay  
SK-BR-3 human breast adenocarcinoma cells were trypsinised and counted as 
described in section 2.1.4.1. The cells were seeded onto two white-bottom Nunc 
Nunclon™ Δ Surface 96- well microplates at a concentration of 20×104 cells/mL 
(100 μL/well). The cells were incubated for ca. 48 h at 37 °C under a 5 % CO2 
atmosphere. 
The culture medium was removed using a micropipette and the cells were washed once 
with PBS-B (100 μL). The nanoparticle samples, anti-HER2 antibody conjugated or non-
conjugated C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs at various Pc concentrations in 
FBS-free McCOY’s 5A medium containing L-glutamine were then added (50 μL/well). 
Additionally, a solution of staurosporine (1 mM in DMSO) dispersed in FBS-free 
McCOY’s 5A medium containing L-glutamine (50 μL; 20 μM) was also used as a positive 
control for cytotoxicity.8 Control cells without any AuNPs loaded were treated with FBS-
free McCOY’s 5A medium containing L-glutamine. The cells were incubated with the 
samples and controls for 3 h at 37 °C under a 5 % CO2 atmosphere. 
Following incubation with the AuNPs, the samples were removed and the cells were 
washed with PBS-B (100 μL) three times. The cells were then resuspended in complete 
McCOY’s 5A medium (100 μL) containing L-glutamine and supplemented with FBS 
(10 %). At this point, one of the plates was irradiated at 633 nm using a 10 mW HeNe 
laser fitted with a biconvex diverging lens for 6 min per well. The laser was located 
50 cm above the 96-well plate, giving an irradiance of 29 mW/cm2 and a total light dose 
of 10.5 J/cm2. The plate not being irradiated was kept covered in aluminium foil in the 
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dark. The cells were further incubated for ca. 48 h at 37 °C under a 5 % CO2 atmosphere 
prior to measuring cell viability. 
MTT reagent (3-(4,5,dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (10 μL; 
5 mg/mL in PBS) was added to each well and incubated for 4 h at 37 °C under a 5 % CO2 
atmosphere.9,10 The medium was then removed from the wells using a micropipette 
and the MTT formazan crystals were washed with PBS-B (100 μL) once and dissolved in 
culture-grade DMSO (200 μL). The contents of the wells were transferred to clear-
bottom Nunc Nunclon™ Δ Surface 96- well microplates. The absorbance intensity was 
then measured at 560 nm. Background absorbance was corrected by subtracting the 
absorbance measurement from McCOY’s 5A medium alone incubated with MTT. Cell 
viability was calculated as a percentage of non-treated, non-irradiated cells. All samples 
were analysed in triplicates. Statistical significance between means was determined 
using a two-tailed Student’s t-test and P values < 0.05 were considered significant.11 
 
2.2.10. CellTiter-Blue® cell viability assay 
SK-BR-3 human breast adenocarcinoma cells and MCF-10A human mammary epithelial 
cells were trypsinised and counted as described in section 2.1.4.1. The cells were 
seeded and treated with the AuNPs samples as detailed in section 2.2.9. 
Following incubation post-PDT treatment, CellTiter-Blue® reagent12 (20 μL) was added 
to each well and incubated for 4 h at 37 °C under a 5 % CO2 atmosphere. Fluorescence 
emission was then measured at 594 nm following excitation at 561 nm. Background 
fluorescence was corrected by subtracting fluorescence emission from McCOY’s 5A 
medium alone incubated with CellTiter-Blue®. Cell viability was calculated as a 
percentage of non-treated, non-irradiated cells. All samples were analysed in 
triplicates. Statistical significance between means was determined using a two-tailed 
Student’s t-test and P values < 0.05 were considered significant.11 
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2.2.11. Confocal laser scanning microscopy 
For imaging experiments, SK-BR-3 cells were cultured in McCOY’s 5A medium 
containing phenol red and supplemented with L-glutamine (1 %) and FBS (10 %). SK-
BR-3 cells were trypsinised and counted as described in section 2.1.4.1. The cells were 
then seeded onto 18 mm diameter glass coverslips inside Nunc 6-well multidishes at a 
concentration of 2×104 cells/mL (3 mL/well). The cells were incubated for ca. 48 h at 
37 °C under a 5 % CO2 atmosphere.  
The culture medium was removed and the cells were washed once with PBS-B (1 mL). 
The nanoparticle samples, anti-HER2 antibody conjugated or non-conjugated C11Pc-
PEG-AuNPs and C3Pc-PEG-AuNPs (0.15 μM or 0.23 μM Pc) in FBS-free McCOY’s 5A 
medium supplemented with L-glutamine (1 %), were then added (1 mL/well). Control 
cells not loaded with any AuNP samples were treated with FBS-free McCOY’s 5A 
medium supplemented with L-glutamine (1 %). The cells were incubated with the 
samples and controls for 3 h at 37 °C under a 5 % CO2 atmosphere.  
Following incubation with the samples, the cells were washed with PBS-B (1 mL) three 
times. They were then resuspended in complete McCOY’s 5A medium (2 mL) 
supplemented with L-glutamine (1 %) and FBS (10 %). At this point, the cells were 
irradiated at 633 nm using a 10 mW HeNe laser fitted with a biconvex diverging lens 
for 6 min per coverslip. The non-irradiated plates were left covered in aluminium foil in 
the dark. Following irradiation, the cells were further incubated for 19 h at 37 °C under 
a 5 % CO2 atmosphere. 
For imaging in the confocal microscope, the 18 mm coverslips were placed in a Ludin 
chamber, which was securely tightened. The cells in the coverslips were washed with 
imaging medium (ca. 1 mL) three times and finally resuspended in imaging medium (ca. 
1 mL). The Ludin chamber was fitted on a heating stage at 37 °C in the confocal 
microscope. A 633 nm HeNe laser was used to excite the Pc on the AuNPs and the 
fluorescence emission was collected in the red channel with a 650 nm long pass filter. 
Differential interference contrast (DIC) images were collected simultaneously using a 
488 nm argon-ion laser.13,14 To test for dead cells, the dead cell marker propidium 
iodide was used. Propidium iodide (5 μL; 1 mg/mL in PBS) was dissolved in imaging 
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medium (1 mL). The solution was directly added to the coverslips, which had been 
previously placed in the Ludin chamber and mounted on the heating stage. The 
propidium iodide solution was incubated with the cells at 37 °C for 5 min in the dark. A 
543 nm HeNe laser was used to excite propidium iodide and the fluorescence emission 
was collected in the pink channel with a band pass filter between 560-615 nm.13,15 
  
2.2.12. Colocalisation studies by confocal laser scanning microscopy 
For imaging experiments, SK-BR-3 cells were cultured in McCOY’s 5A medium 
containing phenol red and supplemented with L-glutamine (1 %) and FBS (10 %). SK-
BR-3 human breast adenocarcinoma cells were dislodged from the flasks by 
trypsination and counted as explained in section 2.1.4.1. The cells were then seeded 
on 18 mm diameter glass coverslips and treated with anti-HER2 antibody conjugated 
C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs (0.15 μM Pc) as described in section 2.2.11, 
but no irradiation was performed.  
For the colocalisation studies, LysoSensor™ Green DND-189 was used to mark the 
acidic organelles inside the cells. Prior to imaging, LysoSensor™ Green (2 μL; 1 mM in 
DMSO) was added to the coverslips in the 6-well plates containing McCOY’s 5A medium 
(2 mL) supplemented with L-glutamine and FBS (10 %). The cells were incubated with 
LysoSensor™ Green for 30 min at 37 °C under a 5 % CO2 atmosphere. For imaging, the 
coverslips were placed in a Ludin chamber, which was mounted on a heated stage in 
the confocal microscope, as explained in section 2.2.11. A 458 nm argon-ion laser was 
used to excite the LysoSensor™ Green and the fluorescence emission was collected in 
the green channel with a band pass filter between 475-525 nm. Simultaneously, a 
633 nm HeNe laser was used to excite the Pc on the AuNPs and the fluorescence 
emission was collected in the red channel with a 650 nm long pass filter. Additionally, 
DIC images were also collected at the same time using a 458 nm argon-ion laser. 
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2.2.13. InCell ELISA for the detection of the HER2 receptor on SK-BR-3 cells 
An InCell Enzyme Linked Immunosorbent Assay (ELISA) was performed to study the 
targeting ability of anti-HER2 antibody towards the HER2 receptor overexpressed on 
the surface of SK-BR-3 cells.16 SK-BR-3 cells were dislodged from the flasks by 
trypsination and counted as described in section 2.1.4.1. The cells were seeded onto a 
clear-bottom Nunc Nunclon™ Δ Surface 96-well microplate at a concentration of 
10×104 cells/mL (100 μL/well). The cells were incubated overnight at 37 °C under a 5 % 
CO2 atmosphere. 
The culture medium was removed and the cells were washed with PBS-B (100 μL) once. 
The nanoparticle samples, anti-HER2 antibody conjugated or non-conjugated C11Pc-
PEG-AuNPs and C3Pc-PEG-AuNPs (0.20 μM Pc) in FBS-free McCOY’s 5A medium 
containing L-glutamine, were then added (50 μL/well). Additionally, a solution of 
staurosporine (1 mM in DMSO) dispersed in FBS-free McCOY’s 5A medium containing 
L-glutamine (50 μL; 20 μM) was used as a positive control for cytotoxicity. Control cells 
not loaded with any AuNP samples were treated with FBS-free McCOY’s 5A medium 
containing L-glutamine (50 μL). The cells were incubated with the samples and controls 
for 3 h at 37 °C under a 5 % CO2 atmosphere.  
During the incubation period, the required buffers for the InCell ELISA were prepared. 
Tris buffered saline (1X; TBS) was prepared by addition of 20X TBS (2.5 mL) to dH2O 
(47.5 mL). Formaldehyde (4 %) was prepared by addition of MeOH-free formaldehyde 
(16 %; 1.5 mL) to 1X TBS (4.5 mL). Permeabilisation buffer was prepared by addition of 
Surfact-Amps X-100 detergent (110 μL) to 1X TBS (11 mL). Quenching solution was 
prepared by addition of hydrogen peroxide (H2O2; 30 %; 380 μL) to 1X TBS (11 mL). 
Washing buffer (1X) was prepared by addition of 20X TBS (7.5 mL) and Surfact-Amps 
20 detergent (1.5 mL) to dH2O (141 mL). Finally, the solution in which the primary 
antibody was diluted (blocking-washing solution) was prepared by addition of blocking 
buffer (3 mL) to washing buffer (1X; 3 mL). 
Following incubation with the AuNPs, the samples were removed and the cells were 
washed with PBS-B (100 μL) three times and resuspended in McCOY’s 5A medium 
(100 μL) containing L-glutamine and supplemented with FBS (10 %). The first part of 
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the assay involved fixing the cells prior to addition of the primary antibody. From this 
point onwards, all incubation steps were performed with gentle shaking of the 
microplate and the plate contents were always removed using a micropipette to 
minimise cell loss. The culture medium was removed and formaldehyde (4 %; 100 μL) 
was added to each well and incubated with the cells for 15 min at room temperature. 
The formaldehyde solution was removed and the plate was washed with 1X TBS 
(100 μL) twice. Permeabilisation buffer (100 μL) was added to each well and incubated 
with the cells for 15 min at room temperature. The permeabilisation buffer was 
removed and the cells were washed with 1X TBS (100 μL) once. Quenching solution 
(100 μL) was added to each well and incubated with the cells for 20 min at room 
temperature. The quenching solution was then removed and the cells were washed 
with 1X TBS (100 μL) once. Following the fixing of the cells, blocking buffer (100 μL) was 
added and incubated with the cells for 30 min at room temperature.  
While the cells were being incubated with blocking buffer, the anti-HER2 primary 
antibody solution was prepared. Anti-HER2 antibody (5 μL; 1 mg/mL in PBS containing 
0.02 % sodium azide) was diluted in the blocking-washing solution (5 mL) previously 
prepared, as explained above, to give a final concentration of 1 μg/mL. Following 
incubation of the cells with blocking buffer, the blocking buffer was removed and anti-
HER2 antibody (50 μL; 1 μg/mL) was added to each well. Non-specific signal control 
wells, i.e., cells not incubated with primary antibody, were incubated with blocking-
washing solution (50 μL) instead. The microplate was sealed with a plate sealer and the 
cells were incubated with the primary antibody overnight (ca. 17 h) at 4 °C. 
The second part of the assay involved the development of an absorbance intensity 
signal for the levels of HER2 present in each sample. Following overnight incubation 
with the primary antibody, the blocking-washing solution was removed and the cells 
were washed with washing buffer (100 μL) three times. HRP conjugate (15 μL) was 
diluted with washing buffer (6 mL). The diluted HRP conjugate (100 μL) was added to 
each well and incubated with the cells for 30 min at room temperature. Following 
incubation, the HRP conjugate was removed and the plate was washed with washing 
buffer (200 μL) three times. The substrate 3,3’,5,5’-tetramethylbenzidine (100 μL; TMB) 
was added to each well and the plate was covered with aluminium foil. The plate was 
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then incubated for 20 min at room temperature in the dark. TMB stop solution (100 μL) 
was then added to stop the reaction between the TMB Substrate and the HRP 
conjugate. The absorbance intensity was measured at 450 nm. Background absorbance 
was corrected by subtracting the absorbance measurement from the non-specific 
signal controls. All samples were analysed in triplicates.  
The third part of the assay involved the whole-cell staining of each well so the values 
of the HER2 receptor could be normalised to cell number. The plate contents were 
emptied and the plate was washed with dH2O (200 μL) twice. Janus Green Whole-Cell 
Stain (100 μL) was added to each well and incubated for 5 min at room temperature. 
The stain was then removed and the plate was washed with dH2O (200 μL) five times 
to remove all excess stain. Elution buffer (100 μL) was added to each well and 
incubated for 10 min at room temperature. The absorbance intensity was then 
measured at 615 nm. Background absorbance was corrected by subtracting the 
absorbance measurement from McCOY’s 5A medium alone. All samples were analysed 
in triplicates. To obtain the values of HER2 expression normalised to cell number in 
each well, the corrected absorbance values at 450 nm were divided by the corrected 
absorbance values at 615 nm. 
 
2.2.14. ApoTox-Glo™ Triplex assay 
SK-BR-3 cells were trypsinised and counted as described in section 2.1.4.1. The cells 
were seeded onto two white-bottom Nunc Nunclon™ Δ Surface 96-well microplates at 
a concentration of 18×104 cells/mL (100 μL/well). The cells were incubated for ca. 48 h 
at 37 °C under a 5 % CO2 atmosphere. 
The culture medium was removed using a micropipette and the cells were washed once 
with PBS-B (100 μL). The nanoparticle samples, anti-HER2 antibody conjugated or non-
conjugated C11Pc-PEG-AuNPs (0.16 μM C11Pc) and C3Pc-PEG-AuNPs (0.15 μM Pc) in 
FBS-free McCOY’s 5A medium containing L-glutamine, were then added (50 μL/well). 
Additionally, a solution of Staurosporine (1 mM in DMSO) dispersed in FBS-free 
McCOY’s 5A medium containing L-glutamine (50 μL; 20 μM) was also used as a positive 
control for cytotoxicity via apoptosis. Control cells without any AuNPs loaded were 
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treated with FBS-free McCOY’s 5A medium containing L-glutamine. The cells were 
incubated with the samples and controls for 3 h at 37 °C under a 5 % CO2 atmosphere. 
Following incubation with the AuNPs, the samples were removed and the cells were 
washed with PBS-B (100 μL) three times. The cells were then resuspended in complete 
McCOY’s 5A medium (100 μL) containing L-glutamine and supplemented with FBS 
(10 %). At this point, one of the plates was irradiated at 633 nm using a 10 mW HeNe 
laser fitted with a biconvex diverging lens for 6 min per well, giving an irradiance of 
29 mW/cm2 and a total light dose of 10.5 J/cm2. The laser was located 50 cm above the 
96-well plate. The plate not being irradiated was kept covered in aluminium foil in the 
dark. Following irradiation, the cells were further incubated for wither 4 h or 48 h at 
37 °C under a 5 % CO2 atmosphere.  
The ApoTox-Glo™ Triplex assay was then performed.17,18 The assay buffer, glycyl-
phenylalanyl-aminofluorocoumarin (GF-AFC) substrate and bis-alanylalanyl-
phenylalanyl-rhodamine 110 (bis-AAF-R110) substrate were thawed in a water bath at 
37 °C. The Caspase-Glo® 3/7 substrate and buffer were thawed at room temperature. 
Once all the reagents had reached room temperature, the Viability/Cytotoxicity 
reagent was prepared by adding GF-AFC susbtrate (10 μL) and bis-AAF-R110 substrate 
(10 μL) to the assay buffer (2 mL). The mixture was vortex-mixed to ensure a 
homogeneous distribution. The Viability/Cytotoxicity reagent (20 μL) was added to 
each well and the plate was mixed by orbital shaking at 300 rpm for 30 seconds. The 
plate was then incubated at 37 °C under a 5 % CO2 atmosphere for 1 h. Fluorescence 
intensity was then measured at two wavelength sets. The fluorescence emission from 
the viability component was measured at 505 nm following excitation at 400 nm. The 
fluorescence emission from the cytotoxicity component was measured at 520 nm 
following excitation at 485 nm.  
The Caspase-Glo® 3/7 reagent was prepared by adding the Caspase-Glo® 3/7 buffer 
(10 mL) to the bottle containing the lyophilized Caspase-Glo® 3/7 substrate. The 
reagent was thoroughly mixed before use. The Caspase-Glo® reagent (100 μL) was then 
added to each well and the plate was mixed by orbital shaking at 300 rpm for 30 
seconds. The plate was incubated at room temperature for 30 min. The luminescence 
signal was then measured using an integration time of 1 second. 
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2.3. Targeted photodynamic therapy of breast cancer cells using lactose-
phthalocyanine gold nanoparticle conjugates 
2.3.1. Synthesis of lactose-C11Pc-AuNPs 
Gold nanoparticles (AuNPs) were synthesised by NaBH4 reduction and functionalised 
with a mixed monolayer of C11Pc and lactose. Initially, a version of the method 
described in section 2.2.1 for the synthesis of C11Pc-PEG-AuNPs was used but replacing 
the PEG ligand with the thiolated lactose ligand. 
C11Pc (2.43 mg; 0.95 μmol) was dissolved in dry THF (1 mL) and left to stir at room 
temperature. Then, lactose (2 mL; 1.31 mM in dH2O) was added to the C11Pc solution 
and stirred at room temperature for 5 min. HAuCl4∙3H2O (1.2 mg; 3.0 μmol) was 
dissolved in dH2O (1.2 mL), added to the C11Pc-lactose mixture and stirred at room 
temperature for a further 5 min. Finally, a solution of NaBH4 (1.5 mg; 39.65 μmol) was 
prepared in dH2O (1.2 mL) and added to the previous mixtures rapidly and under 
vigorous stirring. The reaction was stirred overnight (ca. 17 h) at room temperature in 
the dark at moderate speed.  
The resulting solution was a mixture of free Pc, AuNPs functionalised with Pc only, 
AuNPs functionalised with lactose only and AuNPs functionalised with both Pc and 
lactose. To purify the mixture, excess dry THF (6 mL) was added rapidly and under 
vigorous stirring, followed by centrifugation in Eppendorf tubes (1.5 mL) at 1,300 rpm 
for 2 min at 4 °C. The supernatant was collected and the brown pellet containing AuNPs 
functionalised only with lactose was discarded. The solvent mixture in the supernatant 
was evaporated by rotary evaporation under reduced pressure at 70 °C. For further 
purification, more excess THF (5.4 mL) was added, followed by the same centrifugation 
and evaporation steps as explained previously. Once all the THF had been evaporated, 
MES buffer (3 mL) was added and the solubilisation was assisted using an ultrasonic 
bath. However, most of the solution appeared white, which suggested there was no Pc 
attached to the lactose-AuNPs. The solution was centrifuged in Eppendorf tubes 
(1.5 mL) at 14,000 rpm for 30 min at 4 °C. The pellet containing free Pc and AuNPs 
functionalised only with Pc, and thus not soluble in an aqueous solution, was discarded. 
The supernatant containing the lactose-Pc-AuNPs was collected and filtered through a 
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Millex GP syringe driven filter unit (0.22 μm). The synthesised lactose-Pc-AuNPs were 
characterised using UV-vis spectroscopy between 300-800 nm. The yield for the 
resulting lactose-C11Pc-AuNPs was low as the solution looked colourless and the UV-
vis extinction spectrum showed a small absorption band for C11Pc at 698 nm. 
In an attempt to increase the loading of C11Pc on the lactose-AuNPs, the amount of 
lactose used was reduced. Additionally, the amount of THF in the reaction mixture was 
increased to provide a higher solubility of C11Pc in the mixture. C11Pc (2.43 mg; 
0.95 μmol) was dissolved in dry THF (1.45 mL) and left to stir at room temperature. 
Then, lactose (1 mL; 1.31 mM in dH2O) was added to the C11Pc solution and stirred at 
room temperature for 5 min. HAuCl4∙3H2O (1.2 mg; 3.0 μmol) was dissolved in dry THF 
(1.2 mL), added to the C11Pc-lactose mixture and stirred at room temperature for a 
further 5 min. Finally, a solution of NaBH4 (1.5 mg; 39.65 μmol) was prepared in dH2O 
(1.2 mL) and added to the previous mixtures rapidly and under vigorous stirring. The 
reaction was stirred overnight (ca. 17 h) at room temperature in the dark at moderate 
speed. The purification of the mixture was performed in the same way as that 
described above for the initial synthetic method. The resulting lactose-C11Pc-AuNPs 
were filtered through a Millex GP syringe driven filter unit (0.22 μm) and they were 
characterised using UV-vis spectroscopy between 300-800 nm. The final solution was 
stored at 4 °C. 
 
2.3.2. Synthesis of lactose-C3Pc-AuNPs 
Gold nanoparticles were synthesised by NaBH4 reduction and functionalised with a 
mixed monolayer of C3Pc and lactose. C3Pc (2.22 mg; 0.95 μmol) was dissolved in dry 
THF (1.45 mL) and left to stir at room temperature. The synthesis followed the 
improved method for the synthesis of lactose-C11Pc-AuNPs described at the end of 
section 2.3.1, where the amount of lactose within the reaction mixture was reduced 
while the amount of THF was increased in order to increase the loading of Pc 
immobilised on the surface of the lactose-AuNPs. 
 
 
76 
 
2.3.3. Nanoparticle characterisation with TEM 
The synthesised lactose-C11Pc-AuNPs and lactose-C3Pc-AuNPs were characterised 
using TEM, as described previously in section 2.2.3. 
 
2.3.4. Measurement of singlet oxygen production for lactose-Pc-AuNPs 
Production of 1O2 was measured using the singlet oxygen probe ABMA, as previously 
explained in section 2.2.7.  
 
2.3.5. Synthesis of C11Pc/C3Pc-sPEG-AuNPs 
Gold nanoparticles were synthesised by NaBH4 reduction and functionalised with a 
mixed monolayer of either C11Pc or C3Pc and thiol-dPEG®4-acid (sPEG), a PEG ligand 
with a chain simulating the length of the lactose ligand. C11Pc (2.43 mg; 0.95 μmol) or 
C3Pc (2.22 mg; 0.95 μmol) were dissolved in dry THF (1 mL) and left to stir at room 
temperature. Then, sPEG (0.51 mg; 1.8 μmol) was dissolved in dH2O (1.9 mL), added to 
the phthalocyanine solutions and stirred at room temperature for 5 min. HAuCl4∙3H2O 
(1.2 mg; 3.0 μmol) was dissolved in dH2O (1.2 mL), added to the Pc-sPEG mixtures and 
stirred at room temperature for a further 5 min. Finally, a solution of NaBH4 (1.5 mg; 
39.65 μmol) was prepared in dH2O (1.2 mL) and added to the previous mixtures rapidly 
and under vigorous stirring. The reaction was stirred overnight (ca. 17 h) at room 
temperature in the dark at moderate speed.  
The resulting solution was a mixture of free Pc, AuNPs functionalised with Pc only, 
AuNPs functionalised with sPEG only and AuNPs functionalised with both Pc and sPEG. 
To purify the mixture, excess dry THF (5.4 mL) was added rapidly and under vigorous 
stirring, followed by centrifugation in Eppendorf tubes (1.5 mL) at 1,300 rpm for 2 min 
at 4 °C. The supernatant was collected and the brown pellet containing AuNPs 
functionalised only with sPEG was discarded. The solvent mixture in the supernatant 
was evaporated by rotary evaporation under reduced pressure at 70 °C. For further 
purification, more excess THF (5.4 mL) was added, followed by the same centrifugation 
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and evaporation steps as explained previously. Once all the THF had been evaporated, 
MES buffer (5 mL) was added and the solubilisation was assisted using an ultrasonic 
bath. The solution was centrifuged in Eppendorf tubes (1.5 mL) at 14,000 rpm for 
30 min at 4 °C. The pellet containing free Pc and AuNPs functionalised only with Pc, and 
thus not soluble in an aqueous solution, was discarded. The supernatant containing the 
Pc-sPEG-AuNPs was collected and filtered through a Millex GP syringe driven filter unit 
(0.22 μm). The synthesised Pc-sPEG-AuNPs were characterised using UV-vis 
spectroscopy between 300-800 nm and the solutions were stored at 4 °C. 
 
2.3.6. Synthesis of control sPEG-AuNPs 
Control AuNPs functionalised with sPEG but without photosensitiser were synthesised 
following the method described in section 2.2.6. A solution of sPEG (1.44 mg; 5.1 μmol) 
in dH2O (15 mL) was prepared and left to stir at room temperature. Then, HAuCl4∙3H2O 
(1.2 mg; 3.0 μmol) was dissolved in THF (1.2 mL), added to the sPEG solution and stirred 
at room temperature for 5 min. A fresh solution of NaBH4 (1.5 mg; 39.65 μmol) in dH2O 
(0.5 mL) was prepared and added to the sPEG-HAuCl4 mixture. The reaction was stirred 
for a further 4 h at room temperature. Purification of the AuNPs was then performed. 
Firstly, the THF was evaporated by rotary evaporation under reduced pressure at 60 °C. 
The final solution in dH2O was transferred to vivaspin™ 500 columns and centrifuged 
at 14,000 rpm for 10 min at 4 °C. The sPEG-AuNPs were resuspended in McCOY’s 5A 
phenol red-free, FBS free medium (2 mL) containing L-glutamine and filtered through 
a Millex GP syringe driven filter unit (0.22 μm). The UV-vis extinction spectrum was 
recorded between 250-800 nm. The sPEG-AuNPs were stored at room temperature. 
 
2.3.7. MTT cell viability assay for lactose targeting 
SK-BR-3 human breast adenocarcinoma cells and MDA-MB-231 human breast 
adenocarcinoma cells were dislodged from the flasks by trypsination and counted as 
described in section 2.1.4.1. The cells were then seeded following the procedure 
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described in section 2.2.9 and incubated for ca. 48 h at 37 °C under a 5 % CO2 
atmosphere. 
The culture medium was removed using a micropipette and the cells were washed once 
with PBS-B (100 μL). The nanoparticle samples, lactose-C11Pc-AuNPs and control 
C11Pc-sPEG-AuNPs together with lactose-C3Pc-AuNPs and control C3Pc-sPEG-AuNPs, 
dissolved in FBS-free McCOY’s 5A medium containing L-glutamine at various Pc 
concentrations were then added (50 μL/well). Additionally, a solution of staurosporine 
(1 mM in DMSO) dispersed in FBS-free McCOY’s 5A medium containing L-glutamine 
(50 μL; 20 μM) was used as a positive control for cytotoxicity. Control cells without any 
AuNPs loaded were treated with FBS-free McCOY’s 5A medium containing L-glutamine. 
SK-BR-3 cells were incubated with the samples and controls for 3 h at 37 °C under a 5 % 
CO2 atmosphere. MDA-MB-231 cells were incubated with the samples and controls for 
24 h at 37 °C under a 5 % CO2 atmosphere. 
Following incubation with the AuNPs and controls, the subsequent steps in these MTT 
assays, including cell irradiation, post-PDT incubation and MTT addition and reading, 
were performed following the procedure described in section 2.2.9. Statistical 
significance between means was determined using a two-tailed Student’s t-test and P 
values < 0.05 were considered significant.11 
 
2.3.8. CellTiter-Blue® cell viability assay for lactose targeting 
SK-BR-3 human breast adenocarcinoma cells, MDA-MB-231 human breast 
adenocarcinoma cells and MCF-10A human mammary epithelial cells were dislodged 
from the flasks by trypsination and counted as explained in section 2.1.4.1. The cells 
were then seeded following the procedure described in section 2.2.9 and incubated for 
ca. 48 h at 37 °C under a 5 % CO2 atmosphere. 
The cells were treated with the lactose-C11Pc-AuNPs, lactose-C3Pc-AuNPs, C11Pc-
sPEG-AuNPs and C3Pc-sPEG-AuNPs samples as well as the control samples as explained 
in section 2.3.7. SK-BR-3 and MDA-MB-231 cells were incubated with the samples and 
controls as described previously in section 2.3.7. MCF-10A cells were incubated with 
the samples and controls for either 3 h or 24 h at 37 °C under a 5 % CO2 atmosphere. 
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Following incubation with the AuNPs and controls, the subsequent steps for these 
CellTiter-Blue® cell viability assays were performed following the procedures described 
in section 2.2.9, for cell irradiation and post-PDT incubation, and section 2.2.10, for 
CellTiter-Blue® addition and reading. Statistical significance between means was 
determined using a two-tailed Student’s t-test and P values < 0.05 were considered 
significant.11 
 
2.3.9. Confocal microscopy   ̶ Internalisation and PDT of lactose-C3Pc-AuNPs  
The internalisation of lactose-C3Pc-AuNPs by SK-BR-3 and MDA-MB-231 human breast 
adenocarcinoma cells was studied using confocal laser scanning microscopy. For the 
following imaging experiments, SK-BR-3 cells were cultured in phenol red-free McCOY’s 
5A medium containing L-glutamine and supplemented with FBS (10 %). MDA-MB-231 
cells were cultured in high glucose DMEM medium supplemented with L-glutamine 
(1 %), FBS (10%) and sodium pyruvate (1 mM).  
SK-BR-3 and MDA-MB-231 cells were dislodged from the flasks by trypsination and 
counted as explained in section 2.1.4.1. The cells were then seeded onto 18 mm 
diameter glass coverslips inside Nunc 6-well multidishes at a concentration of 
2×104 cells/mL (3 mL/well). The cells were incubated for ca. 48 h at 37 °C under a 5 % 
CO2 atmosphere. The culture medium was removed and the cells were washed with 
PBS-B (1 mL) once. Lactose-C3Pc-AuNPs (0.17 μM C3Pc) dissolved in FBS-free McCOY’s 
5A medium containing L-glutamine were added (1 mL/well). Control cells not loaded 
with AuNPs were treated with FBS-free McCOY’s 5A medium containing L-glutamine 
(1 mL). SK-BR-3 cells were incubated with the lactose-C3Pc-AuNPs and the control for 
3 h at 37 °C under a 5 % CO2 atmosphere. MDA-MB-231 cells were incubated with the 
lactose-C3Pc-AuNPs and the control for either 3 h or 24 h at 37 °C under a 5 % CO2 
atmosphere. Following incubation with the samples, the subsequent steps in these 
confocal microscopy experiments follow the procedure already described in section 
2.2.11, including irradiation, post-PDT incubation, imaging conditions and testing with 
propidium iodide.  
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2.3.10. InCell ELISA to quantify the levels of galectin-1 on the cell surface 
An InCell ELISA was performed to study the difference in the levels of the galectin-1 
receptor on the surface of MDA-MB-231 cells and SK-BR-3 cells. MDA-MB-231 and SK-
BR-3 cells were dislodged from the flasks by trypsination and counted as explained in 
section 2.1.4.1. The cells were seeded onto a clear-bottom Nunc Nunclon™ Δ Surface 
96- well microplate at a concentration of 10×104 cells/mL (100 μL/well). The cells were 
incubated overnight at 37 °C under a 5 % CO2 atmosphere. 
The culture medium was removed for both cell lines and the cells were washed with 
PBS-B (100 μL) once. A solution of staurosporine (1 mM in DMSO) dispersed in FBS-free 
McCOY’s 5A medium containing L-glutamine (50 μL; 20 μM) was used as a positive 
control for cytotoxicity. Control cells, to detect the levels of galectin-1, were treated 
with FBS-free McCOY’s 5A medium containing L-glutamine (50 μL). Both cell lines were 
incubated with the samples and controls for 3 h at 37 °C under a 5 % CO2 atmosphere.  
During the incubation period, the required buffers for the InCell ELISA were prepared, 
as described in section 2.2.13. Following incubation with the positive control, the 
samples were removed and the cells were washed with PBS-B (100 μL) three times and 
resuspended in the appropriate complete cell culture media, McCOY’s 5A for SK-BR-3 
cells and DMEM for MDA-MB-231 cells. The cells were then fixed with formaldehyde 
and treated with blocking buffer as described in section 2.2.13. While the cells were 
incubated with blocking buffer, the primary antibody was appropriately diluted. In this 
experiment, the primary antibody used was anti-galectin-1 antibody. Anti-galectin-1 
antibody (1 μL; 1.604 mg/mL in a solution containing PBS (49 %), sodium azide (0.01 %), 
glycerol (50 %) and BSA (0.05 %)) was diluted in the blocking-washing solution 
(1.603 mL) previously prepared, to give a final concentration of 1 μg/mL. Following 
incubation of the cells with blocking buffer, the blocking buffer was removed with a 
micropipette and anti-galectin-1 antibody (50 μL; 1 μg/mL) was added to each well. 
Non-specific signal control wells, i.e., cells not incubated with primary antibody, were 
incubated with blocking-washing solution (50 μL) not containing the antibody instead. 
The microplate was sealed with a plate sealer and the cells were incubated with the 
primary antibody overnight (ca. 17 h) at 4 °C. Following incubation with the primary 
antibody, the development of an absorbance signal for the levels of galectin-1 present 
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in each sample was obtained following the procedure outlined in section 2.2.13. 
Additionally, whole-cell staining to normalise the values of galectin-1 to cell number in 
each well was also performed in the same way as described in section 2.2.13. 
 
2.3.11. InCell ELISA to detect lactose targeting 
An InCell ELISA to study the targeting ability of lactose towards the galectin-1 receptor 
on the surface of MDA-MB-231 and SK-BR-3 cells was performed. MDA-MB-231 and 
SK-BR-3 cells were seeded onto a clear-bottom Nunc Nunclon™ Δ Surface 96-well 
microplate as described in section 2.3.10. 
The culture medium was removed with a micropipette and the cells were washed with 
PBS-B (100 μL) once. The nanoparticle samples, lactose-C11Pc-AuNPs and C11Pc-sPEG-
AuNPs together with lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs (0.2 μM Pc), dissolved 
in FBS-free McCOY’s 5A medium containing L-glutamine, were then added (50 μL/well). 
Additionally, a solution of staurosporine (1 mM in DMSO) dispersed in FBS-free 
McCOY’s 5A medium containing L-glutamine (50 μL; 20 μM) was used as a positive 
control for cytotoxicity. Control cells not loaded with any AuNPs samples were treated 
with FBS-free McCOY’s 5A medium containing L-glutamine (50 μL). The cells were 
incubated with the samples and controls for either 3 or 24 h at 37 °C under a 5 % CO2 
atmosphere. Following incubation with the AuNPs samples, the InCell ELISA was 
performed following the procedure described in section 2.2.13. The primary anti-
galectin-1 antibody solution was prepared as explained previously in section 2.3.10. 
 
2.3.12. ApoTox-Glo™ Triplex assay  ̶  Targeting with lactose-C3Pc-AuNPs 
SK-BR-3 and MDA-MB-231 cells were dislodged from the flasks by trypsination and 
counted as explained in section 2.1.4.1. The cells were seeded onto two white-bottom 
Nunc Nunclon™ Δ Surface 96-well microplates at 18×104 cells/mL (100 μL/well) and 
incubated for ca. 48 h at 37 °C under a 5 % CO2 atmosphere. 
The culture medium was removed using a micropipette and the cells were washed once 
with PBS-B (100 μL). The nanoparticle samples, lactose-C3Pc-AuNPs and C3Pc-sPEG-
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AuNPs (0.2 μM) in FBS-free McCOY’s 5A medium containing L-glutamine, were then 
added (50 μL/well). Additionally, a solution of staurosporine (1 mM in DMSO) dispersed 
in FBS-free McCOY’s 5A medium containing L-glutamine (50 μL; 20 μM) was used as a 
positive control for cytotoxicity via apoptosis. Control cells without any AuNPs loaded 
were treated with FBS-free McCOY’s 5A medium containing L-glutamine. SK-BR-3 cells 
were incubated with the samples and controls for 3 h at 37 °C under a 5 % CO2 
atmosphere. MDA-MB-231 cells were incubated with the samples and controls for 24 h 
at 37 °C under a 5 % CO2 atmosphere. Following incubation with the AuNPs samples 
and the controls, the subsequent steps of the ApoTox-Glo™ triplex assay including 
irradiation, post-PDT incubation and addition of the assay components, were 
performed following the procedure described in section 2.2.14.  
 
2.4. The potential use of upconverting nanoparticles as drug carriers for 
photodynamic therapy of cancer 
2.4.1. Synthesis of upconverting nanoparticles 
All the upconverting nanoparticles (UCNPs) used throughout this thesis were 
synthesised by Markus Buchner, PhD student in the group of Dr Thomas Hirsch 
(Institute for Analytical Chemistry, University of Regensburg, Regensburg, Germany).  
The first type of UCNPs studied were dispersed in dimethyl sulfoxide (DMSO). UCNPs 
made of sodium yttrium fluoride (NaYF4) doped with 20 % ytterbium (Yb3+), 2 % erbium 
(Er3+) and 20 % gadolinium (Gd3+) were synthesised. The UCNPs were further modified 
with a NaYF4 shell, giving rise to 17.2 nm UCNPs. The core-shell UCNPs were then 
surface-modified to be functionalised with lysine and the photosensitiser Rose Bengal 
(NaYF4-lysine-RB UCNPs).  
The second type of UCNPs studied were dispersed in dH2O. UCNPs made of NaYF4 
doped with 20 % Yb3+, 2 % Er3+ and 10 % Gd3+ were synthesised. The UCNPs were 
further modified with a NaYF4 shell, giving rise to 28 nm UCNPs. The ligand polyacrylic 
acid (PAA) was used to modify the surface of the UCNPs in order to provide aqueous 
83 
 
solubility to the system. The resulting UCNPs (NaYF4-PAA UCNPs) were only 
functionalised with PAA and no Rose Bengal.  
 
2.4.2. Characterisation of the UCNPs 
The UCNPs were characterised using TEM and luminescence spectroscopy, all obtained 
by Markus Buchner at the University of Regensburg.  
TEM images were obtained using a Philips CM12 Electron Microscope (MicroCal) 
operating at 120 kV and analysed using ImageJ and Origin 8 software. Luminescence 
spectra of the samples were recorded using an Amicron Bowman Series 2 spectrometer 
(Thermo Electron Corporation) coupled with a 200 mW continuous-wave laser 
(λex = 980 nm) between 400-700 nm. 
 
2.4.3. Measurement of singlet oxygen production by UCNPs 
Production of singlet oxygen (1O2) was measured using the singlet oxygen probe ABMA, 
as described in section 2.2.7. The 17.2 nm NaYF4-lysine-RB UCNPs in DMSO and the 
28 nm NaYF4-PAA UCNPs in dH2O were tested for 1O2 production with ABMA at various 
concentrations. Each solution (511 μL) was placed in a 1.5 mL quartz cuvette together 
with ABMA (1 μL; 0.512 mM in MeOH) and a magnetic stirrer bar. Oxygen was bubbled 
through the solutions and the stoppers were fitted on the quartz cuvettes. The 
fluorescence emission intensity of the initial solutions was recorded, between 390-
600 nm, using an excitation wavelength of 380 nm. The samples were then irradiated 
at 980 nm using a 200 mW NIR laser for 40 min with continuous stirring. The laser was 
placed at ca. 5 cm from the samples. A NIR detector card was placed behind the 
cuvettes during irradiation to be able to place the laser light passing through the sample 
inside the cuvette. The fluorescence emission spectrum of the samples was recorded 
every 5 min.  
 
84 
 
2.4.4. Internalisation of NaYF4-lysine-RB UCNPs by SK-BR-3 cells   ̶  Confocal 
microscopy and multi-photon microscopy 
The internalisation of the 17.2 nm NaYF4-lysine-RB UCNPs in DMSO by SK-BR-3 cells 
was studied using both confocal microscopy and multi-photon microscopy. SK-BR-3 
cells were cultured in phenol red-free McCOY’s 5A medium containing L-glutamine and 
supplemented with FBS (10 %) for these imaging experiments. The SK-BR-3 cells were 
seeded on 18 mm glass coverslips and incubated for ca. 48 h at 37 °C under a 5 % CO2 
atmosphere, as described in section 2.2.11. 
The cells were then washed with PBS-B (1 mL) once. The cells were treated with a 
25 μg/mL solution of the 17.2 nm NaYF4-Lysine-RB UCNPs in DMSO dispersed in FBS-
free McCOY’s 5A medium (1 mL) containing L-glutamine. The control cells, not loaded 
with any UCNPs, were treated with FBS-free McCOY’s 5A medium (1 mL) containing L-
glutamine. The cells were incubated for 3 h at 37 °C under a 5 % CO2 atmosphere. 
Following incubation, the cells were washed three times with PBS (1 mL) and kept in 
McCOY’s 5A medium (2 mL) containing L-glutamine and supplemented with FBS (10 %). 
Subsequently, the cells were imaged. For imaging, the 18 mm coverslips were placed 
in a Ludin chamber, which was securely tightened. The coverslips were washed with 
imaging medium (ca. 1 mL) three times and finally resuspended in imaging medium 
(ca. 1 mL). The Ludin chamber was fitted on a heating stage at 37 °C in either the 
confocal microscope or the multi-photon microscope.  
For imaging using the confocal microscope, a 543 nm HeNe laser was used to excite the 
Rose Bengal on the surface of the NaYF4-lysine-RB UCNPs. The fluorescence emission 
was collected in the red channel with a band pass filter between 560-615 nm. DIC 
images were collected simultaneously using a 488 nm argon-ion laser.  
For imaging using the multi-photon microscope, the 880 nm line from a Vision II 
Ti:Sapphire laser (Coherent Ltd., Ely, UK) was used to excite the Rose Bengal on the 
surface of the NaYF4-lysine-RB UCNPs. The fluorescence emission was collected in the 
green channel at 550 ± 42.5 nm. DIC images were collected simultaneously with the 
same 880 nm laser. Additionally, the 980 nm line from the Vision II Ti:Sapphire laser 
was used to collect the luminescence of the UCNPs. The emission was collected with 
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two non-descanned GaAsP detectors in the green channel at 550 ± 42.5 nm and in the 
red channel at 655 ± 20 nm. 
 
2.4.5. PDT effect of NaYF4-lysine-RB UCNPs on SK-BR-3 cells   ̶ Confocal microscopy 
The PDT effect of the 17.2 nm NaYF4-lysine-RB UCNPs in DMSO on SK-BR-3 cells was 
studied using confocal microscopy. SK-BR-3 cells were cultured in phenol red-free 
McCOY’s 5A medium containing L-glutamine and supplemented with FBS (10 %) for 
these imaging experiments. The SK-BR-3 cells were seeded on 18 mm glass coverslips, 
in two 6-well multidishes, and incubated for ca. 48 h at 37 °C under a 5 % CO2 
atmosphere, as described in section 2.2.11. The cells were then washed with PBS-B 
(1 mL) once. The cells were treated with a 15 μg/mL solution of the 17.2 nm NaYF4-
lysine-RB UCNPs in DMSO dispersed in FBS-free McCOY’s 5A medium (1 mL) containing 
L-glutamine. The control cells, not loaded with any UCNPs, were treated with FBS-free 
McCOY’s 5A medium (1 mL) containing L-glutamine. All solutions, control and UCNPs, 
contained a 0.25 % culture grade DMSO. The cells were incubated for 3 h at 37 °C under 
a 5 % CO2 atmosphere. 
Following incubation, the cells were washed three times with PBS (1 mL) and kept in 
McCOY’s 5A medium (2 mL) containing L-glutamine and supplemented with FBS (10 %). 
At this point, one of the 6-well multidishes was irradiated at 980 nm using a 200 mW 
NIR laser for 6 min per coverslip. The laser was located 5 cm above the 6-well multidish. 
A NIR detector card was placed under the well containing the coverslip during the 
irradiation of the sample to be able to place the laser light at the centre of the treated 
coverslip. The other 6-well multidishes, which were not irradiated, were kept covered 
in aluminium foil in the dark during irradiation. Following irradiation, the cells were 
further incubated for ca. 24 h at 37 °C under a 5 % CO2 atmosphere prior to imaging. 
For imaging, the cells were treated, placed on the confocal microscope and analysed 
using the same conditions as described in section 2.4.4. Propidium iodide, to test for 
dead cell staining, was also added and analysed under the same conditions as those 
described in section 2.2.11. 
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2.4.6. CellTiter-Blue® cell viability assay  ̶  NaYF4-lysine-RB UCNPs  
The 17.2 nm NaYF4-lysine-RB UCNPs in DMSO were tested for PDT of SK-BR-3 human 
breast adenocarcinoma cells. SK-BR-3 cells were dislodged from the flasks by 
trypsination and counted as described in section 2.1.4.1. The cells were then seeded 
following the procedure described in section 2.2.9 and incubated for ca. 48 h at 37 °C 
under a 5 % CO2 atmosphere. 
The culture medium was removed using a micropipette and the cells were washed once 
with PBS-B (100 μL). The NaYF4-lysine-RB UCNPs in DMSO were dispersed in FBS-free 
McCOY’s 5A medium containing L-glutamine at concentrations ranging from 5-
25 μg/mL (50 μL/well). All samples with varying concentrations of UCNPs contained a 
constant amount of 0.25 % DMSO, to account for possible solvent effects on the cells. 
Two solvent control consisting of culture grade DMSO (0.25 %) or culture grade DMSO 
(100 %) dispersed in FBS-free McCOY’s 5A medium containing L-glutamine (50 μL) were 
also used to test the effect of DMSO alone on the cells. Control cells, not loaded with 
any UCNPs, were treated with FBS-free McCOY’s 5A medium containing L-glutamine. 
Additionally, a solution of staurosporine (1 mM in DMSO) dispersed in FBS-free 
McCOY’s 5A medium containing L-glutamine (50 μL; 20 μM) was used as a positive 
control for cytotoxicity. The samples and controls were incubated with the SK-BR-3 cells 
for 3 h at 37 °C under a 5 % CO2 atmosphere. 
Following incubation with the UCNPs and controls, the samples were removed and the 
cells were washed with PBS-B (100 μL) three times. The cells were then resuspended in 
complete McCOY’s 5A medium (100 μL) containing L-glutamine and supplemented with 
FBS (100 %). At this point, one of the plates was irradiated at 980 nm using a 200 mW 
NIR laser for 6 min per well. The laser was located 5 cm above the 96-well plate. The 
plate not being irradiated was kept covered in aluminium foil in the dark. Following 
irradiation, the cells were further incubated for ca. 48 h at 37 °C under a 5 % CO2 
atmosphere. Addition of the CellTiter-Blue® reagent, incubation and fluorescence 
measurements were performed following the procedure explained in section 2.2.10.  
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2.4.7. Determination of the extinction coefficient of Rose Bengal 
Rose Bengal (2 mg) was dissolved in dH2O (5 mL) giving an initial concentration of 
393 μM. This initial RB solution was then further diluted with dH2O to obtain 
concentrations ranging from 0-3 μM. These dilutions were prepared in volumetric 
flasks (1 mL). The dilutions were analysed by UV-vis spectroscopy between 300-800 nm 
starting with the lowest concentration. A calibration curve at 549 nm was created and 
a value for the extinction coefficient was obtained. 
 
2.4.8. ApoTox-Glo™ Triplex assay  ̶  NaYF4-lysine-RB UCNPs  
SK-BR-3 cells were dislodged from the flasks by trypsination and counted as explained 
in section 2.1.4.1. The cells were seeded onto two white-bottom Nunc Nunclon™ Δ 
Surface 96-well microplates at a concentration of 18×104 cells/mL (100 μL/well). The 
cells were incubated for ca. 48 h at 37 °C under a 5 % CO2 atmosphere. The culture 
medium was removed using a micropipette and the cells were washed once with PBS-
B (100 μL). The cells were treated with a 15 μg/mL solution of the 17.2 nm NaYF4-lysine-
RB UCNPs in DMSO dispersed in FBS-free McCOY’s 5A medium containing L-glutamine 
(50 μL). The control cells not loaded with any UCNPs were treated with FBS-free 
McCOY’s 5A medium containing L-glutamine (50 μL). Additionally, a solution of 
staurosporine (1 mM in DMSO) dispersed in FBS-free McCOY’s 5A medium containing 
L-glutamine (50 μL; 20 μM) was used as a positive control for cytotoxicity via apoptosis. 
All solutions, control and UCNPs, contained a 0.25 % culture grade DMSO. The cells 
were incubated with the samples and controls for 3 h at 37 °C under a 5 % CO2 
atmosphere. 
Following incubation with the UCNPs samples and the controls, the samples were 
removed and the cells were washed with PBS-B (100 μL) three times. The cells were 
then resuspended in complete McCOY’s 5A medium (100 μL) containing L-glutamine 
and supplemented with FBS (10 %). At this point, one of the plates was irradiated at 
980 nm using a 200 mW NIR laser for 6 min per well. The laser was located 5 cm above 
the 96-well plate. The plate not being irradiated was kept covered in aluminium foil in 
the dark. Prior to measuring cell viability, cytotoxicity and apoptosis, the cells were 
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further incubated for 4 h at 37 °C under a 5 % CO2 atmosphere. The subsequent steps 
of the ApoTox-Glo™ triplex assay including reagent preparation and addition of the 
assay components, were performed following the procedure described in section 
2.2.14.  
 
2.4.9. CellTiter-Blue® cell viability assay  ̶  UCNPs in dH2O without Rose Bengal 
The 28 nm NaYF4-PAA UCNPs in dH2O were tested in vitro using SK-BR-3 cells to 
determine their cytotoxicity before and after irradiation at 980 nm. SK-BR-3 cells were 
seeded in white-bottom 96-well plates following the procedure described in section 
2.2.9. Following the seeding of the cells, the NaYF4-PAA UCNPs samples in dH2O were 
dispersed in FBS-free McCOY’s 5A medium containing L-glutamine at concentrations 
ranging from 10-25 μg/mL. All samples with varying concentrations of UCNPs contained 
a constant amount of 0.63 % dH2O. Additionally, a solvent control consisting of dH2O 
(0.63 %) dispersed in FBS-free McCOY’s 5A medium containing L-glutamine (50 μL) was 
used to test the effect of dH2O alone on the cells. A positive control, consisting of a 
solution of staurosporine (1 mM in DMSO) dispersed in FBS-free McCOY’s 5A medium 
containing L-glutamine (50 μL; 20 μM) was used as a positive control for cytotoxicity. 
Negative control cells, not loaded with any UCNPs samples, were treated with FBS-free 
McCOY’s 5A medium containing L-glutamine (50 μL). The samples and controls were 
incubated with the SK-BR-3 cells for 3 h at 37 °C under a 5 % CO2 atmosphere. Following 
incubation with the UCNPs and the controls, the samples were treated and irradiated 
following the procedure described in section 2.4.6. Addition of the CellTiter-Blue® 
reagent, incubation time and measurement of the fluorescence emission intensity 
were performed following the procedure explained in section 2.2.10. 
 
2.4.10. Confocal microscopy   ̶ UCNPs in dH2O without Rose Bengal 
The toxicity of the 28 nm NaYF4-PAA UCNPs in dH2O was further studied using confocal 
microscopy, to confirm the visual appearance of the cells following incubation with the 
UCNPs samples. SK-BR-3 cells were cultured in phenol red-free McCOY’s 5A medium 
containing L-glutamine and supplemented with FBS (10 %) for these imaging 
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experiments. The SK-BR-3 cells were seeded on 18 mm glass coverslips in two 6-well 
multidishes and incubated for ca. 48 h at 37 °C under a 5 % CO2 atmosphere, as 
described in section 2.2.11. 
The cells were then washed with PBS-B (1 mL) once. The cells were treated with a 
25 μg/mL solution of the 28 nm NaYF4-PAA UCNPs in dH2O dispersed in FBS-free 
McCOY’s 5A medium containing L-glutamine (1 mL). The control cells not loaded with 
any UCNPs were treated with FBS-free McCOY’s 5A medium containing L-glutamine 
(1 mL). The cells were incubated for 3 h at 37 °C under a 5 % CO2 atmosphere.  
Following incubation with the UCNPs and the control, the cells were irradiated, placed 
on the confocal microscope and analysed using the same conditions as described in 
section 2.4.5. Propidium iodide, to test for dead cell staining, was also added and 
analysed under the same conditions as those described in section 2.2.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
2.5. References 
(1) Chambrier, I.; Cook, M. J.; Russell, D. A. Synthesis 1995, 10, 1283. 
(2) Revell, D. J.; Chambrier, I.; Cook, M. J.; Russell, D. A. J. Mater. Chem. 2000, 10, 
31. 
(3) Stuchinskaya, T.; Moreno, M.; Cook, M. J.; Edwards, D. R.; Russell, D. A. 
Photochem. Photobiol. Sci. 2011, 10, 822. 
(4) Obaid, G.; Chambrier, I.; Cook, M. J.; Russell, D. A. Photochem. Photobiol. Sci. 
2015, 14, 737. 
(5) Grabarek, Z.; Gergely, J. Anal. Biochem. 1990, 185, 131. 
(6) Staniford, M. C.; Lezhnina, M. M.; Gruener, M.; Stegemann, L.; Kuczius, R.; 
Bleicher, V.; Strassert, C. A.; Kynast, U. H. Chem. Comm. 2015, 51, 13534. 
(7) Hone, D. C.; Walker, P. I.; Evans-Gowing, R.; FitzGerald, S.; Beeby, A.; Chambrier, 
I.; Cook, M. J.; Russell, D. A. Langmuir 2002, 18, 2985. 
(8) Bertrand, R.; Solary, E.; O’Connor, P.; Kohn, K. W.; Pommier, Y. Exp. Cell Res. 
1994, 211, 314. 
(9) Mosmann, T. J. Immunol. Methods 1983, 65, 55. 
(10) Roy, I.; Ohulchanskyy, T. Y.; Pudavar, H. E.; Bergey, E. J.; Oseroff, A. R.; Morgan, 
J.; Dougherty, T. J.; Prasad, P. N. J. Am. Chem. Soc. 2003, 125, 7860. 
(11) Rodriguez, L.; Vallercosa, P.; Battah, S.; Di Venosa, G.; Calvo, G.; Mamone, L.; 
Sáenz, D.; Gonzalez, M. C.; Batlle, A.; MacRobert, A. J.; Casas, A. Photochem. 
Photobiol. Sci. 2015, 14, 1617. 
(12) O’Brien, J.; Wilson, I.; Orton, T.; Pognan, F. Eur. J. Biochem. 2000, 267, 5421. 
(13) Obaid, G.; Chambrier, I.; Cook, M. J.; Russell, D. A. Angew. Chem., Int. Ed. 2012, 
51, 6158. 
(14) Marín, M. J.; Galindo, F.; Thomas, P.; Russell, D. A. Angew. Chem., Int. Ed. 2012, 
124, 9795. 
(15) Sasaki, D. T.; Dumas, S. R.; Engleman, E. G. Cytometry 1987, 8, 413. 
(16) Thermo Fisher Scientific. InCell ELISA Colorimetric Detection Kit   ̶ Catalog 
number 62200 https://www.thermofisher.com/order/catalog/product/62200 
[Accessed Jan 13th, 2017]. 
(17) Promega. ApoTox-Glo™ Triplex Assay   ̶ Catalog number G6320 
https://www.promega.co.uk/products/cell-health-and-metabolism/apoptosis-
assays/apotox_glo_triplex_assay/ [Accessed Jan 13th, 2017]. 
(18) Niles, A. L.; Moravec, R. A.; Hesselberth, P. E.; Scurria, M. A.; Daily, W. J.; Riss, 
T. L. Anal. Biochem. 2007, 366, 197. 
91 
 
Chapter 3 
Gold nanoparticle enhanced and selective antibody 
targeting photodynamic therapy of breast cancer cells 
This chapter describes the use of gold nanoparticles functionalised with a zinc 
phthalocyanine photosensitiser for photodynamic therapy (PDT) of breast 
adenocarcinoma cells. Two zinc phthalocyanines differing in the length of the carbon 
chain that connects the macrocycle to the surface of the gold nanoparticles were 
compared in terms of singlet oxygen production and PDT efficacy. Additionally, the 
selectivity towards breast cancer cells was increased by addition of a targeting agent, 
anti-HER2 antibody. 
 
3.1. Introduction 
3.1.1. Interactions between metal nanoparticles and fluorophores 
The synthesis and applications of metal nanoparticles have become the subject of 
numerous studies over the years.1 The optical, electronic and chemical properties of 
metal nanoparticles change dramatically from those properties encountered in the 
bulk metal and are dependent on both the size and shape of the synthesised 
nanoparticles.1,2 A particularly interesting property in metal nanoparticles is their 
ability to interact with fluorophores anchored to their surface. Consequently, the study 
of the metal nanoparticle-fluorophore interactions is of particular interest amongst the 
scientific community. Several studies confirm the quenching ability of metal 
nanoparticles on the surrounding fluorophores, while other studies show the opposite 
behaviour, an enhancement in the fluorescence of the fluorophore.3 
One of the most important characteristics of metal nanoparticles, that is significant in 
the study of metal nanoparticles-fluorophore interactions, is surface plasmon 
resonance (SPR).4 The SPR refers to the collective oscillation of the electrons in the 
conduction band of the metal upon interaction with electromagnetic (EM) energy.2,4-6 
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The oscillating electrons, referred to as plasmons, oscillate at the same frequency as 
the electromagnetic wave.4 These oscillations are dependent on the size and shape of 
the nanoparticles, but also on the dielectric constants of both the metal and the 
surrounding material.1 The SPR is responsible for the strong ultraviolet-visible (UV-vis) 
absorption bands, the intense colours seen in solutions of metal nanoparticles as well 
as the ability of metal nanoparticles to both absorb and scatter light.2,4,5 Two types of 
SPR are seen, localised SPR (LSPR) and propagating surface plasmon polaritons (SPPs).7 
LSPR are the confined, non-propagating oscillations while the SPPs are the propagating 
charge oscillations of the electrons on the surface of the metals.7,8 
The SPR and plasmon field created by metal nanoparticles, dependent on the field 
strength upon exposure to incident light, are responsible for the effects observed in 
the fluorescence of fluorophores placed near-by.9 Metal nanoparticles have a 
reputation for being strong fluorescence quenchers, which has been shown 
experimentally in a variety of studies.5,10-16 However, the potential use of metal 
nanoparticles as fluorescence enhancers has also been studied.7,8,17-20 The concept of 
fluorescence enhancement by metallic surfaces was introduced in the 1960s by 
Drexhage and co-workers when they discovered that the decay times of a fluorophore 
could be altered in the presence of a metallic film in a distance-dependent 
manner.19,21,22 Research has continued18,23-29 but it was not until 2002 that the term 
metal-enhanced fluorescence (MEF) was coined by Geddes and Lakowicz.18 Since then, 
the interest in the theory and applications of MEF has gained more attention and other 
researchers have referred to MEF as surface-enhanced fluorescence, plasmon-
enhanced fluorescence and metal-induced fluorescence enhancement.19,30 MEF refers 
to the phenomenon by which metal surfaces and metal nanoparticles increase the 
fluorescence intensity of the fluorophores in the near-field (i.e., near the metal surface, 
usually found within 10 nm), due to an enhanced excitation of the fluorophores.8,18 This 
fluorescence intensity is accompanied by an increase in the fluorescence quantum yield 
(φF), a decrease in the fluorescence lifetime and a higher photostability for the 
fluorophore.18,30 Applications in which MEF could be useful include biological sensors, 
activatable probes, fluorescence microscopy and also PDT.5,7,8,19,31 For PDT, several 
studies have been performed to understand whether this metal-enhanced 
fluorescence could lead to an enhancement in the formation of singlet oxygen, which 
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would thus lead to a higher cell kill.32-35 Indeed, these studies have found a correlation 
between MEF and a higher production of 1O2. In 2006, Geddes and co-workers 
experimentally showed metal-enhanced phosphorescence at low temperature for the 
photosensitiser Rose Bengal in the presence of silver island films.34 Following this, in 
2007 the Geddes’ group published the first report of metal-enhanced 1O2 production 
(ME1O2) by Rose Bengal in close proximity to such silver island films.33 Furthermore, 
ME1O2 was further highlighted in photosensitisers other than Rose Bengal and it was 
shown that certain properties, such as the size and shape of the nanoparticles, the 
distance of the fluorophore and the excitation wavelength of the photosensitiser could 
be modified in order to optimise the extent of ME1O2.35 Huang et al. additionally 
showed the application of ME1O2 in vitro for PDT by using gold nanorods functionalised 
with the photosensitiser chlorin e6.31 MEF and ME1O2 in this system contributed to a 
higher internalisation by HeLa cells and a higher phototoxicity and cell death. 
Therefore, the use of nanotechnology in PDT could lead to increased productions of 
1O2, which in turn could potentially produce an increased photodynamic efficiency.31 
The mechanism by which MEF occurs is still a subject of discussion.30 The groups of 
Geddes and Lakowicz have both proposed mechanisms, with slight differences, by 
which MEF can take place.18,30,36,37 Geddes and Lakowicz proposed the existence of 
three known pathways of interaction between fluorophores and metals.18,19,37 The first 
is non-radiative energy transfer from the fluorophore to the metal, which leads to 
fluorescence quenching. Non-radiative energy transfer is a dipole-dipole dominated 
transfer and is inversely proportional to the distance between the metal and the 
fluorophore (d-3) and thus it primarily occurs at small distances.18,19,37,38 The second 
pathway is the “antenna effect” by which metallic nanoparticles concentrate the 
incident electromagnetic field near the fluorophore, i.e., an increase in the rate of 
excitation, leading to an increase in emission intensity.18,19,37 In the third pathway, the 
metal increases the radiative decay rate of the fluorophore, leading to enhanced 
fluorescence quantum yields and thus fluorescence enhancement.18,19,37 Figure 3.1 
shows a schematic representation of the Jablonski diagram of the fluorophore with and 
without the presence of a metal, which is useful to understand the second and third 
pathways of interaction between metals and fluorophores. 
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Considering the three mechanisms of interaction between fluorophores and metals, it 
was initially proposed that the mechanism of MEF was mainly related to the 
modification of the radiative decay rate of the fluorophore by the close proximity to 
the metal.18,30 Therefore, MEF was thought to be dependent on the fluorescence 
quantum yield of the free fluorophore in solution, i.e., weakly fluorescence molecules 
lead to higher MEF efficiencies while the fluorescence of fluorophores with high 
quantum yields cannot be further enhanced.37,39 However, more recently, Geddes and 
co-workers have proposed a different mechanism underlying the complex interactions 
between fluorophores and metallic surfaces.30,36,40,41 The authors reported that MEF 
results from a combination of electric field effects and induced plasmon effects.36 The 
fluorophore and metal are coupled in the ground and excited states. Therefore, the 
energy of the excited state of the distal fluorophore is partially transferred to the 
surface plasmon of the metal, i.e., the fluorophore radiates through the scattering 
mode of the metal nanoparticle. The surface plasmon then radiates the coupled 
emission, known as quanta.30,42 The electric field and plasmon effects thus result in an 
increased absorption and emission of the fluorophores, an increase in the fluorescence 
emission by the coupled fluorophore-metal system and a decrease in the fluorescence 
Figure 3.1. Jablonski diagram for (A) a free fluorophore and (B) a fluorophore in the 
presence of a conducting metal. Exc represents the excitation rate, Excm the metal-
enhanced excitation rate and VR the non-radiative vibrational relaxation. Additionally, the 
decay rates of the fluorophore are given by the radiative decay rate Г, the metal-enhanced 
radiative decay rate Гm, and the non-radiative decay rate knr. The diagram was adapted 
from Ref. 18. 
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lifetime.36 In this new model, MEF is no longer dependent on the fluorescence quantum 
yield of the free fluorophore; instead there is a wavelength-dependence factor.40,41 
There are different variables that can determine the way in which a fluorophore and a 
metal can interact, thus leading to either fluorescence quenching or enhancement, 
including the choice of metal, the nanoparticle size and shape, the distance between 
the fluorophore and the metal nanoparticle, the nature of the anchor chain that 
connects the fluorophore to the metal core, the geometry adopted by the fluorophore 
relative to the metal nanoparticle, the orientation of the fluorophore’s molecular 
dipole relative to the nanoparticle surface and the spectral overlap between the metal 
nanoparticle and the fluorophore.5,7,8,10,13,22,37 The choice of the metal nanoparticle, 
either silver or gold, can affect the efficiency of MEF. The majority of the published 
reports describing MEF have chosen silver nanoparticles, which have been shown to 
produce high MEF efficiency.43 The use of gold nanoparticles for MEF has been 
overlooked due to gold being a strong fluorescence quencher, even at long distances.44 
However, recently the use of gold nanoparticles for MEF is becoming increasingly 
popular since it has several advantages over silver, including the high chemical stability, 
ease of synthesis and ease to modify the gold surface with biomolecules.44 The first 
report of the use of gold nanoparticles for MEF was performed by Geddes and co-
workers.43 By controlling the size of the nanoparticles and the position of the 
fluorophore relative to the gold nanoparticles, MEF was successfully obtained.43  
The radiating plasmon (RP) model developed by Lakowicz discussed the effect of 
nanoparticle size.20 As it was previously mentioned, metal nanoparticles have the 
ability to both absorb and scatter light. The size of the nanoparticle is the most 
important parameter that influences the efficiency of the absorption and scattering of 
the light. In small spherical nanoparticles (< 40 nm for gold nanoparticles; < 20 nm for 
silver nanoparticles), the light is mainly absorbed, while in larger nanoparticles 
(> 40 nm and especially > 80 nm for gold nanoparticles; > 30 nm for silver 
nanoparticles) the scattering component becomes more relevant.4,5,20,45,46 The RP 
model states that the absorption of light will lead to fluorescence quenching and the 
scattering will lead to fluorescence enhancement.20 As a result, small nanoparticles will 
induce the quenching of the fluorescence, whereas larger nanoparticles will be more 
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likely to induce MEF. The RP model suggested the ideal nanoparticle size for maximum 
fluorescence enhancement, for both silver and gold nanoparticles, to be ca. 40 nm.5,20 
However, other authors have reported the ideal size to be larger than 15 nm for MEF.7 
Recently, Xie and co-workers have challenged the assumption of nanoparticle size 
being relevant for MEF.8 These authors speculated that the extinction properties of 
metallic nanoparticles refer to isolated nanoparticles and not in the presence of a 
coupled system with a fluorophore.8 The shape of the nanoparticles can also influence 
the MEF efficiency to a given fluorophore.37 Lakowicz reported that the largest 
fluorescence enhancement is observed for spheroids.37 Spherical nanoparticles are not 
as efficient fluorescence enhancers and the fluorescence enhancement abilities of 
elongated spheroids are even lower.37 In accordance with Lakowicz, the group of Halas 
experimentally showed that the fluorescence quantum yield of a near-infrared 
fluorophore (IR800; φF = 7 %) was enhanced in the presence of gold nanoshells 
(φF = 86 %) with greater efficiency as compared to gold nanorods (φF = 74 %).45 
Additionally, Swierczewska et al. have reported that, in the case of gold nanoparticles, 
the spherical shape induces the highest fluorescence quenching efficiency.5 
Another important consideration for the quenching or enhancement of the 
fluorescence is the distance between the fluorophore and the metal core of the 
nanoparticles, as shown in Figure 3.2.2 If the fluorophore is placed too close to the 
metal (≤ 5 nm), all the fluorescence will be quenched due to the reduction in the 
oscillating dipole of the fluorophore, electron transfer and non-radiative energy 
transfer from the fluorophore to the metal. The mechanisms of energy transfer that 
best explain this phenomenon are nanometal surface energy transfer (NSET) and 
Fӧrster resonance energy transfer (FRET).5 Quenching by electron usually occurs in 
small nanoparticles (< 5 nm) since these particles present a weak SPR absorption band 
and thus spectral overlap with the fluorophore is poor, which limits the energy transfer 
between the fluorophore and the metal.47 On the other hand, if the fluorophore is 
placed too far from the metal there will be no real change in the fluorescence as the 
distance is too large for any effect to occur. The key for fluorescence enhancement is 
to find an intermediate optimum distance (ca. 5-20 nm; usually ≥ 10 nm) in which there 
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is an effective transfer of the free electrons of the fluorophore to the SPP in the metal 
due to the strong Purcell effect, and thus the fluorescence is enhanced.1-3,9,10,25,37,40,41,47  
 
The distance dependence between the metal and the fluorophore has not only been 
proven theoretically, but it has also been shown experimentally in several 
studies.3,6,9,48-50 Anger et al. showed the first report of the variable fluorescence 
behaviour depending on the distance between the nanoparticle and the fluorophore.3 
These authors found an optimal distance of 5 nm between 80 nm gold nanoparticles 
and a fluorescent molecule, which led to the maximum rate of fluorescence 
enhancement. Additionally Kang et al. studied the distance-dependence between the 
fluorescent dye cypate and 10 nm gold nanoparticles and they revealed similar results.9 
The fluorescence of cypate was completely quenched when it was placed directly on 
the surface of the gold, the fluorescence was significantly increased when it was 
located approximately 5 nm away but started to decrease again when the distance 
increased further. The effect of distance dependence for fluorescence quenching or 
enhancement has also been studied with other metals, especially silver. Cheng and Xu 
showed results for silver nanoparticles to be comparable to those reported for gold 
nanoparticles.50 The fluorescence of fluorescein isothiocyanate was studied as a 
function of its distance from 75 nm silver nanoparticles. The distance was modified 
using a silica (SiO2) spacer. When no spacer was used, the fluorescence was effectively 
quenched. However, when the SiO2 spacer was added, a maximum fluorescence 
Figure 3.2. Schematic representation showing the distance dependence between a metal 
nanoparticle and a fluorophore, leading to either fluorescence quenching or enhancement. 
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enhancement was found at a distance of 21 nm. This fluorescence enhancement 
decreased after reaching this optimal value upon further increasing the distance 
between the metal and the fluorophore.50 Also using silver as the metal, the Geddes 
group studied the distance dependence of MEF and found a similar trend of quenching 
and enhancement to that which had previously been reported.49 Of particular 
importance to the work reported in this thesis, a recent study by Planas et al. has shown 
that this distance-dependence not only influences MEF but also ME1O2.6 The authors 
synthesised 67 nm silver nanoparticles coated with a silica layer, which was modified 
with (3-aminopropyl)triethoxysilane (APTES). The photosensitiser Rose Bengal was 
then attached to the primary amines of APTES via carbodiimide coupling. The 
production of 1O2 by the Rose Bengal functionalised core-shell silver nanoparticles was 
studied. The thickness of the silica layer was modified from 5-100 nm to change the 
distance between the metal and the Rose Bengal. As previously stated, at short 
distances, there was complete quenching of the production of 1O2. However, as the 
distance was increased, the production of 1O2 reappeared, reaching a maximum value 
when the Rose Bengal was placed 11 nm away from the silver core. After this optimum 
distance of 11 nm was further increased, the production of 1O2 started to decrease.6  
The orientation adopted by the fluorophore and its molecular dipole relative to the 
metallic nanoparticle plays an important role in distance-dependent MEF. A 
perpendicular orientation relative to the surface of the nanoparticles can induce the 
maximum fluorescence-enhancement, due to the minimised possibility of non-
radiative energy transfer from the fluorophore to the metal nanoparticle.37 In a parallel 
orientation, quenching is allowed not only because of the possibility of energy transfer 
being enhanced but also due to the dipole in the metal cancelling the dipole in the 
fluorophore. The cancellation of the dipole further slows the radiative decay and 
favours the quenching of the fluorescence.37 The orientation of the fluorophore 
depends on the angle at which the chain connecting the fluorophore to the metal is 
positioned with respect to the metal core. Even though the angle between 
fluorophores and metal nanoparticles has not been widely studied, numerous 
researchers have reported investigations on the possible orientation of alkanethiol 
monolayers on gold surfaces.51-55 Russell and co-workers have studied the relative 
orientation of a zinc phthalocyanine self-assembled monolayer (SAM) on gold 
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surfaces.51,52 The phthalocyanines were connected to the gold surface via an alkyl chain 
containing 3, 8 or 11 carbon atoms. The authors reported that the chains in all three 
phthalocyanines were ca. 20-30 ° tilted from the gold surface. However, the orientation 
of the macrocycles adopted a parallel configuration relative to the gold surface for the 
C3 chain, in contrast to the longer chains, which adopted a more perpendicular 
orientation. As a result, the distance for the C3, C8 and C11 phthalocyanines from the 
surface was 4 Å, 10 Å and 13 Å, respectively. The authors found that the fluorescence 
was quenched for the C3 chain significantly, due to the closeness to the gold surface 
(4 Å), followed by the C8 (10 Å) and C11 (13 Å) chains, respectively. Additionally, the 
odd-even effect, i.e., whether the chain is composed of an odd or even number of 
carbon atoms, was found to be an important parameter that would determine the final 
position of each chain. If it is assumed that the chains are in an all-trans extended 
configuration, then the position of the phthalocyanine macrocycle will be different 
depending on the odd or even nature of the carbon chain. In fact, the C8 macrocycle 
was found to adopt a configuration that was not as perpendicular as the C11 nor as 
parallel as the C3.51 The odd-even effect has not only been reported in this study, it is 
a well-known phenomenon for SAMs on gold and silver surfaces.56 A more recent study 
by Battistini et al. was similar in that it compared the same molecule, a pyrene, linked 
to gold nanoparticles by a carbon chain that differed in length, either 4 carbon atoms 
(C4) or 11 carbon atoms (C11).48 In contrast to the study by Russell and co-workers, 
these authors found a decreased quenching effect for the molecule closer to the gold 
core (C4) as compared to the molecule that was placed further away (C11). This 
behaviour was also attributed to the angle between the gold surface and the 
fluorescent molecules, which was governed by the intra- and inter-molecular 
interactions, but was found to be unrelated to the odd-even effect. The nature of the 
chain that connects the fluorophore to the nanoparticle core was found to be the main 
parameter to determine the relative position of the pyrene with respect to the 
nanoparticle surface. The nature of the chain influences the stronger or weaker 
interactions between chains, such as van der Waals forces, which will induce the chains 
to be closer or further away from one another.48 In this study, it was reported that 
when the chain was shorter the chain-chain interaction was minimal, but this 
interaction became more important as the chain length increased. As a result, the C4 
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chain was tilted ca. 20 ° from the nanoparticle surface, leading to the pyrene molecule 
adopting a more perpendicular position relative to the gold core in order to maximise 
fluorophore-fluorophore interactions. On the other hand, the C11 chain was tilted ca. 
45-48 ° from the nanoparticle surface in order to maximise chain-chain interactions, 
leading the pyrene molecules to lie closer to the gold core, which effectively increases 
the quenching of the fluorescence due to non-radiative energy transfer as previously 
described.48 Even though the authors reported that the odd-even effect was not an 
important parameter, the study of a pyrene connected to a short odd carbon chain, 
i.e., C3 or C5, should be performed for confirmation. These two studies by Russell and 
co-workers and Battistini et al. produced conflicting results. However, it is important to 
consider that one study used SAMs on a planar gold surface, whereas the other focused 
on the use of gold nanoparticles. The difference between the planar surface versus the 
nanoparticle can have an effect in the fluorescence behaviour of the fluorophores. In 
fact, Lakowicz already observed that fluorophores are quenched at short distances 
from a planar metal surface but not quenched at short distances from metal 
nanoparticles.20 Lakowicz suggested that the fluorescence quenching was originated 
from the oscillations created in metals being unable to radiate due to the presence of 
optical restrictions at the metal-fluorophore interface.20 
The nature of the anchor group, such as a thiol, connecting the chain to the metal 
surface has also been reported to influence the higher or lower MEF efficiency.16,57 
Additionally, another factor that should be considered is how closely the fluorophores 
are packed on the surface of the metal nanoparticles, which could lead to dimerisation 
and aggregation and thus induce self-quenching of the fluorescence.10,51 
To summarise, metal nanoparticles can produce different effects on the fluorescence 
of fluorophores anchored onto their surface. The size of the nanoparticles is an 
important consideration, where small particles will lead to fluorescence quenching 
whereas larger particles will have a role in fluorescence enhancement. However, the 
size is not a sole definite measure of how the fluorescence will behave. The distance 
between the fluorophore and the metal nanoparticle is also important to consider. As 
discussed, short distances lead to fluorescence quenching and fluorescence 
enhancement will only be achieved at intermediate optimum distances between the 
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two. Another important parameter to be considered is the orientation at which the 
fluorophore and its molecular dipole are located relative to the metal surface, which 
will determine how close the fluorophore lies towards the metal core. As discussed, 
the orientation is influenced by the nature of the chain connecting the fluorophore to 
the metal core, the nature of the anchor group and whether it has an odd or even 
number of carbon atoms. Additionally, the choice of the metal for the nanoparticles as 
well as the choice of the fluorophore can have a profound effect on the efficiency of 
MEF. 
 
3.1.2. Human epidermal growth factor receptor 2 
The human epidermal growth factor receptor 2 (HER2) is a 1,255 amino acid 
transmembrane glycoprotein (185 KDa) encoded by the proto-oncogene HER2 located 
on chromosome 17q12.58-62 The HER2 receptor belongs to the family of receptor 
tyrosine kinases (RTKs), known as erythoblastoma gene B (ErbB) receptors.58,59,63 The 
term ErbB was coined when the first growth factor receptor was discovered in 1978 
due to its origin in the ErbB gene, responsible for avian erythroblastosis virus.59 The 
ErbB family is composed of four members; the epidermal growth factor receptor 
(EGFR/HER1/ErbB1), HER2/ErbB2/neu, HER3/ErbB3 and HER4/ErbB4.58,59,63  
The four members of the ErbB family are homologous, which means their basic 
structure is the same, as shown in Figure 3.3. The receptors are made up of three parts, 
the extracellular domain, the transmembrane domain and the intracellular domain.58 
The extracellular domain is divided into four subdomains (I, II, III and IV also known as 
L1, S1, L2 and S2). Two of these subdomains (L1 and L2) constitute the ligand-binding 
sites, while the other two (S1 and S2) are the homologous cysteine-rich domains. The 
transmembrane lipophilic domain enters the cell membrane connecting the 
extracellular and intracellular domains. The intracellular domain is located in the 
cytoplasm and it contains a juxtamembrane domain (JM), a protein kinase domain, with 
tyrosine kinase catalytic activity, and the carboxyl end containing the phosphorylation 
sites.58,59,63,64   
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The role of the ErbB receptors is essential for human life, including normal cell growth, 
proliferation and differentiation, wound healing and apoptosis.58,59,63 These processes 
are regulated through the activation of RTKs, which initiates several signal transduction 
pathways.59,63 Activation of the RTKs occurs upon binding of a specific ligand to the 
extracellular domain of the ErbB receptors. When there is no ligand in the environment, 
the receptors stay inactive and in a monomeric form. However, when the ligand 
becomes available and it binds the receptor, dimerisation and oligomerisation start to 
occur. Dimerisation leads to an increase in the kinase catalytic activity and initiates 
phosphorylation, thus inducing the activation of the intracellular signalling.58,59,65,66 
Dimerisation, which is favoured by the higher stability of the dimer complexes as 
compared to the monomers, can be of two types, either homodimerisation, i.e., the 
same two receptors are bound, or heterodimerisation, i.e., two different receptors are 
Transmembrane Domain
Extracellular Domain
Intracellular Domain
NH2
I – L1
III – L2
II – S1
IV – S2
JM
Kinase Domain
Phosphorylation sites
Y992
Y1045
Y1068
Y1148
Y1173
COOH
Figure 3.3. Basic structure of the ErbB receptors. The extracellular domain is composed of 
two cysteine-rich domains (S1, S2) and two ligand-binding sites (L1, L2). The intracellular 
domain is composed of the juxtamembrane domain (JM), the protein kinase domain and 
the autophosphorylation sites located within the carboxyl end. The diagram was adapted 
from Refs. 58 and 64. 
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bound. The resulting activation signal is much stronger for heterodimers, especially 
when HER2 is involved, as compared to homodimers, which produce weaker signals.65 
Activation of each receptor is triggered by specific ligands. HER1 is activated by 
epidermal growth factor (EGF), transforming growth factor α (TGFα), amphiregulin, 
heparin-binding EGF-like growth factor, betacellulin and epiregulin. HER3 and HER4 are 
activated by binding neuregulins (NGFs) 1-4. On the other hand, the only exception is 
HER2, which is an orphan receptor as there is no known ligand that binds specifically 
to it.58,59,63,65 As a result, HER2 stays in a structural conformation that is always able to 
interact with other ErbB receptors to form heterodimers, thus allowing the activation 
of the ligand-less receptor.58  
The members of the ErbB receptor family can play an important role in the 
development of human cancers due to overexpression, underexpression or mutation.58 
The HER2 receptor is particularly important in the development of cancer. Its role in 
cancer was discovered in rat neuroglioblastoma, where the name neu comes from.63 A 
point mutation from valine to glutamate was found in the position 664 of the protein 
sequence, mediated by the increasing ability of HER2 to form dimers. Even though this 
mutation is not found in humans, it has served as a basis to understand the role HER2 
plays in human tumours. Indeed, HER2 is commonly found in a dimeric state within 
cancer cells, in contrast to healthy cells where the inactive form is always found as a 
monomer.63 The high dimerisation rate of HER2 in cancer cells is related to HER2 being 
overexpressed in certain types of cancer, primarily in breast cancer in approximately 
10-34 % of the cases.60 HER2 overexpression is mainly due to ErbB2 gene amplification, 
which leads to a 100-fold increase in the HER2 protein expression.65 The overexpression 
of HER2 leads to a higher production of HER2 heterodimers, but also to the appearance 
of HER2 homodimers, which stimulate aberrant malignant growth. As a result, HER2 
overexpression is linked to poor prognosis, aggressive tumour growth and increased 
metastatic potential.62,65 In fact, the median survival for patients with HER2 positive 
breast cancers is 3 years, whereas it goes up to 6-7 years for non-HER2 breast cancers.62 
Furthermore, HER2 overexpression is thought to increase brain metastasis to 9 % as 
compared to only 1.9 % when the breast cancers are not HER2 positive.67  
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Additionally, it has recently been found that HER2 is also overexpressed in other types 
of cancer, including gastric (10-30 %), ovarian (20-30 %), colon (60-80 %), uterine 
serous endometrial carcinoma (14-85 %), lung (20 %), head and neck, oesophagus and 
bladder cancers.59,68 
 
3.1.3. Antibodies 
An organism reacts to foreign molecules by producing antibodies, serum recognition 
elements that bind selectively to these molecules, referred to as antigens, and 
neutralise their effects. Antibodies bind to a specific site of the antigen, the epitope or 
antigenic determinant, and have an important role in the immune system.69-71  
Antibodies are glycoproteins from the immunoglobulin (Ig) family. In humans, Ig are 
divided into five classes; IgG, IgA, IgM, IgD and IgE. The differences between the Ig 
classes are mainly related to size, charge and composition, both in amino acid 
sequences and carbohydrates.72 All types of antibodies, independent of which Ig class 
they belong to, are made up of four polypeptide chains, two heavy and two light chains, 
which conform a Y-shaped molecule. The chains are subsequently divided into 
domains, each of which contains approximately 110 amino acids.71,72  
The most common antibodies found in blood serum are those belonging to the IgG 
class, found in approximately 80 %, which are involved in secondary immune 
responses.71,73 IgG antibodies are composed of one single Y-shaped molecule, structure 
shown in Figure 3.4, and have an average weight of 150 kDa. The G label stands for 
gamma (γ) heavy chains. The two identical heavy chains are linked between them by 
one to five disulfide bonds and subsequently linked to the two identical light chains by 
one disulfide bond and non-covalent interactions.71-73 The amount of inter-heavy chain 
disulfide bonds present in the antibody differentiates the four IgG subgroups.72 The 
chains are divided into constant and variable domains. Heavy chains contain three 
constant domains and one variable domain, whereas light chains have one domain of 
each type. As their name indicates, constant domains have a relatively constant amino 
acid sequence among all IgG antibodies and are involved in the effector functions of 
the antibody. On the other hand, variable domains have a more variable amino acid 
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sequence since they are responsible for the specificity towards antigens. There are 
three hypervariable regions, also known as complementarity-determining regions 
(CDRs). These CDRs, located at the end of each arm of the Y-shape, constitute the 
antigen binding site (Fab) on each antibody and thus are chemically complementary 
with the antigen they recognise.71,72 The lower part of the antibody at the base, 
containing the CH2 and CH3 domains, is known as basal fragment (Fc). The Fc crystallises 
readily, binds to cell surface receptors and is active in the lysis of target cells but it does 
not bind to antigens.71,73 
 
The second most common type of antibodies found in serum belongs to the IgA class, 
making up between 10-15 %.73 The A label stands for alpha (α) heavy chains. While IgA 
antibodies are found in a monomeric structure in the serum, i.e., one Y-shaped 
molecule similar to IgG, they form a dimer in secretions, i.e., two Y-shaped molecules 
linked by a J chain. Following IgA antibodies, IgM antibodies are found in the serum in 
5-8 % and they are the most important antibodies in primary immune responses since 
they are the first antibodies to be made in the organism.71,73 The M label stands for mu 
Heavy chains
Light chains
COOH
COOHHOOC
HOOC
H2N
NH2
NH2
NH2
CH3
CH2
CH1
CH3
CH2
CH1
CL CL
VL VL
VH VH
Figure 3.4. Structure of a typical IgG antibody, where V and C represent the variable and 
constant domains, respectively; H and L represent the heavy and light chains, respectively 
and CDRs represent the complementarity-determining regions or antigen-binding sites.   
The figure was adapted from Refs. 71-72. 
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(μ) heavy chains. IgM antibodies, with an average molecular weight of 900 KDa, form a 
pentamer made up of five Y-shaped molecules, linked together by disulfide bonds and 
one J chain. In contrast to previous antibody types, the heavy chains of each Y-shaped 
molecule in IgM antibodies contain four constant domains and one variable 
domain.72,73 Finally, IgD and IgE antibodies make up less than 1 % of the antibody 
content in the serum and they are both based on monomeric structures, similar to IgG. 
The D and E labels stand for delta (δ) and epsilon (ε) heavy chains, respectively.73 
Throughout the research reported in this thesis, IgG antibodies were used. IgG 
antibodies are the most widely used type of antibody for immunoassays since they are 
the most commonly found in serum, they have a high affinity towards antigen epitopes 
and remain stable during their purification.72 On the other hand, IgM antibodies are 
mainly reserved for applications related to immunohistochemistry, since they have less 
affinity towards antigen epitopes and are more difficult to purify as compared to IgG 
antibodies. The other Ig classes, IgA, IgD and IgE, are rarely used not only due to their 
low affinity towards antigen epitopes but also to the minimal amounts found in the 
serum.72 
Production of IgG antibodies is derived from B lymphocytes.69,72 B lymphocytes always 
hold one specific antibody on their surface. Upon recognition of an antigen, B 
lymphocytes attract T cells, start to divide and create plasma cells, which can then 
produce many new antibodies.72 There are mainly two types of commercially available 
antibodies, polyclonal and monoclonal antibodies. Polyclonal antibodies are created by 
introduction of an antigen in an earlier sensitised animal, a method which produces a 
mixture of related antibodies with different epitope affinities. Therefore, polyclonal 
antibodies can recognise multiple epitopes on one antigen, which leads to a lower 
specificity and makes them more prone to batch-to-batch variability.72 On the contrary, 
monoclonal antibodies are identical antibodies able to recognise only one epitope in 
the antigen of interest. Monoclonal antibodies are created using hybridoma cells in a 
method developed by Köhler and Milstein in 1975.74 Hybridoma cells are a fusion 
between B lymphocytes and immortal myeloma cancer cells, which gives them the 
ability to induce the production of antibodies as well as grow indefinitely, similar to 
cancer cells.70,72 Monoclonal antibodies are therefore produced in an identical manner 
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in all batches and consequently have a higher specificity than polyclonal antibodies. 
The main disadvantage with the use of monoclonal antibodies is that they are often 
too specific to recognise the antigen of interest and they can be vulnerable to the loss 
of epitope occurring after chemical treatment of the antigen. 
The use of antibodies for cancer treatment is being widely studied. It is important to 
choose antibodies that target specific antigens that are only overexpressed on 
malignant cancer cells, but not on healthy cells.75 Antibodies can, by themselves, be 
used as therapeutic agents. This is the case of the antibody Trastuzumab (Herceptin®), 
a humanised IgG antibody used to target the overexpressed HER2 receptor on breast 
cancer cells. Trastuzumab is thought to work in three different ways; inducing 
antibody-dependent cell cytotoxicity, decreasing the amount of HER2 receptors on the 
surface of the cancer cells by antibody internalisation that leads to lysosomal 
destruction, and preventing the dimerisation of the HER2 receptors.76  Additionally, 
trastuzumab can be combined with therapies such as chemotherapy, which increases 
response to the treatment and decreases cancer progression thus leading to higher 
survival rates.67 The main problems with the use of therapeutic antibodies is that the 
cancer cells are prone to create resistance to them. The use of trastuzumab leads to 
breast cancer recurrence one year after treatment with the antibody therapy.67 
Therefore, the use of antibodies as carriers for drug delivery is becoming more popular. 
In this mechanism, antibodies bind to the specific receptors overexpressed on the 
surface of cancer cells and are subsequently internalised via receptor-mediated 
endocytosis.75,76 The use of the anti-HER2 antibody as a targeting agent for breast 
cancer has been combined with nanotechnology in previous studies.77,78 
 
3.1.4. Aim of the research reported in this chapter 
As discussed in Chapter 1, gold nanoparticles have been and still are widely used for 
the delivery of photosensitisers for PDT of cancer. The synthesis of gold nanoparticles 
(ca. 3-5 nm; AuNPs) functionalised with a mixed monolayer of PEG and a zinc 
phthalocyanine photosensitiser separated from the gold core by a carbon chain 
consisting of 11 carbon atoms has been previously reported (C11Pc).77-79 In this 
chapter, a second zinc phthalocyanine will be introduced, which possesses the same 
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macrocycle as C11Pc but is separated from the gold core by a carbon chain of only 3 
carbon atoms (C3Pc). As a result, when AuNPs are functionalised with PEG and C3Pc, 
the phthalocyanine lies closer to the gold core as compared to the C11Pc. The goal of 
the research reported in this chapter was to compare both nanoparticle systems and 
their efficiency for PDT. 
As it was reported in section 3.1.1, the interaction between metal nanoparticles and 
fluorophores can lead to different effects in the fluorescence of the fluorophore 
anchored onto their surface. The effects of the AuNPs on the fluorescence of C11Pc 
and C3Pc were studied. Furthermore, the production of 1O2 by the two different 
systems was also studied. Finally, in vitro PDT of SK-BR-3 human breast 
adenocarcinoma cells using C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs was analysed and 
compared. The rate of phototoxicity and cell death of the breast cancer cell line using 
each of the nanoparticle systems were investigated. 
In the second part of the research, the use of the anti-HER2 antibody as a targeting 
agent was explored. Anti-HER2 antibody was conjugated to the C11Pc-PEG-AuNPs and 
also to the C3Pc-PEG-AuNPs to selectively target HER2 overexpressing SK-BR-3 cells. 
The use of anti-HER2 antibody was shown to increase the uptake of the AuNPs and to 
reduce the differences between C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs observed 
during the first part of the research presented in this chapter. 
 
3.2. Results and discussion 
3.2.1. Zinc phthalocyanine photosensitisers 
In this study, two zinc phthalocyanine photosensitisers were explored. The structures 
of both phthalocyanines are shown in Figure 3.5. Both phthalocyanines are dimeric 
structures composed of two macrocycles linked to one another by a disulfide bond. The 
difference in the two photosensitisers relies on the length of the carbon chain that 
connects the macrocycle to the sulfur bond. One photosensitiser is connected via three 
carbons (C3Pc), whereas the other is connected via eleven carbons (C11Pc). During 
nanoparticle synthesis, the disulfide bond will lead to self-assembly of the 
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photosensitiser onto the gold nanoparticle surface. The self-assembly will cause the 
disulfide bond to break, leading to the functionalisation of the gold core with 
monomeric structures, consisting of only one macrocycle. As a result, C3Pc is expected 
to be much closer to the gold core than the C11Pc. 
 
 
 
 
 
 
 
 
 
 
 
 
The extinction coefficients for both C11Pc and C3Pc were calculated by creating a 
calibration curve, as explained in section 2.2.4. The experimental procedure for the 
C11Pc was straightforward, since the C11Pc was provided as a dry solid, it was easily 
weighed and a value for the extinction coefficient was calculated readily. The 
corresponding calibration curve for C11Pc is shown in Figure 3.6. On the other hand, 
the experimental procedure for C3Pc proved to be more problematic. During the 
addition of the zinc metal to the phthalocyanine post-synthesis, the final C3Pc 
compound was obtained in THF, which was then evaporated under reduced pressure 
using a rotary evaporator. However, the C3Pc solid could not be completely dried as it 
became particularly difficult to remove all the excess THF. As a result, weighing the 
C3Pc to obtain an accurate value was difficult. An initial value for the extinction 
(A) 
(B) 
Figure 3.5. Structure of the two phthalocyanines, (A) C3Pc and (B) C11Pc. 
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coefficient was obtained, Figure 3.7 A-B. However, to obtain a more accurate value, 
C3Pc was further dried under vacuum in the rotary evaporator for ca. 2 h. Following 
this procedure, the final C3Pc solid appeared drier than the previous sample. Therefore, 
a second value for the extinction coefficient was obtained, Figure 3.7 C-D. The 
numerical values of the extinction coefficients obtained experimentally are shown in 
Table 3.1 for both C11Pc and C3Pc. 
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Figure 3.6. (A) UV-vis absorbance spectra of C11Pc in THF at various concentrations and 
(B) the corresponding calibration curve measured using an absorbance intensity at 698 nm. 
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Sample ε / M-1 · cm-1 
Confidence 
interval (95 %) 
R2 
C11Pc 2.75×105 3,731 0.999 
C3Pc A 2.50×105 6,839 0.997 
C3Pc B 2.74×105 11,112 0.993 
 
For the purpose of this thesis, it will be assumed that the value of the extinction 
coefficient for C3Pc is 2.74×105 M-1 ∙ cm-1, the value obtained after thoroughly drying 
the C3Pc to eliminate as much excess THF as possible. The structures of C11Pc 
(calculated ε = 2.75×105 M-1 ∙ cm-1) and C3Pc are identical in the macrocycle of the 
pthahlocyanine. As a result, it is expected that their extinction coefficients would be 
similar to one another.  
Table 3.1. Extinction coefficients obtained for C11Pc and C3Pc. 
(A) (B) 
Figure 3.7.  (A, C) UV-vis absorbance spectra of C3Pc in THF at various concentrations and 
(B, D) the corresponding calibration curves measured using an absorbance intensity at 
698 nm. 
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3.2.2. Synthesis of gold nanoparticles 
Gold nanoparticles (ca. 3-5 nm) were simultaneously synthesised and functionalised 
with a mixed monolayer of one of the two phthalocyanines and PEG by sodium 
borohydride reduction, as described in section 2.2.1. The functionalisation of the 
nanoparticles with PEG allows for the aqueous dispersibility of the phthalocyanines 
within the system. A schematic representation of the synthesised AuNPs is shown in 
Figure 3.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
Figure 3.8. Schematic representation of (A) C11Pc-PEG-AuNPs and (B) C3Pc-PEG-AuNPs. 
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The synthesised nanoparticles were resuspended in MES buffer. The AuNPs were 
characterised by recording the UV-vis extinction spectra (Figure 3.9 A). The UV-vis 
extinction band at ca. 698 nm is characteristic of the monomeric form of zinc 
phthalocyanines, while the band centered at ca. 645 nm is characteristic of the dimeric 
form. The fact that the band at 698 nm is much higher than the one at 645 nm, for both 
C11Pc-PEG-AuNPs and C3Pc-AuNPs, indicates that most of the phthalocyanine is 
present in the active monomeric form.77,79 Furthermore, the absence of an extinction 
band in the 500 nm region suggests the nanoparticles are smaller than 10 nm in 
diameter. Both nanoparticle solutions presented a light blue colour, characteristic of 
substituted zinc phthalocyanines (Figure 3.9 B).77,80,81 
 
 
 
 
 
 
 
 
 
 
The nanoparticles, dissolved in MES buffer, were further characterised by transmission 
electron microscopy (TEM) to evaluate the size. Analysis of the TEM for the C3Pc-PEG-
AuNPs indicated that the nanoparticles have an average diameter of 3.83 ± 0.99 nm, 
following analysis of 562 nanoparticles, with a median value of 3.76 ± 0.99 nm. TEM 
images of the C3Pc-PEG-AuNPs, together with a histogram showing their size 
distribution, are shown in Figure 3.10. Analysis of the TEM for the C11Pc-PEG-AuNPs 
indicated that the nanoparticles have an average diameter of 3.41 ± 1.16 nm, following 
analysis of 282 nanoparticles, with a median value of 3.21 ± 1.35 nm. TEM images of 
Figure 3.9. (A) UV-vis extinction spectra of C11Pc-PEG-AuNPs (i) and C3Pc-PEG-AuNPs (ii) 
in MES buffer. (B) Image showing the solution of nanoparticles functionalised with C11Pc 
(i) and C3Pc (ii), respectively. 
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the C11Pc-PEG-AuNPs, together with a histogram showing their size distribution, are 
shown in Figure 3.11. The size distribution for C11Pc-PEG-AuNPs is slightly skewed. 
Therefore, the median value of 3.76 ± 0.99 nm could be a better representation of the 
average size of the C11Pc-PEG-AuNPs.82 It is important to note that, in both cases, for 
C3Pc-PEG-AuNPs and C11Pc-PEG-AuNPs, the batch-to-batch reproducibility was very 
high, with extinction spectra, TEM images and size distributions being very similar every 
time the nanoparticles were synthesised. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. (A-B) Transmission electron micrographs of a sample of C3Pc-PEG-AuNPs, 
where the scale bars represent 20 nm. (C) Histogram of the C3Pc-PEG-AuNPs with a 
median value of 3.76 ± 0.99 nm (n = 562). (D) Size distribution of the C3Pc-PEG-AuNPs 
showing the Gaussian fit, with an average size of 3.83 ± 0.99 nm (n = 562).  
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The synthesised C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs were prepared following the 
same synthetic procedure with identical concentrations of Pc, PEG, gold chloride and 
sodium borohydride. However, the immobilisation of either of the phthalocyanines, 
C11Pc or C3Pc, on the surface of the AuNPs could be different due to the difference in 
the carbon chain length. The difference in the length of the carbon chain can lead to a 
different orientation of each Pc on the surface of the AuNPs, as previously reported by 
Revell et al..51 In order to obtain a ratio of the concentration of Pc to the concentration 
of AuNPs in the sample, the concentrations of both the Pc and the AuNPs need to be 
calculated. For the phthalocyanines, the extinction coefficients reported in section 
3.2.1 together with the extinction intensity at 698 nm (Figure 3.9 A) can be used to 
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Figure 3.11. (A-B) Transmission electron micrographs of a sample of C11Pc-PEG-AuNPs, 
where the scale bars represent 20 nm. (C) Histogram of the C11Pc-PEG-AuNPs with a 
median value of 3.21 ± 1.35 nm (n = 282). (D) Size distribution of the C11Pc-PEG-AuNPs 
showing the Gaussian fit, with an average size of 3.41 ± 1.16 nm (n = 282).  
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obtain the concentration of the Pc in the sample via the Beer-Lambert law (Equation 
3.1). 
 
The concentration of the AuNPs in the sample cannot be directly calculated due to the 
absence of a SPR absorption band in the extinction spectrum of the AuNPs with 
diameters smaller than 10 nm. For this purpose, an estimation of the concentration of 
AuNPs in the sample was performed following the procedure described by Haiss et al..83 
These authors experimentally determined the values for the extinction coefficients at 
450 nm of AuNPs with a diameter of 2-100 nm. Additionally, the authors reported that 
it was possible to calculate the concentration of uncoated spherical AuNPs in water 
using the ε450 and the absorbance intensity at 450 nm, as shown in Equation 3.2. This 
method is more accurate for AuNPs larger than 5 nm in diameter, due to the surface 
effects taking place in smaller AuNPs. Considering that the AuNPs reported in this study 
are smaller than 5 nm and are not uncoated, this method can only give an estimation 
of the possible concentration of AuNPs in the sample and thus an estimation of the 
ratio of Pc to AuNPs. The data required to calculate the concentrations of Pc and AuNPs, 
as well as the results of the ratio of Pc to AuNPs are shown in Table 3.2. 
 
 
 
 
A =  ε ∙ c ∙  l 
Equation 3.1. Beer-Lambert law. A is the absorbance intensity; ε is the extinction coefficient 
(M-1 ∙ cm-1) c is the concentration (M); and l is the path length of the quartz cuvette (1 cm). 
c =
A450
ε450
 
Equation 3.2. Equation used to calculate the concentration of AuNPs in an aqueous 
solution, as reported by Haiss et al. (Ref. 83). 
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Sample A450 [AuNP] / M A698 [Pc] / M Ratio 
C3Pc-PEG-
AuNPs 
0.137 3.78×10-8 1.026 3.75×10-6 99 
C11Pc-PEG-
AuNPs 
0.101 2.79×10-8 0.886 3.22×10-6 115 
 
 
The results in Table 3.2 suggest that the C3Pc-PEG-AuNPs have less phthalocyanines 
immobilised per AuNP (ca. 99) as compared to C11Pc-PEG-AuNPs, which will have more 
phthalocyanines per AuNP (ca. 115). As a result, at the same concentration of 
phthalocyanine, the C11Pc-PEG-AuNPs sample will contain less AuNPs than the C3Pc-
PEG-AuNPs sample. An accurate value for the number of phthalocyanines immobilised 
per AuNPs can be obtained by performing inductively coupled plasma mass 
spectrometry (ICP-MS) on each of the samples, as previously reported.77,79 ICP-MS 
measurements should be performed in the future for confirmation. 
 
3.2.3. Fluorescence studies 
The fluorescence emission of the free phthalocyanines was analysed and compared to 
the fluorescence emission obtained from the functionalised gold nanoparticles. In 
order to be able to compare the emission spectra of the samples, all were required to 
be at the same concentration. Therefore, the UV-vis extinction of all samples was 
initially recorded to ensure this was the case. The solutions were excited at 633 nm and 
the fluorescence emission was collected between 650 and 850 nm. The free 
phthalocyanines were dissolved in THF, whereas the functionalised nanoparticles were 
dissolved in MES buffer for the analysis. The fluorescence emission spectra are shown 
in Figure 3.12 A. Figure 3.12 B-C shows the normalised fluorescence emission spectra 
of the free phthalocyanines and the Pc-PEG-AuNPs, respectively, so that the change in 
fluorescence can be more readily compared. The normalised fluorescence emission 
was calculated by taking the fluorescence of the more fluorescent sample to be 100 % 
Table 3.2. Estimation of the ratio of Pc to AuNPs. 
For 4 nm AuNPs, ε450 = 3.62×106 M-1 ∙ cm-1. Value obtained from Ref. 83. 
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at the emission maximum. The fluorescence measurement and analysis were repeated 
five times, obtaining the same results on each occasion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
As observed in Figure 3.12 A-B, the fluorescence emission intensity of C3Pc in solution 
is much lower than that of C11Pc. These results are in agreement with the finding of a 
higher extinction coefficient for C11Pc as compared to C3Pc. However, when the 
phthalocyanines are self-assembled on the AuNPs, the opposite effect is observed. 
Gold nanoparticles functionalised with C3Pc produce more fluorescence than those 
functionalised with C11Pc (Figure 3.12 C). The functionalisation of the AuNPs with 
C11Pc and C3Pc induces a quenching in the fluorescence for both phthalocyanines 
(Figure 3.12 A). This quenching effect by the metal centre is significantly lower for C3Pc, 
which is closer to the gold core, than for C11Pc. The quenching effect observed for the 
phthalocyanines self-assembled on the AuNPs could be due to the solvent in which they 
Figure 3.12. (A) Fluorescence emission spectra of free C11Pc (i), free C3Pc (ii), C3Pc-PEG-
AuNPs (iii) and C11Pc-PEG-AuNPs (iv). (B) Normalised fluorescence emission spectra of free 
C11Pc (i) and free C3Pc (ii). (C) Normalised emission spectra of C11Pc-PEG-AuNPs (i) and 
C3Pc-PEG-AuNPs (ii). 
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are dissolved. While the free phthalocyanines are dissolved in THF, the AuNPs samples 
are dissolved in an aqueous buffer. Additionally, the presence of the gold metal could 
be contributing to the reported quenching of the Pc-PEG-AuNPs as compared to the 
free Pcs. To confirm these results, fluorescence quantum yields were recorded for both 
the free phthalocyanines in THF and the functionalised gold nanoparticles in MES 
buffer. Zinc 2,9,16,23-tetra-tert-butyl-29H,31H-phthalocyanine (ZnPc) was used as the 
reference sample as it has been reported to have a fluorescence quantum yield of 0.33 
(33 %) in toluene.84 This reference sample has absorbance and fluorescence emission 
spectra similar to those of C11Pc and C3Pc, which allows for their comparison. The 
structure and UV-vis absorption and fluorescence emission spectra of ZnPc can be seen 
in Figure 3.13.  
 
 
 
 
 
 
 
 
 
 
 
Fluorescence quantum yields were recorded for the free phthalocyanines and the 
phthalocyanines attached to the surface of the gold nanoparticles. The quantum yields 
were obtained via a calibration curve, as explained in section 2.2.5. The absorbance 
and fluorescence emission of each sample were recorded at different concentrations 
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Figure 3.13. (A) Structure of ZnPc. (B) Absorption spectrum of ZnPc in toluene. (C) 
Fluorescence emission spectrum of ZnPc in toluene (λex = 640 nm). 
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to produce the calibration curve. Then, the gradients of each calibration curve were 
used to calculate the final value for the quantum yield, following Equation 3.3. The 
calibration curves obtained are shown in Figure 3.14, and the final numerical 
fluorescence quantum yield values are shown in Table 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
nTHF85 = 1.407; nToluene86 = 1.496; nH2O
87 = 1.330 
Figure Sample Gradient R2 value Φ / % 
3.14 A 
ZnPc 1.20×106 0.998 33.00 
Free C11Pc 1.89×105 0.997 4.80 
Free C3Pc 9.08×104 0.994 2.60 
3.14 B 
ZnPc 1.19×106 0.999 33.00 
C11Pc-PEG-AuNPs 9.11×103 0.998 0.20 
C3Pc-PEG-AuNPs 1.91×104 0.980 0.42 
Equation 3.3. Equation used to calculate the fluorescence quantum yields via the 
calibration method. 
Where: 
Φ = Fluorescence quantum yield 
ref= Reference sample 
x = Experimental samples 
Grad = Gradient 
n = Refractive index of solvent 
Table 3.3. Values obtained for the fluorescence quantum yields. 
∅x= ∅ref  
Gradx
Gradref
  
nx
2
nref
2
  
Figure 3.14. (A) Calibration curves for the free C11Pc (i) and C3Pc (ii) in THF together with 
ZnPc in toluene (iii). (B) Calibration curves for C11Pc-PEG-AuNPs (i) and C3Pc-PEG-AUNPs 
(ii) in MES buffer, together with ZnPc in toluene (iii). 
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The fluorescence quantum yields for the free phthalocyanines are rather low; 4.8 % for 
C11Pc and 2.6 % for C3Pc. A possible explanation for the low values obtained for the 
fluorescence quantum yields of the Pc in solution could be related to the dimeric 
structure of the phthalocyanines, as shown in Figure 3.5. Previous studies have 
reported that the strong fluorescence of monomeric phthalocyanines is usually 
quenched upon dimerisation and aggregation.88-90 As an example, the Zefirov group 
reported the synthesis of a magnesium phthalocyanine (2-hydroxy-9(10), 16(17), 
23(24)-tri-tert-butylphthalocyanine [Mg]) and its corresponding dimer.89 The authors 
found that the fluorescence quantum yield of the dimer was 1.4 %, a value smaller than 
half that obtained for the monomeric form (4.8 %).89 Additionally, the Zefirov group 
also reported the synthesis of a zinc phthalocyanine (2-hydroxy-9(10), 16(17), 23(24)-
tri-tert-butyl-29H,31H-phthalocyanine [zinc]) and its corresponding dimer.90 The 
authors found that the fluorescence quantum yield of the dimer was reduced by 1.5-3 
times as compared to the fluorescence quantum yield of the monomer in THF. The 
decrease in fluorescence quantum yield was found to be solvent-dependent and it was 
attributed to the energy transfer between the macrocycles upon excitation, which 
induces changes in the flexible structure of the dimeric phthalocyanine in the S1 excited 
state.90 However, it is also important to note that other studies have reported the 
successful synthesis of dimeric phthalocyanines with fluorescence quantum yield 
values exactly the same as for their monomeric counterparts.91 Relevant to the present 
study, the fluorescence quantum yield of the monomeric C11Pc phthalocyanine has 
been reported to be 12 %.92 This value is slightly more than double of the value 
obtained for the dimeric C11Pc in this study, in accordance with the reports of the 
Zerifov group. A value for the fluorescence quantum yield of the monomeric C3Pc 
phthalocyanine has not been reported in the literature. However, it could be assumed 
that the fluorescence quantum yield of the monomeric C3Pc would likely be more than 
double that of the dimeric C3Pc. 
The fluorescence quantum yields estimated for the Pc-PEG-AuNPs are low, 0.42 % for 
C3Pc-PEG-AuNPs and 0.20 % for C11Pc-PEG-AuNPs. It is important to note that the 
refractive index of the MES buffer in which the nanoparticles were dissolved was taken 
to be the same as that of water (1.33), as reported in Table 3.3. However, MES buffer 
contains MES (50 nM) and Tween-20 (0.05 %). It has been reported that the presence 
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of MES increases the refractive index of water, and this increase in refractive index is 
concomitant with an increase in the concentration of MES buffer in the sample.93 As a 
result, the refractive index of MES buffer could be slightly higher than that of water, 
which would lead to slightly higher values of the fluorescence quantum yields for the 
Pc-PEG-AuNPs than those reported here. 
The estimated fluorescence quantum yields confirm the results obtained with the 
analysis of the fluorescence spectra as described above. The fluorescence quantum 
yield is higher for the free C11Pc (4.8 %) as compared to the free C3Pc (2.6 %). When 
the phthalocyanines are attached to the AuNPs, there is a quenching of the 
fluorescence in both C11Pc and C3Pc. Additionally, the fluorescence quantum yield for 
C11Pc-PEG-AuNPs (0.2 %) is lower than that of C3Pc-PEG-AuNPs (0.42 %). This 
behaviour can be explained by analysing the interaction between the fluorophores and 
the metal nanoparticles, as discussed in section 3.1.1. The RP model developed by 
Lakowicz suggests that small spherical nanoparticles (< 40 nm) will quench the 
fluorescence of the fluorophores since such nanoparticles primarily absorb light.20 This 
explains the quenching effect seen for both C11Pc and C3Pc when they are attached to 
the AuNPs as compared to the quantum yield values obtained in solution.  
The second result, by which the fluorescence from C3Pc is not quenched as much as 
that of C11Pc on the surface of the AuNPs, can be explained by the distance-
dependence and the orientation-dependence parameter between the fluorophores 
and the metal nanoparticles. The distance-dependent parameter states that there are 
three regions where the fluorescence emission intensity behaves differently in the 
presence of the metal nanoparticles. Firstly, when the fluorophores are placed directly 
on the surface of the AuNPs or close to it (≤ 5 nm), the fluorescence is quenched. 
However, if the fluorophore is placed at an intermediate distance (ca. 5-20 nm, usually 
≥ 10 nm), the fluorescence will be enhanced. Finally, if the fluorophore is placed too far 
away (≥ 20 nm) from the metal centre, there will be no interaction between the two, 
which leads to no effect in the fluorescence emission intensity.2,3,9 Additionally, as 
discussed in section 3.1.1, the orientation adopted by the fluorophores relative to the 
metal nanoparticles is also an important parameter. In 2007 Battistini et al. reported 
similar observations to that observed in the present study.48 In their work, a pyrene 
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fluorophore was connected to the AuNPs by either a 4 atom-carbon chain or 11 atoms 
and the fluorescence of the C4 was not quenched as much as that of C11. The authors 
attributed this effect to the angle in which each chain is positioned in respect to the 
AuNPs. For the C4 molecule, the chain was ca. 20 ° tilted relative to the normal of the 
nanoparticle surface and thus the fluorophore was thought to be placed almost 
perpendicular to the AuNPs. On the contrary, the C11 molecule was thought to be at 
an angle much flatter towards the AuNPs, 45 °. As a result, the C11 molecule lies closer 
to the metal surface, which effectively quenches the fluorescence since non-radiative 
energy transfer and charge transfer between the pyrene in close contact with the 
AuNPs are more likely to occur as compared to the C4.48 In conflict with these results 
is a previous study reported by Russell and co-workers in which the same C3Pc and 
C11Pc used in the present study were analysed as SAMs on a planar gold surface.51 
These authors observed the tilting angle to be the same for both chains (ca. 20 °) but 
the orientation of the Pc macrocyle was more perpendicular for the C11Pc than for the 
C3Pc, leading to them being 13 Å and 4 Å away from the metal surface, respectively. As 
a result, the fluorescence from the C3Pc was quenched more efficiently than for the 
longer chain, and the fluorescence became stronger as the chain length increased.51 
In the present study, a direct comparison with the study by Russell and co-workers 
cannot be done since, even though the phthalocyanines used have the same structure, 
the metal surface consists of gold nanoparticles rather than a planar gold surface. The 
results obtained in the present study suggest that the different structure of the metal 
surface affects the relative orientation adopted by the anchor chains. The fluorescence 
intensity of the C3Pc was found to be greater than the C11Pc on the surface of the 
AuNPs, suggesting that the C11Pc lies more parallel relative to the gold core as 
compared to the C3Pc, as speculated by Battistini et al. for the pyrenes C4 and C11 
chains. Battistini et al. speculated that intermolecular interactions were the driving 
force for the final orientation of the chains; and it was unrelated to the odd or even 
number of carbons present in each chain. Considering that the fluorescence quenching 
in the study by Battistini et al. and since the present study follows the same trend, i.e., 
enhanced quenching for the C11 longer chain, the present results suggest that the odd-
even effect has a minimal effect as compared to the intra- and inter-molecular 
interactions, which is the overriding parameter deciding the orientation of the chains 
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and hence the macrocycles. In the present study, it is possible that the C11Pc chain will 
adopt a more parallel configuration relative to the AuNPs in order to maximise 
interactions between the chains. On the other hand, the C3Pc chain adopts a more 
perpendicular orientation due to the short nature of the chain, in which chain-chain 
interactions will be minimal. The presence of the PEG on the surface of the AuNPs is 
another factor to consider. Given the large size and flexible nature of the PEG chain 
used in this study, it is expected that there will be minimal interaction between the 
phthalocyanines and the PEG since the chains, even for the longer C11Pc, are a lot 
shorter than that of the PEG. Additionally, the phthalocyanines are expected to be 
oriented in a ‘face-to-face’ orientation relative to one another so that aggregation and 
dimerisation are minimised, consistent with the extinction spectrum indicative of 
monomeric phthalocyanines obtained for both C3Pc-PEG-AuNPs and C11Pc-PEG-
AuNPs (see Figure 3.9). The closer angle in which the C11Pc lies towards the AuNPs is 
an indication that the C11Pc will be more closely packed on the surface of the AuNPs 
as compared to the C3Pc. The more densely packed structure would further maximise 
intermolecular chain interactions and is consistent with the estimation of the number 
of C11Pc and C3Pc per AuNPs shown in section 3.2.2, by which more C11Pc than C3Pc 
molecules are immobilised on the surface of AuNPs. 
To summarise, the gold nanoparticles reported in the present study are of small size 
(ca. 4 nm in diameter) and thus, according to Lakowicz’s RP model, are expected to 
quench the fluorescence of fluorophores placed near-by.20 Additionally, the orientation 
of the phthalocyanines and their molecular dipoles relative to the gold core is an 
important consideration. The results of Battistini et al., together with the results 
presented in this chapter, suggest that the C11Pc lies at a more horizontal angle 
towards the gold core than the C3Pc. Therefore, the macrocycle in C11Pc is speculated 
to be in a parallel orientation relative to the gold nanoparticles, while the C3Pc will be 
placed more perpendicular. The parallel orientation enhances the quenching effect 
seen for C11Pc due to the cancellation in the molecular dipoles of the phthalocyanine 
and the AuNPs, which radiate out of phase and thus decrease the radiative rate of the 
phthalocyanines.12,37 Furthermore, the parallel orientation of the C11Pc would cause 
the C11Pc to lie closer to the gold core as compared to the C3Pc, thus facilitating 
electron transfer between the C11Pc and the small AuNPs, leading to a higher 
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quenching effect.47 On the contrary, the perpendicular orientation of the C3Pc would 
be ideal for metal-enhanced fluorescence. However, the fluorescence intensity of C3Pc 
on the surface of the AuNPs does not seem to be enhanced in comparison to the free 
C3Pc in solution. Even though part of this quenching effect is expected to be due to the 
different solvents in which the samples were dissolved, as previously discussed, it is 
speculated that the small size of the nanoparticles used in this study, together with the 
distance between the AuNPs and the C3Pc are enhancing the quenching efficiency of 
the phthalocyanine. The use of AuNPs of larger size should be studied in the future to 
confirm whether MEF can be seen with C3Pc. 
 
3.2.4. Spectroscopic analysis of singlet oxygen production 
Results from the fluorescence analysis, together with the literature review in section 
3.1.1, suggest that C3Pc-PEG-AuNPs might be more efficient at producing singlet 
oxygen (1O2) than the C11Pc-PEG-AuNPs. In order to test this possibility, the production 
of 1O2 by each of the two systems was spectroscopically studied. Firstly, the production 
of 1O2 was measured using the probe 9,10-anthracenediyl-bis(methylene) dimalonic 
acid (ABMA). ABMA is a water soluble fluorescent anthracene derivative. It selectively 
reacts with 1O2, which causes the photobleaching of the probe, leading to the 
formation of a non-fluorescent 9,10-endoperoxide product.94 The reaction between 
ABMA and 1O2 is shown in Figure 3.15.  When 1O2 is present, fluorescence emission and 
absorbance intensity from ABMA are quenched due to the photobleaching reaction. 
The change in the spectra are best appreciated in the fluorescence emission spectrum. 
Figure 3.15. Reaction between ABMA and 1O2 to give the corresponding non-fluorescent 
9,10-endoperoxide product. The fluorescence of the endoperoxide product is quenched 
compared to the initial ABMA. 
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Before 1O2 production was measured, ABMA was characterised using fluorescence 
spectroscopy. By doing this, the optimum conditions for excitation (em = 430 nm) and 
emission (ex = 380 nm) were found. As explained in section 2.2.7, the phthalocyanine 
samples were mixed with ABMA (1 μM). The samples were then irradiated at 633 nm 
using a HeNe laser for 40 min. The laser was located 50 cm from the cuvette. The 
fluorescence emission spectrum of ABMA was recorded every 5 min. To confirm that 
the production of 1O2 is possible due to the presence of the photosensitiser in the 
sample, control PEG-AuNPs were synthesised and production of 1O2 by these control 
particles was also measured. The results for both C11Pc-PEG-AuNPs and C3Pc-PEG-
AuNPs dissolved in MES buffer confirm that 1O2 is being produced, as there is a decrease 
in ABMA fluorescence, typical of the photobleaching caused by the formation of the 
non-fluorescent 9,10-endoperoxide product (Figure 3.16). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Fluorescence emission spectra of ABMA showing the quenching of the 
fluorescence, thus confirming the formation of 1O2 in (A) C11Pc-PEG-AuNPs and (B) C3Pc-
PEG-AuNPs in MES buffer. (C) No quenching of ABMA is observed in the presence of control 
PEG-AuNPs. (D) Photobleaching of ABMA in the presence of C11Pc-PEG-AuNPs (i) or C3Pc-
PEG-AuNPs (ii) (1 μM Pc) as a function of time; and no photobleaching observed for control 
PEG-AuNPs (iii). Error bars represent the SD (n = 3) within a 95 % confidence interval.  
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The maximum amount of ABMA photobleaching for each phthalocyanine was 
calculated and normalised to the concentration of Pc using Equation 3.4.95 The values 
obtained for each of the gold nanoparticle conjugates are shown in Table 3.4 below. 
 
 
 
 
The results on Table 3.4 show the maximum amount of ABMA photobleaching (i.e., 
after the first 5 min) to be 2.5 % for the C3Pc-PEG-AuNPs and 2.1 % for the C11Pc-PEG-
AuNPs. These results indicate that the photobleaching of ABMA is higher in the 
presence of C3Pc-PEG-AuNPs. The use of ABMA to detect the production of 1O2 is 
usually a qualitative measurement and the fluorescence measurements can be subject 
to high errors. Taking the errors into consideration, 2.5 ± 1.5 % for C3Pc-PEG-AuNPs 
and 2.1 ± 0.1 % for C11Pc-PEG-AuNPs, the results could mean that the maximum 
amount of ABMA photobleaching and thus production of 1O2 by both systems is similar. 
However, by looking at the photobleaching of ABMA over time (Figure 3.16 D), it can 
be clearly seen that the C3Pc-PEG-AuNPs induce more photobleaching (1.9 ± 0.3 %) of 
ABMA than the C11Pc-PEG-AuNPs (1.0 ± 0.1 %) after 40 min, even when the errors are 
taken into consideration. The higher photobleaching of ABMA in the presence of the 
C3Pc-PEG-AuNPs over time is a strong indication that the C3Pc-PEG-AuNPs produce 
more 1O2. In order to better understand the production of 1O2 by both systems, the 
quantum yield of singlet oxygen was studied, as explained in the following section.  
Time / min Sample [Pc] / μM % Fluor t=0min  % Fluor t=m min % ABMA 
5 C11Pc-PEG-
AuNPs 
1.0 100 
89.6 ± 0.7 2.1 ± 0.1 
40 59.0 ± 2.4 1.0 ± 0.1 
5 C3Pc-PEG-
AuNPs 
1.0 100 
87.5 ± 7.6 2.5 ±  1.5 
40 24.6 ± 12.9 1.9 ± 0.3 
Equation 3.4. Equation used to calculate the maximum amount of ABMA photobleaching 
for the gold nanoparticle conjugates. 
Table 3.4. Maximum amount of ABMA photobleaching for each nanoparticle 
sample. 
% ABMA photobleaching =  
 % Fluor431nm t =  0 min − (% Fluor431 nm  t = m min)
m min  ×  Pc /μM
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3.2.5. Singlet oxygen quantum yields 
The measurement of 1O2 quantum yield was analysed for the free phthalocyanines 
initially, to check for possible differences between the two photosensitisers. 
Perinaphthenone was used as a reference, which is known to have a 1O2 quantum yield 
of 1.0 in toluene.80 The singlet oxygen quantum yield was measured via time-resolved 
luminescence. As explained in section 2.2.8, the samples were irradiated at 355 nm 
using the third harmonic of a Q-switched Nd:YAG laser. The luminescence was then 
collected at 90° and passed through a narrow band-pass interference filter (1,270 nm). 
Finally, the signal due to 1O2 was detected by a germanium photodiode, cooled with 
liquid nitrogen. The intensity of 1O2 emission (I1O2; mV) was plotted against the intensity 
of light absorbed by the system (IA; mV), which produced a calibration curve. By 
comparing the slope of the curves, the quantum yield of 1O2 in the unknown samples 
can be calculated. The intensity of light absorbed by the system was calculated using 
the Beer-Lambert law, Equation 3.5. The results are shown in Figure 3.17. 
 
 
 
 
 
 
 
 
 
𝐼𝐴 =  𝐼0(1 − 10
𝐴) 
Equation 3.5. Beer-Lambert law equation used to calculate IA. 
Figure 3.17. (A) Example of the intensity of 1O2 emission versus time for C11Pc (i), C3Pc (ii) 
and perinaphthenone (iii). (B) Calibration curves for C11Pc (i), C3Pc (ii) and 
perinaphthenone (iii) used to calculate the 1O2 quantum yields. 
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Following Equation 3.6, the quantum yields were calculated and the results are shown 
in Table 3.5. 
 
 
 
nToluene86 = 1.496 
 
The 1O2 quantum yields obtained for the free phthalocyanines in solution were found 
to be 40 %, the same for C11Pc and C3Pc. This result is in agreement with a previously 
reported value for the 1O2 quantum yield of C11Pc, which was found to be 45 %.80 
The measurement of 1O2 quantum yield for the AuNPs was more complex. The 
nanoparticles are dispersed in an aqueous solution, MES buffer. The presence of water 
produces a quenching effect of the 1O2 emission, thus making it difficult for the signal 
to be seen spectroscopically. Therefore, the calculation of the quantum yield was not 
possible. In an attempt to solve this problem, the nanoparticles were dispersed in 
deuterium oxide (D2O). Following irradiation at 355 nm, as previously described, the 
signal recorded for 1O2 was low for both samples. As a result, the calculation of a 
numerical value for the quantum yield was not possible. The signal was recorded at 
two different laser powers, 4 and 4.5 mJ, (Figure 3.18). The absorbance intensity values 
at the excitation wavelength were the same for C11Pc-PEG-AuNPs (A355 nm = 0.278) and 
C3Pc-PEG-AuNPs (A355 nm = 0.280). In order to confirm that the signal seen was due to 
Sample Gradient R2 value ΦΔ / % 
Perinaphthenone 1.968 0.998 100 
Free C11Pc 0.773 0.999 40 
Free C3Pc 0.774 0.999 40 
Table 3.5. Values obtained for the 1O2 quantum yields. 
Equation 3.6. Equation used to calculate the fluorescence quantum yields via the 
calibration method. 
Where: 
Φ = 1O2 quantum yield 
ref= Reference sample 
x = Experimental samples 
Grad = Gradient 
n = Refractive index of solvent 
∅x= ∅ref  
Gradx
Gradref
  
nx
2
nref
2
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1O2, the samples were deoxygenated with helium. This confirmed that the signal was 
indeed produced due to 1O2, as shown in Figure 3.18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results in Figure 3.18 C-D confirm that 1O2 is being produced by the AuNPs, as the 
intensity of the 1O2 signal decreases as the samples are deoxygenated with helium. 
However, a numerical value for the 1O2 quantum yield could not be obtained due to the 
low signals observed (Figure 3.18 A-B). Even though the signal of 1O2 emission in D2O 
is too low to obtain a value for the quantum yield, the results suggest that both samples 
produce a similar amount of 1O2. The 1O2 emission (Figure 3.18 A-B) for both samples, 
at the same Pc concentration, overlap, showing that the production of 1O2 by the two 
nanoparticle samples is similar. However, the results are not conclusive and further 
experiments should be performed. 
Figure 3.18. Intensity of 1O2 emission versus time for (i) C11Pc-PEG-AuNPs and (ii) C3Pc-
PEG-AuNPs, using a laser power of (A) 4 mJ or (B) 4.5 mJ. (C, D) Decrease in the 1O2 
emission signal due to the deoxygenation of C11Pc-PEG-AuNPs (C) or C3Pc-PEG-AuNPs (D) 
with helium. 
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3.2.6. Cell viability assays 
Cell viability was measured on SK-BR-3 human breast adenocarcinoma cells using two 
different cytotoxicity assays, MTT and CellTiter-Blue®. Initially, the MTT assay was used. 
MTT (3-(4,5,dimethylthiazol-2-l)-2,5-diphenyltetrazolium bromide) is a reagent used to 
assess cell viability.96 MTT is water soluble and non-toxic to the cells. In the presence 
of metabolically active cells (i.e., viable cells), MTT is reduced to MTT formazan. MTT 
formazan appears in the form of crystals since it is insoluble in aqueous media. 
However, the MTT formazan can be dissolved in organic solvents such as dimethyl 
sulfoxide (DMSO). The MTT molecule presents a yellow colour, whereas the reduced 
MTT formazan product appears pink-purple. The absorbance spectrum of MTT 
formazan can be measured between 500-600 nm. The reaction scheme is shown in 
Figure 3.19.96 
 
As described in section 2.2.9, SK-BR-3 cells were incubated for 3 h with varying 
concentrations of C11Pc-PEG-AuNPs or C3Pc-PEG-AuNPs, ranging between 0 - 0.25 μM 
of each phthalocyanine. All samples were dispersed in serum-free McCOY’s 5A phenol 
red-free medium, to avoid interference between the absorbance of phenol red and that 
of MTT, which overlap in the same region. A positive control for cytotoxicity to induce 
cell apoptosis, consisting of a solution of staurosporine (1 mM in DMSO) dispersed in 
serum-free McCOY’s 5A phenol red-free medium to give a final concentration of 20 μM 
was also used.79,97,98 Following incubation with the samples, the cells were either 
Figure 3.19. Reduction reaction of MTT when in contact with metabolically active cells, to 
produce MTT formazan. 
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irradiated at 633 nm using a HeNe laser for 6 mins, or non-irradiated. The results for 
both C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs are shown in Figure 3.20.  
 
 
 
 
 
 
 
As can be seen in Figure 3.20, neither the C11Pc-PEG-AuNPs nor the C3Pc-PEG-AuNPs 
appear to produce dark toxicity, which means that the AuNPs are not toxic in the 
absence of light. When the samples are irradiated with the 633 nm laser, there is a 
significant difference between the C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs. Cells 
treated with C11Pc-PEG-AuNPs remain viable and unharmed following irradiation. On 
the contrary, the C3Pc-PEG-AuNPs induce cell death following irradiation. The increase 
in cell death is concomitant with the increase in C3Pc concentration. These results show 
that PDT with the C3Pc-PEG-AuNPs is more efficient as compared to the C11Pc-PEG-
AuNPs. However, these MTT assays show negative values of cytotoxicity for the positive 
control, +ve St. Furthermore, the samples, especially the non-irradiated cells, show 
high error bars. In order to eliminate these problems and confirm the results obtained 
with the MTT assay, a different assay, CellTiter-Blue® cell viability assay, was 
performed. 
CellTiter-Blue® is a fluorescence-based cell viability assay. It contains the non-
fluorescent blue reagent resazurin. In the presence of viable cells, resazurin is reduced 
to the highly fluorescent resorufin, which is pink in colour. The fluorescence of 
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Figure 3.20. MTT cell viability assay for SK-BR-3 cells incubated with (A) C11Pc-PEG-AuNPs 
or (B) C3Pc-PEG-AuNPs. Cells were either irradiated with a 633 nm HeNe laser (A orange, B 
yellow) or non-irradiated (A dark cyan, B green). Staurosporine (+ve St) was used as a 
positive control for cytotoxicity. Error bars represent the SD (n = 3) within a 95 % confidence 
interval. 
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resorufin can be measured at 594 nm following excitation at 560 nm. On the contrary, 
non-viable cells, which have lost their metabolic capacity, cannot reduce resazurin and 
thus do not generate a fluorescence signal.99 The reduction reaction of resazurin to 
resorufin is shown in Figure 3.21.100  
 
SK-BR-3 cells were treated with the C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs following 
the procedure previously described for the MTT assay. The results of the assay are 
shown in Figure 3.22. The results from the CellTiter-Blue® assay are in agreement with 
those of the MTT assay. There is no dark toxicity for either of the nanoparticle 
conjugates, C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs, as cell viability remains high with 
minimal cell death following incubation with the AuNPs. Furthermore, cells subjected 
to PDT after incubation with the C11Pc-PEG-AuNPs are also undamaged, as no cell 
death is observed. On the other hand, cells subjected to PDT after incubation with the 
C3Pc-PEG-AuNPs show increasing levels of cell death as the concentration of C3Pc is 
increased, reaching up to 85 % cell death. These results not only confirmed the MTT 
assay results, but the assay significantly improved signal and reduced background 
noise. The staurosporine positive control no longer produces negative cell viability 
values and the variability (i.e., the error bars) is reduced. As a result, the CellTiter-Blue® 
assay was found to provide results that were more reliable than the MTT assay. The 
CellTiter-Blue® assay was repeated five times and the results were reproducible in 4 of 
the 5 repeats. 
 
 
Figure 3.21. Reduction reaction of resazurin in contact with metabolically active cells, to 
produce resorufin. 
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These results shown in Figure 3.22 indicate that at the same concentrations, the C3Pc 
conjugated nanoparticles are more effective at producing cytotoxicity following light 
irradiation, as confirmed by the P values that show statistical significance between 
C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs. There are two possible explanations for this 
observation. The first is related to the higher fluorescence quenching of C11Pc than 
that of C3Pc on the surface of the AuNPs, as shown in section 3.2.3. The cell viability 
results suggest that there is an enhanced production of 1O2 by the C3Pc-PEG-AuNPs, 
which leads to a more efficient PDT effect. However, this possibility could not be 
confirmed since the measurement of 1O2 quantum yields, as shown in section 3.2.5, 
were inconclusive. A second explanation for these results could be that the C3Pc-PEG-
AuNPs are better internalised by the SK-BR-3 cells than the C11Pc-PEG-AuNPs. Such 
increased uptake would lead to a higher concentration of the C3Pc-PEG-AuNPs inside 
the cells with a consequent greater photodynamic effect. To assess the internalisation 
of both C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs, confocal microscopy was used, as 
described in the following section. 
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Figure 3.22. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with (A) C11Pc-
PEG-AuNPs or (B) C3Pc-PEG-AuNPs. Cells were either irradiated with a 633 nm HeNe laser 
(A orange, B yellow) or non-irradiated (A dark cyan, B green). Staurosporine (+ve St) was 
used as a positive control for cytotoxicity. Error bars represent the SD (n = 3) within a 95 % 
confidence interval. Statistically significant difference between C11Pc-PEG-AuNPs and 
C3Pc-PEG-AuNPs is indicated by * at P < 0.008 and ** at P < 0.0001, obtained using a two-
tailed Student’s t-test, where P < 0.05 is considered statistically significant. 
* 
** 
** 
** 
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3.2.7. Study of the internalisation of the AuNPs by the SK-BR-3 cells 
To confirm that the enhanced cell death following PDT seen for the C3Pc-PEG-AuNPs is 
indeed due to a higher production of 1O2, the internalisation of the AuNPs by the SK-
BR-3 cells was studied. Internalisation studies were performed via confocal laser 
scanning microscopy, as explained in section 2.2.11, using a concentration of 0.23 μM 
Pc. Additionally, the cell death was also visualised using propidium iodide. Propidium 
iodide is a dead cell marker that intercalates with the DNA in the nucleus once the cell 
membrane is broken, therefore it can only stain dead cells.101 Figure 3.23 shows the 
results of SK-BR-3 control cells incubated with McCOY’s 5A FBS-free medium (Figure 
3.23 A-B) and SK-BR-3 cells incubated with either C11Pc-PEG-AuNPs (Figure 3.23 C-D) 
or C3Pc-PEG-AuNPs (Figure 3.23 E-F) both before and after irradiation with a 633 nm 
HeNe laser.  
The internalisation of C11Pc-PEG-AuNPs (Figure 3.23 C) and C3Pc-PEG-AuNPs (Figure 
3.23 E) at 0.23 μM appear to be similar. Both types of AuNPs are efficiently internalised 
by the cells, as shown by the red fluorescence seen from within the cells and not in the 
extracellular space. Additionally, following light irradiation, the SK-BR-3 cells treated 
with the C11Pc-PEG-AuNPs (Figure 3.23 D) are mostly viable, as shown by the minimal 
staining with propidium iodide. On the contrary, the SK-BR-3 cells treated with the 
C3Pc-PEG-AuNPs and irradiated with 633 nm light (Figure 3.23 F) show high levels of 
cell death as most cells within the samples are stained with propidium iodide, and the 
cell membranes appear to be disintegrated. This result is a further indication that the 
C3Pc-PEG-AuNPs are producing more 1O2 than the C11Pc-PEG-AuNPs. This is because 
the C11Pc-PEG-AuNPs, which are shown to be efficiently internalised by the SK-BR-3 
cells, do not lead to any cell death, as shown by the assay results in Figure 3.22. The 
most likely explanation for this is that the production of 1O2 by the C11Pc-PEG-AuNPs 
is not sufficient to induce cytotoxicity. On the other hand, the C3Pc-PEG-AuNPs are 
inducing up to 85 % cell death at this same concentration. Control cells not incubated 
with any AuNPs appear undamaged and are not stained with propidium iodide either 
before (Figure 3.23 A) or after (Figure 3.23 B) light irradiation, showing that the 633 nm 
HeNe laser light does not induce toxicity to the SK-BR-3 cells. 
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Figure 3.23. Confocal fluorescence microscopy images of SK-BR-3 cells control samples (A-
B), incubated with C11Pc-PEG-AuNPs (C-D) or C3Pc-PEG-AuNPs (E-F) (0.23 μM Pc). The 
samples were either non-irradiated (A, C, E) or irradiated (B, D, F) with a 633 nm HeNe 
laser. Images taken from 1) DIC, 2) fluorescence from C11Pc or C3Pc collected in the red 
channel (λex = 633 nm; above 650 nm), 3) fluorescence from propidium iodide collected in 
the pink channel (λex = 543 nm; 560-615 nm) and 4) composite images of DIC, red channel 
and pink channel. Scale bars (A-D) 5 μm and (E, F) 10 μm. 
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The C11Pc-PEG-AuNPs were incubated with SK-BR-3 cells at higher concentrations to 
determine whether an elevated concentration could induce phototoxicity, as shown in 
Figure 3.24. At a concentration of 1.2 μM C11Pc, dead cells were found over the 
coverslip following irradiation, which was confirmed by the staining with propidium 
iodide (Figure 3.24 D). C11Pc-PEG-AuNPs can also induce cell cytotoxicity, however it 
seems that a higher concentration is required as compared to the C3Pc-PEG-AuNPs. 
The healthy appearance of control cells before and after irradiation (Figure 3.24 A-B)  
and cells treated with C11Pc-PEG-AuNPs but non-irradiated (Figure 3.24 C), together 
with the absence of propidium iodide staining, shows that the laser does not induce 
toxicity and the C11Pc-PEG-AuNPs do not induce dark toxicity at high concentrations. 
  
 
 
 
Figure 3.24. Confocal fluorescence microscopy images of SK-BR-3 cells control samples (A-
B) or incubated with 1.2 μM C11Pc-PEG-AuNPs (C-D). The samples were either non-
irradiated (A, C) or irradiated (B, D) with a 633 nm HeNe laser. Images taken from 1) DIC, 
2) fluorescence from C11Pc collected in the red channel (λex = 633 nm; above 650 nm), 3) 
fluorescence from propidium iodide collected in the pink channel (λex = 543 nm; 560-
615 nm) and 4) composite images of DIC, red channel and pink channel. Scale bars (A, D) 
5 μm and (B, C) 10 μm. 
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3.2.8. Functionalisation of the Pc-PEG-AuNPs with anti-HER2 antibody  
The large surface area of the gold nanoparticles allows for their functionalisation with 
multiple ligands. As a result, gold nanoparticles can be functionalised with biological 
ligands in order to target specific types of cancer. As explained in section 3.1.2, 
between 10-34 % of breast cancers are HER2 positive.60 HER2 positive breast cancers, 
including SK-BR-3 cells, overexpress the HER2 receptor on their surface, which makes 
them highly invasive and metastatic cancers.62,63,65 Anti-HER2 antibody (anti-HER2-Ab) 
has been previously used to target the HER2 receptor in breast cancer cells for 
increased PDT efficacy.77,78 
Both C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs were functionalised with anti-HER2-Ab 
via the PEG ligand. The terminal carboxyl group of the PEG ligand was conjugated to 
the amine groups on the antibody via amide coupling. The amide coupling was 
performed using EDC/NHS.77 EDC and NHS react with the carboxyl group at the 
terminus of the PEG, forming an N-hydroxysuccinimidyl ester at the end of the PEG 
ligand. This ester then reacts with the amine groups of the antibody, creating the amide 
coupling that links the antibody to the PEG and thus to the surface of the AuNPs. The 
reaction scheme is shown in Figure 3.25.102  
Figure 3.25. Reaction between the terminal carboxyl group in PEG, EDC, NHS and the 
primary amine of an antibody to give the final amide bond that links the PEG and the 
antibody. 
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Anti-HER2-Ab was conjugated to both C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs. 
Following the conjugation reaction, the AuNP conjugates were washed until no excess 
unbound antibody was present. This was confirmed via UV-vis spectroscopy, by 
monitoring the decrease of unbound antibody absorbance intensity between 200-
500 nm in each of the washing steps (Figure 3.26 A-B). The purified anti-HER2-Ab 
functionalised AuNPs were then resuspended in serum-free McCOY’s 5A phenol red-
free medium and the UV-vis extinction spectra were recorded (Figure 3.26 C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The number of antibodies immobilised per AuNP can be estimated. In section 3.2.2, an 
estimation of the ratio of Pc to AuNPs was calculated and it was found that C11Pc-PEG-
AuNPs contain ca. 115 C11Pc per AuNPs while C3Pc-PEG-AuNPs contain ca. 99 C3Pc per 
AuNPs. Considering the number of Pc per AuNPs and the concentration of the solutions 
of the C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs (Table 3.6), the concentration of AuNPs 
Figure 3.26. Decrease in absorbance intensity of the unbound antibody in the washes of 
(A) C11Pc-PEG-AuNPs and (B) C3Pc-PEG-AuNPs. (C) Extinction spectra of anti-HER2-Ab 
functionalised C11Pc-PEG-AuNPs (i) and anti-HER2-Ab functionalised C3Pc-PEG-AuNPs (ii). 
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in each solution can be estimated (Table 3.6). Then, the ratio of the concentration of 
anti-HER2 antibody initially used to the concentration of AuNPs in the sample can be 
calculated (Table 3.6), following the method reported by Obaid et al..78 The calculations 
estimate that a maximum of ca. 3 and ca. 2 anti-HER2 antibodies are immobilised on 
the C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs, respectively. 
 
Sample [Pc] / nM 
Ratio Pc per 
AuNP 
[AuNPs] / 
nM 
[Antibody] / 
nM 
Ratio 
C11Pc-PEG-
AuNPs 
2.40×103 115 20.87 65 3.11 
C3Pc-PEG-
AuNPs 
2.68×103 99 27.07 65 2.40 
 
 
3.2.9. Targeted PDT in vitro 
The anti-HER2-Ab functionalised AuNPs were tested in vitro using SK-BR-3 cells, in the 
same manner as for the non-functionalised AuNPs as reported in section 3.2.6. SK-BR-
3 cells are HER2 positive and thus it was expected that a higher amount of AuNPs would 
be internalised, leading to a higher proportion of cell death. MTT assays were initially 
performed, but the results showed high error bars and some negative values of cell 
viability for several samples, including the positive control. Therefore, as previously 
used for the analysis of non-functionalised AuNPs, CellTiter-Blue® assay was performed 
to minimise error and increase accuracy of the cell viability assay. The results of the 
CellTiter-Blue® assay are shown in Figure 3.27. 
 
 
 
 
 
Table 3.6. Ratio of anti-HER2 antibody to AuNPs. 
141 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following irradiation with a 633 nm HeNe laser, cells treated with either anti-HER2-Ab-
C11Pc-PEG-AuNPs (Figure 3.27 A) or anti-HER2-Ab-C3Pc-PEG-AuNPs (Figure 3.27 B) 
show a high degree of cell death, a significant improvement of cell phototoxicity from 
the results seen with the non-functionalised AuNPs (Figure 3.22, section 3.2.6). 
Additionally, the levels of cell death are similar for anti-HER2-Ab-C11Pc-PEG-AuNPs and 
anti-HER2-Ab-C3Pc-PEG-AuNPs, both showing cytotoxicity in up to 99 % of the treated 
cells. These results indicate that anti-HER2-Ab is effectively targeting the HER2 receptor 
on the surface of the SK-BR-3 cells. As a result, cytotoxicity following PDT treatment is 
increased from 0 % with 0.25 μM C11Pc-PEG-AuNPs (Figure 3.22 A) to 99 % with 
0.25 μM anti-HER2-Ab-C11Pc-PEG-AuNPs (Figure 3.27 A); and from 85 % with 0.23 μM 
C3Pc-PEG-AuNPs (Figure 3.22 B) to 99 % with 0.23 μM anti-HER2-Ab-C3Pc-PEG-AuNPs 
(Figure 3.27 B). 
On the other hand, the cells incubated with the anti-HER2-Ab functionalised AuNPs, 
but not subjected to PDT treatment (i.e., not irradiated with light), show different 
results for the C11Pc and the C3Pc photosensitisers. Dark toxicity in the cells treated 
with anti-HER2-Ab-C11Pc-PEG-AuNPs (Figure 3.27 A) is negligible. However, cells 
treated with anti-HER2-Ab-C3Pc-PEG-AuNPs (Figure 3.27 B) show increasing levels of 
dark toxicity with increasing concentration of C3Pc. In section 3.2.2, an estimation of 
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Figure 3.27. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with (A) anti-
HER2-Ab-C11Pc-PEG-AuNPs or (B) anti-HER2-Ab-C3Pc-PEG-AuNPs. Cells were either 
irradiated with a 633 nm HeNe laser (A orange, B yellow) or non-irradiated (A dark cyan, 
B green). Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars 
represent the SD (n = 3) within a 95 % confidence interval.  
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the ratio of Pc to AuNPs was performed. It was estimated that there would be ca. 115 
C11Pc per AuNP and ca. 99 C3Pc per AuNP. As a result, at the same concentration of 
phthalocyanine, the C3Pc-PEG-AuNPs sample contains more AuNPs than the C11Pc-
PEG-AuNPs sample. The higher amount of gold nanoparticles internalised by the SK-
BR-3 cells could lead to the increase in dark toxicity seen in Figure 3.27 B. These results 
suggest that, even though both nanoparticle systems induce the same levels of 
cytotoxicity (ca. 99 %), anti-HER2-Ab-C11Pc-PEG-AuNPs should be used in preference 
since they do not induce any dark toxicity.  
The results indicate that the anti-HER2-Ab functionalised AuNPs are internalised by SK-
BR-3 cells more readily and in increased amounts than the non-functionalised AuNPs. 
In order to confirm that this increased uptake is due to the specific interaction between 
anti-HER2-Ab and the HER2 receptor overexpressed on the surface of SK-BR-3 cells, an 
InCell ELISA was performed. InCell ELISA is a type of indirect ELISA used to assess 
protein levels on the surface of cells. During an InCell ELISA, the cells are immobilised 
on 96-well microplates. An antibody, selective to the receptor in question, is then 
added to the cells. The antibody will bind to the free receptors on the surface of the 
cells. A secondary antibody bound to HRP is then added, which will bind to all the 
primary antibodies already immobilised on the surface of the cells. Interaction of HRP 
with a substrate such as 3,3’,5,5’-tetramethylbenzidine (TMB) leads to the 
development of a coloured solution, with an absorbance intensity at 450 nm 
proportional to the amount of antibody bound to the cells, and thus to the amount of 
receptor present on the surface of the cells. In this study, the interest relies on the 
specific receptor-mediated endocytosis of the anti-HER2-Ab functionalised AuNPs. 
Therefore, prior to addition of the anti-HER2 primary antibody, the cells were treated 
with the anti-HER2-Ab functionalised AuNPs for 3 h. This treatment leads to the 
targeting of HER2 receptors on the surface of the cells, which will no longer be available 
for the primary antibody during the ELISA. As a result, the cells treated with the anti-
HER2-Ab functionalised AuNPs should produce a lower signal at 450 nm as compared 
to untreated cells or cells treated with non-functionalised AuNPs, in which all the HER2 
receptor sites on the surface of the cells are free. The values obtained can be 
normalised to cell number in each sample by using the whole-cell stain Janus Green. 
143 
 
Janus Green stains whole cells and gives an absorbance value at 615 nm, which is 
proportional to the number of cells in the sample. The results are shown in Figure 3.28.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28 shows the change in HER2 protein expression when the cells are treated 
with the anti-HER2-Ab functionalised AuNPs relative to untreated cells. For those 
samples treated with anti-HER2-Ab-C3Pc-PEG-AuNPs there is a 32 % reduction in HER2 
expression (Figure 3.28 C). For samples treated with anti-HER2-Ab-C11Pc-PEG-AuNPs 
there is a 38 % reduction in HER2 expression (Figure 3.28 C). These results suggest that 
the anti-HER2-Ab functionalised AuNPs are binding to some of the HER2 receptor sites 
Figure 3.28. InCell ELISA for the detection of the HER2 receptor on the surface of SK-BR-3 
cells. (A) Absorbance at 450 nm representing the amount of HER2 receptor present in each 
sample. (B) Absorbance at 615 nm representing the number of cells per sample. (C) 
Normalised value of HER2 receptor per cell number in each sample. Untreated refers to 
cells only treated with McCOY’s 5A medium; C3 and C11 refer to cells treated with C3-PEG-
AuNPs and C11Pc-PEG-AuNPs, respectively; Ab-C3 and Ab-C11 refer to cells treated with 
anti-HER2-Ab-C3Pc-PEG-AuNPs and anti-HER2-Ab-C11Pc-PEG-AuNPs, respectively. Error 
bars represent the SD (n = 3) within a 95 % confidence interval. 
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on the cell surface. On the other hand, the change in samples treated with either of the 
non-functionalised nanoparticles, C3Pc-PEG-AuNPs or C11Pc-PEG-AuNPs, is negligible 
(Figure 3.28 C). These results suggest that the anti-HER2-Ab functionalised AuNPs are 
internalised by the cells via receptor-mediated endocytosis, which leads to a higher 
nanoparticle uptake and thus more efficient photodamage. 
 
3.2.10. Confocal microscopy study of targeted PDT  
The uptake and PDT effect of the nanoparticles in SK-BR-3 cells was studied using 
confocal microscopy to evaluate the difference in internalisation before and after 
functionalisation of the AuNPs with anti-HER2 antibody. The phthalocyanines were 
used at a concentration of 0.15 μM since at this concentration the cell death for 
targeted PDT was high in both systems with minimal dark toxicity, either containing 
C11Pc or C3Pc (see Figure 3.27). The cells were treated with the anti-HER2-Ab 
functionalised and non-functionalised AuNPs for 3 h and subsequently washed to 
eliminate all the non-internalised nanoparticles, as described in section 2.2.11. 
Confocal microscopy images were then taken either right after incubation with the 
AuNPs (0 h) or 19 h after incubation with the AuNPs. During those 19 h, the cells were 
kept in an incubator at 37 °C under a 5 % CO2 atmosphere. As reported in section 3.2.7, 
propidium iodide was used to stain dead cells. The results are shown in Figure 3.29 for 
the control samples, Figure 3.30 for the samples treated with C11Pc-PEG-AuNPs and 
Figure 3.31 for the samples treated with C3Pc-PEG-AuNPs.  
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Figure 3.29. Confocal fluorescence microscopy images of SK-BR-3 cells control samples 
incubated with serum-free McCOY’s 5A medium for 3 h. The samples were either non-
irradiated and imaged right after incubation with the medium (A), non-irradiated and 
imaged 19 h following incubation (B) or irradiated with a 633 nm HeNe laser 19 h following 
incubation (C). Images taken from: 1) DIC, 2) fluorescence collected in the red channel 
(λex = 633 nm; above 650 nm), 3) fluorescence from propidium iodide collected in the pink 
channel (λex = 543 nm; 560-615 nm) and 4) composite images of DIC, red channel and pink 
channel. Scale bars 5 μm. 
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Figure 3.30. Confocal fluorescence microscopy images of SK-BR-3 cells incubated with non-
conjugated (A-C) or anti-HER2-Ab conjugated (D-F) C11Pc-PEG-AuNPs, either non-
irradiated and imaged right after incubation with the AuNPs (A, D), non-irradiated and 
imaged 19 h following incubation (B, E) or irradiated with a 633 nm HeNe laser 19 h 
following incubation (C, F). Images taken from: 1) DIC, 2) fluorescence from C11Pc 
collected in the red channel (λex = 633 nm; above 650 nm), 3) fluorescence from propidium 
iodide collected in the pink channel (λex = 543 nm; 560-615 nm) and 4) composite images 
of DIC, red channel and pink channel. Scale bars 5 μm. 
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Figure 3.31. Confocal fluorescence microscopy images of SK-BR-3 cells incubated with non-
conjugated (A-C) or anti-HER2-Ab conjugated (D-F) C3Pc-PEG-AuNPs, either non-irradiated 
and imaged right after incubation with the AuNPs (A, D), non-irradiated and imaged 19 h 
following incubation (B, E) or irradiated with a 633 nm HeNe laser 19 h following incubation 
(C, F). Images taken from: 1) DIC, 2) fluorescence from C3Pc collected in the red channel 
(λex = 633 nm; above 650 nm), 3) fluorescence from propidium iodide collected in the pink 
channel (λex = 543 nm; 560-615 nm) and 4) composite images of DIC, red channel and pink 
channel. Scale bars 5 μm. 
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It can be seen from the images shown above, for both C11Pc (Figure 3.30) and C3Pc 
(Figure 3.31), that the functionalisation with anti-HER2 antibody greatly enhances the 
uptake by SK-BR-3 cells. Additionally, the anti-HER2 antibody functionalised AuNPs are 
initially located around the cell membrane following a 3 h incubation period (Figure 
3.30 D and Figure 3.31 D). As time progresses (up to 19 h after incubation), the AuNPs 
appear to be in specific locations within the cells, most likely the acidic organelles 
(Figure 3.30 E and Figure 3.31 E). The AuNPs are shown to induce no dark toxicity as 
non-irradiated samples are not stained with propidium iodide and are thus viable. 
Furthermore, it can be seen that, at this concentration of 0.15 μM, C11Pc-PEG-AuNPs 
only induced cytotoxicity after light irradiation when the antibody is used to target the 
SK-BR-3 cells, in accordance with the cell viability results shown in Figures 3.22 and 
3.27. For the 0.15 μM C3Pc-PEG-AuNPs, targeting the cells with the antibody highly 
increased the photodynamic efficacy and cell death, as shown in Figure 3.27. However, 
prior to antibody conjugation, the C3Pc-PEG-AuNPs at 0.15 μM were already able to 
induce ca. 60 % cell death, as shown by the cell viability assays (see Figure 3.22). The 
confocal microscopy images here reported for the SK-BR-3 cells treated with 0.15 μM 
C3Pc-PEG-AuNPs following irradiation (Figure 3.31 C), show viable cells not stained 
with propidium iodide. During the confocal microscopy experiments, this coverslip is 
populated with ca. 40 % viable cells and ca. 60 % dead cells (see Figure 3.22). 
Therefore, it is easy to find viable cells within the sample. These results further 
confirmed the cell viability results seen in sections 3.2.6 and 3.2.9. Therefore, it can be 
confirmed that the functionalisation of the AuNPs with anti-HER2 antibody increases 
the internalisation by the SK-BR-3 cells and thus leads to higher levels of cell death for 
both the anti-HER2-Ab-C11Pc-PEG-AuNPs and the anti-HER2-Ab-C3Pc-PEG-AuNPs. 
 
3.2.11. Colocalisation studies 
The location of the gold nanoparticles functionalised with anti-HER2 antibody within 
the cells was further studied using confocal microscopy by investigating the 
colocalisation with the acidic organelle marker LysoSensor™ Green DND-189. 
LysoSensor™ Green is a fluorescent molecule that marks the acidic organalles inside 
the cells, namely the lysosomes.103 The colocalisation studies were performed using the 
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anti-HER2-Ab functionalised AuNPs at 0.15 μM. Following treatment with the anti-
HER2-Ab-C11Pc-PEG-AuNPs or the anti-HER2-Ab-C3Pc-PEG-AuNPs for 3 h and removal 
of the non-internalised AuNPs by washing, the cells were further incubated between 0-
19 h before treatment with LysoSensor™ Green and imaging. However, it was not until 
19 h after nanoparticle treatment that the nanoparticles were located in the acidic 
organelles, as shown in Figure 3.32 by the partial colocalisation between the red 
fluorescence from the functionalised AuNPs and the green fluorescence from the 
LysoSensor™ Green. Control cells not incubated with AuNPs (Figure 3.32 A) show the 
green fluorescence from the LysoSensor™ Green, marking the acidic organelles. Cells 
treated with the anti-HER2-Ab-C11Pc-PEG-AuNPs (Figure 3.32 B) and the anti-HER2-
Ab-C3Pc-PEG-AuNPs (Figure 3.32 C) clearly show that the red fluorescence from the 
AuNPs (Figure 3.32 B-C 2)) is in the same locations as the green fluorescence from 
LysoSensor™ Green (Figure 3.32 B-C 3)). The colocalisation of the green and red 
channels suggests that the anti-HER2-Ab functionalised AuNPs are located in the acidic 
organelles inside the cells, i.e., the lysosomes.  
 
 
 
 
Figure 3.32. Confocal fluorescence microscopy images of SK-BR-3 cells control samples (A), 
incubated with anti-HER2-Ab-C11Pc-PEG-AuNPs (B) or anti-HER2-Ab-C3Pc-PEG-AuNPs (C). 
Images were taken 19 h following incubation with the AuNPs. Images taken from 1) DIC, 
2) fluorescence from C11Pc or C3Pc collected in the red channel (λex = 633 nm; above 
650 nm), 3) fluorescence from LysoSensor™ Green collected in the green channel (λex = 
458 nm; 475-525 nm) and 4) composite images from DIC, red and green channels. Scale 
bars 5 μm. 
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3.2.12. Toxicity and PDT effect in non-cancerous mammary epithelial cells  
In order to fully compare the photosensitisers C3Pc and C11Pc regarding their PDT 
efficacy, it was important to test these nanoparticle conjugates using a non-cancerous 
cell line. The MCF-10A cell line consists of non-cancerous human fibrocystic mammary 
epithelial cells.104 Therefore, these cells can be used to assess the effect of the AuNPs 
on healthy neighbouring cells. The cells were treated with the AuNPs following the 
procedure developed for the SK-BR-3 cancer cell line. The AuNPs, both non-conjugated 
and conjugated with anti-HER-Ab, were tested, as shown in Figure 3.33.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33. CellTiter-Blue® cell viability assay for MCF-10A cells incubated with (A) C11Pc-
PEG-AuNPs, (B) C3Pc-PEG-AuNPs, (C) anti-HER2-Ab-C11Pc-PEG-AuNPs and (D) anti-HER2-
Ab-C3Pc-PEG-AuNPs. Cells were either irradiated with a 633 nm HeNe laser (green) or non-
irradiated (orange). Staurosporine (+ve St) was used as a positive control for cytotoxicity. 
Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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Both the non-conjugated C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs (Figure 3.33 A-B) 
produce minimal damage to the cells following incubation, even at the highest 
concentrations. All samples, before and after irradiation at 633 nm, show high levels of 
cell viability. This suggests the AuNPs are not being internalised by the non-cancerous 
cells and thus no cell damage is observed. Further studies to investigate the 
internalisation pathway followed by MCF-10A cells should be performed to understand 
why MCF-10A cells do not internalise the functionalised AuNPs as readily as the 
cancerous SK-BR-3 cells. However, when anti-HER2-Ab is conjugated to the AuNPs, the 
results are significantly different, especially for the anti-HER2-Ab-C3Pc-PEG-AuNPs. The 
HER2 receptor is expressed in normal healthy cells in lower amounts than cancerous 
cells, as it is involved in cell growth and differentiation.65 As a result, it is expected that 
at high concentrations, some of the AuNPs will be taken up by the MCF-10A cells via 
receptor-mediated endocytosis facilitated by the presence of the HER2 receptor on the 
cell surface. This is the case for anti-HER2-Ab-C11Pc-PEG-AuNPs, as seen in Figure 3.33 
C. When there is no irradiation, the cells show high levels of viability, even at the higher 
concentrations. However, once the 633 nm light is used to irradiate the samples, the 
cells die as the concentration is increased. This confirms the hypothesis that the HER2 
receptors on the surface of the healthy cells are facilitating the internalisation of the 
AuNPs. For anti-HER2-Ab-C3Pc-PEG-AuNPs, the cells are killed at concentrations as low 
as 0.08 μM, even without light irradiation. The conjugation of anti-HER2-Ab to C3Pc-
PEG-AuNPs not only increases the internalisation by the healthy cells, but it also makes 
the AuNPs toxic for healthy mammary cells even at low C3Pc concentrations. The 
difference in dark toxicity between anti-HER2-Ab-C11Pc-PEG-AuNPs and anti-HER2-Ab-
C11Pc-PEG-AuNPs could be related to the higher amount of AuNPs for the anti-HER2-
Ab-C3Pc-PEG-AuNPs at the same concentration as anti-HER2-Ab-C11Pc-PEG-AuNPs, as 
explained in section 3.2.9. 
These results, together with the cell viability results reported in sections 3.2.6 and 
3.2.9, suggest that C3Pc-PEG-AuNPs are superior phototoxic agents than the C11Pc-
PEG-AuNPs. Neither of the two types of nanoparticles are toxic for healthy cells. 
However, C3Pc-PEG-AuNPs induces far more cancerous cell death following PDT than 
C11Pc-PEG-AuNPs, as shown in Figure 3.22. On the other hand, when anti-HER2-Ab is 
conjugated to the AuNPs, the C11Pc-PEG-AuNPs respond better than the C3Pc-PEG-
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AuNPs. This is because while both types of nanoparticles induce high levels of 
cancerous cell death following PDT (see Figure 3.27), the anti-HER2-Ab-C11Pc-PEG-
AuNPs do not damage healthy cells, as opposed to the anti-HER2-Ab-C3Pc-PEG-AuNPs, 
which are toxic even at low concentrations (0.08 μM C3Pc). 
 
3.2.13. Studies of cell viability 19 h after incubation 
As seen in sections 3.2.10 and 3.2.11, the AuNPs are initially located around the cell 
membrane and it is not until 19 h following incubation that they locate in the acidic 
organelles inside the cells. To study whether the phototoxic effects would have greater 
efficiency when the AuNPs are located in the lysosomes, a CellTiter-Blue™ cell viability 
assay was performed in which the cells were irradiated both immediately after 
incubation with the AuNPs, as previously performed in sections 3.2.6 and 3.2.9, and 
19 h following incubation with the AuNPs. Following irradiation, the cells were 
incubated for ca. 48 h prior to measuring cell viability. The concentrations of the 
phthalocyanines were 0.16 μM for C11Pc and 0.15 μM for C3Pc.  
Figure 3.34 shows the results for the SK-BR-3 cells treated with C11Pc-PEG-AuNPs 
(Figure 3.34 A-B) and C3Pc-PEG-AuNPs (Figure 3.34 C-D). When the cells are irradiated 
immediately after incubation with the nanoparticles (Figure 3.34 A,C) the results are 
similar to those shown in sections 3.2.6 and 3.2.9. There is minimal dark toxicity in all 
samples. Furthermore, the nanoparticles not functionalised with anti-HER2-Ab only 
induce cell death when they contain C3Pc but not C11Pc, even with the slightly lower 
concentration of 0.15 μM vs 0.16 μM for C3Pc and C11Pc, respectively. When the 
nanoparticles are functionalised with anti-HER-Ab, cell death reaches 99 % cell death 
in both cases. On the other hand, when the cells are irradiated 19 h following 
incubation with the nanoparticles (Figure 3.34 B,D) the results are different. No cell 
death is seen when the nanoparticles are not functionalised with anti-HER-Ab, for 
either the C3Pc or the C11Pc. Additionally, when the cells are treated with 
nanoparticles functionalised with anti-HER-Ab, either containing C3Pc or C11Pc, the cell 
death is considerably less than when irradiation is performed immediately after 
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nanoparticle incubation. Cell death only reaches up to 60 % for both C3Pc and C11Pc, 
a considerable difference to the 99 % cell death that was seen previously.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The lower cell death values seen in the in vitro experiments when the cells are 
irradiated 19 h post-incubation could be related to the localisation of the AuNPs inside 
the cells. As shown in Figures 3.30-3.32, the AuNPs are internalised by the cells and are 
(D) (C) 
(B) (A) 
Figure 3.34. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with (A-B) anti-
HER2-Ab functionalised and non-functionalised C11Pc-PEG-AuNPs (0.16 μM C11Pc) or (C-
D) anti-HER2-Ab functionalised and non-functionalised C3Pc-PEG-AuNPs (0.15 μM C3Pc). 
Cells were either irradiated with a 633 nm HeNe laser (A-B orange, C-D yellow) or non-
irradiated (A-B dark cyan, C-D green). Irradiated samples were either irradiated 0 h (A, C) 
or 19 h (B, D) following incubation with the AuNPs. Control are samples not incubated with 
any AuNPs. Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars 
represent the SD (n = 3) within a 95 % confidence interval. 
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then encapsulated in the lysosomes, during the 19 h following incubation. The 
localisation of the AuNPs in the intracellular space enhances the cell destruction as 
opposed to the localisation inside the lysosomes due to the small radius of action of 
1O2 in the cytoplasm (ca. 10-55 nm).105,106 When the AuNPs are located in the 
lysosomes, the radius of action of 1O2 allows for the destruction of the lysosomes. 
Following destruction of the lysosomes, the AuNPs are released into the cytosol, where 
the production of 1O2 can lead to the destruction of the whole cell. Therefore, the cell 
viability of the SK-BR-3 cells treated with the functionalised AuNPs and irradiated 19 h 
following incubation should be monitored more than 48 h after irradiation, in order to 
give sufficient time for the AuNPs to be released from the lysosomes and kill the cells. 
This mechanism has been reported by Berg and co-workers for the destruction of 
tumour cells via photochemical internalisation (PCI).107-110 During PCI, an anti-cancer 
drug is encapsulated in the lysosomes, which are surrounded by photosensitisers. 
Activation of the photosensitisers by light irradiation leads to the destruction of the 
lysosomes and thus the release of the anti-cancer drug into the cytosol, which is then 
used for cancer therapy.107-110 
 
3.2.14. ApoTox-Glo™ Triplex assay for cell death mechanism 
The ApoTox-Glo™ Triplex assay was performed to study the cell death mechanism that 
the SK-BR-3 cells undergo following PDT with the anti-HER2-Ab conjugated and non-
conjugated C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs. The triplex assay measures three 
components: cell viability; cell cytotoxicity; and apoptotic response. Cell viability is 
measured using a cell-permeant peptide substrate, GF-AFC. GF-AFC goes into living 
cells and is cleaved by a protease activity, creating a fluorescent signal which can be 
measured at 505 nm following excitation at 400 nm. On the other hand, GF-AFC 
becomes inactive in the presence of dead cells due to the breakage of the cell 
membrane, which inactivates the live-cell protease. Cell cytotoxicity is measured using 
a cell-impermeant peptide substrate, bis-AAF-R110. Bis-AAF-R110 measures the 
protease activity that has been released into the culture medium by dead cells 
following breakage of the cell membrane. This reaction produces a fluorescent signal 
that can be measured at 520 nm following excitation at 485 nm. Bis-AAF-R110 is unable 
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to recognise healthy cells because their cell membrane is intact. The viability and 
cytotoxicity component of the assay thus act in a ratiometric manner. When the 
viability fluorescence values are high, the cytotoxicity fluorescence values should be 
low and vice versa. The apoptotic response of the cells is measured using a substrate 
for caspase 3/7. Both caspases 3 and 7 become active and promote apoptosis. 
Therefore, measuring the activity of these caspases is an indication of apoptosis in the 
sample. The caspase 3/7 substrate contains an aspartate-glutamate-valine-aspartate 
tetrapeptide sequence, known as DEVD, which is cleaved upon reaction with the active 
caspases. The final product, aminoluciferin, produces a luminescent signal that is 
proportional to the amount of caspase activity and thus to the apoptotic response in 
the sample.111  
Initially, as explained in section 2.2.14, the triplex assay was performed ca. 48 h 
following PDT (results not shown), to mimic the experiments in which cell viability was 
assessed through MTT and CellTiter-Blue® assays. Staurosporine was used as a positive 
control for cytotoxicity that follows the apoptotic pathway.97 The assay did not show 
the anticipated results, as they did not agree with the previous assay results. 
Additionally, the cytotoxicity and apoptosis components produced unexpected results 
since the positive control did not show high levels of cell cytotoxicity or apoptosis, even 
though staurosporine is a well-known apoptosis inducer. The unexpected results 
obtained could be related to the post-PDT incubation period of 48 h. The biomarkers 
for cytotoxicity and apoptosis are prone to degradation over time. As a result, the 
cytotoxicity protease activity can be degraded by the time the assay components are 
added, which would lead to an underestimation of the cytotoxicity levels within the 
sample. This is also true for drugs that induce cell-cycle arrest (i.e., antiproliferative 
effects). During the cell-cycle arrest, not only cytotoxicity is underestimated, but also 
the caspase activation might be underestimated.112 These effects are exacerbated 
when the drugs induce necrosis, which is a fast-acting cell death pathway. In an attempt 
to avoid these problems and obtain better results for the triplex assay, the incubation 
period post-PDT was decreased from 48 h to 4 h. The results for the ApoTox-Glo™ 
Triplex assay performed 4 h post-PDT are shown in Figure 3.35 A for cells treated with 
C11Pc-PEG-AuNPs and Figure 3.35 B for cells treated with C3Pc-PEG-AuNPs. In the 
viability component (Figure 3.35 1)), the untreated control cells are viable whereas the 
156 
 
cells treated with the positive control show low levels of viability, as expected. 
Additionally, the samples treated with the functionalised AuNPs are all shown to induce 
cell death following PDT. However, the cell death values do not agree with previous 
results found from the cell viability assays reported in sections 3.2.6 and 3.2.9. 
Furthermore, the dark toxicity for the anti-HER2-Ab-C3Pc-PEG-AuNPs appears to be 
significantly high, leading to cell death similar to the irradiated sample. This result also 
disagrees with those previously reported (see Figure 3.27). 
The cytotoxicity component of the assay (Figure 3.35 2)) still provides results that are 
difficult to explain, as shown by the absence of fluorescence in the samples treated 
with the positive control staurosporine, which is expected to induce the highest values 
of cytotoxicity. The fact that the cytotoxicity component is producing low fluorescent 
values for most samples could be an indication that the cells are in a cell-cycle arrest 
following PDT. The apoptosis component of the assay (Figure 3.35 3)) shows a 
significant improvement after reducing the post-PDT incubation time to 4 h, since the 
positive control has the highest values of luminescence of all samples. The samples 
treated with the AuNPs show much lower levels of luminescence, especially those 
treated with the anti-HER2 Ab functionalised AuNPs. The lower luminescence values of 
the AuNPs-treated cells are a possible indication of cell death occurring via a non-
apoptotic pathway, such as necrosis. However, a firm conclusion cannot be reached 
since the results of the assay were difficult to interpret and did not agree with the 
previous CellTiter-Blue® assay results. 
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Figure 3.35. ApoTox-Glo™ Triplex assay for SK-BR-3 cells incubated with (A) anti-HER2-Ab 
conjugated and non-conjugated C11Pc-PEG-AuNPs (0.16 μM C11Pc) or (B) anti-HER2-Ab 
conjugated and non-conjugated C3Pc-PEG-AuNPs (0.16 μM C3Pc). Cells were either 
irradiated with a 633 nm HeNe laser (A orange, B yellow) or non-irradiated (A dark cyan, B 
green). The cells were treated with the triplex assay 4 h following PDT. (1) Fluorescence 
from the GF-AFC substrate giving the cell viability values, (2) Fluorescence from bis-AAF-
R110 substrate giving the cell cytotoxicity values and (3) Luminescence from the Caspase 
3/7 substrate giving the values for apoptosis. The sample No AuNPs refers to samples not 
incubated with any AuNP used as the reference negative control. Staurosporine (+ve St) 
was used as a positive control for cytotoxicity via apoptosis. Error bars represent the SD 
(n = 3) within a 95 % confidence interval. 
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3.3. Conclusions 
In this chapter, two zinc phthalocyanines, differing in the length of the carbon chain 
that connects the macrocycle to the sulfur atom, were compared. C11Pc has a carbon 
chain consisiting of 11 carbon atoms, whereas C3Pc consists of only 3 carbon atoms. 
Gold nanoparticles were synthesised and functionalised with a mixed monolayer of 
PEG, to provide aqueous solubility to the system, together with either C11Pc or C3Pc. 
Gold nanoparticles functionalised with C11Pc-PEG (C11Pc-PEG-AuNPs) had an average 
size of 3.41 ± 1.16 nm. Gold nanoparticles functionalised with C3Pc-PEG (C3Pc-PEG-
AuNPs) had an average size of 3.83 ± 0.99 nm. 
The fluorescence of C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs was analysed and 
compared to the fluorescence of the free ligands in solution. The fluorescence of the 
free ligands was found to be more intense for the C11Pc as compared to the C3Pc. On 
the other hand, when the ligands are on the AuNPs, the fluorescence intensity was 
greater for the C3Pc-PEG-AuNPs. To confirm this result, the fluorescence quantum 
yields were estimated and they were found to be 4.8 % for free C11Pc, 2.6 % for free 
C3Pc, 0.2 % for C11Pc-PEG-AuNPs and 0.42 % for C3Pc-PEG-AuNPs. These results were 
rationalised by consideration of the interactions between fluorophores and metal 
nanoparticles. The quenching of the fluorescence of both C11Pc and C3Pc when self-
assembled on the surface of the AuNPs, is due to the small size of the nanoparticles, as 
explained by the RP model.20 The fact that C3Pc-PEG-AuNPs experience less 
fluorescence quenching than C11Pc-PEG-AuNPs was probably related to the 
orientation and the distance between the fluorophore and the AuNPs. The enhanced 
quenching present for the C11Pc could be explained by the orientation of the 
phthalocyanine molecules in respect to the AuNPs. The orientation of the longer C11 
chain is influenced by the important chain-chain intermolecular interactions taking 
place. As a result, it is possible that the C11 chain will be oriented at an angle more 
parallel to the gold core, such that the C11Pc molecule lies more horizontal with respect 
to the AuNPs. By contrast, the chain-chain interactions in the C3Pc will be minimal due 
to the short nature of the chain. Therefore, it is possible that the C3 chain will be 
oriented more perpendicular relative to the AuNPs. The relative orientations of the 
phthalocyanines in respect with the nanoparticles has an effect in their fluorescence 
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properties. The parallel orientation in which the C11Pc is speculated to be positioned 
leads to the phthalocyanine’s molecular dipole and the dipole of the AuNPs to radiate 
out of phase, thus decreasing the radiative decay of the fluorophore.12 The angles at 
which the chains are positioned influences how close the phthalocyanines will be to 
the gold core. In the present study, it was speculated that the C11Pc molecule lies 
closer to the gold core, which could explain the higher quenching effect observed, 
mainly due to electron transfer between C11Pc and the AuNPs. On the other hand, the 
C3Pc molecule is speculated to be oriented in a perpendicular orientation, which allows 
for the enhancement of the radiative decay rate of the fluorophore. Even though the 
perpendicular orientation of the C3Pc is ideal for MEF, the absence of fluorescence 
enhancement seen in the present study could be related to the small size of the 
nanoparticles, which are strong fluorescence quenchers. These results opened the 
possibility for an increased production of 1O2 by C3Pc-PEG-AuNPs. Analysis of the 
production of 1O2 with ABMA indicated that C3Pc-PEG-AuNPs produced more 1O2 than 
the C11Pc-PEG-AuNPs. To confirm these results, the quantum yield of 1O2 production 
for both nanoparticle conjugates was analysed. Unfortunately, the AuNPs were 
dissolved in an aqueous solvent, which leads to the quenching of the 1O2 signal. 
Therefore, it was not possible to estimate a value for the 1O2 quantum yields. 
In vitro studies of both C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs in SK-BR-3 human 
breast adenocarcinoma cells showed a great difference between the two systems. 
While C11Pc-PEG-AuNPs do not show any cell death after irradiation with a 633 nm 
HeNe laser, C3Pc-PEG-AuNPs shows high levels of cell cytotoxicity, which increase with 
increasing concentration of C3Pc. Additionally, internalisation by the SK-BR-3 cells 
proved to be similar for C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs, as shown by confocal 
microscopy. These results further support the idea that there is an increased 
production of 1O2 by the C3Pc-PEG-AuNPs. However, in order to confirm that the 
internalisation of both nanosystems by the SK-BR-3 cells is the same, a quantification 
experiments should be performed, such as flow cytometry. In vitro studies in MCF-10A 
human mammary epithelial cells showed no toxicity for neither C11Pc-PEG-AuNPs nor 
C3Pc-PEG-AuNPs. Therefore, the C3Pc-PEG-AuNPs were shown to be optimal as they 
induce high cell kill in cancer cells and no damage to healthy cells. 
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Anti-HER2-Ab was used to target the overexpressed HER2 receptor on the surface of 
SK-BR-3 cells. Anti-HER2-Ab was conjugated to the terminal end of the PEG in both 
C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs via EDC-NHS coupling. In vitro studies in SK-
BR-3 cells showed a marked improvement in the rate of cell death by both AuNPs 
systems due to the presence of the anti-HER2-Ab. The difference between anti-HER2-
Ab-C11Pc-PEG-AuNPs and anti-HER2-Ab-C3Pc-PEG-AuNPs was minimal, as both 
systems led to similar levels of cell death (99 %) following PDT. Confocal microscopy 
studies of anti-HER2-Ab functionalised AuNPs to investigate uptake and PDT confirmed 
the previous results. The anti-HER2-Ab led to higher levels of internalisation as 
compared to the non-functionalised AuNPs. Additionally, it was found that the anti-
HER2-Ab functionalised AuNPs colocalised with the acidic organelles inside the cells 
19 h after incubation. Studies in MCF-10A cells showed high levels of cytotoxicity 
before and after irradiation for anti-HER2-Ab-C3Pc-PEG-AuNPs whereas there was 
minimal photodamage when anti-HER2-Ab-C11Pc-PEG-AuNPs were used. Therefore, 
anti-HER2-Ab-C11Pc-PEG-AuNPs were found to be preferred as they induce efficient 
cell kill in cancer cells while leaving healthy cells unaffected. 
The ApoTox-Glo™ Triplex assay was performed to check the cell death pathway 
followed after PDT. An indication that the cells follow a non-apoptotic cell death 
pathway, i.e., necrosis, was obtained. However, these results were not conclusive since 
several components of the assay gave unexpected results and were not in agreement 
with the other assay results. Further studies to evaluate the cell death mechanism 
followed by the SK-BR-3 cells after PDT treatment with the C11Pc-PEG-AuNPs and C3Pc-
PEG-AuNPs should be performed.  
In this chapter, the use of an antibody to target breast cancer cells was found to 
significantly increase the internalisation and PDT efficacy of the functionalised AuNPs. 
The use of other types of ligands to target specific receptor overexpressed on the 
surface of cancer cells has been explored, including the use of carbohydrates, lectins 
and aptamers, as explained in Chapter 1.79,113-115 The use of a carbohydrate, lactose, as 
a potential targeting ligand to improve the PDT efficacy in breast cancer cells will be 
explored in Chapter 4. 
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Chapter 4 
Targeted photodynamic therapy of breast cancer cells using 
lactose-phthalocyanine gold nanoparticle conjugates 
This chapter describes the use of a carbohydrate, lactose, as a targeting agent for the 
selective uptake of gold nanoparticles functionalised with a zinc phthalocyanine for 
photodynamic therapy of human breast adenocarcinoma cells.  
 
4.1. Introduction 
4.1.1. Aberrant glycosylation in cancer 
Glycobiology has become an important field of study in cancer research.1 
Carbohydrates are organic structures widely found in nature.2 The most basic 
structures of carbohydrates, monosaccharides, can be linked via glycosidic bonds to 
form more complex structures, oligosaccharides and polysaccharides also known as 
glycans.2,3 Glycans are not encoded by the genome. Instead, the enzymes 
glycosyltransferases and glycosidases catalyse the biosynthesis of glycans, which then 
lead to the formation of glycoproteins and glycolipids.2-4 Glycans and proteins can be 
either N-linked, when the glycan is bound to the amide group of an asparagine residue 
on the protein, or O-linked, when the glycan is bound to the hydroxyl group of serine 
or threonine residues on the protein.2,3,5,6 Additionally, glycolipids are created via 
sphingolipids, when the glycans are linked to lipid ceramides.1,3 Therefore, glycans are 
expressed in a specific pattern on the surface of all cells.2,7  
The surface of all cells also expresses other carbohydrate-related molecules, known as 
lectins. Lectins are carbohydrate-binding proteins that recognise glycans in a specific 
manner via their carbohydrate-recognising domains (CRDs).2,6,7 Lectins preferentially 
bind those carbohydrates found on glycoproteins and glycolipids, i.e., natural 
polysaccharides, with dissociation constants (Kd) in the nanomolar range. However, 
they can also bind free carbohydrates but this interaction is weaker (Kd = ca. 10-4 M). 
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The multivalent nature of the lectin-carbohydrate interactions allows for multiple weak 
binding that can induce high overall affinity.2,8-10 Even though there is not a generally 
accepted classification for endogenous lectins, there are four main categories that 
include the majority of known animal lectins; C-type, S-type, I-type and P-type 
lectins.2,11 C-type lectins are calcium-dependent lectins that are always found bound to 
a carbohydrate. They include selectins, collectins, endocytic receptors and 
proteoglycans.2,12 S-type lectins, most commonly known as galectins, are calcium-
independent lectins found non-glycosylated that have specificity towards β-galactose-
containing glycans.2,13 I-type lectins belong to the immunoglobulin superfamily. The 
most important and well known subgroup involves the siglecs, sialic acid-binding 
lectins.2,14 P-type lectins are specific towards mannose-6-phosphate, also known as 
M6P receptors.11 
Glycans and lectins play important roles in normal healthy tissue. They are involved in 
embryonic development, cell growth, differentiation and adhesion, apoptosis, cell 
signalling, cell-cell recognition, interactions between cells and the extracellular matrix 
(ECM) and protein folding.2,5,6 Additionally, they have roles in the immune system in 
regulating host-pathogen interactions and inflammation.2,6 These functions are 
regulated when lectins on one cell bind their corresponding carbohydrates, present on 
the surface of other cells.7  
Changes in the phenotypic distribution of glycans and lectins on the surface of the cells 
is linked with cancer, since they can promote cell migration and metastasis.1-3,5-7,15,16 
The most common changes in the phenotype of glycans are related to the under- or 
over-expression of the enzymes involved in their biosynthesis, glycosyltransferases and 
glycosidases.1,6,16 Aberrant glycosylation usually occurs by two main pathways, the first 
one being the expression of truncated or shorter glycans as what would normally be 
seen in healthy cells and the second one being a change in the terminal sequences of 
the glycans.15 As a result, an increased expression of α-2,6 sialylation, fucosylation, O-
glycan truncation, β-1,6 branching of N-linked glycans and Lewisa/x antigens together 
with the expression of oncofetal antigens are seen.1,5,6,15,16 These changes in the 
glycosylation pattern are mediated by two mechanisms, neo-synthesis and incomplete 
synthesis, and are usually linked to poor prognosis in cancers.1-3,6,15 Modifications in the 
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expression of lectins on the surface of the cells is also linked to cancer. The two most 
important and well-characterised types of lectins in cancer research are selectins and 
galectins.2,7 Galectins and their role in cancer will be further discussed in section 4.1.2. 
 
4.1.2. Galectins and their role in cancer 
Galectins are a type of lectins that have preference towards β-galactoside 
carbohydrates.17 Galectins are encoded by the gene LGALS, which stands for lectin 
galactoside-binding soluble.17,18 To date, fifteen different galectins have been 
identified, which can be classified into three distinct groups.18-23 Galectins in the first 
group are referred to as prototype galectins and they include galectins 1, 2, 5, 7, 10, 
13, 14 and 15.19 Prototype galectins have a dimeric structure and contain one single 
CRD (Figure 4.1 A).19,21,22 Galectins in the second group are referred to as tandem-
repeat galectins and they include galectins 4, 6, 8, 9 and 12.19 Tandem-repeat galectins 
contain two non-identical CRDs linked by a peptide domain and thus they are also 
known as biCRD (Figure 4.1 B).19,21,22 Finally, the third group of galectins is known as 
chimera.19-21 Only galectin-3 is part of this group and it is composed of one CRD linked 
to a proline, tyrosine and glycine rich domain and an NH2-terminal domain 
(Figure 4.1 C).17,21,22,24,25 Galectin-3 is found as a monomer in solution but it can form 
multivalent aggregates as it binds to a ligand with its carbohydrate specificity.17,24  
 
 
 
 
All galectins are composed of a core CRD sequence consisting of 130 amino acids.17,18,26 
As it was previously mentioned, galectins recognise the β-galactoside domain of 
carbohydrates.17 This definition is not restricted to the monosaccharide galactose. 
Galectins, especially galectins-1 and 2, have also been found to recognise lactose, via 
Figure 4.1. Typical structures for each type of galectin: (A) prototype galectin (B) tandem-
repeat (biCRD) galectin and (C) chimera galectin. This figure was adapted from Ref. 17.  
(A) (B) (C) 
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the galactose residue present within the lactose disaccharide. Surprisingly, in the case 
of galectins-1 and 2, there must be an interaction with the glucose residue on lactose 
too. This is because galectins-1 and 2 have a much higher affinity towards lactose than 
galactose.17 The problem with lactose is that it needs a high concentration of galectin-
1 in the cells for an effective inhibition.18,27 Naturally encountered ligands for galectins 
include glycoconjugates that contain polylactosamine chains within their structure.17,24 
Galectins are cytosolic proteins expressed not only intracellularly, specifically within 
the cytoplasm and in the nucleus of the cells, but also on the cell surface and 
extracellularly within the ECM. Externalisation of galectins is possible due to their 
secretion via non-classical secretion pathways, unrelated to the standard pathway via 
the endoplasmic reticulum and the Golgi apparatus.17,18,20,22-24 Galectins play a variety 
of roles in the body. Even though their mechanism of action is not yet understood, the 
main roles of galectins are triggered by the recognition of carbohydrates present on 
the surface of the cells.22 Some of the most important roles include cell-to-cell and cell-
to-ECM adhesion, regulation of cell growth, proliferation, migration and apoptosis, 
neurite elongation, inflammation, embryogenesis and pre-mRNA splicing.20-22,24,26 
Additionally, over- or under-expression of galectins has been linked with cancer, 
especially with tumour spreading, metastasis and angiogenesis.21,22 The best 
characterised and widely studied galectins in cancerous tissue are galectin-1 and 
galectin-3.17,21,24 
Galectin-1 is a 14 kDa pro-tumorigenic galectin encoded by the gene LGALS1 located 
on chromosome 22q12.17,18,22,23,28 Due to its mass, it has also been referred to as L-14 
lectin.17 The dimeric structure of galectin-1 allows it to crosslink inter- and intra-
molecularly by binding to more than one galactoside-containing carbohydrate, which 
leads to the activation of signal transduction pathways and triggers its biological 
functions.22,24 Natural carbohydrates that lead to the activation of galectin-1 include 
the ECM glycoproteins laminin and fibronectin, polylactosamine-rich lysosome-
associated membrane proteins (LAMPs) and the T-cell surface glycoproteins CD43, 
CD45 and CD7.21,24 
Galectin-1 is expressed in a variety of healthy and cancerous tissue. The normal tissue 
includes the thymus, lymph nodes, prostate, kidney, spleen, lungs, placenta, motor and 
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sensory neurons, skin and also endothelial cells and fibroblasts.17,24 In all these organs, 
galectin-1 can be found in the nucleus and cytoplasm inside the cells and also anchored 
onto the cell surface.18,23 Additionally, galectin-1 is secreted to the extracellular 
compartments, where its mass increases to 15 kDa as a result of the post-translational 
modifications that it undergoes during externalisation.23 The localisation of galectin-1 
within the cells varies from normal healthy tissue to cancerous tissue. In healthy cells, 
the majority of galectin-1 is found intracellularly, specifically located inside the nucleus 
of endothelial cells. On the other hand, in cancer cells galectin-1 is located 
extracellularly in much higher amounts.23  
Expression of galectin-1 within cancer cells is well known. Galectin-1 is found 
overexpressed in a variety of cancer types including breast, colon, endometrium, ovary, 
prostate, pancreatic, bladder and head and neck cancers. Additionally, overexpression 
of galectin-1 has also been linked to thyroid tumours, melanoma, astrocytoma, 
glioblastoma and the tumour vasculature, mainly endothelial cells.18-20,22-24,27,29-31 
Overexpression of galectin-1 in cancer is correlated with an increased aggressiveness 
and poor prognosis because galectin-1 mediates several functions that change the 
tumour microenvironment and are essential for cancer progression.18,27 Galectin-1 
induces metastasis and proliferation in cancer cells since it can promote the adhesion 
of the tumour cells and endothelial cells to the ECM.18,23,27 However, this enhancement 
in cell adhesion depends on the tumour type as well as the cellular localisation of 
galectin-1. In some cases, the opposite effect, where cell adhesion is inhibited, could 
be seen.23,24,27 As it was previously discussed, galectin-1 is overexpressed in the 
endothelial cells within the tumours. Endothelial cells are responsible for the creation 
of new “leaky” blood vessels, which leads to angiogenesis in cancer.18 The presence of 
galectin-1 stimulates the migration and proliferation of endothelial cells and provides 
a support for the formation of angiogenic blood vessels.18,27,29 Additionally, galectin-1 
has a role in the tumour-immune escape as it induces T-cell apoptosis via interaction 
with the CD glycoproteins mentioned above.24,27 
Galectin-3 is another pro-tumorigenic galectin with a mass ranging between 29-34 kDa 
encoded by the gene LGALS3 located in chromosome 1p13.17,19,32 Galectin-3 has been 
referred to as L-29, L-31 and εBP previously.17 Galectin-3 is found as a monomer in 
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solution. However, it has the ability for multimerisation upon binding to its specific 
receptors.17 Multimerisation of galectin-3 allows for its ability to cross-link inter- and 
intra-molecularly. Natural binding ligands specific towards galectin-3 include the ECM 
glycoproteins laminin and fibronectin, LAMPs 1 and 2, IgE and its receptor, the 
apoptosis regulator Bcl-2, a 90 kDa glycoprotein found in epithelial cells known as 
Mac2-BP and the RNA in the nucleus of the cells.17,24,33-35  
Galectin-3 is expressed in a variety of healthy tissue including cells of the immune 
system.17,24 The main locations for galectin-3 are macrophages, basophils, mast cells, 
monocytes, some sensory neurons, endothelial cells and epithelial cells of several 
tissues such as intestine, kidney, colon and breast.17,24 These cells express galectin-3 
primarily in the cytoplasm, but it can also be found in the nucleus, cell surface and 
circulating within the extracellular space.21,33,36 Galetin-3 plays important roles in cell 
adhesion, inflammation, bacterial colonisation, neutrophil and macrophage activation 
and protection of T-cells against apoptosis.17,24  
Expression of galectin-3 in cancerous tissue has been the subject of many studies. There 
is a well-known correlation between galectin-3 and cancer progression as this lectin is 
found overexpressed in certain types of cancers including central nervous system (CNS) 
tumours, lymphoma, melanoma, head and neck, gastric, liver, pancreatic, bladder and 
non-small cell lung cancer.19-22 For CNS tumours, galectin-3 is only found overexpressed 
in high grade, i.e., highly aggressive, tumours such as glioblastoma (grade IV) and grade 
III astrocytoma.20,37 Low-grade brain tumours, i.e., slow-growth tumours, do not show 
galectin-3 expression. The role and expression of galectin-3 in breast, colon, ovary, 
uterus and thyroid tumours is a conflicting issue. There are studies that show an 
overexpression of galectin-3 in breast, colon, ovary, uterus and thyroid cancers, which 
is related to metastatic potential.32,34,35,38-40 However, other studies have shown that 
galectin-3 is highly downregulated in breast, colon, ovary, uterus and thyroid cancers, 
and it is this downregulation that is correlated with histological grade.20,21,25,34,41 The 
contradicting values of galectin-3 expression in previous studies could be explained by 
the use of anti-galectin-3 antibodies that have cross-reactivity towards 67 laminin 
receptor (67LR) to detect galectin-3 levels.41 The expression of 67LR increases in 
cancers with increasing metastatic potential, which would explain the reason why 
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galectin-3 was found in high levels in some studies.41 The role of galectin-3 in cancer is 
to promote cell adhesion, invasion, proliferation and metastasis, inhibit T cell apoptosis 
and nitric oxide (NO) mediated apoptosis and stimulate anoikis resistance and tumour 
angiogenesis.22,24,34,36,40,42-44 However, the level of expression of galectin-3 and its role 
in cancer progression are dependent on the location of galectin-3 within the cells as 
well as tumour-specific factors, including the stage in which the tumour is at.24,25,34  
Cytoplasmic galectin-3 in circulation and galectin-3 circulating in the extracellular space 
tend to promote tumour progression and metastasis. On the other hand, galectin-3 
present in the nucleus has pro-apoptotic properties.34,45 Independent of its localisation, 
galectin-3 free mice are healthy, which suggests inhibition of galectin-3 could be 
important to prevent cancer progression.34 Additionally, inhibiting galectin-3 has been 
found to reduce the frequency of lung metastasis by 90 %.43 
In this chapter, the cancer of interest is breast adenocarcinoma. There is consensus of 
the overexpression of galectin-1 in breast cancer epithelial cells, as well as in their 
associated stromal cells. Therefore, galectin-1 is an ideal candidate for targeted breast 
cancer therapy since it has been shown that its suppression prevents tumour growth 
and metastasis.24,31 Overexpression of galectin-1 has been particularly shown in MDA-
MB-231 human breast adenocarcinoma cells.28,30,31,46 The expression of galectin-3 in 
breast cancer cells has led to the production of conflicting reports. Studies of galectin-
3 overexpression in different types of breast cancer have shown an indication that 
there is an increased expression of galectin-3 only in triple-negative breast cancers 
(TNBC). TNBC are those that do not overexpress neither of the hormonal receptors, 
estrogen and progesterone, nor the HER2 receptor and they account for approximately 
15 % of breast cancers.42,47 One commonly studied TNBC cell line is MDA-MB-231, 
which has been associated with an increased production of galectin-3.44,48 On the other 
hand, the HER2 positive SK-BR-3 human breast adenocarcinoma cell line has been 
associated with downregulation and zero-expression of galectin-3.48 However, it is only 
an indication and conflict still exists on the expression of galectin-3 on TNBC as other 
studies have found no cell-surface galectin-3 in MDA-MB-231 cells.46 Therefore, 
targeting breast cancer cells via β-galactoside-containing carbohydrates should be 
preferentially directed towards galectin-1. 
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4.1.3. Targeting cancer glycosylation 
As it was discussed in section 4.1.1, cancer cells present an aberrant glycosylation on 
their surface. The aberrant glycosylation affects both glycoconjugates and lectins. As a 
result, carbohydrates and lectins are ideal candidates for targeted cancer therapy. The 
interaction between lectins and carbohydrates (kd = ca. 10-3-10-6 M) is specific but of 
lower affinity than the interaction between antigens and antibodies (kd = 10-8-10-12 M), 
or enzymes and their substrates.49,50 Therefore lectin-targeting can be used for 
selective cancer treatment. There are two types of lectin-targeting, reverse and 
direct.49,51,52 Reverse lectin-targeting involves the use of exogenous lectins that will be 
recognised by the glycoconjugates expressed on the surface of cancer cells (Figure 4.2 
A). Direct lectin-targeting, also known as glycotargeting, involves the use of 
carbohydrates that are selectively recognised by endogenous lectins expressed on 
cancer cells (Figure 4.2 B).49,51,52  
 
          
           
           
           
           
           
           
           
           
 
 
There are numerous studies showing both direct and reverse lectin targeting for cancer 
therapy. In direct targeting, Durand and co-workers have published several studies.53-
57 These authors use mesoporous silica nanoparticles (MSN) functionalised with a 
photosensitiser and mannose for targeted PDT.53 The breast cancer cell line MDA-MB-
231 was incubated with the functionalised MSN for 24 h followed by 40 min irradiation 
Figure 4.2. Schematic representation showing (A) reverse and (B) direct lectin targeting. 
(B) (A) 
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for PDT. The functionalisation of mannose proved to be effective in increasing cellular 
uptake of the MSN as there was a 54 % increase in cell death as compared to MSN not 
functionalised with mannose.53 These mannose-photosensitiser functionalised MSN 
were further used for two-photon excitation (TPE)-PDT in breast and colon cancer 
cells.54 Similar results were obtained with no dark toxicity and a higher nanoparticle 
uptake for mannose functionalised MSN as compared to non-functionalised MSN. For 
further studies, the Durand group combined mannose functionalised MSN-PDT with 
drug delivery.55,56 The anti-cancer drug camptothecin (Cp) was loaded onto the 
mannose functionalised MSN yielding Cp-Man-MSN. The Cp-Man-MSN were used to 
target highly metastatic breast, colon and pancreatic cancer, and retinoblastoma cells. 
Following a 24 h incubation with either Cp-Man-MSN or non-functionalised MSN, the 
cellular internalisation was higher for the former, which thus led to a higher cell death 
after PDT. The presence of the anti-cancer drug in the system was essential for further 
enhancing the cell death efficacy. Mannose was replaced with galactose, synthesising 
MSN nanoparticles functionalised with galactose and camptothecin (Cp-Gal-MSN).55,56 
The use of galactose did not alter the results as it was also thought to be enhancing 
internalisation of the MSN via receptor-mediated endocytosis.55,56 Additionally, the 
retinoblastoma cells were subjected to TPE-PDT, which was shown to induce even 
better PDT efficiency than one-photon excitation PDT.56 The Durand group further 
studied mannose targeting using a slightly different type of nanoparticles.57 In this case, 
the MSN were modified by introducing a magnetic Fe3O4 core. The authors obtained 
similar results to those reported with other types of nanoparticles previously 
mentioned. Mannose was found to be essential to provide a good cellular uptake and 
thus cytotoxic effect after PDT.57 The use of mannose and galactose, together with 
other carbohydrates such as glucose, has been studied in combination with silver 
nanoparticles (AgNPs).58 It was found that the AgNPs were more effectively internalised 
by Neuro-2A brain neuroblastoma and HepG2 hepatocellular carcinoma cells when the 
carbohydrates were loaded onto the AgNPs. Additionally, the use of either mannose or 
galactose showed the least toxicity, which suggests they should be used in preference 
to glucose.58  
Further studies using galactose as the targeting agent have been reported. Pereira et 
al. developed a phthalocyanine surrounded by sixteen galactose molecules in a 
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dendrimer (PcGal16) for targeted PDT of bladder cancer cells.59 The galactose molecules 
specifically recognised the overexpressed galectin-1 receptors on the surface of 
bladder cancer cells. Additionally, the glucose-transporter-1 (GLUT1) receptor also has 
specificity towards galactose and it is overexpressed in bladder cancer cells. As a result, 
PcGal16 was easily and quickly internalised, only a 4 h incubation with the cells was 
required, via receptor-mediated endocytosis. PcGal16 was found to induce no dark-
toxicity but high levels of cell death following PDT.59 In another study, Peng et al. 
successfully used galactose functionalised fluorescent nanoparticles to target the 
asyaloglycoprotein receptor on the surface of liver cells.60 
Carbohydrate ligands have also been used to inhibit the action of certain endogenous 
lectins that promote tumour growth. Park et al. reported the potential use of lactose 
conjugated chlorins to target the galectin-3 receptor, which is sometimes 
overexpressed in cancer cells.45 Other examples of possible galectin inhibitors include 
lactulose amines, thiodigalactoside and davanat.23 The use of orally ingested 
polysaccharides that can target and inhibit the action of pro-tumorigenic lectins has 
also been reported. Pienta et al. used modified citrus pectin, which contains galactose 
residues, to reduce metastasis promoted by galectins on the surface of prostate cancer 
cells.61 A similar study was performed by Sathisha et al. to inhibit the action of galectin-
3 on several cancer cells using dietary inhibitors. The dietary galectin inhibitors used 
included citrus pectin, swallow root and black cumin.44 
The mannose-6-phosphate/insulin-like growth factor (M6P/IGF-II), overexpressed in 
breast cancer, pancreatic cancer, gastric cancer, melanoma and hepatocellular 
carcinoma, has been targeted with human serum albumin modified with M6P moieties 
(M6P-HSA).62 M6P-HSA was effectively internalised via receptor-mediated endocytosis 
by B16 melanoma cells. The addition of the anti-cancer drug doxorubicin (DOX) to the 
system allowed for efficient internalisation and release of DOX in the cells, which 
contributed to the inhibition of tumour progression and metastasis.62 Another 
carbohydrate used for cancer targeting is the glycoprotein transferrin.63 Transferrin 
selectively recognises the transferrin receptor, sometimes overexpressed in cancer 
cells, including bladder,64 brain,65 and breast.66  
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Reverse lectin-targeting has also been extensively studied. The lectin Helix Pomatia 
agglutinin (HPA) has been used to target the monosialylated oligosaccharide HPAgly1 
receptor overexpressed on the surface of breast cancer cells.67 The lectin Wheat Germ 
agglutinin (WGA), which has a preference towards N-acetyl-D-glucosamine and sialic 
acid, has also been used to target cancer cells.68,69 Polymeric nanoparticles with a 
quantum dot core were functionalised with WGA and they were used to target Caco-2 
colon cancer cells.68 Caco-2 cancer cells overexpress WGA binding receptors on their 
surface, especially the N-acetyl-D-glucosamine glycoprotein, which facilitates an easy 
internalisation of the WGA functionalised nanoparticles. The addition of an anti-cancer 
drug, paclitaxel, to the WGA functionalised polymer nanoparticles allowed for an 
effective drug delivery inside the cells, which inhibits tumour proliferation.69 The lectins 
Ricis communis agglutinin (RCA120) and concanavalin A (ConA) have been used to target 
HeLa cervical cancer cells.70 These lectins were conjugated to 13 nm AuNPs and 
effectively detected glycosyl complexes on the surface of the HeLa cells. 
The podoplanin (PDPN) transmembrane receptor, overexpressed in breast, oral and 
skin cancers has been targeted with a lectin obtained from the seeds of Maackia 
amurensis (MASL).71 In the experiment by Ochoa-Alvarez et al., the PDPN on the surface 
of melanoma cells was targeted following oral ingestion of MASL. Ingestion of MASL 
led to the effective binding of MASL to the PDPN receptors, which induced the 
inhibition of malignant growth and proliferation.71 Another example of an orally 
ingested lectin is the tomato lectin (TL).72 TL was conjugated to fluorescent 
nanoparticles and effectively used to target cells in the intestine of female Wistar rats. 
Reverse lectin-targeting has also been used for PDT.73 The lectin Jacalin, obtained from 
Jackfruit (Artocarpus integrifolia), was used to target the oncofetal Thomsen-
Friedenreich dissacharide (T antigen) overexpressed on the surface of colon cancer 
cells. Jacalin was conjugated to 4 nm AuNPs functionalised with the zinc phthalocyanine 
derivative C11Pc and PEG (Jacalin-C11Pc-PEG-AuNPs). Jacalin-C11Pc-PEG-AuNPs were 
efficiently internalised by the HT-29 colon cancer cells via receptor-mediated 
endocytosis. Following PDT, a marked enhancement of the cell death (95 % cell death) 
was observed as compared to C11Pc-PEG-AuNPs without Jacalin (8 % cell death).73 
 
178 
 
4.1.4. Aims of the research reported in this chapter 
In this chapter, direct lectin-targeting of breast adenocarcinoma cells was studied. 
Lactose was chosen as the targeting agent due to its selective binding towards galectin-
1, overexpressed on the surface of breast cancer cells. Two cells lines were used, MDA-
MB-231 and SK-BR-3 cells. 
Gold nanoparticles (ca. 2-4 nm) were synthesised and functionalised with a mixed 
monolayer of lactose and the zinc phthalocyanine derivative C11Pc (lactose-C11Pc-
AuNPs). In this system, lactose was used to provide aqueous dispersibility for the AuNPs 
as well as used as a potential targeting agent. In order to test the targeting ability of 
lactose, “control” AuNPs were synthesised and functionalised with C11Pc and sPEG 
(C11Pc-sPEG-AuNPs). The sPEG was chosen to provide aqueous dispersibility and its 
chain length was similar to that of the lactose. Lactose-C11Pc-AuNPs and C11Pc-sPEG-
AuNPs were tested in vitro in MDA-MB-231 and SK-BR-3 cells. Additionally, the ability 
of lactose to target galectin-1 on the surface of the breast cancer cells was analysed 
using an InCell ELISA. 
In the second part of the research, C3Pc replaced C11Pc as the photosensitiser. Gold 
nanoparticles (ca. 2-4 nm) were synthesised and functionalised with a mixed 
monolayer of lactose and C3Pc (lactose-C3Pc-AuNPs). “Control” AuNPs were also 
synthesised (C3Pc-sPEG-AuNPs). Lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs were 
tested in vitro in MDA-MB-231 and SK-BR-3 cells. InCell ELISAs were also performed to 
evaluate the degree of lactose targeting towards each cell line. Additionally, the 
intracellular uptake and PDT effect were visually studied using confocal microscopy. 
 
4.2. Results and discussion 
4.2.1. Lactose and galectin-1 levels 
Lactose is a disaccharide composed of a galactose subunit and a glucose subunit. The 
terminal end of lactose connected to the glucose subunit was modified with a thiol in 
order to self-assemble the lactose to the surface of the AuNPs. The modified lactose 
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was kindly provided by Dr Alan Haines (School of Chemistry, University of East Anglia, 
Norwich, UK). The structure of the thiolated lactose74 is shown in Figure 4.3. 
 
 
 
 
 
As shown in Figure 4.3, galactose is the terminal subunit in the lactose derivative 
molecule. This opens the possibility to use lactose as a targeting agent for galactose-
binding cell receptors. As described in section 4.1.2, galectins are β-galactoside-binding 
proteins, which have been found to be potential cancer biomarkers, as they are 
overexpressed in malignant epithelial and tumour-associated stromal cells.19,34 
Galectin-1 is the most relevant galectin in breast cancer as there is consensus regarding 
its overexpression on the surface of breast cancer cells, especially the MDA-MB-231 
cell line.31 The presence of galectin-3 on breast cancer cells is debated as some reports 
suggest it is overexpressed and other state it is highly downregulated.20,21,25,32,39-41 
Furthermore, the overexpression has found to be only related to triple-negative breast 
cancers in some studies, including MDA-MB-231 cells, but these results are also 
inconclusive.42,46-48 Taking into consideration the previously reported data on galectin 
overexpression in breast cancer cells, it was decided to evaluate and compare the levels 
of galectin-1 on MDA-MB-231 and SK-BR-3 human breast adenocarcinoma cells to 
determine whether galectin-1 could be used as a target for cancer therapy. This was 
achieved using an InCell ELISA. The InCell ELISA was performed as described in section 
2.3.10. The results from the InCell ELISA are presented in three different graphs (Figure 
4.4).  
  
 
 
Figure 4.3. Structure of the thiolated lactose, taken from Ref. 74.  
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Figure 4.4 A shows the absorbance at 450 nm for each cell line. Absorbance at 450 nm 
is directly proportional to the amount of galectin-1 in the sample. Figure 4.4 B shows 
the absorbance at 615 nm for each cell line. The absorbance at 615 nm detects the 
amount of Janus Green whole-cell stain in the sample and is thus directly proportional 
to the amount of cells in each sample. Figure 4.4 C shows the ratio between the 
absorbance at 450 nm and the absorbance at 615 nm. This ratio normalises the amount 
of galectin-1 to the number of cells in each sample. As a result, the final value gives an 
estimation of the relative amount of galectin-1 per cell in each sample. The results 
presented showed that MDA-MB-231 cells present a much higher amount of galectin-
1 on their surface as compared to SK-BR-3 cells. 
 
Figure 4.4. InCell ELISA for the detection of galectin-1 on the surface of SK-BR-3 and MDA-
MB-231 cells. (A) Absorbance at 450 nm representing the amount of galectin-1 in each 
sample. (B) Absorbance at 615 nm representing the number of cells per sample. (C) 
Normalised value of galectin-1 per cell in each sample. Error bars represent the SD (n = 3) 
within a 95 % confidence interval. 
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4.2.2. Synthesis and characterisation of lactose-C11Pc-AuNPs 
Lactose-C11Pc-AuNPs, a schematic representation of which is shown in Figure 4.5 A, 
were synthesised according to the procedure reported in section 2.3.1. Initially, the 
synthesis was attempted following the method used for the results presented in 
Chapter 3 for the synthesis of C11Pc-PEG-AuNPs. The molar concentrations of C11Pc, 
HAuCl4 and NaBH4 were kept constant. The only difference was the addition of lactose 
instead of PEG. Lactose was dissolved in dH2O, rather than using THF as the solvent, 
due to solubility issues. Following overnight incubation, the dark green solution was 
purified to remove all the AuNPs not functionalised with both C11Pc and lactose. The 
final purified solution dissolved in MES buffer appeared to be colourless. However, 
upon measuring the extinction spectrum, as shown in Figure 4.5 B, a small absorption 
band at ca. 698 nm was observed. This absorption band showed that there was some 
functionalisation with the C11Pc, since the characteristic absorption band for Pc was 
observed at a low extinction intensity. Additionally, the AuNPs were soluble in an 
aqueous solution, which confirmed their functionalisation with lactose.  
 
 
 
 
 
 
 
 
 
 
(B) (A) 
Figure 4.5. (A) Schematic representation of lactose-C11Pc-AuNPs. (B) UV-vis extinction 
spectrum of the synthesised lactose-C11Pc-AuNPs, with the low loading of C11Pc on the 
AuNPs surface. Inset: UV-vis extinction spectrum of the synthesised lactose-C11Pc-AuNPs 
amplified in the region 300-800 nm. 
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In an attempt to increase the loading of C11Pc on the nanoparticles, a few changes 
were made on the synthetic method, as reported in section 2.3.1. Lactose had 
previously been added at 2.5 μmol. This was in considerable excess as compared to the 
amount of C11Pc added, only 1.8 μmol. Therefore, the amount of lactose added was 
reduced to 1.8 μmol to be equimolar to the C11Pc. Additionally, the solution during 
synthesis contained more dH2O than THF, since lactose is insoluble in THF. This could 
cause problems for C11Pc solubility during synthesis. Therefore, the THF:dH2O ratio 
was kept at 1:1. Following overnight incubation, the reaction mixture was purified in 
the same manner as previously described. The synthesised lactose-C11Pc-AuNPs 
presented a blue colour, characteristic of C11Pc and were dispersed in MES buffer. The 
UV-vis extinction spectrum shows the band at ca. 698 nm, which is typical of these 
substituted phthalocyanines, thus showing the functionalisation of the nanoparticles 
with C11Pc. Furthermore, functionalisation with lactose can be confirmed since the 
AuNPs were soluble in an aqueous buffer, which would not be possible if the 
nanoparticles were only functionalised with the C11Pc. The UV-vis extinction spectrum 
and a cuvette containing a solution of the synthesised lactose-C11Pc-AuNPs are shown 
in Figure 4.6 A and B respectively.  
  
 
 
 
 
 
 
 
 
(B) (A) 
Figure 4.6. (A) UV-vis extinction spectrum of lactose-C11Pc-AuNPs and (B) image showing 
a cuvette containing a solution of the synthesised lactose-C11Pc-AuNPs.  
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The synthesised lactose-C11Pc-AuNPs were further characterised using TEM to 
evaluate their mean size. TEM analysis indicated that the lactose-C11Pc-AuNPs had an 
average diameter of 2.37 ± 1.65 nm, following analysis of 340 nanoparticles, with a 
median value of 1.79 ± 2.71 nm. TEM images of the lactose-C11Pc-AuNPs, together 
with a histogram showing their size distribution, are shown in Figure 4.7. As it can be 
seen in Figure 4.7, the size distribution histogram is positively skewed. In these 
situations, the median value could sometimes be taken as a better representation of 
the population than the mean.75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. (A-B) Transmission electron micrographs of a sample of lactose-C11Pc-AuNPs, 
where the scale bars represent (A) 20 nm and (B) 50 nm. (C) Histogram of the lactose-
C11Pc-AuNPs with a median value of 1.79 ± 2.71 nm (n = 340). (D) Size distribution of the 
lactose-C11Pc-AuNPs showing the Gaussian fit, with an average size of 2.37 ± 1.65 nm 
(n = 340). 
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To confirm whether the synthesised lactose-C11Pc-AuNPs could be used for PDT, the 
production of reactive oxygen species needs to be proven. The singlet oxygen probe 
ABMA was used to confirm the production of 1O2 by lactose-C11Pc-AuNPs, as described 
in sections 2.3.4 and 3.2.4. The results are shown in Figure 4.8. It can be seen that, in 
the presence of lactose-C11Pc-AuNPs, the fluorescence of ABMA is quenched when the 
sample is irradiated with a 633 nm HeNe laser. This confirms that 1O2 is being produced 
by the lactose-C11Pc-AuNPs upon irradiation. Additionally, the negligible fluorescence 
quenching of ABMA in the presence of control PEG-AuNPs indicates that the C11Pc is 
essential for the production of 1O2. 
 
 
 
 
 
 
The maximum amount of ABMA photobleaching, i.e., following the first 5 min of 
irradiation, can be calculated following Equation 3.4 in section 3.2.4. The maximum 
amount of ABMA photobleaching was found to be 1.1 ± 0.7 % for lactose-C11Pc-AuNPs. 
This value indicates the ability of the lactose-C11Pc-AuNPs to produce 1O2 after only 
5 min irradiation. In Chapter 3, the maximum amount of ABMA photobleaching for the 
C11Pc-PEG-AuNPs was found to be 2.1 ± 0.1 %, which is considerably higher than the 
rate found for lactose-C11Pc-AuNPs. This result indicates that the C11Pc-PEG-AuNPs 
produce more 1O2 and thus, at the same concentration, should have a higher PDT 
efficiency than the lactose-C11Pc-AuNPs presented in this chapter. 
Figure 4.8. (A) Fluorescence emission spectra of ABMA showing the quenching of the 
fluorescence following irradiation of the lactose-C11Pc-AuNPs, thus confirming the 
production of 1O2. (B) Photobleaching of ABMA in the presence of (i) lactose-C11Pc-AuNPs 
(0.734 μM C11Pc) as a function of time. No photobleaching was observed for control PEG-
AuNPs (ii). Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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4.2.3. Synthesis and characterisation of control C11Pc-sPEG-AuNPs 
In order to provide a control for the study of the targeting ability of lactose towards the 
overexpressed galectin-1 on the surface of breast cancer cells, AuNPs without a 
targeting agent were synthesised. Similarly to that reported in Chapter 3, a PEG chain 
was used to provide the aqueous solubility to the nanoparticle system. In this case, the 
PEG chain (282.35 g/mol) was shorter than that used in Chapter 3 (PEG; 3,073 Da) so 
that the molecule would provide a similar length to that of the lactose derivative of the 
lactose-C11Pc-AuNPs for a direct comparison. This shorter PEG chain will be labelled as 
sPEG. The structure of sPEG, together with a schematic representation of the gold 
nanoparticles functionalised with a mixed monolayer of C11Pc and sPEG (C11Pc-sPEG-
AuNPs) are shown in Figure 4.9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. (A) Structure of the sPEG used throughout the results presented in Chapter 4. 
(B) Schematic representation of C11Pc-sPEG-AuNPs. 
(B) 
(A) 
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C11Pc-sPEG-AuNPs were synthesised following the improved method for lactose-
C11Pc-AuNPs as described in section 2.3.5. Given the short nature of this sPEG chain, 
solubility of C11Pc within the C11Pc-sPEG-AuNPs became more challenging. Therefore, 
this particular synthetic route does not provide a high loading of C11Pc on the 
nanoparticles, which were obtained in a low yield. The extinction spectrum of the 
synthesised C11Pc-sPEG-AuNPs dispersed in MES buffer, together with an image to 
show the final colour of a solution of the nanoparticles, are shown in Figure 4.10 A and 
B respectively. 
 
 
 
 
 
 
 
 
The synthesised C11Pc-sPEG-AuNPs were used as a control to the lactose-C11Pc-AuNPs 
to evaluate the targeting ability of the lactose ligand towards the galectin-1 receptor 
on the surface of breast cancer cells. 
 
4.2.4. In vitro studies in MDA-MB-231 cells using lactose-C11Pc-AuNPs  
Initially, MDA-MB-231 human breast adenocarcinoma cells were used to test the 
potential targeting ability of the synthesised lactose-C11Pc-AuNPs. MDA-MB-231 cells 
were chosen since, as discussed in section 4.2.1, there is an increased expression of 
galectin-1 in this cell line as compared to SK-BR-3 cells, see Figure 4.4. As a result, it 
would be expected that the lactose would target the MDA-MB-231 cells more 
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Figure 4.10. (A) UV-vis extinction spectra of C11Pc-sPEG-AuNPs and (B) image showing a 
vial containing a solution of the synthesised C11Pc-sPEG-AuNPs.  
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efficiently than the SK-BR-3 cells and so the nanoparticles would be internalised more 
readily, potentially leading to higher cell death following PDT.  
A CellTiter-Blue® cell viability assay was performed, as described in section 2.3.8. MDA-
MB-231 cells were seeded on 96-well microplates and incubated with the lactose-
C11Pc-AuNPs and C11Pc-sPEG-AuNPs (0.25 μM C11Pc) for 3 h. Following incubation 
with the AuNPs, the cells were washed to eliminate the non-internalised AuNPs and 
irradiated with a 633 nm HeNe laser for 6 min. Cell viability was measured ca. 48 h 
following PDT. The results of the viability assay are shown in Figure 4.11. 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 shows that there is no cell death in any of the samples. These results were 
highly reproducible in a further four attempts. The inability of any of the nanoparticle 
conjugates to induce cell death following PDT could be related to the incubation time 
of the AuNPs with the cells. The lactose-C11Pc-AuNPs and C11Pc-sPEG-AuNPs were 
incubated with the MDA-MB-231 cells for only 3 h. The CellTiter-Blue® cell viability 
assay results suggest that a 3 h incubation period is not sufficient for efficient AuNPs 
internalisation. Therefore, the incubation period was increased to 24 h. Other than 
changing the incubation period, the MDA-MB-231 cells were treated with the AuNPs in 
Figure 4.11. CellTiter-Blue® cell viability assay results for MDA-MB-231 cells incubated 
with C11Pc-sPEG-AuNPs (sPEG) or lactose-C11Pc-AuNPs (lactose) for 3 h. Cells were either 
irradiated with a 633 nm HeNe laser (yellow) or non-irradiated (green). Control refers to 
samples treated with sPEG-AuNPs without the presence of C11Pc. Untreated refers to cells 
treated with growth medium only. Staurosporine (+ve St) was used as a positive control 
for cytotoxicity. Error bars represent the SD (n = 3) within a 95 % confidence interval.  
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the same manner as described previously (0.25 μM C11Pc). The results of the extended 
incubation period experiments are shown in Figure 4.12. 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 4.12, following the 24 h incubation period of the nanoparticles with 
the MDA-MB-231 cells, cell death was observed after irradiation with a 633 nm HeNe 
laser for both lactose-C11Pc-AuNPs and C11Pc-sPEG-AuNPs. The non-irradiated 
samples, with either type of nanoparticles, showed no dark toxicity. The cell death 
levels induced after irradiation were higher for the C11Pc-sPEG-AuNPs (56 %) than the 
lactose-C11Pc-AuNPs (40 %). This seems to suggest that the lactose is not effectively 
targeting the galectin-1 receptor on the surface of the MDA-MB-231 cells. To confirm 
these results, the CellTiter-Blue® cell viability assay, together with MTT cell viability 
assays, were repeated. Figure 4.13 shows the results of the repeated CellTiter-Blue® 
and MTT cell viability assays, using the same conditions for the assay performed for 
Figure 4.12. Unfortunately, the results from the CellTiter-Blue® and MTT cell viability 
assays were found to be non-reproducible. As shown in Figure 4.13, the results from 
the cell viability assays are very different every time the experiment is performed under 
the same conditions. 
Figure 4.12. CellTiter-Blue® cell viability assay results for MDA-MB-231 cells incubated 
with C11Pc-sPEG-AuNPs (sPEG) or lactose-C11Pc-AuNPs (lactose) for 24 h. Cells were 
either irradiated with a 633 nm HeNe laser (orange) or non-irradiated (dark cyan). 
Untreated refers to cells treated with growth medium only. Staurosporine (+ve St) was 
used as a positive control for cytotoxicity. Error bars represent the SD (n = 3) within a 95 % 
confidence interval. 
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As shown in Figure 4.13, the results of PDT treatment of MDA-MB-231 cells incubated 
with lactose-C11Pc-AuNPs or C11Pc-sPEG-AuNPs for 24 h were inconclusive. Out of the 
five performed cell viability assays, only one CellTiter-Blue® assay showed an indication 
of cell death following irradiation, as seen in Figure 4.12, but these results were not 
reproducible. Even when cell death was observed, there was no evidence of targeting 
by the lactose ligand. The majority of the assays performed showed no effect from 
lactose, which suggests that the lactose-C11Pc-AuNPs are not effective for targeted 
PDT of MDA-MB-231 cells. 
 
4.2.5. In vitro studies in SK-BR-3 cells using lactose-C11Pc-AuNPs  
Given the negative results for PDT with lactose-C11Pc-AuNPs and C11Pc-sPEG-AuNPs 
in MDA-MB-231 cells following 3 h incubation with the nanoparticles, and the non-
reproducible results following 24 h incubation with the nanoparticles, it was decided 
to test the effects of the nanoparticles with SK-BR-3 cells. Even though SK-BR-3 cells 
have a lower level of galectin-1 on their surface (Figure 4.4), there is a possibility that 
the lactose ligand also recognises the GLUT1 receptor, which has been reported to be 
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Figure 4.13. (A) CellTiter-Blue® cell viability assay results and (B) MTT cell viability assay 
results for MDA-MB-231 cells incubated with C11Pc-sPEG-AuNPs (sPEG) or lactose-C11Pc 
-AuNPs (lactose) for 24 h. Cells were either irradiated with a 633 nm HeNe laser (orange) 
or non-irradiated (dark cyan). Untreated refers to cells only treated with growth medium. 
Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars represent 
the SD (n = 3) within a 95 % confidence interval. 
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overexpressed in breast cancer.76-81 GLUT1 is known to react with galactose moieties.59 
Therefore, there is a potential for the targeting of SK-BR-3 cells with lactose via 
receptors other than galectin-1.  
CellTiter-Blue® cell viability assays were performed on SK-BR-3 cells incubated with 
either lactose-C11Pc-AuNPs or C11Pc-sPEG-AuNPs for 3 h. The assays were repeated 
multiple times to evaluate the reproducibility. Typical results are shown in Figure 4.14. 
The assays were repeated 9 times and the results were obtained with 67 % 
reproducibility. 
 
 
 
The results shown in Figure 4.14 show low dark toxicity for the samples treated with 
either C11Pc-sPEG-AuNPs or lactose-C11Pc-AuNPs. Following irradiation, phototoxicity 
was only induced in cell samples treated with the C11Pc-sPEG-AuNPs, leading to 77 % 
cell death. These results suggest that the lactose-C11Pc-AuNPs are not effective for PDT 
and the lactose ligand is not enhancing the uptake and subsequent PDT effect. In an 
attempt to improve these results reported above, the SK-BR-3 cells were further 
treated with either lactose-C11Pc-AuNPs or C11Pc-sPEG-AuNPs increasing the 
incubation period from 3 h to 24 h. Increasing the incubation period with the 
nanoparticles could enhance the uptake by the SK-BR-3 cells and lead to more reliable 
results. CellTiter-Blue® and MTT cell viability assays were performed. The results for 
Figure 4.14. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with C11Pc-
sPEG-AuNPs (sPEG) or lactose-C11Pc-AuNPs (lactose) for 3 h. Cells were either irradiated 
with a 633 nm HeNe laser (orange) or non-irradiated (green). Untreated refers to cells 
only treated with growth medium. Staurosporine (+ve St) was used as a positive control 
for cytotoxicity. Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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the CellTiter-Blue® assay are shown in Figure 4.15. In this case, the reproducibility was 
significantly improved since for 4 repetitions of this assay, 75 % of the times the results 
reported below were obtained. 
  
 
 
 
 
The results shown in Figure 4.15 suggest that, following a 24 h incubation with the 
AuNPs, there is targeting via the lactose ligand towards the SK-BR-3 cells, as confirmed 
by the P values that show there is a statistically significant difference between the 
samples. The samples treated with lactose-C11Pc-AuNPs induced up to 90 % cell death, 
while the samples treated with C11Pc-sPEG-AuNPs only led to 61 % cell death. 
Surprisingly, the cells treated with C11Pc-sPEG-AuNPs for 24 h were killed less 
efficiently than those cells treated with C11Pc-sPEG-AuNPs for 3 h (77 % cell death), 
see Figure 4.14. The longer incubation period of 24 h enables the cancer cells to grow 
for a longer period of time. Therefore, if there is a plateau in the level of C11Pc-sPEG-
AuNPs internalised, this could help explain why less cells die after 24 h incubation 
compared to 3 h incubation. With an increased growth of cells and similar levels of 
C11Pc-sPEG-AuNPs internalised, the cell death is not as high. 
Figure 4.15. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with C11Pc-
sPEG-AuNPs (sPEG) or lactose-C11Pc--AuNPs (lactose) for 24 h. Cells were either irradiated 
with a 633 nm HeNe laser (yellow) or non-irradiated (green). Untreated refers to cells only 
treated with growth medium. Staurosporine (+ve St) was used as a positive control for 
cytotoxicity. Error bars represent the SD (n = 3) within a 95 % confidence interval. 
Statistically significant difference between C11Pc-sPEG-AuNPs and lactose-C11Pc-AuNPs 
is indicated by * at P < 0.006, obtained using a two-tailed Student’s t-test, where P < 0.05 
is considered statistically significant. 
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In order to evaluate whether the galectin-1 receptor is involved in this possible 
targeting by lactose towards SK-BR-3 cells, an InCell ELISA was performed, following 
the procedure described in section 2.3.11. InCell ELISA was used to detect the amount 
of galectin-1 on the surface of the cells. As explained in section 3.2.9, prior to treating 
the cells with anti-galectin1 antibody, the cells were incubated with either lactose-
C11Pc-AuNPs or C11Pc-sPEG-AuNPs for 24 h. This treatment can lead to the targeting 
of the galectin-1 receptors on the surface of the cells, which would then be no longer 
available for the anti-galectin1 primary antibody during the ELISA. Therefore, the 
lactose-C11Pc-AuNPs should produce a lower absorbance signal as compared to C11Pc-
sPEG-AuNPs, in which all the galectin-1 receptors are free, if selective targeting 
between lactose and galectin-1 is taking place. The results, shown in Figure 4.16, 
indicate that the levels of galectin-1 after treatment with either the lactose-C11Pc-
AuNPs or the C11Pc-sPEG-AuNPs are similar to the levels of galectin-1 in untreated SK-
BR-3 cells. These results suggest that the galectin-1 receptor is not involved in lactose 
targeting of SK-BR-3 cells. Other galactose-binding receptors on the surface of SK-BR-3 
cells, such as the GLUT1 receptor previously discussed, should be studied to verify the 
possible selective targeting by lactose. This could be done using an InCell ELISA or via 
Western blotting, with the specific antibodies towards the GLUT1 receptor. 
 
 
 
The results reported in this section of the thesis suggest that targeting SK-BR-3 cells 
with lactose-C11Pc-AuNPs requires a 24 h incubation with the nanoparticles before any 
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Figure 4.16. InCell ELISA for the detection of galectin-1 on the surface of SK-BR-3 cells 
showing the normalised value of galectin-1 per cell number in each sample. Untreated 
refers to cells treated with McCOY’s 5A medium only, for 24 h; sPEG refers to cells treated 
with C11Pc-sPEG-AuNPs for 24 h; and Lactose refers to cells treated with lactose-C11Pc-
AuNPs for 24 h. Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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cytotoxic effects can be observed. Additionally, an indication of targeting was found as 
the levels of cell death induced by the lactose-C11Pc-AuNPs (90 %) were much higher 
than those induced by the C11Pc-sPEG-AuNPs (61 %). However, an InCell ELISA 
suggested that galectin-1 is not involved as the receptor for such lactose targeting. 
Other receptors, overexpressed on the surface of SK-BR-3 cells, should be investigated 
to establish why the lactose-C11Pc-AuNPs preferentially induce a significant PDT effect 
following a 24 h incubation. 
 
4.2.6. Synthesis and characterisation of lactose-C3Pc-AuNPs 
The use of C3Pc as the photosensitiser in the lactose-AuNPs system rather than the 
C11Pc could be a way to increase the targeting ability of lactose. C3Pc has a shorter 
carbon chain than C11Pc and thus it allows the lactose ligand to extend slightly further 
away from the surface of the AuNPs than C3Pc photosensitiser. As a result, the lactose 
ligand should be able to interact with galectin-1, or other receptors, on the surface of 
the cells easier without hinderance by the longer chain attached to the Pc macrocycle. 
This can be readily seen in Figure 4.17, where a schematic representation of both the 
lactose-C11Pc-AuNPs and the lactose-C3Pc-AuNPs is shown.  
 
 
 
 
 
 
 
 
(B) (A) 
Figure 4.17. Schematic representation of (A) lactose-C11Pc-AuNPs and (B) lactose-C3Pc-
AuNPs. 
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The synthesis of lactose-C3Pc-AuNPs was performed via the optimal method described 
for the lactose-C11Pc-AuNPs in section 2.3.2. The use of lactose as a means to provide 
aqueous solubility to the phthalocyanine-gold nanoparticle system is more effective 
with the C3Pc than the C11Pc. This is possibly related to the shorter nature of the C3Pc 
carbon chain, which allows the lactose to surround the C3Pc molecule. The synthesis 
of the lactose-C3Pc-AuNPs is thus more facile and gives a higher yield than the synthesis 
of lactose-C11Pc-AuNPs. The higher yield of lactose-C3Pc-AuNPs is the first advantage 
of using the C3Pc as compared to C11Pc. The UV-vis extinction spectrum and an image 
of the synthesised lactose-C3Pc-AuNPs dissolved in MES buffer are shown in Figure 
4.18 A and B respectively. The extinction spectrum clearly shows the characteristic 
C3Pc phthalocyanine absorbtion band at ca. 698 nm and the solution presents a deep 
blue colour, a lot more intense than that observed for the lactose-C11Pc-AuNPs (Figure 
4.6) because, in the final 5 mL solutions of synthesised AuNPs, the amount of C3Pc 
(1.8×10-8 mol) immobilised in the AuNPs is significantly greater than that of C11Pc 
(7.2×10-9 mol). 
 
 
 
 
 
 
 
 
The synthesised lactose-C3Pc-AuNPs were further characterised using TEM to evaluate 
their mean size. TEM analysis indicated that the lactose-C3Pc-AuNPs had an average 
diameter of 3.10 ± 1.32 nm, following analysis of 466 nanoparticles, with a median 
value of 2.72 ± 1.74 nm. TEM images of the lactose-C3Pc-AuNPs, together with a 
histogram showing their size distribution, are shown in Figure 4.19. The size 
(B) (A) 
Figure 4.18. (A) UV-vis extinction spectrum of lactose-C3Pc-AuNPs and (B) image showing 
a vial containing a solution of the synthesised lactose-C3Pc-AuNPs in MES buffer. 
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distribution is slightly skewed to the left. In these situations, the median value could 
sometimes be taken as a better representation of the population than the mean.75 
 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm the production of 1O2 by the lactose-C3Pc-AuNPs, the probe ABMA was 
used, as previously described in sections 2.3.4 and 3.2.4. The results confirm the 
photobleaching of ABMA in the presence of lactose-C3Pc-AuNPs as 1O2 is being 
produced upon irradiation with a 633 nm HeNe laser (Figure 4.20). On the contrary, 
PEG-AuNPs not functionalised with C3Pc show no photobleaching, indicating the 
importance of the photosensitiser for the generation of 1O2. The maximum amount of 
photobleaching of ABMA in the presence of lactose-C3Pc-AuNPs was calculated, 
following Equation 3.4 in section 3.2.4, and it was found to be 2.5 ± 1.5 %. This value is 
higher to that obtained for the lactose-C11Pc-AuNPs (1.1 ± 0.7 %), which constitutes a 
Figure 4.19. (A-B) Transmission electron micrographs of a sample of lactose-C3Pc-AuNPs, 
where the scale bars represent 20 nm. (C) Histogram of the lactose-C3Pc-AuNPs with a 
median value of 2.72 ± 1.74 nm (n = 466). (D) Size distribution of the lactose-C3Pc-AuNPs 
showing the Gaussian fit, with an average size of 3.10 ± 1.32 nm (n = 466). 
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further advantage of the use of C3Pc over C11Pc, but similar to the value obtained for 
C3Pc-PEG-AuNPs (2.5 ± 1.5 %) in Chapter 3. 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.7. Synthesis and characterisation of control C3Pc-sPEG-AuNPs 
As previously described for C11Pc nanoparticles, control C3Pc-sPEG-AuNPs were 
synthesised. The sPEG chain used, see Figure 4.9, was shorter than that used in Chapter 
3 so that the molecule would provide a similar length to that of the lactose derivative 
in the lactose-C3Pc-AuNPs for a direct comparison of the cell viability results. A 
schematic representation of the C3Pc-sPEG-AuNPs is shown in Figure 4.21. 
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Figure 4.20. (A) Fluorescence emission spectra of ABMA showing the quenching of the 
fluorescence, thus confirming the formation of 1O2 following irradiation at 633 nm of 
lactose-C3Pc-AuNPs. (B) Photobleaching of ABMA in the presence of (i) lactose-C3Pc-
AuNPs (0.734 μM C3Pc) as a function of time. No photobleaching was observed for the 
control PEG-AuNPs (ii). The photobleaching shown for the control PEG-AuNPs is the same 
as that previously reported in Figure 4.8. Error bars represent the SD (n = 3) within a 95 % 
confidence interval. 
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Similarly to the results obtained with the lactose-C3Pc-AuNPs, the C3Pc-sPEG-AuNPs 
were easier to synthesise and were produced with a higher yield than the C11Pc-sPEG-
AuNPs. Figure 4.22 shows the UV-vis extinction spectrum and an image of a solution of 
the synthesised C3Pc-sPEG-AuNPs. 
 
 
 
 
 
 
 
 
 
4.2.8. In vitro studies in MDA-MB-231 cells using lactose-C3Pc-AuNPs 
Initially, intracellular studies using lactose-C3Pc-AuNPs and their corresponding control 
C3Pc-sPEG-AuNPs were performed in MDA-MB-231 cells aiming to target the galectin-
Figure 4.21. Schematic representation of the C3Pc-sPEG-AuNPs. 
(B) (A) 
Figure 4.22. (A) UV-vis extinction spectrum of C3Pc-sPEG-AuNPs and (B) image showing a 
vial containing a solution of the synthesised C3Pc-sPEG-AuNPs in MES buffer. 
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1 receptor on the cell surface. The cells were incubated with the AuNPs for 3 h and 
CellTiter-Blue® cell viability assays were performed. The lactose-C3Pc-AuNPs and C3Pc-
sPEG-AuNPs were added to the cells at various concentrations. Following incubation, 
the cells were washed to eliminate all the non-internalised AuNPs, irradiated for 6 min 
with a 633 nm HeNe laser and cell viability was measured ca. 48 h following PDT. The 
results are shown in Figure 4.23. Reproducibility for these assays was found to be good 
since the same results were obtained the three times the assays were performed. 
 
 
 
 
 
 
 
 
 
 
As it can be seen from Figure 4.23, neither the lactose-C3Pc-AuNPs nor the C3Pc-sPEG-
AuNPs produce any visible cell death following a 3 h incubation and irradiation with the 
633 nm laser. Similar to the results obtained with lactose-C11Pc-AuNPs and C11Pc-
sPEG-AuNPs following a 3 h incubation with MDA-MB-231 cells (see Figure 4.11), the 
incubation period appears to be too short for any efficient internalisation. Therefore, 
no cell death is seen following PDT. However, the concentrations reported in Figure 
4.23 were lower than those used for the C11Pc photosensitiser (0.25 μM). To confirm 
that the concentration was not the reason why cell death was not observed, the 
concentration of the C3Pc photosensitiser in both lactose-C3Pc-AuNPs and C3Pc-sPEG-
AuNPs was increased to 0.20 μM and a further cell viability assay was performed 
Figure 4.23. CellTiter-Blue® cell viability assay results for MDA-MB-231 cells incubated 
with (A) C3Pc-sPEG-AuNPs or (B) lactose-C3Pc-AuNPs for 3 h. Cells were either irradiated 
with a 633 nm HeNe laser (A orange, B yellow) or non-irradiated (A dark cyan, B green). 
Control refers to samples treated with sPEG-AuNPs without the presence of the C3Pc 
photosensitiser. Staurosporine (+ve St) was used as a positive control for cytotoxicity. 
Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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(Figure 4.24). The results shown in Figure 4.24 confirmed that the concentration was 
not the issue as, with a higher concentration of C3Pc, cell death is still negligible 
following PDT. 
 
Since higher concentrations did not lead to increase in cell death, it was decided to 
increase the incubation period of the nanoparticles with the cells prior to irradiation. 
MDA-MB-231 cells were incubated with lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs 
(0.20 μM C3Pc) for 24 h. CellTiter-Blue® and MTT cell viability assays were performed 
ca. 48 h after PDT. The assays were repeated seven times. Typical results (63 % 
reproducibility) are shown in Figure 4.25. 
 
 
 
 
 
 
Figure 4.24. MTT cell viability assay for MDA-MB-231 cells incubated with C3Pc-sPEG-
AuNPs (sPEG) or lactose-C3Pc-AuNPs (lactose) for 3 h. Cells were either irradiated with a 
633 nm HeNe laser (orange) or non-irradiated (green). No AuNPs refers to cells treated 
with growth medium only. Staurosporine (+ve St) was used as a positive control for 
cytotoxicity. Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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As shown in Figure 4.25, following a 24 hour incubation period, the results are different 
to those obtained previously. Both the lactose-C3Pc-AuNPs and the C3Pc-sPEG-AuNPs 
are shown to induce cell death following irradiation, while there is minimal dark 
toxicity. The results are supported by both cell viability assays, CellTiter-Blue® and MTT. 
The MTT assay (Figure 4.25 B) has larger error bars as compared to the CellTiter-Blue® 
assay (Figure 4.25 A). This was previously discussed in Chapter 3 section 3.2.6. Even 
with the large error bars, both the MTT and the CellTiter-Blue® assays give similar 
results, showing cell death only after irradiation. Additionally, there is an indication of 
improved PDT with the lactose-C3Pc-AuNPs with possible targeting via lactose (Figure 
4.25), but this indication is not statistically significant as shown by the P values obtained 
(P < 0.09) using a two-tailed Student’s t-test. The values of cell death, taken from the 
CellTiter-Blue® assay, are higher for the samples treated with lactose-C3Pc-AuNPs 
(52 %) than for samples treated with C3Pc-sPEG-AuNPs (36 %) (Figure 4.25 A).  
In order to confirm the potential targeting of lactose-C3Pc-AuNPs towards galectin-1 
on the surface of MDA-MB-231 cells, an InCell ELISA for the detection of galectin-1 was 
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Figure 4.25. (A) CellTiter-Blue® and (B) MTT cell viability assays for MDA-MB-231 cells 
incubated with C3Pc-sPEG-AuNPs (sPEG) or lactose-C3Pc-AuNPs (lactose) for 24 h. Cells 
were either irradiated with a 633 nm HeNe laser (A yellow, B orange) or non-irradiated 
(green). Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars 
represent the SD (n = 3) within a 95 % confidence interval. No statistically significant 
difference between C3Pc-sPEG-AuNPs and lactose-C3Pc-AuNPs, as indicated by the P 
values (P < 0.09) obtained using a two-tailed Student’s t-test, where P < 0.05 is considered 
statistically significant. 
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performed. The InCell ELISA was performed using the same method previously 
described in section 4.2.5, incubating the AuNPs for both 3 h and 24 h. The results are 
shown in Figure 4.26.  
 
 
 
 
 
 
 
 
 
The results from the InCell ELISA shown in Figure 4.26 A indicate that lactose selectively 
targets the galectin-1 receptor on the surface of the MDA-MB-231 cells following a 3 h 
incubation with the AuNPs. These results, however, do not match those results seen 
previously with the cell viability assays. The cell viability assays showed no cell death 
following a 3 h incubation with either lactose-C3Pc-AuNPs or C3Pc-sPEG-AuNPs 
(Figures 4.23-4.24). This could possibly be due to a low uptake of nanoparticles by the 
cells following a 3 h incubation and hence why no cell death is observed. However, the 
galectin-1 receptors on the surface of the MDA-MB-231 cells are selectively recognising 
the lactose ligand on the AuNPs and they appear to require longer incubation periods 
for complete internalisation.  
Additionally, when the AuNPs were incubated for 24 h, Figure 4.26 B, there is also an 
indication of selective targeting. However, the error bars from the samples treated with 
lactose-C3Pc-AuNPs are so large that it cannot be completely confirmed. Selective 
targeting via the galectin-1 receptor on the surface of MDA-MB-231 cells can 
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Figure 4.26. InCell ELISA for the detection of galectin-1 on the surface of MDA-MB-231 cells. 
The graphs show the normalised values of galectin-1 per cell in each sample. The samples 
were incubated with C3Pc-sPEG-AuNPs (sPEG) or lactose-C3Pc-AuNPs (lactose) for either 
(A) 3 h or (B) 24 h. Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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potentially explain the higher cell death seen for samples treated with lactose-C3Pc-
AuNPs as compared to the control C3Pc-sPEG-AuNPs (Figure 4.25) following PDT. 
 
4.2.9. Studies of lactose-C3Pc-AuNPs internalisation by MDA-MB-231 cells 
The cell viability assays reported in section 4.2.8 showed that cell death was induced 
by lactose-C3Pc-AuNPs when they were incubated with the MDA-MB-231 cells for 24 h. 
To understand what the difference in AuNPs uptake following either 3 h or 24 h 
incubation was due to, internalisation studies using confocal microscopy were 
performed, as described in section 2.3.9. MDA-MB-231 cells were incubated with the 
lactose-C3Pc-AuNPs for either 3 h or 24 h, washed to remove all the non-internalised 
AuNPs and irradiated to visually assess the PDT effect. Following irradiation, the cells 
were incubated for a further ca. 24 h prior to imaging. The results are shown in Figure 
4.27 for the cells incubated with lactose-C3Pc-AuNPs for 3 h and Figure 4.28 for the 
cells incubated with lactose-C3Pc-AuNPs for 24 h. 
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Figure 4.27. Confocal fluorescence microscopy images of MDA-MB-231 cells. (A, C) control 
cells incubated only with growth medium for 3 h and (B, D) cells incubated with lactose-
C3Pc-AuNPs for 3 h. The cells were either non-irradiated (A, B) or irradiated (C, D) with a 
633 nm HeNe laser. All samples were imaged 24 h following treatment. Images taken 
from: 1) DIC, 2) fluorescence from C3Pc collected in the red channel (λex = 633 nm; above 
650 nm), 3) fluorescence from propidium iodide collected in the pink channel (λex = 
543 nm; 560-615 nm) and 4) composite images of DIC, fluorescence from C3Pc collected 
in the red channel and fluorescence from propidium iodide collected in the pink channel. 
Scale bars represent 10 μm. 
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Figure 4.27 B shows that there is low internalisation of lactose-C3Pc-AuNPs by MDA-
MB-231 cells following a 3 h incubation. The fluorescence seen in the red channel is 
similar in the cells treated with lactose-C3Pc-AuNPs and the control cells that were only 
treated with growth medium during the incubation period (Figure 4.27 A). This is an 
indication that there is some background fluorescence in the MDA-MB-231 cell line. In 
addition, following a 3 h incubation period, the internalisation of lactose-C3Pc-AuNPs 
Figure 4.28. Confocal fluorescence microscopy images of MDA-MB-231 cells. (A, C) control 
cells incubated only with growth medium for 24 h and (B, D) cells incubated with lactose-
C3Pc-AuNPs for 24 h. The cells were either non-irradiated (A, B) or irradiated (C, D) with a 
633 nm HeNe laser. All samples were imaged 24 h following treatment. Images taken from: 
1) DIC, 2) fluorescence from C3Pc collected in the red channel (λex = 633 nm; above 650 
nm), 3) fluorescence from propidium iodide collected in the pink channel (λex = 543 nm; 
560-615 nm) and 4) composite images of DIC, fluorescence from C3Pc collected in the red 
channel and fluorescence from propidium iodide collected in the pink channel. Scale bars 
represent 10 μm. 
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is not significant enough to see any cytotoxicity following PDT as shown in 
Figure 4.27 D, highlighted by the lack of propidium iodide staining. 
When the MDA-MB-231 cells were subjected to a 24 h incubation period, the results 
were different. In this case, there is a significant difference in the red fluorescence seen 
in the control cells treated only with growth medium (Figure 4.28 A) as compared to 
those cells treated with lactose-C3Pc-AuNPs (Figure 4.28 B). Additionally, the red 
fluorescence seen for the cells treated with lactose-C3Pc-AuNPs for 24 h (Figure 4.28 
B) is significantly more intense than that seen after only a 3 h incubation period (Figure 
4.27 B). As a result, following irradiation with a 633 nm HeNe laser for 6 min, cell death 
can be visualised in the MDA-MB-231 cells treated with lactose-C3Pc-AuNPs for 24 h, 
as confirmed by the staining with the dead cell marker propidium iodide and the 
change in cell morphology, i.e., disintegration of the cell membrane, (Figure 4.28 D). 
After irradiation, there is a mixture of dead and live cells in the samples since the cell 
viability was 48 %, as indicated by the cell viability assays (Figure 4.25). These results 
indicate that the lactose-C3Pc-AuNPs should be incubated for 24 h with the MDA-MB-
231 cells in order to achieve an efficient internalisation that will thus lead to cell death 
following PDT treatment. 
MDA-MB-231 cells are thus efficiently targeted using the lactose-C3Pc-AuNPs when 
they are incubated with the AuNPs for 24 h. These results present an improvement to 
those seen when C11Pc was used as the photosensitiser. Lactose-C11Pc-AuNPs were 
unable to induce cytotoxicity following PDT of the MDA-MB-231 cells at either 3 h or 
24 h incubation. It can be concluded that the use of C3Pc rather than C11Pc does 
facilitate the targeting ability of lactose towards MDA-MB-231 cells. 
 
4.2.10. In vitro studies in SK-BR-3 cells using lactose-C3Pc-AuNPs  
Lactose-C11Pc-AuNPs were shown to induce targeting and cytotoxicity following PDT 
in SK-BR-3 cells after a 24 h incubation (section 4.2.5). Therefore, the lactose-C3Pc-
AuNPs were also tested in SK-BR-3 cells to confirm whether these nanoparticles would 
improve the results previously shown by the lactose-C11Pc-AuNPs.  
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SK-BR-3 cells were incubated with lactose-C3Pc-AuNPs and their corresponding control 
C3Pc-sPEG-AuNPs for 3 h at various C3Pc concentrations. Following incubation, the 
cells were washed to remove all of the non-internalised AuNPs and then irradiated with 
a 633 nm HeNe laser for 6 min. Before measuring cell viability using a CellTiter-Blue® 
cell viability assay, the cells were further incubated for ca. 48 h. The results, as shown 
in Figure 4.29, indicate that both lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs were 
effectively internalised by the cells. Furthermore, all of the nanoparticle samples show 
minimal dark toxicity, which highlights that they were not toxic in the absence of light. 
More importantly, both C3Pc-lactose-AuNPs and C3Pc-sPEG-AuNPs show cell death 
following irradiation. However, the targeting via lactose is only limited as the amount 
of cell death induced by lactose-C3Pc-AuNPs (95 % with 0.20 μM C3Pc) is similar to that 
induced by C3Pc-sPEG-AuNPs (92 % with 0.20 μM C3Pc), indicating both types of 
nanoparticles are internalised in a similar manner. However, at the lowest 
concentration of 0.5 μM C3Pc, there is an indication of targeting by lactose, as shown 
by the P values in Figure 4.29. The fact that the cell death values are lower than with 
higher concentration of lactose-C3Pc-AuNPs indicates that there could be an error in 
this part of the assay. The study of lower concentrations of C3Pc within the sample 
could help understand whether there is selective lactose targeting towards the SK-BR-
3 cells. The present results show that, even though lactose is not inducing specific 
targeting, the nanoparticles are effective at inducing cell death following PDT after only 
a 3 h incubation period. The cell viability assays, repeated five times, were highly 
reproducible (80 %). 
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The results shown in Figure 4.29 display a marked improvement to those seen with 
lactose-C11Pc-AuNPs (see Figure 4.14), where after a 3 h incubation period no cell 
death was observed. For lactose-C11Pc-AuNPs, a 24 h incubation period was required 
before targeting and cytotoxicity was seen. Therefore, for comparison purposes, the 
lactose-C3Pc-AuNPs were also incubated with the SK-BR-3 cells for 24 h and the cell 
viability was assessed. SK-BR-3 cells were incubated for 24 h only with 0.20 μM C3Pc 
for both lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs since this concentration produced 
the highest levels of cell death following a 3 h incubation. The results are shown in 
Figure 4.30. Following a 24 h incubation, the results are similar to those shown 
previously in Figure 4.29. There was cell death after irradiation for both types of AuNPs 
and only a slight indication that there could be targeting via lactose. The lactose-C3Pc-
AuNPs induced 96 % cell death and C3Pc-sPEG-AuNPs induced 95 % cell death. The dark 
toxicity of the lactose-C3Pc-AuNPs did appear to be less that that observed for the 
C3Pc-sPEG-AuNPs. 
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Figure 4.29. CellTiter-Blue® cell viability assay results for SK-BR-3 cells incubated with (A) 
C3Pc-sPEG-AuNPs or (B) lactose-C3Pc-AuNPs for 3 h. Cells were either irradiated with a 
633 nm HeNe laser (A orange, B yellow) or non-irradiated (A dark cyan, B green). 
Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars represent 
the SD (n = 3) within a 95 % confidence interval. Statistically significant difference between 
C3Pc-sPEG-AuNPs and lactose-C3Pc-AuNPs (0.05 μM C3Pc) is indicated by * at P < 0.003, 
obtained using a two-tailed Student’s t-test, where P < 0.05 is considered statistically 
significant. At higher concentrations (> 0.1 μM), the difference is not statistically significant 
(P < 0.2). 
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Once again, to confirm whether this limited targeting was due to the galectin-1 
receptor on the surface of the SK-BR-3 cells, an InCell ELISA was performed. The results, 
shown in Figure 4.31, indicate that the levels of galectin-1 in untreated cells and cells 
treated with either lactose-C3Pc-AuNPs or C3Pc-sPEG-AuNPs are similar. Therefore, the 
results shown in Figure 4.31 suggest that there is no effective targeting towards the 
galectin-1 receptor. These results are consistent with the fact that galectin-1 is not 
expressed in high amounts on the surface of SK-BR-3 cells.48 As previously mentioned, 
other receptors such as the GLUT1 receptor, could be responsible for the selective 
targeting with galactose-containing carbohydrates. Further studies would need to be 
performed to confirm this possibility.  
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Figure 4.30. CellTiter-Blue® cell viability assay results for SK-BR-3 cells incubated with 
C3Pc-sPEG-AuNPs (sPEG) or lactose-C3Pc-AuNPs (lactose) (0.2 μM C3Pc) for 24 h. Cells 
were either irradiated with a 633 nm HeNe laser (orange) or non-irradiated (green). 
Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars represent 
the SD (n = 3) within a 95 % confidence interval. No statistically significant difference 
between C3Pc-sPEG-AuNPs and lactose-C3Pc-AuNPs, as confirmed by the P values 
(P < 0.1) obtained with a two-tailed Student’s t-test, where P < 0.05 is considered to be 
statistically significant. 
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The results with SK-BR-3 cells suggest that the use of lactose-C3Pc-AuNPs should be 
preferred over lactose-C11Pc-AuNPs. Lactose-C3Pc-AuNPs induce cell death after only 
3 h incubation, whereas the lactose-C11Pc-AuNPs require a longer incubation period 
of 24 h before any cell death following irradiation is observed.  
 
4.2.11. Internalisation of lactose-C3Pc-AuNPs and PDT effect in SK-BR-3 cells 
Confocal microscopy was used for a visual inspection of the SK-BR-3 cells following 
incubation and PDT with lactose-C3Pc-AuNPs. The lactose-C3Pc-AuNPs were incubated 
with the SK-BR-3 cells for 3 h, since this incubation period was enough to induce high 
cytotoxic effects following PDT (see Figure 4.29). The results for the confocal 
microscopy study are shown in Figure 4.32 and they confirm the results obtained with 
the cell viability assays. SK-BR-3 cells show good internalisation of the lactose-C3Pc-
AuNPs as the red fluorescence is intense (Figure 4.32 B) in contrast to control cells not 
incubated with any AuNPs (Figure 4.32 A), where there is no red fluorescence. 
Furthermore, cell death can be seen following irradiation with a 633 nm HeNe laser 
(Figure 4.32 D) indicated by the staining with the dead cell marker propidium iodide, in 
pink. To observe cell death, the presence of the lactose-C3Pc-AuNPs is essential, as 
Figure 4.31. InCell ELISA for the detection of galectin-1 on the surface of SK-BR-3 cells. The 
figure shows the normalised values of galectin-1 per cell in each sample. The samples were 
incubated with C3Pc-sPEG-AuNPs (sPEG) or lactose-C3Pc-AuNPs (lactose) for either (A) 3 h 
or (B) 24 h. Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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irradiation of the control cells not treated with AuNPs does not induce any cell death 
(Figure 4.32 C). 
 
 
 
 
 
 
 
 
 
Figure 4.32. Confocal fluorescence microscopy images of SK-BR-3 cells. (A, C) control cells 
incubated only with growth medium for 3 h and (B, D) cells incubated with C3Pc-lactose-
AuNPs for 3 h. The cells were either non-irradiated (A, B) or irradiated (C, D) with a 633 nm 
HeNe laser. All samples were imaged 24 hours following treatment. Images taken from: 1) 
DIC, 2) fluorescence from C3Pc collected in the red channel (λex = 633 nm; above 650 nm), 
3) fluorescence from propidium iodide collected in the pink channel (λex = 543 nm; 560-
615 nm) and 4) composite images of DIC, fluorescence from C3Pc collected in the red 
channel and fluorescence from propidium iodide collected in the pink channel. Scale bars 
represent 10 μm. 
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4.2.12. Mechanism of cell death post-PDT by lactose-C3Pc-AuNPs  
The ApoTox-Glo™ Triplex assay was performed to study the cell death mechanism that 
the SK-BR-3 and MDA-MB-231 cells undergo following PDT with the lactose-C3Pc-
AuNPs and C3Pc-sPEG-AuNPs. The ApoTox-Glo™ Triplex assay measures cell viability, 
cell cytotoxicity and apoptosis as three different components. The mechanisms behind 
this assay were described in section 3.2.14.  
The ApoTox-Glo™ Triplex assay was performed with the optimal incubation times 
found for each cell line, using the AuNPs with a 0.20 μM C3Pc concentration. For SK-
BR-3 cells, a short incubation time of 3 h with the lactose-C3Pc-AuNPs was enough to 
induce high levels of cytotoxicity after PDT (section 4.2.10). On the other hand, for 
MDA-MB-231 cells a longer incubation period of 24 h was required for cell death to be 
observed following PDT (section 4.2.8). 
Following the procedure described in section 2.3.12, the triplex assay was performed 
ca. 4 h after the cells were treated with PDT. The incubation period post-PDT of 4 h is 
considerably lower than the 48 h used during the MTT and CellTiter-Blue® cell viability 
assays previously reported. However, it was chosen in order to reproduce the 
experiments reported in section 3.2.14, where a 48 h post-PDT incubation period was 
found to be too long for the ApoTox-Glo™ Triplex assay, which led to the degradation 
of the cytotoxicity and apoptosis biomarkers and thus produced erroneous results. The 
results for SK-BR-3 and MDA-MB-231 cells incubated with lactose-C3Pc-AuNPs and 
C3Pc-sPEG-AuNPs incubated for 3 h and 24 h, respectively, are shown in Figure 4.33. 
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Figure 4.33. ApoTox-Glo™ Triplex assay for (A) SK-BR-3 cells incubated for 3 h and (B) 
MDA-MB-231 cells incubated for 24 h with lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs 
(0.2 μM C3Pc). Cells were either irradiated with a 633 nm HeNe laser (A orange, B yellow) 
or non-irradiated (A dark cyan, B green). The cells were treated with the triplex assay ca. 
4 h following PDT. (1) Fluorescence from the GF-AFC substrate giving the cell viability 
values, (2) fluorescence from bis-AAF-R110 substrate giving the cell cytotoxicity values 
and (3) luminescence from the Caspase 3/7 substrate giving the values for apoptosis. The 
sample ‘No AuNPs’ refers to samples not incubated with any AuNPs used as the reference 
negative control. Staurosporine (+ve St) was used as a positive control for cytotoxicity via 
apoptosis. Error bars represent the SD (n = 3) within a 95 % confidence interval. 
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The results presented in Figure 4.33 show the three different components of the 
ApoTox-Glo™ Triplex assay. For the viability part of the assay (Figure 4.33 A1-B1), the 
results indicate targeting by lactose in both SK-BR-3 and MDA-MB-231 cells. However, 
the values for cell death following irradiation to the samples treated with lactose-C3Pc-
AuNPs (95 % MDA-MB-231 cells and 88 % SK-BR-3 cells) and C3Pc-sPEG-AuNPs (67 % 
MDA-MB-231 cells and 36 % SK-BR-3 cells) are not the same as those reported with the 
cell viability assays; lactose-C3Pc-AuNPs (52 % MDA-MB-231 cells and 95 % SK-BR-3 
cells) and C3Pc-sPEG-AuNPs (36 % MDA-MB-231 cells and 92 % SK-BR-3 cells). The 
Triplex assay was only performed once, whereas the cell viability assays were 
performed multiple times, as previously reported. Therefore, the values obtained from 
the cell viability assays are taken to be more accurate than those for the ApoTox-Glo™ 
Triplex assay. For the cytotoxicity part of the assay (Figure 4.33 A2-B2), the results 
obtained are difficult to interpret. The positive control (+ve St) should produce the 
highest fluorescence signals but this is not the case. In fact, the fluorescence values 
from +ve St are amongst the lowest of all samples. Additionally, the apoptosis part of 
the assay (Figure 4.33 A3-B3) also gives results that are difficult to explain. Once again, 
the positive control (+ve St) should give the highest luminescent values since it is a 
known apoptosis inducer. On the other hand, the luminescent intensity values for 
viable cells should be low. However, even though the positive control gives the highest 
luminescence intensity for SK-BR-3 cells (Figure 4.33 A3), this is not the case for MDA-
MB-231 cells (Figure 4.33 B3). Additionally, the luminescence intensity values for the 
viable cells are also relatively high (Figure 4.33 A3-B3). It can be concluded that there 
is indication that the cells treated with lactose-C3Pc-AuNPs do not follow an apoptotic 
cell death pathway because the luminescent values for these samples are the lowest 
for both cell lines. However, this conclusion cannot be confirmed since the assay is 
producing results that are difficult to interpret in all three components, cell viability, 
cytotoxicity and apoptosis. It is possible that a necrotic cell death pathway may be the 
mechanism induced by the lactose-C3Pc-AuNPs. However, this mechanism of action 
would need further confirmation. 
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4.2.13. Effects of lactose-C3Pc-AuNPs in non-cancerous MCF-10A cells 
Analysis of PDT induced by both lactose-C11Pc-AuNPs and lactose-C3Pc-AuNPs 
indicated that lactose-C3Pc-AuNPs are better at inducing cell death in both SK-BR-3 and 
MDA-MB-231 cells. As a result, it was decided to study the effect of PDT of lactose-
C3Pc-AuNPs, and its corresponding control C3Pc-sPEG-AuNPs, in non-cancerous 
mammary epithelial cells, MCF-10A cells. MCF-10A cells were incubated with lactose-
C3Pc-AuNPs and C3Pc-sPEG-AuNPs at a concentration of 0.20 μM as described in 
section 2.3.8. The cells were incubated with the AuNPs for either 3 h or 24 h. Following 
incubation, the cells were washed to remove all non-internalised AuNPs. MCF-10A cells 
were irradiated using a 633 nm HeNe laser for 6 min and incubated for a further 
ca. 48 h before cell viability was measured. The results are shown in Figure 4.34. 
 
 
 
 
 
 
 
 
 
 
 
As it can be seen in Figure 4.34, non-cancerous MCF-10A cells are not damaged by 
either lactose-C3Pc-AuNPs or C3Pc-sPEG-AuNPs. Therefore, the AuNPs reported in this 
chapter can be used for efficient PDT since they induce cell death to cancerous cells 
but leave healthy cells undamaged. Further studies on the internalisation of lactose-
C3Pc-AuNPs and C3Pc-sPEG-AuNPs by the MCF-10A cells should be performed to 
understand why the cells do not internalise the nanoparticles as readily as cancer cells 
and thus no cell death is observed. 
Figure 4.34. CellTiter-Blue® cell viability assay for MCF-10A cells incubated with C3Pc-sPEG-
AuNPs (sPEG) and lactose-C3Pc-AuNPs (lactose) (0.2 M C3Pc) for either (A) 3 h or (B) 24 h. 
Cells were either irradiated with a 633 nm HeNe laser (orange) or non-irradiated (blue). 
Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars represent 
the SD (n = 3) within a 95 % confidence interval. 
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4.3. Conclusions  
In this chapter, the use of lactose as a targeting agent for breast adenocarcinoma cells 
was explored. MDA-MB-231 and SK-BR-3 cells were compared for the expression of 
galectin-1 on their surface. Galectin-1 is a β-galactoside-binding lectin that has been 
found to be overexpressed on the surface of certain cancers, including breast 
cancer.18,23,24,31 MDA-MB-231 cells were found to have a higher amount of galectin-1 
on their surface as compared to SK-BR-3 cells. Therefore, it was expected that MDA-
MB-231 cells would be better candidates for targeted PDT using lactose.  
Lactose-C11Pc-AuNPs were successfully synthesised and dissolved in an aqueous 
buffer, MES buffer, with a mean diameter of 2.37 ± 1.65 nm, as confirmed by TEM 
analysis. The production of 1O2 by the lactose-C11Pc-AuNPs was confirmed using the 
1O2 probe ABMA. Additionally, a PEG ligand (sPEG) with a short chain that would 
resemble the length of the lactose derivative was used to synthesise C11Pc-sPEG-
AuNPs. These nanoparticles were used as a control to confirm targeting by lactose. 
Lactose-C11Pc-AuNPs and C11Pc-sPEG-AuNPs were initially used to target MDA-MB-
231 cells, with incubation periods of either 3 h or 24 h, as summarised below: 
 Incubation of MDA-MB-231 cells with the lactose-C11Pc-AuNPs and C11Pc-
sPEG-AuNPs for 3 hours led to no cell death following PDT, suggesting the 
incubation period was too short for effective internalisation of the AuNPs. 
 Increasing the incubation period of MDA-MB-231 cells with the lactose-C11Pc-
AuNPs and C11Pc-sPEG-AuNPs to 24 hours led to inconclusive results, 
suggesting that the PDT efficacy was low or negligible. 
Since the results were negative for MDA-MB-231 cells, it was decided to attempt the 
use of lactose-C11Pc-AuNPs to target SK-BR-3 cells. The main findings are summarised 
below: 
 Initial incubation of SK-BR-3 cells with the lactose-C11Pc-AuNPs and C11Pc-
sPEG-AuNPs for 3 hours led to no cell death following PDT. This was an 
indication that a 3-hour incubation period was not sufficient for effective 
internalisation of the AuNPs. 
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 An increase in the incubation period of SK-BR-3 cells with lactose-C11Pc-AuNPs 
and C11Pc-sPEG-AuNPs to 24 hours led to PDT cytotoxicity being induced. 
Moreover, the lactose-C11Pc-AuNPs induced more cell death (90 %) than the 
C11Pc-sPEG-AuNPs (61 %), with statistical significance (P < 0.006). This was an 
indication that the lactose ligand was selectively targeting the SK-BR-3 cells. 
 To confirm whether the selective targeting between lactose-C11Pc-AuNPs and 
SK-BR-3 cells following a 24 h incubation period was indeed due to the presence 
of galectin-1 on the surface of the SK-BR-3 cells, an InCell ELISA was performed. 
Unfortunately, there was no indication of targeting the galectin-1 receptor. 
Therefore, the possible targeting seen in the viability assays could be due to the 
selective recognition between lactose and another receptor on the surface of 
the SK-BR-3 cells, such as GLUT1. Additional studies with GLUT1 should be 
performed to confirm this possibility. 
In the second part of the research reported in this chapter, C3Pc was used as a 
photosensitiser in an attempt to facilitate the targeting ability of the lactose ligand. 
C3Pc has a shorter carbon chain than C11Pc, and slightly shorter than the lactose ligand. 
As a result, the lactose ligand extends further than the C3Pc from the surface of the 
AuNPs, which could allow for an unhindered binding between lactose and galectin-1. 
Lactose-C3Pc-AuNPs were successfully synthesised and dissolved in an aqueous buffer, 
MES buffer, with a mean diameter of 3.10 ± 1.32 nm. The first advantage of lactose-
C3Pc-AuNPs over lactose-C11Pc-AuNPs was that the former were easier to synthesise 
since the shorter chain of C3Pc allows for a better dispersibility in water and thus a 
higher C3Pc loading on the AuNPs. Control C3Pc-sPEG-AuNPs were synthesised to 
directly assess the targeting ability of lactose-C3PC-AuNPs. The ability of lactose-C3Pc-
AuNPs to produce 1O2 was also confirmed using ABMA.  
Lactose-C3Pc-AuNPs were initially incubated with MDA-MB-231 cells for either 3 h or 
24 h. A summary of the main findings are reported below: 
 Incubation of MDA-MB-231 cells with the lactose-C3Pc-AuNPs and C3Pc-sPEG-
AuNPs for 3 hours led to no cell death following PDT, as shown by the cell 
viability assays as well as using confocal microscopy, indicating that 3 hours was 
too short for effective internalisation of the AuNPs. 
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 Increasing the incubation period of MDA-MB-231 cells with lactose-C3Pc-
AuNPs and C3Pc-sPEG-AuNPs to 24 hours was effective at inducing cell death 
following PDT, as confirmed by the cell viability assays together with visual 
inspection using confocal microscopy. There was a slight evidence of targeting 
by lactose since the lactose-C3Pc-AuNPs induced higher levels of cell death 
(52 %) than the C3Pc-sPEG-AuNPs (36 %). However, this evidence was not 
statistically significant. 
 To confirm whether the possible targeting seen between lactose-C3Pc-AuNPs 
and MDA-MB-231 cells following a 24 h incubation period was due to the 
interaction between lactose and galectin-1, an InCell ELISA was performed. 
Indeed, there was an indication that galectin-1 was involved in the 
internalisation of lactose-C3Pc-AuNPs.  
 These results present an advantage of the use of lactose-C3Pc-AuNPs over 
lactose-C11Pc-AuNPs, which did not induce cell death in MDA-MB-231 cells at 
either incubation period. 
The effect of lactose-C3Pc-AuNPs was also tested on SK-BR-3 cells. The main 
conclusions are reported below: 
 Incubation of SK-BR-3 cells with lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs for 
3 hours effectively induced cytotoxicity following PDT, as confirmed by cell 
viability assays and confocal microscopy. Additionally, at low concentrations 
(0.05 μM C3Pc) there was an indication of targeting by lactose, as confirmed 
statistically (P < 0.003). 
 Incubation of SK-BR-3 cells with lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs for 
24 hours was also effective at inducing cell death following PDT. 
 With reference to lactose targeting, there was an indication of targeting with 
the cell viability assays, especially following a 3 h incubation period with low 
concentrations of C3Pc. However, an InCell ELISA revealed that the possible 
targeting seen in the cell viability assays did not involve the galectin-1 receptor 
on the surface of SK-BR-3 cells.  
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 These results present an advantage of lactose-C3Pc-AuNPs over lactose-C11Pc-
AuNPs, which were only effective at inducing PDT cell death when the SK-BR-3 
cells were incubated with AuNPs for 24 h.  
Considering that the lactose-C3Pc-AuNPs were more efficient than the lactose-C11Pc-
AuNPs, the effect of lactose-C3Pc-AuNPs on non-cancerous mammary epithelial cells 
(MCF-10A cells) was assessed. It was found that neither lactose-C3Pc-AuNPs nor C3Pc-
sPEG-AuNPs induce any damage to healthy cells. This suggests that lactose-C3Pc-AuNPs 
are ideal candidates for PDT since they only target cancerous cells and induce no 
damage to healthy cells. The mechanism of cell death followed by SK-BR-3 and MDA-
MB-231 cells following PDT with lactose-C3Pc-AuNPs was studied. There was an 
indication that the most likely route was a non-apoptotic pathway such as necrosis. 
However, the results of the ApoTox-Glo™ Triplex assay were difficult to interpret and 
thus inconclusive. 
The research in Chapter 4 has revealed that lactose can be used, rather than PEG, to 
synthesise aqueous-dispersable AuNPs with either C3Pc or C11Pc. Additionally, lactose-
C3Pc-AuNPs were found to be more efficient than lactose-C11Pc-AuNPs for 1O2 
production and PDT of both cell lines, MDA-MB-231 and SK-BR-3: 
 Lactose-C11Pc-AuNPs only targeted and induced cell death to SK-BR-3 cells 
following a 24 h incubation period. On the contrary, lactose-C11Pc-AuNPs were 
inefficient on MDA-MB-231 cells. 
 Lactose-C3Pc-AuNPs efficiently targeted and induced cell death of SK-BR-3 cells 
after only a 3 h incubation period. Additionally, lactose-C3Pc-AuNPs targeted 
and induced cell death of MDA-MB-231 cells following a 24 h incubation period. 
 The galectin-1 receptor on the surface of the SK-BR-3 cells was not involved in 
the targeting seen by lactose-AuNPs. On the contrary, the galectin-1 receptor 
on the surface of the MDA-MB-231 cells showed an indication of selective 
recognition of the lactose on the lactose-C3Pc-AuNPs. 
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Chapter 5 
The potential use of upconverting nanoparticles as drug 
carriers for photodynamic therapy of cancer 
This chapter describes the potential use of upconverting nanoparticles as drug carriers 
for photodynamic therapy of cancer. The upconverting nanoparticles, functionalised 
with Rose Bengal (RB) as a photosensitiser, were tested for near-infrared (NIR)-PDT 
with human breast adenocarcinoma cells. 
 
5.1. Introduction 
5.1.1. Upconverting nanoparticles 
Upconverting nanoparticles (UCNPs), as described in Chapter 1, have recently received 
much attention due to their ability to emit light in the visible region (high energy, short-
wavelength radiation) upon excitation with light in the NIR region (long-wavelength 
radiation, usually 980 nm), in a process known as upconversion.1-6 Upconversion 
disobeys classical linear optics, by which absorption of high energy photons leads to 
the Stokes emission of low energy, long wavelength radiation, due to the loss of energy 
that occurs when the system relaxes back to the ground state.1,7,8 Therefore, 
upconversion can be defined as an anti-Stokes non-linear optical process.1,2,6-10 It is 
important to note the difference between upconversion and another non-linear optical 
process, two-photon or multiphoton absorption (TPA). While TPA refers to the 
simultaneous absorption of two or more photons, upconversion occurs upon 
sequential absorption of those photons.5,11-13 As a result, upconversion is a more 
efficient process, which allows for the use of a low-cost continuous wave diode NIR 
laser as the excitation source rather than the more expensive ultrashort pulsed lasers 
required for TPA.11,12 
The mechanisms by which upconversion takes place can be classified into three main 
groups; excited-state absorption (ESA), energy transfer upconversion (ETU) and photon 
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avalanche (PA).1,2,8,9,14,15 All these mechanisms have in common the sequential 
absorption of photons leading to a highly excited state from which emission then takes 
place.1 Excited-state absorption (Figure 5.1 A), discovered by Bloembergen in 1959,16 
involves the absorption of two photons by a single ion. Absorption of the first photon 
promotes the excitation of the ion in the ground state (G) into an intermediate excited 
state (E1) with a long half-life. The ion in E1 is then excited into the higher level E2 via 
absorption of a second photon. Relaxation of the ion from E2 to the ground state leads 
to the upconverted luminescence emission.9,12,15 Energy transfer upconversion (Figure 
5.1 B) was discovered by Auzel in 1966, which he termed APTE (from the French 
‘addition de photon par transferts d’energie’), and it is the most efficient upconversion 
phenomenon.1,8,9,14,15 ETU involves sequential energy transfer between two 
neighbouring ions, one acting as the donor (i.e., sensitiser) and the second one acting 
as the acceptor (i.e., activator). Both the sensitiser and the activator are excited to the 
E1 level upon absorption of a photon. The sensitiser in the E1 level transfers its energy 
to the activator, also in the E1 level. As a result, the activator is excited to level E2 and 
the sensitiser relaxes back to the ground state. Relaxation of the activator from level 
E2 to the ground state leads to upconverted luminescence emission.1,9,12,15 The ETU 
phenomenon resulting from identical sensitiser and activator ions is known as cross-
relaxation (CR).9,14 CR involves the interaction between an ion in the E2 state and an 
ion in the ground state. The ETU between the two ions leads to both ions transitioning 
to the E1 excited level (Figure 5.1 C).12 Additionally, cooperative processes, namely 
cooperative sensitisation and cooperative luminescence, are a type of energy transfer 
upconversion but with a much lower efficiency.9,12,14 Cooperative processes can take 
place between two ions or between a pair of ions and a third ion.14 Finally, photon 
avalanche (Figure 5.1 D) was discovered by Chivian in 1979.17 It is the most complex 
process and it is initiated by the excitation of an ion to its E1 level, followed by 
excitation to the E2 level via ESA. The excited ion in level E2 interacts with a near-by 
ion in the ground state via CR. The ions can readily be excited to the E2 level and the 
process is repeated, in an avalanche manner, leading to strong upconversion.9,15 
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Requirements for the formation of upconversion are the presence of two metastable 
excited states and a ladder-like arrangement of the energy levels with similar distances 
between one another.1,13 Both requirements are fulfilled by some d and f elements. 
Rare-earth ions, i.e., lanthanides, provide high upconversion efficiency and are thus 
normally used for the synthesis of UCNPs.1 UCNPs consist of a crystalline host lattice 
and lanthanide dopants.1,7,9,12,15,18 The selection of both the host lattice and the 
dopants is important in order to achieve high upconversion efficiency.12 The host lattice 
plays an essential role within the UCNPs, as it will regulate the distance between the 
dopants, their relative position and coordination number as well as the chemical 
environment surrounding the dopants.1,7 As a result, the host lattices are required to 
be chemically and physically stable, transparent in the spectral region of interest and 
should have low phonon energies to minimise non-radiative loss and maximise 
upconverted emission.1,2,7,9,12,15 Considering all of these prerequisites, a combination of 
alkali (i.e., Na2+, Ca2+) and rare-earth metal (i.e., Y3+, Gd3+) fluorides are ideal as host 
lattices for UCNPs. Common examples are sodium yttrium fluoride (NaYF4) or sodium 
gadolinium fluoride (NaGdF4) crystal lattices. The geometry of the crystal structure has 
also been found to contribute to a higher or lower upconverted emission. For example, 
the use of hexagonal (β-phase) NaYF4 leads to much higher upconversion efficiencies 
as compared to the cubic (α-phase) NaYF4 structure.1,2,7,9,12,15  
Figure 5.1. Energy level diagrams showing the upconversion mechanisms: (A) excited-
state absorption (ESA), (B) energy transfer upconversion (ETU), (C) cross-relaxation (CR) 
and (D) simplified figure of photon avalanche (PA). The red arrows represent photon 
excitation, the blue lines and arrows represent energy transfer and the green arrows 
represent upconverted emission. The figure was adapted from Ref. 1 and Ref. 12. 
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The selection of the dopants has also been studied. As it was previously mentioned, the 
most important upconversion mechanism in UCNPs is ETU, with considerably higher 
efficiency than ESA. As a result, the host lattice is co-doped with a sensitiser and an 
activator.1 The most commonly used sensitiser is ytterbium (Yb3+), whose energy level 
is simple and facilitates the energy transfer to the activators.1,7,9,12,15 For the selection 
of the activators, they should have an energy level compatible with that of the 
sensitiser, Yb3+, and metastable excited states. The lanthanides erbium (Er3+), thulium 
(Tm3+) and holmium (Ho3+) are ideal candidates to be used as activators. Additionally, 
the concentration of the dopants is important in order to avoid loss of energy via CR. 
Typically, sensitisers are included at high concentrations (≥ 20 mol %) but activators are 
added at low concentrations (≤ 2 mol %).1,7,9,12,15 Lithium ions (Li+) have also been 
reported as potential dopants for UCNPs since Li+ can lead to a 30-fold enhancement 
of the luminescence efficiency as compared to other lanthanide dopants.19 
The most efficient structure for UCNPs has been found to be β-phase NaYF4 co-doped 
with Yb3+ and Er3+.3,5-7,15,18,20-22 However, the combination NaYF4 co-doped with Yb3+ and 
Tm3+ is also being widely studied as it leads to high upconversion efficiency.7 The ETU 
diagrams for both combinations can be seen in Figure 5.2, where it is clearly shown 
that NaYF4 co-doped with Yb3+/Er3+ leads to red, green and blue emission while NaYF4 
co-doped with Yb3+/Tm3+ leads to only red and blue emission.1,7,15,18,22,23 The addition 
of Gd3+ to these systems is encouraged because it facilitates the conversion of NaYF4 
from the cubic phase to the hexagonal phase crystal structure and it provides the 
possibility to use the UCNPs as contrast agents for bioimaging.6,10,20,23,24 
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UCNPs have a lower luminescence efficiency than their bulk counterparts due to their 
large surface-to-volume ratio.1,12 As a result, the dopants are exposed to surface 
deactivation processes, which can lead to the quenching and energy loss of the 
upconverted luminescence and thus low efficiency.1,12 A technique to solve this 
problem is to cover the surface of the UCNPs with a shell. The core-shell structure of 
the UCNPs could either be homogeneous or heterogeneous relative to the host 
material.12 Additionally, the shell can either be active or passive. Passive shells do not 
contain any dopants whereas active shells are doped with lanthanides in the same way 
as the core.1,12 As a result, core-shell UCNPs will have much higher luminescence 
intensities and their use is encouraged. 
Figure 5.2. Energy level diagrams showing the upconversion mechanisms for NaYF4 co-
doped with the sensitiser Yb3+ and either Er3+ or Tm3+ as activator. The arrows indicate 
absorption (orange), energy transfer (black dots), non-radiative relaxation (pink dash) and 
upconverted luminescence emission at different wavelengths (red, green and blue). The 
2S+1LJ notation used to label the f energy levels refer to spin (S), orbital (L) and angular 
momentum (J) quantum numbers according to the Russell-Saunders notation. The 
diagram was adapted from Ref. 1. 
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The synthesis of UCNPs can be performed via several methods. The most common 
synthetic routes followed are thermal decomposition, co-precipitation, solvothermal 
synthesis, sol-gel processing, Ostwald-Ripening strategy, combustion synthesis, flame 
synthesis and microwave-assisted heating.5,12,15,19 The main challenge in these 
syntheses is that the final UCNPs are capped with organic ligands containing long alkyl 
chains, usually oleate, and are thus highly hydrophobic. As a result, to obtain water-
dispersable or water-soluble UCNPs, the hydrophobic UCNPs need to be subjected to 
post-synthesis surface modifications.1,5,12,25 Common strategies of surface modification 
include: The addition of a water soluble inorganic shell (SiO2 or TiO2); The chemical 
modification of the organic ligand via ligand oxidation; The coating of the UCNPs with 
amphiphilic polymers such as phospholipids, PEG or polyacrylic acid (i.e., ligand 
attraction); The layer-by-layer assembly of charged molecules through electrostatic 
interactions; and the complete elimination of the organic ligand via ligand 
exchange.5,7,12 Ligand exchange is divided in two methods. Firstly, a one-step exchange 
process. Secondly, a two-step process in which the UCNPs are either treated with 
nitrosonium tetrafluoroborate (NOBF4) or a strong acid for the removal of the organic 
ligand, followed by the addition of a water-soluble coating.5 
 
5.1.2. Biological applications of UCNPs 
The use of UCNPs for biomedicine has recently received considerable attention.26 The 
ability of UCNPs to convert NIR light into higher energy visible or UV light provides them 
with several advantages over currently used nanomaterials such as quantum dots 
(QDs) and nanoparticles functionalised with organic dyes.2,3,12,26-30 Excitation in the NIR 
region allows for a deeper penetration into the tissue, due to the low absorbance of 
biological tissue in that region, as well as reduced photodamage towards the cells 
under long-term irradiation. Additionally, unlike QDs, the luminescence emission of 
UCNPs is not size-dependent, it allows for the possibility to tune multicolour emission, 
and the emission bands are narrow, which is another advantage for multiplexed 
imaging. Further advantages over QDs include the non-blinking, non-bleaching nature 
of the UCNPs, which provides less scattering and a high resistance to photobleaching. 
Adding to these qualities, UCNPs are biocompatible, synthesised with a narrow size 
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distribution and have enhanced photostability as well as low cytotoxicity. Furthermore, 
the NIR excitation also contributes to lower autofluorescence, which essentially leads 
to no background noise during bioimaging and thus increases the signal-to-noise ratio. 
As a result, UCNPs are ideal candidates for bioimaging, biosensing, drug delivery and 
therapeutic applications.2,3,7,9,12,26-39 
It was previously discussed that UCNPs have low cytotoxicity. Studies on the toxicity of 
UCNPs are challenging since toxicity is dependent on many factors including UCNPs 
size, shape, composition, charge and surface ligands but also on cell and tissue type 
and the route of exposure and incubation conditions used.7,8 Therefore, results cannot 
be easily extrapolated from one UCNP model to another and cannot be directly 
compared with the toxicity of other types of nanoparticles.7,8 Additionally, results from 
in vitro and in vivo studies do not always correlate. In vitro studies are usually 
performed on cells cultured on a monolayer so the concentration of UCNPs used are in 
direct contact with the cells. Most in vitro studies, up to date, have shown that UCNPs 
at concentrations as high as 400-500 g/mL incubated with cell cultures for as long as 
48 h do not show any cytotoxicity.7 In vivo studies are more complex because only a 
partial dose of the UCNPs being used actually reaches the site of interest, i.e., the 
tumour cells, and it is highly dependent on the route of exposure, metabolism, 
excretion pathway and immune response.7 One of the most important in vivo studies 
for the toxicity of UCNPs was reported by Xiong et al..40 The authors studied NaYF4 
nanoparticles, co-doped with Yb3+ and Tm3+ and functionalised with polyacrylic acid, in 
mice. It was found that accumulation of the UCNPs in the liver and spleen is slowly 
cleared from the animal during a four-month period and no health damage was 
observed to the treated mice.7,8,40 UCNPs functionalised with other ligands such as PEG 
and polyethylenimine (PEI) have also been reported to accumulate in several organs 
including lungs, kidney, liver and spleen but eliminated from the body ca. 7 days post 
injection.7,8 The use of UCNPs containing Gd, considered the most toxic element upon 
release of free Gd3+ ions in the body, have also been shown to induce no harm in mice 
up to 150 days following injection.8 The inclusion of the Gd strongly bonded to the host 
lattice avoids the release of the ions and thus reduces the toxicity associated with free 
Gd3+ ions.8 The majority of the studies performed to date indicate UCNPs have a low 
toxicity and are thus good candidates for biomedical applications. However, long-term 
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toxicity, decomposition of UCNPs leading to secondary toxicity effects via their 
decomposition products and the possibility of the chemical properties of UCNPs 
activating unwanted cellular signalling have not been studied. Therefore, it cannot be 
fully concluded that UCNPs do not pose any health risks. The results reported up to 
date are promising but further studies on the toxicology of UCNPs are required to 
effectively assess the possible hazards towards humans.8  
Current investigation on the use of UCNPs involve several applications, as previously 
discussed. The use of Förster resonance energy transfer (FRET), a non-radiative process 
of energy transfer between an excited donor and an acceptor in the ground state, plays 
an important role in the use of UCNPs for biomedicine.38 The UCNPs, excited with NIR 
light, act as the energy donor to a molecule placed on the nanoparticle surface, which 
can be excited with the light being emitted by the UCNPs. Therefore, the key 
requirement for FRET to occur is the spectral overlap between the fluorescence 
emission of the donor, i.e., the UCNPs, and the UV-vis absorption of the acceptor, i.e., 
the fluorophore placed on the surface of the UCNPs. FRET has been used for 
applications such as biosensing, bioassays, bioimaging and cancer therapeutics, 
especially PDT.38 One of the most relevant and researched applications of UCNPs is PDT 
(for a review on the use of UCNPs for PDT see Chapter 1). The use of FRET in UCNPs-
mediated PDT is essential for the effective production of singlet oxygen. Excitation of 
the UCNPs at 980 nm leads to upconverted luminescence emission, which can then be 
used to excite the photosensitiser on the nanoparticle surface and induce the 
generation of singlet oxygen. An energy level diagram showing the FRET process 
between UCNPs and the photosensitiser Rose Bengal, which leads to the generation of 
singlet oxygen, is shown in Figure 5.3.  
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The use of UCNPs as biosensors has been reported for the detection of oxygen,37 
glutathione,36 avidin,41 temperature,42 and small interference RNA (siRNA).43 UCNPs 
cannot directly detect the analytes of interest. Therefore, the use of a molecule 
sensitive to the analyte of interest, that will receive energy transfer from the UCNPs 
emission, i.e., FRET, is required. In the case of oxygen sensing, an iridium (III) complex 
(Ir) that has a fluorescence signal known to be quenched in the presence of oxygen was 
used.37 Effective FRET between the UCNPs and Ir led to the fluorescence emission of Ir, 
which was then used for sensing oxygen in the environment.37 In the case of 
glutathione sensing, sheets of MnO2 were used to cover the surface of the UCNPs.36 
FRET between the UCNPs and MnO2 lead to the quenching of the UCNPs luminescence, 
which was recovered upon addition of glutathione. As a result, quantification of 
glutathione in the environment was possible.36 For the detection of trace amounts of 
avidin, UCNPs were conjugated to gold nanoparticles and efficient FRET between the 
two systems led to the successful detection of avidin.41 
Figure 5.3. Energy level diagrams showing the upconversion mechanisms for NaYF4 co-
doped with the sensitiser Yb3+ and the activator Er3+. Efficient FRET between the UCNPs 
and Rose Bengal leads to the generation of singlet oxygen (1O2) upon reaction of the 
excited photosensitiser with molecular oxygen (3O2). The arrows indicate absorption 
(orange), energy transfer (black dots), fluorescence (pink), phosphorescence (pink dash) 
and upconverted luminescence emission at different wavelengths (red and green). The 
Russell-Saunders (2S+1LJ) notation used to label the f energy levels refer to spin (S), orbital 
(L) and angular (J) quantum numbers. The diagram was adapted from Ref. 38. 
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The use of UCNPs for both in vitro and in vivo imaging has been widely studied.2 The 
use of UCNPs for in vivo imaging is restricted to several conditions; biocompatibility, 
water-solubility, bright luminescence, small diameter (< 10 nm) and the possibility to 
attach targeting ligands to the surface of the UCNPs.30,44 For bright luminescence, the 
use of UCNPs with a core-shell structure is encouraged because the addition of a shell 
can increase the luminescence of the UCNPs,45 as explained in section 5.1.1. The 
synthesis of UCNPs with these characteristics has been reported and successfully used 
for in vitro imaging46 but more importantly in vivo imaging, including vascular 
imaging.30,44 The addition of targeting ligands has also been used for tumour-targeted 
imaging. Chatterjee et al. coated PEI modified NaYF4 UCNPs with folic acid to 
specifically target the folic acid receptors overexpressed on certain types of cancer. The 
presence of folic acid increased the uptake of the UCNPs by the cells and led to 
successful in vitro but also in vivo imaging.29 Other groups have reported the use of 
peptides as the targeting moiety. In particular, cyclic arginine-glycine-aspartic acid 
(RGD) has been used to target the v3 integrin receptor overexpressed in cancer. The 
RGD functionalised UCNPs have been effectively used to image tumours in vivo.2,47 The 
use of targeted imaging shows great potential for successful cancer imaging. 
Additionally, another important contribution of UCNPs to imaging is the use of 
multimodal imaging.2 The inclusion of Gd3+ in the UCNPs formulation allows for dual 
imaging via the UCNPs luminescence emission and the ability of Gd3+ to be used as a 
contrast agent in magnetic resonance imaging (MRI). An alternative to Gd3+ is the use 
of iron oxide nanoparticles (IONPs) for dual MRI and UCNPs imaging.2  
Drug delivery is also an important application for which UCNPs can be used. The use of 
UCNPs to deliver drugs such as doxorubicin (DOX) and ibuprofen (IBU) has been 
particularly studied.31,33,35,48-50 Lin and co-workers used pH-sensitive UCNPs for the 
delivery of the anticancer drug DOX into cancerous cells.31,48 UCNPs synthesised with 
NaYF4 co-doped with Yb3+ and Tm3+ were functionalised with hydrazine, to which DOX 
was attached via a hydrazone bond. The hydrazone bond was pH sensitive and easily 
cleaved under mildly acidic conditions (pH 4.5-5.0). As a result, DOX was effectively 
released upon endocytosis, which leads to the formation of acidic endosomes and 
lysosomes. The DOX release could be easily monitored using confocal microscopy via 
FRET, since the luminescence of the UCNPs is quenched in the presence of DOX, but 
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recovered as DOX is released into the environment. The release of DOX into cancer cells 
was effective at inducing cell death.31 The use of pH-sensitive drug release was also 
studied by Hou et al..49,50 The authors synthesised silica nanofibers via electrospinning 
to which UCNPs were attached. The release of both DOX and IBU into cancer cells was 
effective in both of their studies. The delivery of DOX has also been possible via NIR 
light-triggered release.33 Liu et al. synthesised NaYF4 UCNPs co-doped with Yb3+ and 
Tm3+, which were covered with a mesoporous silica shell to which azobenzene groups 
were attached. Additionally, DOX was loaded on the silica shell of the UCNPs. Excitation 
of the UCNPs with NIR light led to FRET with the azobenzene groups. The absorption of 
light by the azobenzene groups induced a continuous rotation-inversion movement, 
which is responsible for the release of DOX into the environment, i.e., the cancer cells.33 
This NIR light-triggered release has also been used for the release and activation of 
caged compounds, which can be used for cancer therapy and gene expression.51-53   
Importantly, the use of UCNPs as multifunctional agents for both therapy and imaging 
has also been studied. Multifunctional UCNPs have received a lot of interest and have 
become the subject of many studies.3,26-28,54-58 The Liu group synthesised NaYF4 UCNPs, 
decorated these nanoparticles with a layer of IONPs, further covered the surface with 
a gold shell and finally functionalised the resultant particles with PEG.28,58 As a result, 
these nanoparticles could be used for a combination of dual MRI and UCNPs imaging 
due to the presence of the IONPs, and PTT due to the presence of the Au shell. 
Additionally, the use of folic acid as a targeting agent allowed for tumour-targeted 
imaging. In vitro and in vivo studies showed a good response of these multifunctional 
nanoparticles for dual MRI and luminescence imaging, as well as PTT. The use of PTT 
was further improved by magnetically guiding the nanoparticles towards the tumour 
cells via an external magnet, thanks to the presence of the IONPs within the system. As 
a result, these multifunctional nanoparticles were effective for a range of applications; 
imaging via the luminescence of the UCNPs and MRI together with magnetically-guided 
PTT.28,58 The use of UCNPs decorated with IONPs has also been studied by Xu et al..27 
The authors further functionalised the UCNPs with an amphiphilic polymer and DOX, 
which could be used for novel imaging-guided therapy and magnetic-targeted drug 
delivery both in vitro and in vivo. Additionally, Zhang et al. further used UCNPs 
functionalised with IONPs and DOX for effective magnetic-targeted drug delivery and 
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MRI.56 The combination of PTT and PDT together with dual MRI and UCNPs imaging 
was developed by Chen et al..55 The authors fabricated Gd-based UCNPs, useful for 
MRI, and further functionalised these nanoparticles with Rose Bengal for PDT, the NIR 
absorbing dye IR825 for PTT and the protein bovine serum albumin (BSA) to provide 
good stability in aqueous solutions.55 
It can be readily seen that UCNPs hold great potential in biomedicine. The use of NIR 
light, typically 980 nm, offers important advantages for both imaging and therapeutic 
applications. More recently, the use of lower excitation wavelengths, 808 nm or 
915 nm, have been explored, as discussed in section 1.2.3.59,60 The use of these lower 
wavelengths for excitation of the UCNPs offer further advantages. Absorption of water 
at 808 nm or even 915 nm is minimised, which avoids overheating of the biological 
sample while allowing larger imaging depth.59,60 The use of neodymium (Nd3+) as the 
sensitiser agent rather than Yb3+ to allow excitation at lower wavelengths is being 
studied and reported in the literature.60  
In this chapter, UCNPs functionalised with the photosensitiser Rose Bengal were used 
for PDT. As it has been previously mentioned, an extensive review on the current use 
of UCNPs for in vitro and in vivo PDT was covered in Chapter 1. 
 
5.1.3. Aim of the research reported in this chapter 
The application of UCNPs in biomedicine, especially in the field of PDT, is becoming 
increasingly popular. The interest in the use of UCNPs for PDT relies on the NIR 
excitation of the UCNPs, which allows for a better penetration into the tissue, reaching 
deeper tumours. Additionally, FRET between the UCNPs and a photosensitiser attached 
to their surface leads to the generation of 1O2 for effective cell death. 
In this chapter, the use of core-shell NaYF4 UCNPs co-doped with Yb3+/Er3+/Gd3+, the 
most luminescence efficient UCNPs found to date, surface-modified with lysine and 
functionalised with the photosensitiser Rose Bengal for PDT was studied. Initially, the 
ability of the UCNPs to generate 1O2 via the efficient FRET between the UCNPs and RB 
was investigated. Additionally, in vitro studies were performed on SK-BR-3 human 
breast adenocarcinoma cells. The internalisation of the UCNPs by the SK-BR-3 cells was 
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investigated via confocal laser scanning microscopy and multi-photon microscopy. 
Furthermore, studies on cell viability and cytotoxicity before and after PDT treatment 
were performed to evaluate the use of these UCNPs as potential candidates for PDT.  
In the second part of the research reported in this chapter, UCNPs without the RB 
photosensitiser were analysed. First, the potential production of 1O2 by the UCNPs 
without the presence of a photosensitiser was studied. Furthermore, in vitro studies on 
SK-BR-3 cells were also performed to evaluate the potential cytotoxicity associated 
with RB-free UCNPs both before and after PDT treatment. 
 
5.2. Results and discussion 
5.2.1. Synthesis and characterisation of the UCNPs 
The UCNPs used throughout the research reported in this thesis were synthesised, 
characterised and kindly provided by Markus Buchner, PhD student in the group of Dr 
Thomas Hirsch (Institute for Analytical Chemistry, University of Regensburg, 
Regensburg, Germany). 
The UCNPs used in the first part of Chapter 5 were based on a hexagonal sodium 
yttrium fluoride (β-NaYF4) structure doped with the lanthanides Yb3+ (20 %), Er3+ (2 %) 
and Gd3+ (20 %) with an average size of 16.2 nm. In order to enhance the luminescence 
intensity of the UCNPs, a cubic shell of NaYF4 (α-NaYF4; 2-3 nm) was grown around the 
core of the UCNPs. The luminescence spectra of the core and core-shell UCNPs (Figure 
5.4 A) show distinctive emission bands at ca. 550 nm and ca. 650 nm. These two bands 
are responsible for the green and red emission of the UCNPs, respectively. It can be 
clearly seen that the luminescence intensity of the core-shell UCNPs (Figure 5.4 A (ii)) 
is much higher than the luminescence of the core UCNPs (Figure 5.4 A (i)). The size of 
the core-shell UCNPs was analysed by TEM (Figure 5.4 B-D). Analysis of the TEM 
indicates that the nanoparticles are uniform and spherical and have an average 
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diameter of 17.2 ± 0.98 nm, following analysis of 991 nanoparticles, with a median 
value of 17.2 ± 0.95 nm.  
 
 
 
 
 
The surface of the core-shell NaYF4 (Yb3+, Er3+, Gd3+)-NaYF4 UCNPs was modified with 
lysine, to which the photosensitiser Rose Bengal was attached (NaYF4-lysine-RB) (Figure 
5.5 A). The functionalised UCNPs were soluble in DMSO. The luminescence spectra of 
the functionalised and non-functionalised UCNPs are shown in Figure 5.5 B. NaYF4-
lysine-RB UCNPs (Figure 5.5 B (ii)) is distinctly different to that of the non-
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Figure 5.4. (A) Luminescence spectra of the core NaYF4 (Yb3+, Er3+, Gd3+) UCNPs (i) and of 
the core-shell NaYF4 (Yb3+, Er3+, Gd3+)-NaYF4 UCNPs (ii) in cyclohexane. (B) Transmission 
electron micrograph of a sample of core-shell NaYF4 (Yb3+, Er3+, Gd3+)-NaYF4 UCNPs, where 
the scale bar represents 60 nm. (C) Histogram of the core-shell NaYF4 (Yb3+, Er3+, Gd3+)-
NaYF4 UCNPs with a median value of 17.2 ± 0.95 nm (n = 991). (D) Size distribution of the 
core-shell NaYF4 (Yb3+, Er3+, Gd3+)-NaYF4 UCNPs showing the Gaussian fit, with an average 
size of 17.2 ± 0.98 nm (n = 991). Data obtained by Markus Buchner at the University of 
Regensburg (Germany). 
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functionalised UCNPs (Figure 5.5 B (i)). The green emission of the UCNPs was 
significantly decreased due to the energy transfer from the UCNPs to the RB, which 
absorbs light in that region (ca. 550 nm). Additionally, emission from RB at ca. 600 nm 
following NIR excitation clearly shows the functionalisation of the surface of the UCNPs 
with the RB photosensitiser. 
 
 
 
 
 
 
 
 
 
 
In the second part of Chapter 5, UCNPs dispersed in dH2O were used. The structure was 
again based on β-NaYF4 doped with Yb3+ (20 %), Er3+ (2 %) and Gd3+ (10 %), with an 
average size of 22 nm. These UCNPs were also modified with an α-NaYF4 shell, for 
luminescence intensity enhancement. The size of the core-shell UCNPs was analysed 
by TEM. Analysis of the TEM indicated that the nanoparticles were uniform and 
spherical and have an average diameter of 28 ± 3.17 nm, following analysis of 266 
nanoparticles, with a median value of 28.5 ± 10 nm. The TEM results are shown in 
Figure 5.6.  
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Figure 5.5. (A) Schematic representation of the NaYF4-lysine-RB UCNPs in DMSO, RB 
shown in red. (B) Luminescence spectra of non-functionalised NaYF4 UCNPs (i) and NaYF4-
lysine-RB UCNPs in DMSO (ii). Spectra obtained by Markus Buchner at the University of 
Regensburg (Germany). 
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To provide the aqueous dispersibility, the UCNPs were functionalised with polyacrylic 
acid (PAA) ligands. A schematic representation of the NaYF4-PAA UCNPs together with 
a luminescence spectrum are shown in Figure 5.7 A and B respectively. As previously 
mentioned, the luminescence spectrum shows the green and red emission from the 
UCNPs at ca. 550 and 650 nm, respectively. These UCNPs in dH2O, not functionalised 
with RB, were used to test the cytotoxic effects of the UCNPs alone and their potential 
ability to induce cell death before and after irradiation with a 980 nm NIR laser. 
 
Figure 5.6. (A) Transmission electron micrograph of a sample of core-shell NaYF4 (Yb3+, 
Er3+, Gd3+)-NaYF4 UCNPs in dH2O, where the scale bar represents 60 nm. (B) Histogram of 
the core-shell NaYF4 (Yb3+, Er3+, Gd3+)-NaYF4 UCNPs with a median value of 28.5 ± 10 nm 
(n = 266). (C) Size distribution of the core-shell NaYF4 (Yb3+, Er3+, Gd3+)-NaYF4 UCNPs 
showing the Gaussian fit, with an average size of 28 ± 3.17 nm (n = 266). Data obtained by 
Markus Buchner (University of Regensburg, Germany). 
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5.2.2. Singlet oxygen production by the NaYF4-lysine-RB UCNPs 
The RB-functionalised UCNPs, dissolved in DMSO, were analysed for 1O2 production. In 
order to use these UCNPs for PDT, RB should produce 1O2 upon excitation of the UCNPs 
at 980 nm. Energy transfer between the UCNPs and the RB should occur for efficient 
1O2 production. Specifically, the green emission (max = 541 nm) from the UCNPs 
following excitation at 980 nm should excite the RB (absorption max = 540-550 nm) on 
the surface, leading to the production of 1O2. The probe ABMA was used to study the 
production of 1O2. ABMA, as described in section 3.2.4, is photobleached in the 
presence of 1O2. As a result, the fluorescence of ABMA is quenched upon reaction with 
1O2.    
The NaYF4-lysine-RB UCNPs were dispersed in either DMSO (100 %) or McCOY’s 5A 
medium (containing between 6-10 % DMSO) to evaluate the production of 1O2 in each 
solvent. The concentration of the UCNPs was either 1 mg/mL or 25 μg/mL. The latter 
concentration was used to simulate the typical low concentrations that were used in 
the intracellular experiments. The fluorescence quenching of ABMA over time (Figure 
5.8) clearly confirms that 1O2 is being produced by the RB on the surface of the NaYF4-
lysine-RB UCNPs upon irradiation at 980 nm. This confirms the energy transfer between 
the UCNPs and RB. As expected, the production of 1O2 is significantly higher when the 
UCNPs are dispersed in DMSO as compared to that obtained when the nanoparticles 
Figure 5.7. (A) Schematic representation of the NaYF4-PAA UCNPs in dH2O. (B) 
Luminescence spectrum of NaYF4-PAA UCNPs in dH2O. Spectrum obtained by Markus 
Buchner at the University of Regensburg (Germany). 
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are dispersed in McCOY’s 5A medium. The reduced production of 1O2 in McCOY’s 5A 
medium is probably due to the higher quenching of the fluorescence in the presence 
of an aqueous solution. A similar result with lower 1O2 production for the samples 
dispersed in McCOY’s 5A medium was obtained for both concentrations at 1 mg/mL 
and 25 μg/mL of UCNPs. As would be expected, the 1 mg/mL sample led to a higher 
ABMA photobleaching both in DMSO and McCOYs’ 5A medium. These results confirm 
that the production of 1O2 is dependent on both the concentration of the UCNPs and 
the solvent in which they are dissolved. Conclusively, it can be confirmed that the 
NaYF4-lysine-RB UCNPs are able to generate 1O2 upon irradiation at 980 nm, even at 
low concentrations, and can thus be potentially used for NIR-PDT. 
 
5.2.3. Internalisation studies of the NaYF4-lysine-RB UCNPs by SK-BR-3 cells 
The results shown in section 5.2.2 clearly demonstrate the production of 1O2 by the RB 
on the NaYF4-lysine-RB UCNPs upon irradiation with a 980 nm NIR laser. Therefore, 
these UCNPs are potential candidates for PDT. In vitro studies using SK-BR-3 human 
breast adenocarcinoma cells were performed to evaluate the suitability of the NaYF4-
lysine-RB UCNPs for PDT.  
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Figure 5.8. Quenching of ABMA fluorescence at 432 nm in the presence of NaYF4-lysine-
RB UCNPs dispersed in either DMSO (i, ii) or McCOY’s 5A medium (iii, iv) upon irradiation 
with a 980 nm NIR laser. The RB on the NaYF4-lysine-RB UCNPs was at a concentration of 
either 1 mg/mL (i, iii) or 25 μg/mL (ii, iv). 
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The internalisation of the NaYF4-lysine-RB UCNPs by the SK-BR-3 cells was initially 
studied using confocal laser scanning microscopy. The main challenge with the use of 
confocal microscopy for this purpose, with the available lasers, was that the UCNPs 
could not be directly excited due to the NIR wavelength (980 nm) required. Therefore, 
to prove the presence of the UCNPs inside the cells via confocal microscopy, the RB in 
the sample was directly excited using a HeNe laser at 543 nm. As described in section 
2.4.4, the UCNPs at a concentration of 25 μg/mL were incubated with the SK-BR-3 cells 
for 3 h prior to imaging. Following incubation, the internalisation of the UCNPs by the 
cells was investigated. The emission due to the RB (max ≈ 567 nm) in the UCNPs was 
collected in the red channel using a band pass filter between 560-615 nm. Additionally, 
the morphology of the cells was evaluated from the DIC images, which were obtained 
using a 488 nm argon-ion laser. Confocal microscopy images are shown in Figure 5.9.  
 
 
Figure 5.9. Confocal fluorescence microscopy images of SK-BR-3 cells: control cells 
incubated with McCOY’s 5A phenol red-free medium (A-B) or cells incubated with 
25 μg/mL NaYF4-lysine-RB UCNPs (C-D). Images taken from: 1) DIC, 2) fluorescence from 
RB collected in the red channel (λex = 543 nm; 560-615 nm), 3) composite images of DIC 
and red channel. Scale bars 10 μm. 
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Samples treated with the UCNPs (Figure 5.9 C-D) clearly show the red fluorescence 
emitted from the RB functionalised on the surface of the UCNPs. The intense red 
fluorescence is located only inside the cells, as confirmed by Figure 5.9 C3, D3, where 
it is clearly seen that the space surrounding the cells does not show any fluorescence. 
On the other hand, control cells, not treated with the UCNPs (Figure 5.9 A-B), do not 
show any fluorescence. The cell morphology of the cells treated with the UCNPs is 
shown to be intact. This confirms that the cells remain viable following incubation with 
the UCNPs.  
The results obtained from the confocal microscope confirm that the cells have 
efficiently internalised the RB, which suggests that the UCNPs themselves have been 
fully internalised. However, for definitive proof of internalisation of the UCNPs, the 
UCNPs should be excited at 980 nm to obtain the green and red emission from the 
UCNPs directly, and not the emission from RB alone. For this purpose, a multi-photon 
microscope was used, which allows the excitation of NIR-excitable fluorophores. The 
cells were treated in the same manner as previously described for the confocal 
microscope experiments. For imaging in the multi-photon microscope, the cells were 
excited at two different wavelengths, 880 nm and 980 nm (Figure 5.10). Excitation at 
880 nm should enable the production of the DIC images (Figure 5.10 A-D (1)) as well as 
the excitation of the RB on the surface of the UCNPs (Figure 5.10 A-D (2)). Excitation at 
980 nm should lead to the direct excitation of the UCNPs (Figure 5.10 A-D (4-5)). 
Fluorescence emission was collected in either the green channel (550 ± 42.5 nm) or the 
red channel (655 ± 20 nm). Both the green and the red channel show emission from 
the UNCPs upon excitation at 980 nm (Figure 5.10 A-D (4-5)). Additionally, the green 
channel also shows emission from the RB on the surface of the UCNPs upon excitation 
at 880 nm (Figure 5.10 C-D (2)). 
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It is important to note that fluorescence or luminescence emission is only seen in 
samples incubated with the NaYF4-lysine-RB UCNPs (Figure 5.10 C-D), whereas the 
control samples not incubated with UCNPs do not show any fluorescence or 
luminescence in any of the four channels (Figure 5.10 A-B). Following excitation at 
880 nm, fluorescence emission is only seen in the green channel but not in the red 
channel (Figure 5.10 C-D (2)). This indicates that the fluorescence seen is due to the RB 
on the surface of the UCNPs. Following excitation at 980 nm, fluorescence emission is 
seen in both the green and red channels (Figure 5.10 C-D (4-5)), as expected from the 
luminescence spectrum of the UCNPs (Figure 5.5). The emission of the SK-BR-3 cells 
incubated with the NaYF4-lysine-RB UCNPs upon excitation at 980 nm (Figure 5.10 C-D 
Figure 5.10. Multi-photon microscopy images of SK-BR-3 cells control cells incubated with 
McCOY’s 5A phenol red-free medium (A-B) or incubated with 25 μg/mL NaYF4-lysine-RB 
UCNPs  (C-D). Images taken from: 1) DIC (λex = 880 nm), 2) fluorescence from RB collected 
in the green channel (λex = 880 nm; 550 ± 42.5 nm), 3) fluorescence collected in the red 
channel (λex = 880 nm; 655 ± 20 nm), 4) luminescence from UCNPs collected in the green 
channel (λex = 980 nm; 550 ± 42.5 nm), 5) luminescence from UCNPs collected in the red 
channel (λex = 980 nm; 655 ± 20 nm). Scale bars (A-B) 30 μm or (C-D) 20 μm. 
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(4-5)) provided images of low resolution with a distorted representation of the 
luminescence of the UCNPs, with the nanoparticles appearing to be aggregated. Similar 
low quality images have previously been reported.61 Yu et al. associated this lack of 
definition to several interferences in the sample. Axial interference coming from the 
out-of-focus luminescence of the UCNPs, in combination with lateral interference 
coming from the scattering within the focal plane greatly contributed to the absence 
of in-focus detail, leading to the images shown in Figure 5.10 C-D (4-5). Yu et al. 
reported that the use of a multi-photon microscope fitted with a pinhole leads to the 
suppression of the axial and lateral interferences and thus to clear images with high 
quality and resolution.61 While such a ‘pinhole’ was not available for these studies, the 
results reported in Figure 5.10 confirm the internalisation of the UCNPs by the SK-BR-
3 cells, not only by the fluorescence emission of the RB but also with the luminescence 
of the UCNPs, which is only seen in those samples treated with NaYF4-lysine-RB UCNPs. 
 
5.2.4. PDT using NaYF4-lysine-RB UCNPs  ̶  CellTiter-Blue® cell viability assays 
Following confirmation that SK-BR-3 cells effectively internalise the NaYF4-lysine-RB 
UCNPs, the efficacy of the UCNPs for PDT was investigated. A CellTiter-Blue® cell 
viability assay was used to evaluate the PDT effect. The CellTiter-Blue® assay has been 
previously described in section 3.2.6.  
As described in section 2.4.6, SK-BR-3 cells were incubated with the NaYF4-lysine-RB 
UCNPs at various concentrations for 3 h. Following incubation, the cells were 
thoroughly washed with PBS-B to remove all of the non-internalised UCNPs. At this 
point, some samples were subjected to PDT irradiation for 6 min using a 980 nm NIR 
laser. The non-irradiated samples were kept in the dark under the same conditions. Cell 
viability was studied ca. 48 h later. Figure 5.11 shows that, following PDT treatment 
(i.e., post-irradiation), there is a decrease in the viability of the SK-BR-3 cells, 
concomitant with an increase in the concentration of the UCNPs in the sample. The 
main drawback was that at high concentrations, the UCNPs become toxic even before 
irradiation with a 980 nm NIR laser. This dark toxicity starts to appear with increasing 
concentration and it is especially high when the cells are incubated with 25 μg/mL of 
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the UCNPs. Four control samples were included in this assay. The first one, denoted as 
‘0’ in Figure 5.11, shows the viability of the cells that were not incubated with UCNPs. 
It can be seen that the cells remain viable before and after irradiation, confirming that 
the 980 nm NIR laser light does not induce toxicity to the cells. The second control 
sample, denoted as ‘a’ in Figure 5.11, refers to cells incubated with DMSO. In this case, 
the DMSO was completely toxic for the cells as almost 100 % of the cells were killed. 
The third control sample, denoted as ‘b’ in Figure 5.11, refers to cells incubated with 
DMSO dispersed in McCOY’s 5A phenol red-free medium (0.25 % DMSO). This control 
sample simulates the amount of DMSO in all UCNPs samples. It was confirmed that, 
under the conditions used to perform the cell viability assay, DMSO is not toxic for the 
cells as the SK-BR-3 cells remain viable (ca. 97 %). Therefore, dispersing the UCNPs in 
McCOY’s 5A medium is a good way to decrease the toxicity that would otherwise be 
induced by DMSO. The final control sample, ‘+ve St’, was a solution of staurosporine in 
McCOY’s 5A phenol red-free medium, a positive control for cytotoxicity.  
Figure 5.11. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with NaYF4-
lysine-RB UCNPs. Cells were either irradiated with a 980 nm NIR laser (orange) or non-
irradiated (dark cyan). DMSO (a) was used as a control to test its cytotoxic effect in SK-
BR-3 cells. DMSO diluted to 0.25 % (b) was also used as a control to test the effects of 
DMSO under the conditions used to perform the cell viability assay. Staurosporine (+ve 
St) was used as a positive control for cytotoxicity. Error bars represent the standard 
deviation (n = 3) within a 95 % confidence interval. Statistically significant difference 
between non-irradiated and irradiated samples is indicated by * at P < 0.04, ** at P < 0.01 
and *** at P < 0.0004, obtained using a two-tailed Student’s t-test, where P < 0.05 is 
considered statistically significant. 
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Further studies to determine the ideal concentration of the UCNPs for maximum PDT 
efficacy were performed. The lowest concentration of 5 μg/mL was removed since it 
did not lead to any significant cell death following PDT, as shown in Figure 5.11. 
Additionally, the highest concentration of 25 μg/mL was also removed due to its high 
dark toxicity. A new concentration of 17 μg/mL was added to the following cell viability 
assays. The results are shown in Figure 5.12. In nine repetitions, the majority of the 
assays always provided the same trend in relation to cell viability and cell death. The 
exact values for each sample were variable but the error was usually included within a 
95 % confidence interval. As seen in Figure 5.12, a decrease in cell viability after PDT 
treatment (i.e., after irradiation with a 980 nm laser) is concomitant with an increase 
in the concentration of the UCNPs, and thus an increase in the concentration of RB. 
Dark toxicity levels remained low, but they were also seen to grow as the concentration 
of UCNPs increased.  
 
 
 
 
 
 
 
From all of the cell viability assays, it was found that 15 μg/mL was the ideal 
concentration for PDT. Cells incubated with 15 μg/mL showed minimal levels of dark 
toxicity (ca. 5-15 %) while inducing effective cell death (ca. 40-67 %) following PDT. 
Higher concentrations (17-20 μg/mL) are also effective at inducing cell death. However, 
Figure 5.12. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with NaYF4-
Lysine-RB UCNPs, where (A) and (B) are repetitions of the same assay under the same 
conditions. Cells were either irradiated with a 980 nm NIR laser (orange) or non-irradiated 
(dark cyan). DMSO diluted to 0.25 % (b) was also used as a control to test the effects of 
DMSO under the conditions used to perform the cell viability assay. Staurosporine (+ve St) 
was used as a positive control for cytotoxicity. Error bars represent the standard deviation 
(n = 3) within a 95 % confidence interval. 
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the greater levels of dark toxicity should be considered. As a result, 15 μg/mL was 
chosen as the ideal concentration for further studies. 
 
5.2.5. Estimation of the concentration of RB on the UCNPs 
The concentration of RB on the UCNPs can be estimated by recording the UV-vis 
extinction spectrum of the UCNP samples. Additionally, a value for the extinction 
coefficient of RB needs to be estimated. The extinction coefficient of RB was estimated 
in dH2O at 549 nm (Figure 5.13) and it was found to be 87,334 ± 1,010 M−1∙cm−1. A 
literature value of 95,000 M-1∙cm-1 at 545 nm has been previously reported.62 
 
 
 
 
 
 
 
 
 
Once a value for the extinction coefficient of RB had been estimated, the UV-vis 
extinction spectrum of a sample of NaYF4-lysine-RB UCNPs in DMSO at a concentration 
of 1 mg/mL was recorded (Figure 5.14). Using the absorbance intensity of RB with a 
maximum at 549 nm (1.006) and the extinction coefficient of RB, the concentration of 
RB can be calculated using the Beer-Lambert law, which was found to be 11.52 μM. 
From this value, several dilutions were prepared to reach the concentrations used in 
the cell viability assays ([UCNPs] = 5, 10, 15, 17, 20, 25 μg/mL). The concentrations of 
RB in each of these dilutions was then calculated using Equation 5.1. The results are 
shown in Table 5.1.  
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Figure 5.13.  (A) UV-vis absorption spectrum of RB in dH2O at various concentrations and 
(B) its corresponding calibration curve at 549 nm. 
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As reported in section 5.2.4, an ideal concentration of the UCNPs for PDT was found to 
be 15 μg/mL. At a 15 μg/mL concentration of UCNPs, there is 0.173 μM of RB in the 
sample. 
 
5.2.6. Evaluation of PDT effect using confocal microscopy 
To further establish the potential of the NaYF4-lysine-RB UCNPs as PDT agents, the PDT 
effect in SK-BR-3 cells was studied using laser scanning confocal microscopy. As it was 
[UCNPs] / μg ∙ mL-1 V1 / μL V2 / μL [RB] / μM 
5 5 1,000 0.058 
10 10 1,000 0.115 
15 15 1,000 0.173 
17 17 1,000 0.196 
20 20 1,000 0.230 
25 25 1,000 0.288 
Equation 5.1.  Equation used to calculate the concentration of RB in each of the diluted 
UCNPs samples. Where V1 is the volume of UCNPs at 1 mg/mL used; M1 is the concentration 
of RB in the 1 mg/mL solution (11.52 μM); M2 is the concentration of RB to be calculated in 
each sample; and V2 is the final volume.  
Table 5.1. Calculated values of the concentration of RB in different UCNPs samples. 
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Figure 5.14.  Extinction spectrum of a sample of NaYF4-lysine-RB UCNPs diluted to 1 mg/mL 
in DMSO.  
M1 V1 =  M2 V2 
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previously explained in Chapter 3, the evaluation of cell death via confocal microscopy 
can achieved in two ways. Firstly, the morphology of the cells significantly changes 
following cell death. The change in cell morphology can be easily evaluated using the 
DIC brightfield image of the confocal microscope. Additionally, the dead cell marker 
propidium iodide can be used in order to fluorescently stain dead cells. 
The fluorescence from RB on the surface of the UCNPs overlaps with that of propidium 
iodide (Figure 5.15). As a result, the excitation and emission parameters in which the 
fluorescence was collected using the confocal microscope are exactly the same; i.e., 
fluorescence from RB and propidium iodide were collected in the same channel (Figure 
5.15) with excitation at 543 nm and emission collected between 560-615 nm.  
 
 
 
 
 
 
 
 
 
 
Figure 5.15. Normalised fluorescence intensity excitation and emission spectra of (A) 
propidium iodide (λex = 500 nm, λem = 630 nm) and (B) Rose Bengal (λex = 530 nm, λem = 
590 nm). (C) Comparison of the fluorescence excitation spectra of propidium iodide (green 
line) and Rose Bengal (blue line), showing the excitation wavelength (λex = 543 nm) used 
with the confocal microscope (red line). (D) Comparison of the fluorescence emission 
spectra of propidium iodide (green line) and Rose Bengal (blue line), showing where the 
emission (λem = 560-615 nm) is collected with the confocal microscope (red box). 
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Collecting the fluorescence of RB and propidium iodide in the same channel could 
create a challenge to distinguish the fluorescence from RB on the UCNPs to that of the 
propidium iodide. However, it was found that by modulating the laser power, from 
100 % to only 4 %, this problem could be solved. At low laser powers, the fluorescence 
of the RB on the UCNPs is low and remains undetectable. However, upon staining of 
propidium iodide, the fluorescence at 4 % laser power is intense. Therefore, the 
detection of propidium iodide staining can be easily identified upon excitation with a 
laser power of 4 % intensity.  
As explained in section 2.4.5, SK-BR-3 cells were incubated with 15 μg/mL NaYF4-lysine-
RB UCNPs for 3 h. The concentration of 15 μg/mL was chosen since it was found to be 
ideal for PDT, as shown in section 5.2.4. Following incubation, the cells were thoroughly 
washed with PBS-B to remove all of the non-internalised UCNPs. Additionally, the cells 
were irradiated for 6 min using a 980 nm NIR laser, to stimulate the generation of 1O2. 
The cells were then imaged ca. 24 h later. Three control experiments were also 
performed. In the first one, SK-BR-3 cells were not incubated with UCNPs and non-
irradiated (Figure 5.16 A). In the second control, SK-BR-3 cells were not incubated with 
UCNPs but were irradiated with the 980 nm laser for 6 min (Figure 5.16 B). In the third 
control, SK-BR-3 cells were incubated with the NaYF4-lysine-RB UCNPs and non-
irradiated (Figure 5.16 C). 
Cells treated with the NaYF4-lysine-RB UCNPs and irradiated with the 980 nm laser 
(Figure 5.16 D-E) show clear changes in cell morphology, as compared to healthy cells. 
The disintegration of the cell membrane can be easily identified in these images (Figure 
5.16 D-E (1)), which is a strong indicator of cell death. Additionally, the UCNPs were 
preferentially located within the nucleus of dead cells (Figure 5.16 D (2-3)), which is in 
contrast to the location of the UCNPs in viable cells (Figure 5.9 section 5.2.3). Following 
incubation with propidium iodide, the intensity of the fluorescence in the red channel 
drastically increases (Figure 5.16 E), which is an indication of the positive staining with 
propidium iodide and thus further confirms the death of the SK-BR-3 cells after PDT 
treatment. On the other hand, all control cells have a very healthy appearance in the 
DIC channel and show no indication of staining with propidium iodide. This confirms 
that neither the 980 nm NIR laser nor the NaYF4-lysine-RB UCNPs by themselves induce 
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toxicity in the cells. The irradiation of the NaYF4-lysine-RB UCNPs is required in order to 
induce production of 1O2, which leads to cell death. 
 
 
 
 
 
Figure 5.16. Confocal fluorescence microscopy images of SK-BR-3 cells. Control cells 
incubated with McCOY’s 5A phenol red-free medium containing 0.25 % DMSO and treated 
with propidium iodide before (A) or after (B) irradiation with a 980 nm NIR laser. SK-BR-3 
cells incubated with 15 μg/mL NaYF4-lysine-RB UCNPs and treated with propidium iodide 
before irradiation with a 980 nm NIR laser (C). SK-BR-3 cells incubated with 15 μg/mL 
NaYF4-lysine-RB UCNPs following irradiation with a 980 nm laser either before (D) or after 
(E) treatment with propidium iodide. Images taken from: 1) DIC, 2) fluorescence from RB 
and propidium iodide collected in the red channel (λex = 543 nm with a 4 % laser power; 
560-615 nm), 3) composite images of DIC and red channel. Scale bars 10 μm. 
(A1)
(B1)
(C1)
(A2) (A3)
(B2) (B3)
(C2) (C3)
(D1) (D2) (D3)
(E1) (E2) (E3)
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The images shown in Figure 5.16 were taken with a laser power of 4 % for the red 
channel (λex = 543 nm). This low laser power was chosen to be able to identify and 
distinguish the fluorescence from propidium iodide from that of the RB on the surface 
of the UCNPs, as previously explained. As a result, the fluorescence of the RB on the 
UCNPs is undetected for the non-irradiated cells incubated with NaYF4-lysine-RB UCNPs 
and treated with propidium iodide (Figure 5.16 C). In order to confirm the 
internalisation of the UCNPs by these non-irradiated cells, the laser power was 
increased to 100 % and further images were collected, as shown in Figure 5.17. Indeed, 
increasing the laser power confirmed the internalisation of the NaYF4-lysine-RB UCNPs 
by non-irradiated SK-BR-3 cells (Figure 5.17 B), which was not seen in control cells only 
incubated with growth medium containing 0.25 % DMSO (Figure 5.17 A). It is worth 
noting that the UCNPs do not accumulate in the nucleus of SK-BR-3 cells prior to PDT 
irradiation (Figure 5.17 B). The preferential location of the UCNPs inside the nucleus 
was only seen following PDT (Figure 5.16 D-E), which was another indicator for cell 
death. 
 
 
 
 
In order to fully show the extent of cell death following irradiation with a 980 nm NIR 
laser (i.e., after PDT), images with a larger cell sample size were recorded. These are 
Figure 5.17. Confocal fluorescence microscopy images of non-irradiated SK-BR-3 cells 
control cells incubated with McCOY’s 5A phenol red-free medium containing 0.25 % DMSO 
(A) or incubated with 15 μg/mL NaYF4-lysine-RB UCNPs (B). These images were taken prior 
to treatment with propidium iodide. Images taken from: 1) DIC, 2) fluorescence from RB 
collected in the red channel (λex = 543 nm with a 100 % laser power; 560-615 nm), 3) 
composite images of DIC and red channel. Scale bars 10 μm. 
(A1)
(B1)
(A2) (A3)
(B2) (B3)
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shown in Figure 5.18. Images of control cells incubated with growth medium containing 
0.25 % DMSO and irradiated with the 980 nm laser were also recorded for comparison 
(Figure 5.18 A). These images were recorded following treatment of the cells with 
propidium iodide and using a laser power of 4 % to excite the red channel 
(λex = 543 nm). It can be clearly seen that following PDT, SK-BR-3 cells stain positive for 
propidium iodide (Figure 5.18 B), as compared to control cells. Additionally, the 
morphology of the cell membrane is drastically different, since the cell membrane in 
the PDT-treated cells is shown to be disintegrated. 
 
 
 
 
 
 
The results obtained from the confocal microscopy, together with the results from the 
CellTiter-Blue® assays shown in section 5.2.4, clearly show that the NaYF4-lysine-RB 
UCNPs in DMSO are good candidates for PDT. The NaYF4-lysine UCNPs were readily 
internalised by SK-BR-3 cells. Additionally, these UCNPs at 15 μg/mL are only toxic to 
the SK-BR-3 cells following irradiation with a 980 nm NIR laser, which induces 
generation of 1O2 by the RB following energy transfer between the UCNPs and the RB. 
Neither the NIR laser nor the UCNPs themselves induce any toxicity of the SK-BR-3 cells.  
Figure 5.18. Confocal fluorescence microscopy images of non-irradiated SK-BR-3 cells. 
Control cells incubated with McCOY’s 5A phenol red-free medium containing 0.25 % 
DMSO (A) or cells incubated with 15 μg/mL NaYF4-lysine-RB UCNPs (B). All cells were 
irradiated with a 980 nm laser for 6 min and treated with propidium iodide. Images taken 
from: 1) DIC, 2) fluorescence from RB and propidium iodide collected in the red channel 
(λex = 543 nm with a 4 % laser power; 560-615 nm), 3) composite images of DIC and red 
channel. Scale bars 10 μm. 
(A1)
(B1)
(A2) (A3)
(B2) (B3)
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5.2.7. ApoTox-Glo™ Triplex assay to investigate the mechanism of cell death 
The mechanism of cell death followed by the SK-BR-3 cells post NIR-PDT using the 
NaYF4-lysine-UCNPs was studied via an ApoTox-Glo™ Triplex assay. As explained in 
section 3.2.14, the ApoTox-Glo™ Triplex assay measures cell viability, cell cytotoxicity 
and apoptotic response within the sample using three different biomarkers for each of 
these processes.  
SK-BR-3 cells were incubated with the NaYF4-lysine-RB UCNPs for 3 h. The NaYF4-lysine-
RB UCNPs were used at a concentration of 15 μg/mL, which was found to be ideal for 
PDT via both cell viability assays (section 5.2.4) and confocal microscopy (section 
5.2.6). Following incubation with the UCNPs, the cells were thoroughly washed to 
remove all non-internalised UCNPs and they were subjected to irradiation with a 
980 nm NIR laser for 6 min. The ApoTox-Glo™ Triplex assay was performed 4 h 
following PDT. This incubation period of 4 h was used considering the results of the 
ApoTox-Glo™ Triplex assay obtained and explained in section 3.2.14 and section 
4.2.12.  
The cell viability results (Figure 5.19 A) show that the positive control (+ve St) has killed 
the cells since the assay results in low viability. Both control samples not incubated with 
UCNPs have high viability. These values indicate that the viability component of the 
assay is working correctly. However, the cells incubated with the UCNPs display dark 
toxicity and no significant cell death following irradiation. These results contradict 
those results already reported for cell viability assays (with the CellTiter®-Blue assays) 
and confocal microscopy. The cell cytotoxicity measures a biomarker that can only 
fluoresce when the cells in the sample are dead. As a result, it was expected that the 
positive control (+ve St) would give the highest fluorescence intensity values. However, 
the results obtained (Figure 5.19 B) show relatively high levels for all samples, always 
higher for the irradiated samples than the non-irradiated samples. The fact that the 
negative control also produced high values, together with the lower values obtained 
for the positive control prior to irradiation, indicate that the assay is giving erroneous 
results.  
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Finally, the apoptosis results (Figure 5.19 C) show that the positive control (+ve St) has 
the highest luminescence intensity values of all samples. This is expected because 
staurosporine is a known apoptosis inducer.63 Additionally, the values obtained for the 
negative control cells not incubated with UCNPs, are among the lowest as expected for 
viable samples. On the other hand, those cells incubated with the UCNPs, show high 
levels of luminescence both before and after irradiation with the 980 nm NIR laser. The 
non-irradiated sample, according to the results previously described in section 5.2.4, 
are non-toxic and thus their luminescence values should be as low as those seen for 
the negative controls. However, the luminescence values for the non-irradiated sample 
is high, almost at the same level as the values for the irradiated sample. The fact that 
the luminescence values for the irradiated samples are almost as high as the positive 
control indicates that the most likely route of cell death followed by cells treated with 
NIR PDT would be apoptosis. However, the mechanism of cell death cannot be fully 
confirmed due to the erroneous results seen in this assay. The most likely explanation 
for these results possibly could be the degradation of the biomarkers in solution. 
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Figure 5.19. ApoTox-Glo™ Triplex assay for SK-BR-3 cells incubated for 3 h with 15 μg/mL 
NaYF4-lysine-RB UCNPs. Cells were either irradiated with a 980 nm NIR laser (orange) or 
non-irradiated (dark cyan). The cells were treated with the triplex assay ca. 4 h following 
PDT. (A) Fluorescence from the GF-AFC substrate giving the cell viability values, (B) 
fluorescence from bis-AAF-R110 substrate giving the cell cytotoxicity values and (C) 
luminescence from the Caspase 3/7 substrate giving the values for apoptosis. 
Staurosporine (+ve St) was used as a positive control for cytotoxicity via apoptosis. Error 
bars represent the standard deviation (n = 3) with a 95 % confidence interval. 
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5.2.8. Analysis of UCNPs without Rose Bengal 
In this section, the results of in vitro studies using UCNPs not functionalised with RB to 
investigate the potential cytotoxic effects of the UCNPs alone without the presence of 
a photosensitiser are reported. In this case, core-shell NaYF4-PAA UCNPs were used. 
The surface modification of the UCNPs with polyacrylic acid (PAA) is similar to that of 
lysine, which was previously used. The advantage of using PAA rather than lysine is that 
PAA will provide a higher stability in aqueous media as compared to lysine. As a result, 
the NaYF4-PAA UCNPs can be dissolved in dH2O. The average diameter of the NaYF4-
PAA UCNPs was found to be 28 nm. This is slightly larger than the NaYF4-lysine-RB 
UCNPs, which had an average diameter of 17.2 nm. The larger diameter means that the 
NaYF4-PAA UCNPs will show greater luminescence and potentially could be more toxic 
than the smaller UCNPs. 
The first study performed on the NaYF4-PAA UCNPs in dH2O was to evaluate the 
production of 1O2 by the system. Production of 1O2 was investigated using the 1O2 probe 
ABMA, as previously described in section 3.2.4. It was expected that the quenching of 
ABMA would be negligible or limited since the UCNPs do not present any 
photosensitisers on their surface. However, the results showed a decrease in the 
fluorescence of ABMA upon irradiation of the UCNPs with a 980 nm NIR laser (Figure 
5.20). The generation of 1O2 by the NaYF4-PAA UCNPs in dH2O was studied at two 
different concentrations, either 0.5 mg/mL (Figure 5.20 i) or 25 μg/mL (Figure 5.20 ii). 
The 0.5 mg/mL NaYF4-PAA UCNPs led to a maximum photobleaching of ABMA of 12 % 
following a 5 min irradiation period. On the other hand, the 25 μg/mL NaYF4-PAA 
UCNPs only led to a maximum photobleaching of ABMA of 6 %. This indicates that the 
photobleaching of ABMA is dependent on the concentration of UCNPs. Additionally, a 
control sample consisting of ABMA dissolved in dH2O without the presence of UCNPs 
was used as a control (Figure 5.20 iii). Control ABMA is not photobleached upon 
irradiation at 980 nm, which suggests that the photobleaching seen in the UCNPs 
samples (Figure 5.20 i-ii) is due to the production of 1O2 upon irradiation of the 
samples. 
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The results presented in Figure 5.20 indicate that the NaYF4-PAA UCNPs in dH2O induce 
the generation of 1O2. Previous studies have reported a limited production of 1O2 by 
naked UCNPs not functionalised with a photosensitiser.64 In the study by Idris et al., the 
production of 1O2 by UCNPs functionalised with a single photosensitiser was similar to 
that of the naked UCNPs. However, generation of 1O2 was enhanced by the conjugation 
of the UCNPs to two photosensitisers.64 In the present study, a direct comparison 
between the non-functionalised NaYF4-PAA UCNPs and the RB functionalised NaYF4-
lysine-RB UCNPs cannot be done. This is due to two factors. Firstly, the NaYF4-PAA 
UCNPs without RB are larger in size (28 nm) than the NaYF4-lysine-RB UCNPs (17.2 nm). 
Secondly, the UCNPs are soluble in different solvents, dH2O vs DMSO. The solvent plays 
a key role in the photobleaching of the ABMA probe, as previously seen in section 5.2.2 
for the NaYF4-lysine-RB UCNPs. The solubilisation of the NaYF4-lysine-RB UCNPs in 
either DMSO or McCOY´s 5A medium had a big impact in the production of 1O2. As a 
result, the photobleaching of ABMA for NaYF4-lysine-RB UCNPs and NaYF4-PAA UCNPs 
cannot be directly compared. The synthesis of water-soluble NaYF4-PAA-RB UCNPs of 
the same size as the NaYF4-PAA UCNPs will be necessary to compare the production of 
1O2 with and without the presence of RB. 
Figure 5.20. Quenching of ABMA fluorescence at 432 nm in the presence of 0.5 mg/mL (i) 
or 25 μg/mL (ii) NaYF4-PAA UCNPs dispersed in dH2O. No photobleaching is observed for a 
control sample of ABMA in dH2O (iii). 
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Following the analysis of 1O2 production, the NaYF4-PAA UCNPs were tested in vitro 
using SK-BR-3 cells. The cell viability assays were performed in the same manner as 
those assays previously performed for the NaYF4-lysine-RB UCNPs, following the 
procedure described in section 2.4.9.  
Figure 5.21 shows that the NaYF4-PAA UCNPs do not induce any cytotoxicity in SK-BR-
3 cells under the concentrations studied (10-25 μg/mL). Cells treated with the UCNPs 
remain viable before and after irradiation. Additionally, control cells not loaded with 
UCNPs also remain viable, confirming that the 980 nm NIR laser light is not toxic. These 
results indicate that the production of 1O2 in UCNPs without a photosensitiser is not 
efficient enough to induce cell death.  
 
The absence of PDT-induced cytotoxicity was further confirmed via confocal laser 
scanning microscopy, which was used to evaluate the morphology of the cells and the 
potential staining with propidium iodide. Control cells not loaded with UCNPs appear 
to be healthy both before (Figure 5.22 A) and after (Figure 5.22 B) irradiation with a 
980 nm NIR laser. Additionally, there was no staining with propidium iodide, which 
further confirmed that the cells remained viable. This result is a further confirmation 
0
20
40
60
80
100
120
0     10    15    17    20   25  +veSt  a
 
 
C
e
ll
 V
ia
b
il
it
y
 /
 %
[NaYF
4
-PAA UCNPs] / g mL
-1
Figure 5.21. CellTiter-Blue® cell viability assay for SK-BR-3 cells incubated with NaYF4-PAA 
UCNPs. Cells were either irradiated with a 980 nm NIR laser (orange) or non-irradiated 
(dark cyan). H2O diluted to 0.63 % with McCOY’s 5A medium (a) was used as a control to 
test the effects of dH2O under the conditions used to perform the cell viability assay. 
Staurosporine (+ve St) was used as a positive control for cytotoxicity. Error bars represent 
the standard deviation (n = 3) within a 95 % confidence interval. 
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that the 980 nm NIR is not, by itself, toxic to the SK-BR-3 cells. For cells treated with 
NaYF4-PAA UCNPs, the cell morphology also indicated that the cells were healthy both 
before (Figure 5.22 C) and after (Figure 5.22 D) PDT treatment. Staining with propidium 
iodide of the cell nucleus following PDT was not observed. Therefore, these results 
indicate that NaYF4-PAA UCNPs, without a photosensitiser, are not effective candidates 
for PDT. The functionalisation of the NaYF4-PAA UCNPs with a photosensitiser, such as 
RB, could improve the results and lead to effective cell kill following PDT treatment. 
 
 
 
 
 
Figure 5.22. Confocal fluorescence microscopy images of SK-BR-3 cells (A-B) control cells 
incubated with McCOY’s 5A phenol red-free medium containing 0.63 % dH2O or (C-D) cells 
incubated with 25 μg/mL NaYF4-PAA UCNPs dispersed in McCOY’s 5A phenol red-free 
medium. Prior to imaging, all samples were treated with propidium iodide. Images taken 
from: 1) DIC, 2) fluorescence from propidium iodide collected in the red channel (λex = 
543 nm with a 10 % laser power; 560-615 nm), 3) composite images of DIC and red 
channel. Scale bars (A-C) 10 μm and (D) 5 μm. 
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The microscopy experiments shown in Figure 5.22 do not confirm the internalisation 
of the NaYF4-PAA UCNPs by the SK-BR-3 cells. The UCNPs are not functionalised with 
RB and thus, there is no fluorescence signal seen in the confocal microscopy images. 
Further experiments using the multi-photon microscope should be performed to 
evaluate the uptake of the NaYF4-PAA UCNPs by the SK-BR-3 cells, following excitation 
with a 980 nm NIR laser. 
 
5.3. Conclusions 
In this chapter, the potential use of UCNPs for PDT has been described. The UCNPs, 
synthesised and characterised by Markus Buchner at the University of Regensburg, 
contained a hexagonal β-phase NaYF4 host lattice co-doped with Yb3+, Er3+ and Gd3+. 
Additionally, the UCNPs were covered with a cubic α-phase NaYF4 passive shell to 
maximise the luminescence efficiency emitted by the system. The UCNPs were surface 
modified with lysine and functionalised with the photosensitiser Rose Bengal for PDT. 
The NaYF4-lysine-RB UCNPs were soluble in DMSO. Upon TEM characterisation, it was 
found that the core-shell NaYF4-lysine-RB UCNPs had an average size of 17.2 ± 0.98 nm. 
Furthermore, the luminescence spectrum of the NaYF4-lysine-RB UCNPs successfully 
confirmed FRET energy transfer between the UCNPs and the RB because the green 
emission of the UCNPs was visibly quenched due to absorption of the RB at this region. 
On the other hand, the red emission of the UCNPs remained as high as that observed 
prior to functionalisation with RB. 
The ability of the NaYF4-lysine-RB UCNPs to generate singlet oxygen was evaluated 
using the 1O2 probe ABMA. It was found that the RB in the sample led to the generation 
of 1O2 upon excitation of the UCNPs at 980 nm. The generation of 1O2 was found to be 
both concentration-dependent and solvent-dependent. This result further confirmed 
the efficient FRET taking place between the UCNPs and RB. Once the ability to produce 
1O2 was confirmed, the NaYF4-lysine-RB UCNPs were used for in vitro studies with SK-
BR-3 human breast adenocarcinoma cells. Initially, the internalisation of the UCNPs by 
the SK-BR-3 cells was investigated via confocal laser scanning microscopy as well as 
multi-photon microscopy. Results from the confocal microscope confirmed the 
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presence of RB inside the cells following only a 3 h incubation, with the fluorescence 
from RB only seen in those cells treated with the UCNPs but not in the untreated 
controls. More importantly, the results from the multi-photon microscope, where 
excitation at 980 nm was possible, confirmed that the UCNPs were efficiently 
internalised by the treated SK-BR-3 cells. The results from the multi-photon microscopy 
were important to confirm that the RB was still on the surface of the UCNPs and had 
not been released. The presence of the RB on the surface of the UCNPs is important in 
order to achieve NIR-PDT. 
Cell viability studies were then performed to evaluate the PDT potential of the NaYF4-
lysine-RB UCNPs. Following a 3 h incubation, SK-BR-3 cells were irradiated with a 
980 nm NIR laser to induce the generation of 1O2. Cell viability was measured 48 h after 
PDT treatment. The results showed that the UCNPs induce minimal levels of dark 
toxicity with the SK-BR-3 cells, i.e., minimal cell death prior to irradiation with the 
980 nm laser, at a concentration range between 5-20 μg/mL. Importantly, post-PDT the 
SK-BR-3 cells were effectively killed in a concentration-dependent manner. The ideal 
concentration for PDT was found to be 15 μg/mL since it led to ca. 40-67 % cell death 
following irradiation but induced minimal levels of dark toxicity. Control cells not 
incubated with UCNPs but irradiated with the 980 nm light remained viable, showing 
that the NIR laser does not pose a hazard to the SK-BR-3 cells by itself. The promising 
results obtained with the cell viability assays were further confirmed via confocal laser 
scanning microscopy. The drastic changes in cell morphology together with the positive 
staining with the dead cell marker propidium iodide confirmed cell death of the SK-BR-
3 cells treated with 15 μg/mL of the UCNPs during 3 h. Furthermore, control cells not 
treated with UCNPs, and treated with UCNPs but non-irradiated were not stained by 
propidium iodide, confirming those cells remained viable after the treatment. An 
ApoTox-Glo™ Triplex assay was performed in order to assess the cell death pathway 
followed by SK-BR-3 cells post-NIR-PDT with the NaYF4-lysine-RB UCNPs. 
Unfortunately, the assay produced erroneous results, most likely due to the 
degradation of the cell viability, cytotoxicity and apoptosis biomarkers in solution. 
However, there was an indication that the most probable cell death pathway followed 
would be apoptosis.  
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In the second part of the research, UCNPs not functionalised with RB were used. The 
UCNPs, again synthesised and characterised by Markus Buchner at the University of 
Regensburg, contained a hexagonal β-phase NaYF4 host lattice co-doped with Yb3+, Er3+ 
and Gd3+ and were covered with a cubic α-phase NaYF4 passive shell. The UCNPs were 
surface modified with polyacrylic acid to enable water-dispersibility. Upon TEM 
characterisation, it was found that the core-shell NaYF4-PAA UCNPs had an average size 
of 28 ± 3.17 nm. The ability of the NaYF4-PAA UCNPs to generate 1O2 was studied using 
the 1O2 probe ABMA. It was found that the fluorescence of ABMA was quenched upon 
irradiation with a 980 nm NIR laser. This result was an indication that the NaYF4-PAA 
UCNPs induce the generation of 1O2 without the presence of a photosensitiser. Direct 
comparison to the 1O2 production by the NaYF4-lysine-RB UCNPs in DMSO was not 
possible due to differences in the solvent and the size of each of the UCNPs.   
In vitro cell viability and confocal laser scanning microscopy studies on SK-BR-3 cells 
using the NaYF4-PAA UCNPs showed that these UCNPs induced no cytotoxicity either 
before or after irradiation with a 980 nm NIR laser. These results highlight the need of 
a photosensitiser for effective PDT using UCNPs. However, it should be noted that the 
results here presented for the NaYF4-PAA UCNPs do not confirm the internalisation of 
the UCNPs by the cells. The confocal microscopy images are unable to show the 
fluorescence of the UCNPs due to the absence of a NIR laser for the excitation of the 
nanoparticles. Therefore, future studies should be performed using a multi-photon 
microscope to confirm the presence of the water-soluble UCNPs inside the SK-BR-3 
cells. 
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Chapter 6 
Conclusions and future work 
This thesis describes the use of nanoparticles for photodynamic therapy of breast 
adenocarcinoma cells. This chapter summarises the conclusions of the investigations 
reported throughout this thesis, including the use of metal-enhanced fluorescence and 
antibody targeting, the potential use of lactose as a breast-cancer specific targeting 
ligand and the use of upconverting nanoparticles for deep-penetration PDT. 
Furthermore, suggestions of experiments to be performed in the future to continue 
this research are given.  
 
6.1. Gold nanoparticle enhanced and selective antibody targeting 
photodynamic therapy  
Chapter 3 explored the use of metal-enhanced fluorescence for PDT. Two zinc 
phthalocyanines, C11Pc and C3Pc, differing in the length of the carbon chain that 
connects the macrocycle to the gold core were compared. The chain for C11Pc 
consisted of 11 carbon atoms, and only 3 carbon atoms for C3Pc. Gold nanoparticles 
(AuNPs) functionalised with a mixed monolayer of polyethylene glycol (PEG) and either 
C11Pc (C11Pc-PEG-AuNPs) or C3Pc (C3Pc-PEG-AuNPs) were synthesised. PEG provides 
aqueous solubility to the system and allows for an increased circulation time in the 
serum, thus increasing the ability of the AuNPs to be internalised by the tumour.1,2 The 
C11Pc-PEG-AuNPs had an average diameter of 3.41 ± 1.16 nm while the C3Pc-PEG-
AuNPs had an average diameter of 3.83 ± 0.99 nm. 
A fluorescence spectroscopic comparison between C11Pc-PEG-AuNPs and C3Pc-PEG-
AuNPs was performed in order to investigate the potential for metal-enhanced 
fluorescence within these nanosystems. The fluorescence intensity of the free 
photosensitisers, dissolved in THF, was found to be significantly greater for C11Pc 
(φF = 4.80 %) than C3Pc (φF = 2.60 %). On the contrary, the fluorescence of the 
nanosystems dissolved in an aqueous buffer was found to be much higher for C3Pc-
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PEG-AuNPs (φF = 0.42 %) as compared to C11Pc-PEG-AuNPs (φF = 0.20 %). The 
interaction between fluorophores and metal nanoparticles is complex. The effect of 
the metal on the fluorescence emitted by the fluorophore depends on many 
parameters, including the size and shape of the metal nanoparticles,3-6 the distance 
between the metal core and the fluorophore,6-9 the nature of the anchor chain that 
connects the fluorophore to the metal surface,10 the angle at which the fluorophore is 
positioned relative to the metal surface,6,8,10 and the spectral overlap between the 
metal nanoparticle and the fluorophore.6,9 According to the radiating plasmon model 
developed by Lakowicz in 2005, small nanoparticles will induce a strong quenching 
effect while larger nanoparticles will induce a fluorescence enhancement, due to the 
relative contributions of the scattering and absorption components of the nanoparticle 
extinction.3,11,12 In relation to the distance between the metal and the fluorophore, 
there are three main regions of interest.7,9 When the fluorophore is placed too close 
(≤ 5 nm) to the metal, the fluorescence is highly quenched.7-9 When the fluorophore is 
placed far away from the metal (≥ 20 nm), the interaction between the metal and the 
fluorophore is negligible. For metal-enhanced fluorescence, the key relies on locating 
the fluorophore at an optimal distance (ca. 5-20 nm, usually ≥ 10 nm), at which the 
fluorescence emission is enhanced.7,13,14 In the C11Pc-PEG-AuNPs and C3Pc-PEG-
AuNPs, the fluorescence of the photosensitisers is quenched by presence of the AuNPs 
as compared to the free photosensitisers in solution, as confirmed by the fluorescence 
quantum yields. This quenching could be explained by the small size of the AuNPs 
(< 5 nm). However, interestingly, the fluorescence of C11Pc is more effectively 
quenched than that of C3Pc. The enhanced quenching effect seen by the C11Pc-PEG-
AuNPs might be related to the orientation of the phthalocyanines with respect to the 
AuNPs. Russell and co-workers investigated the orientation of the same 
phthalocyanines used in this thesis, C3Pc and C11Pc, as self-assembled monolayers on 
a planar gold surface.15 The authors found that the fluorescence emission of the C3Pc 
was quenched more intensely than that of C11Pc. This observation was attributed to 
the position of each phthalocyanine with respect to the gold surface; the C3Pc lies more 
horizontal while the C11Pc is more perpendicular. The perpendicular orientation 
induces a larger distance between the gold surface and the phthalocyanine and thus 
the fluorescence is not quenched as much.15 Even though this study used the same 
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phthalocyanines that are reported in the present thesis, a direct comparison cannot be 
performed due to the different nature of the metal, either planar gold surface or gold 
nanoparticles. Given that the results obtained in this thesis are in disagreement to what 
was reported previously, it can be concluded that the planar or spherical nature of the 
metal is the most important parameter that dictates the relative orientation of the 
fluorophores with respect to the metal. In another study by Battistini et al., the authors 
investigated the relative orientation of a pyrene connected to gold nanoparticles by 
either a four (C4) or eleven (C11) carbon chain.10 The authors reported similar results 
to what is seen in this thesis, as the C4 pyrene was found to have a higher fluorescence 
on the surface of the AuNPs as compared to the C11 pyrene. These authors speculated 
that the shorter C4 chain will adopt a perpendicular orientation relative to the AuNPs, 
while the longer C11 chain will lead to a conformation flatter towards the AuNPs. As a 
result, the charge and energy transfer between the AuNPs and the pyrenes will only 
take place for the C11 chain, which leads to the higher quenching effect. The 
orientations adopted by each pyrene chain were attributed to the intermolecular chain 
interactions, which are stronger in the longer chain and lead to the C11 chains 
positioning closer together to one another to maximise chain-chain interactions.10 In 
the present study, the results are similar to those reported by Battistini et al. since the 
phthalocyanine with the longer chain (C11Pc) experiences more quenching than the 
phthalocyanine with the shorter chain (C3Pc). Therefore, it is speculated that the C11Pc 
is oriented more parallel towards the gold core than C3Pc. The parallel conformation 
induces the cancellation of the dipoles from the C11Pc and the AuNPs, which radiate 
out of phase, and induce a decrease in the radiative decay rate of the C11Pc. 
Additionally, the angle at which the C11Pc is located might lead to the macrocyle being 
closer to the gold core than the C3Pc macrocycle, thus facilitating electron transfer 
between the C11Pc and the AuNPs, which also leads to fluorescence quenching. On the 
contrary, it was speculated that the C3Pc will adopt a more perpendicular orientation 
with respect to the AuNPs. The perpendicular orientation allows for the interaction 
between the dipoles, which induces metal-enhanced fluorescence. However, the 
absence of metal-enhanced fluorescence reported in this study could be related to the 
small size of the AuNPs, in agreement with Lakowicz’s RP model, as previously 
discussed. 
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The fluorescence spectroscopy results opened the possibility for an increased 
production of 1O2 by the C3Pc-PEG-AuNPs given that the fluorescence of C3Pc-PEG-
AuNPs is higher than that of C11Pc-PEG-AuNPs. The production of 1O2 was analysed 
using the probe ABMA, which suggested that the C3Pc-PEG-AuNPs were producing 
more 1O2 than the C11Pc-PEG-AuNPs. To confirm these results, the quantum yields of 
1O2 were analysed. Unfortunately, the AuNPs were dissolved in an aqueous buffer, 
which led to the quenching of the 1O2 signal. The use of D2O as an alternative to avoid 
the quenching of the 1O2 signal was attempted. However, the 1O2 signal obtained was 
low and the 1O2 quantum yields could not be determined.  
In vitro studies with SK-BR-3 human breast adenocarcinoma cells were performed in 
order to compare the photodynamic efficiency of C11Pc-PEG-AuNPs and C3Pc-PEG-
AuNPs. Confocal laser scanning microscopy confirmed that both C11Pc-PEG-AuNPs and 
C3Pc-PEG-AuNPs were effectively internalised by the SK-BR-3 cells following a 3 h 
incubation period. Cell viability was assessed using a CellTiter-Blue® and MTT cell 
viability assays. Prior to irradiation, both C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs were 
biocompatible and non-toxic, since the cells remain viable as shown by the cell viability 
assays. Following irradiation with a 633 nm HeNe laser for 6 min, only the cells treated 
with C3Pc-PEG-AuNPs showed high levels of cytotoxicity, concomitant with an increase 
in the concentration of C3Pc in the sample. These results further the idea that there is 
an increased production of 1O2 by the C3Pc-PEG-AuNPs as compared to the C11Pc-PEG-
AuNPs. In vitro studies with MCF-10A human mammary epithelial cells showed that 
there was no toxicity associated with either the C11Pc-PEG-AuNPs or the C3Pc-PEG-
AuNPs, before or after irradiation. Therefore, the use of C3Pc-PEG-AuNPs is 
encouraged since these nanoparticles induce high cell kill in cancer cells (ca. 85 % at 
0.23 μM C3Pc) and no damage to healthy cells. 
In the second part of Chapter 3, anti-HER2 antibody (Ab) was used as a targeting agent 
for the HER2 receptor. The HER2 receptor is overexpressed in ca. 10-34 % aggressive 
breast cancers,16 including SK-BR-3 cells. The Ab was conjugated to the terminal end of 
PEG in both C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs through an amide bond, using 
EDC/NHS coupling. Confocal laser scanning microscopy confirmed that the addition of 
anti-HER2 antibody increased the internalisation of the AuNPs by the SK-BR-3 cells. The 
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internalisation was confirmed to occur via receptor-mediated endocytosis using both 
an InCell ELISA and confocal microscopy, which showed partial colocalisation with the 
acidic organelles 19 h after incubation. The increased internalisation resulted in 
increased levels of cell death following PDT. The levels of cell death induced by either 
Ab-C11Pc-PEG-AuNPs or Ab-C3Pc-PEG-AuNPs were similar (ca. 99 % cell death at 
0.2 μM Pc). However, while the Ab-C11Pc-PEG-AuNPs were non-toxic in the dark, Ab-
C3Pc-PEG-AuNPs induced high levels of dark toxicity, ca. 70 % cell death, at a 
concentration as low as 0.08 μM. Studies in MCF-10A cells showed high levels of 
cytotoxicity both before and after irradiation for Ab-C3Pc-PEG-AuNPs, whereas there 
was minimal photodamage for Ab-C11Pc-PEG-AuNPs. In conclusion, the use of Ab-
C11Pc-PEG-AuNPs is preferred since these nanoparticles induced high levels of cell 
death following PDT and no dark toxicity in cancer cells together with no damage to 
healthy cells. 
The mechanism of cell death followed by the C3Pc-PEG-AuNPs and C11Pc-PEG-AuNPs 
with or without conjugation to anti-HER2 antibody was investigated using an ApoTox-
Glo™ Triplex assay. The results suggested that apoptosis was not the mechanism of cell 
death, opening the possibility for other cell death pathways such as necrosis. 
Unfortunately, the results obtained from this assay were difficult to interpret and a 
conclusion could not be drawn.  
In conclusion, Chapter 3 showed that metal-enhanced fluorescence is possible for 
C3Pc-PEG-AuNPs as compared to C11Pc-PEG-AuNPs. However, the small size of the 
AuNPs could limit the rate of fluorescence enhancement. The enhanced fluorescence 
of C3Pc-PEG-AuNPs as compared to C11Pc-PEG-AuNPs leads to enhanced 
photodynamic efficacy. As a result, C3Pc-PEG-AuNPs perform better than C11Pc-PEG-
AuNPs in vitro. Additionally, the use of a breast cancer-specific targeting agent, anti-
HER2 antibody, effectively increased the internalisation of the conjugated 
nanoparticles by the cells, leading to enhanced photodynamic efficacy.  
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6.2. Targeting breast cancer cells with lactose 
Chapter 4 investigated the use of lactose as a potential targeting agent for breast 
cancer cells. Lactose is a disaccharide composed of a glucose subunit and a galactose 
subunit. The lactose derivative used to obtain the results presented in this chapter was 
thiolated at the terminal end connected to the glucose subunit,17 to allow self-assembly 
to the surface of the AuNPs. Lactose is selectively recognised by galectins, β-
galactoside-binding lectins, via the galactose residue.18 Galectins are expressed on the 
surface of the cells, and their under- or over-expression has been linked with 
cancer.19,20 Overexpression of galectin-1 in breast cancer cells has been previously 
reported.21-24 The expression of galectin-1 was assessed using two breast cancer cell 
lines, SK-BR-3 and MDA-MB-231 human breast adenocarcinoma cells. Using an InCell 
ELISA, MDA-MB-231 cells were found to have a higher expression of galectin-1 on their 
surface as compared to SK-BR-3 cells. Therefore, targeting with lactose was expected 
to be more efficient towards MDA-MB-231 cells. 
The thiolated lactose derivative was used to synthesise lactose-C11Pc-AuNPs and act 
as both the targeting ligand and the water-solubility inducer. Lactose-C11Pc-AuNPs 
were successfully synthesised with a mean diameter of 2.37 ± 1.65 nm, as confirmed 
by TEM analysis. Production of 1O2 by these nanoparticles was confirmed using ABMA. 
Additionally, a PEG ligand (sPEG) with a short chain that resembles the length of the 
lactose derivative was used to synthesise C11Pc-sPEG-AuNPs, used as a control to 
confirm lactose targeting. Lactose-C11Pc-AuNPs and C11Pc-sPEG-AuNPs were 
incubated with MDA-MB-231 cells for either 3 h or 24 h. Unfortunately, CellTiter-Blue® 
cell viability assays showed no cell death following PDT at 633 nm for 6 min. Therefore, 
the incubation time was increased to 24 h to give more time for the nanoparticles to 
be internalised. The results of the cell viability assays following a 24 h incubation were 
non-reproducible and cell death following PDT could not be confirmed. Since the 
results were negative for MDA-MB-231 cells, in vitro studies in SK-BR-3 cells were 
performed. A 3 h incubation period with the lactose-C11Pc-AuNPs and C11Pc-sPEG-
AuNPs was found to be insufficient for effective internalisation since no cell death was 
observed in the cell viability assays. However, the increase of the incubation time to 
24 h was successful as cell death was induced with both lactose-C11Pc-AuNPs (90 %) 
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and C11Pc-sPEG-AuNPs (61 %), indicating selective targeting via the lactose ligand. 
However, an InCell ELISA did not show any indication of targeting the galectin-1 
receptor. As a result, the possible targeting seen in the viability assays could be due to 
the selective recognition between lactose and another receptor on the surface of the 
SK-BR-3 cells. 
In an attempt to improve the targeting ability of lactose, C3Pc was used as the 
photosensitiser. The carbon chain of C3Ps is not only shorter than the C11Pc, but also 
slightly shorter than the lactose ligand. As a result, binding between the galectin-1 
receptor and lactose should not be hindered by the large C11Pc carbon chain. Lactose-
C3Pc-AuNPs were successfully synthesised with an average diameter of 3.10 ± 1.32 nm, 
as confirmed by TEM analysis. The synthesis and aqueous solubilisation of lactose-
C3Pc-AuNPs was found to be easier than lactose-C11Pc-AuNPs, since the shorter 
carbon chain of C3Pc in combination with the lactose derivative allowed for a better 
dispersiblity in water and a higher loading of C3Pc on the surface of the AuNPs. 
Production of 1O2 by lactose-C3Pc-AuNPs was confirmed using ABMA. Control C3Pc-
sPEG-AuNPs were also synthesised to assess the targeting ability of lactose. MDA-MB-
231 cells were incubated with lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs for either 3 h 
or 24 h. A 3 h incubation period was found to be insufficient for efficient internalisation, 
as confirmed by confocal laser scanning microscopy and by the absence of cell death 
following PDT observed in the cell viability assays. On the contrary, a 24 h incubation 
period was sufficient time for the internalisation of the nanoparticles, as shown by 
confocal microscopy. Following PDT at 633 nm for 6 min, cytotoxicity was effectively 
induced in MDA-MB-231 cells by both lactose-C3Pc-AuNPs (52 %) and C3Pc-sPEG-
AuNPs (36 %), with slight evidence of lactose targeting, even though not statistically 
significant. An InCell ELISA indicated that the galectin-1 receptor on the surface of the 
MDA-MB-231 cells was involved in the internalisation of lactose-C3Pc-AuNPs, 
suggesting internalisation via receptor-mediated endocytosis. SK-BR-3 cells were also 
studied for the PDT effect of lactose-C3Pc-AuNPs and C3Pc-sPEG-AuNPs. With this cell 
line, a 3 h incubation period was sufficient for effective nanoparticle internalisation and 
cell death post-PDT, confirmed by the cell viability assays as well as confocal 
microscopy. Additionally, a 24 h incubation period showed similar results. Even though 
the cell death levels induced by both lactose-C3Pc-AuNPs and C3Ps-sPEG-AuNPs were 
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comparable, lactose-C3Pc-AuNPs induced less dark toxicity as compared to C3Pc-sPEG-
AuNPs, which provides an advantage for their use. An InCell ELISA confirmed that the 
galectin-1 receptor on the surface of SK-BR-3 cells was not involved in the 
internalisation of the lactose-C3Pc-AuNPs.  
These results indicate that lactose-C3Pc-AuNPs are more efficient than lactose-C11Pc-
AuNPs. The mechanism of cell death followed by both SK-BR-3 and MDA-MB-231 cells 
incubated with the more efficient lactose-C3Pc-AuNPs was investigated using an 
ApoTox-Glo™ Triplex assay. The results suggested that the most likely cell death route 
was necrosis. However, the results from the assay were inconclusive. The effect of 
lactose-C3Pc-AuNPs was also assessed with non-cancerous MCF-10A cells. Neither 
lactose-C3Pc-AuNPs nor C3Pc-sPEG-AuNPs induced damage to the cells either before 
or after PDT treatment.  
In conclusion, the results presented in Chapter 4 have shown that lactose can be used 
as an alternative to PEG to provide water-solubility of the Pc-AuNPs. Lactose-C3Pc-
AuNPs were found to be more efficient at targeting and inducing PDT than lactose-
C11Pc-AuNPs in both cell lines, MDA-MB-231 and SK-BR-3 cells. For SK-BR-3 cells, 
lactose-C3Pc-AuNPs were found to be efficiently internalised and induce good 
cytotoxicity effects after only a 3 h incubation period. On the contrary, lactose-C11Pc-
AuNPs required a 24 h incubation period in order to see efficient cytotoxicity post-PDT. 
The use of lactose in SK-BR-3 cells suggested that selective targeting could be taking 
place. However, galectin-1 was not involved in this targeting, as confirmed by InCell 
ELISA. For MDA-MB-231 cells, only lactose-C3Pc-AuNPs were efficiently internalised 
and induced cell death following a 24 h incubation and PDT, with evidence for targeting 
galectin-1. As a result, the use of lactose-C3Pc-AuNPs is preferred due to the low dark 
toxicity, effective phototoxicity and selective targeting towards galectin-1. 
 
6.3. Upconverting nanoparticles for photodynamic therapy 
The results presented in Chapter 5 investigated the use of upconverting nanoparticles 
(UCNPs), synthesised and characterised by Markus Buchner at the University of 
Regensburg (Germany), for PDT. The UCNPs consisted of hexagonal β-phase NaYF4 
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(Yb3+, Er3+, Gd3+) covered with a cubic α-phase NaYF4 shell and surface modified with 
lysine and Rose Bengal (NaYF4-lysine-RB UCNPs), dissolved in DMSO. The average size 
of the NaYF4-lysine-RB UCNPs was 17.2 ± 0.98 nm. Generation of 1O2 by the NaYF4-
lysine-RB UCNPs was evaluated using the probe ABMA. Irradiation using a 980 nm NIR 
laser induced the effective excitation of RB upon emission of the UCNPs. Excitation of 
RB led to the generation of 1O2, which was concentration-dependent and solvent-
dependent, confirming efficient FRET between the UCNPs and RB. 
The breast cancer cell line SK-BR-3 was used for the in vitro studies. Firstly, the 
internalisation of the NaYF4-lysine-RB UCNPs needed to be confirmed. Confocal laser 
scanning microscopy confirmed the presence of Rose Bengal inside the cells following 
a 3 h incubation with 25 μg/mL NaYF4-lysine-RB UCNPs. Excitation of the RB for the 
confocal microscopy images was performed using a 543 nm laser. These results, while 
confirming the presence of RB inside the cells, do not confirm uptake of the NaYF4-
lysine-RB UCNPs due to the absence of a 980 nm laser in the confocal microscope to 
directly excite the UCNPs. In order to see the fluorescence emission of the NaYF4-lysine-
RB UCNPs inside the cells, a multi-photon microscope was used, which was able to 
excite the samples at 980 nm. Direct excitation of the UCNPs confirmed the 
internalisation of the NaYF4-lysine-RB UCNP by the cells, since the luminescence 
emission was only detected inside the cells. The results from the microscopy 
experiments confirmed that the RB was still attached to the surface of the NaYF4-lysine-
RB UCNPs and the whole system was efficiently internalised by SK-BR-3 cells. The PDT 
effect was evaluated using CellTiter-Blue® cell viability assays and confocal microscopy. 
The results showed that the NaYF4-lysine-RB UCNPs were efficient at inducing cell 
death following a 3 h incubation and irradiation with a 980 nm NIR laser for 6 min, in a 
concentration-dependent manner. The ideal concentration for PDT was found to be 
15 μg/mL, which contains 0.173 μM of RB, since it induced minimal levels of dark 
toxicity and ca. 40-67 % cell death post-PDT. Control cells, not incubated with UCNPs 
but irradiated at 980 nm, remained highly viable, showing that the NIR laser is not toxic 
to the SK-BR-3 cells by itself. The mechanism of cell death was investigated using an 
ApoTox-Glo™ Triplex assay, which showed an indication of apoptosis following NIR-PDT 
with the NaYF4-lysine-RB UCNPs. Unfortunately, this conclusion could not be confirmed 
since the results were difficult to interpret. 
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In the second part of Chapter 5, UCNPs not functionalised with RB were synthesised 
and characterised by Markus Buchner at the University of Regensburg (Germany). The 
UCNPs consisted of hexagonal β-phase NaYF4 (Yb3+,Er3+, Gd3+) covered with a cubic α-
phase NaYF4 shell and modified with polyacrilic acid (PAA) to provide water-solubility 
(NaYF4-PAA), with an average size of 28 ± 3.17 nm. Using ABMA, it was found that the 
NaYF4-PAA UCNPs were able to induce 1O2 production. Even though direct comparison 
with the NaYF4-lysine-RB UCNPS was not possible due to the difference in size and 
solvent, there was an indication that the NaYF4-lysine-RB UCNPs produced higher 
amounts of 1O2. The NaYF4-PAA UCNPs were studied in vitro in SK-BR-3 cells. Cell 
viability assays showed that NaYF4-PAA UCNPs induce no cytotoxicity either before or 
after NIR-PDT, highlighting the need of a photosensitiser for effective PDT.  
In conclusion, Chapter 5 has shown that the NaYF4-lysine-RB UCNPs can be used for 
PDT since they induce good phototoxicity following irradiation at 980 nm but no dark 
toxicity in a concentration range of 10-20 μg/mL.  
 
6.4. Future work 
In this thesis, the use of AuNPs and UCNPs for PDT was explored. In Chapter 3, the 
potential of metal-enhanced fluorescence for PDT was studied using two 
phthalocyanines, C3Pc and C11Pc. The use of inductively-coupled plasma mass 
spectrometry should be performed to confirm the estimation of the number of C11Pc 
and C3Pc molecules immobilised per AuNPs reported in Chapter 3. To obtain a better 
understanding of the interactions between the phthalocyanines and the AuNPs here 
reported, the synthesis of a similar phthalocyanine with a carbon chain somewhere in 
between 3 and 11 carbon atoms, i.e., 5-9 atoms, should be performed. The 
fluorescence intensity of a third phthalocyanine will provide a better understanding of 
the orientation adopted by the macrocycles relative to the gold nanoparticles as well 
as their distance. Additionally, the application for PDT of such a phthalocyanine should 
also be performed to further evaluate how the chain length affects the efficiency of 
PDT in vitro. Furthermore, following Lakowicz’s RP model, the synthesis and application 
of larger nanoparticles could lead to increased MEF and increased production of 1O2. 
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As a result, PDT could be improved, leading to higher cell death at lower 
concentrations.  
In Chapter 4, SK-BR-3 cells were found to have a low expression of galectin-1. As a 
result, the potential targeting ability of lactose was not related to the galectin-1 
receptor. To understand whether the lactose ligand is targeting SK-BR-3 cells, other 
galactose-binding receptors should be studied. Previous studies report that the glucose 
transport receptor 1 (GLUT1) is selectively recognised by galactose-binding 
carbohydrates.25 Therefore, the possibility of lactose binding the GLUT1 receptor 
should be studied. The levels of galectin-1 on the surface of MDA-MB-231 cells were 
found to be significantly higher than on the surface of SK-BR-3 cells. InCell ELISAs 
suggested that lactose is selectively recognising the galectin-1 receptor on the surface 
of MDA-MB-231 cells. To fully confirm this selective targeting, competition studies to 
block the galectin-1 receptor should be performed. Competition studies will assess 
whether the internalisation of the lactose-C3Pc-AuNPs and thus the PDT efficacy are 
inhibited when the galectin-1 receptor is blocked. Additionally, the use of other ligands 
such as galactose should be explored to evaluate a better targeting towards breast 
cancer cells. Finally, the ability of lactose to target other cancers overexpressing 
galectin-1, such as pancreatic cancer, should be explored.  
In Chapter 5, the NaYF4-lysine-RB UCNPs were dissolved in DMSO. The preparation of 
water-soluble UCNPs functionalised with RB should be performed to further minimise 
the potential toxicity of the UCNPs. Furthermore, the synthesis of NaYF4-lysine-RB 
UCNPs in water will enable the direct comparison with the NaYF4-PAA UCNPs to 
evaluate the generation of 1O2 with and without the presence of a photosensitiser. The 
investigation of NaYF4-PAA UCNPs presented in Chapter 5 did not confirm the 
internalisation of the UCNPs, since only confocal microscopy studies were performed. 
Consequently, investigations into the uptake of the water soluble NaYF4-PAA UCNPs by 
SK-BR-3 cells should be performed using a multi-photon microscope, which allows for 
the direct excitation of the UCNPs at 980 nm. This investigation will give value to the 
cell viability assays presented in this thesis, where the NaYF4-PAA UCNPs were shown 
to induce no toxicity to the cells either before or after PDT treatment. The use of the 
NaYF4-lysine-RB UCNPs for deep-penetration PDT should be studied. Previous reports 
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have placed pork tissue between the cells and the laser. As a result, the penetration of 
NIR light (980 nm) can be compared to visible light (543 nm for RB). The disadvantages 
of using excitation at 980 nm is the notable absorption of such wavelengths by water 
and thus the overheating effect. The use of UCNPs with excitation at 808 nm can avoid 
such problems and should be studied for PDT. 
In all chapters, the study of the cell death mechanism was inconclusive. The use of 
alternative assays for the investigation of the mechanism of cell death followed should 
be used, including apoptosis/necrosis detection kits or apoptosis detection based on 
annexin v. The AuNPs and UCNPs studied throughout this thesis were found to be ideal 
candidates for PDT. However, in vitro studies are limited due to the one-dimensional 
culture of the cells. To further confirm the promising results obtained and reported in 
this thesis, 3D culture models could be used. The cell culture in a 3D model provides a 
structure that is more similar to tumour tissue. Furthermore, in vivo studies should be 
performed. Investigations in animal models will show the selective uptake of each of 
the nanoparticles described in this thesis by the tumour tissue. Additionally, the rate of 
tumour growth and tumour destruction will also be obtained. More importantly, the 
use of in vivo models is useful to evaluate the toxicity associated with the nanoparticles 
towards the body and their potential excretion routes. The internalisation of the 
nanoparticles by certain organs, such as the liver, can lead to undesired toxicity, which 
should be diminished for effective PDT treatment. 
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